Document:

EX-10.16

 Exhibit 10.16 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH
(I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY
DISCLOSED. 
 EXECUTION VERSION 

COLLABORATION, OPTION, AND LICENSE AGREEMENT 

This COLLABORATION, OPTION, AND LICENSE
AGREEMENT (this “Agreement”) is made as of 23 May, 2018 (the “Execution Date), and effective as of the Effective Date (as defined herein) by and between
VIR BIOTECHNOLOGY, INC., a Delaware corporation, having a place of business at 499 Illinois Street, San Francisco, California 94158, United States of America (“Vir”),
BIIG THERAPEUTICS LIMITED, DBA BRII BIOSCIENCES LIMITED, a corporation organized under the laws of the Cayman Islands,
having a registered office at Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1—1205 Cayman Islands (“Parent”), and BRII
BIOSCIENCES OFFSHORE LIMITED a corporation to be established by Parent in accordance with Section 17.1 of this Agreement and organized under the laws of the
Cayman Islands, having a registered office at Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1—1205 Cayman Islands (“Brii Bio”). Vir, Parent and Brii Bio
(following the Effective Date) are referred to in this Agreement individually as a “Party” and collectively as the “Parties.” 

RECITALS 

WHEREAS, Vir is a biopharmaceutical company that is engaged in the research, development, and
commercialization of biopharmaceutical products, including for the treatment of infectious diseases, for commercialization within the United States and globally; 

WHEREAS, Brii Bio is a biopharmaceutical company that will be wholly-owned by Parent and will be engaged,
itself or through its Affiliates, in the research, development, and commercialization of pharmaceutical products in the greater China market that is exploring opportunities to acquire rights in other programs for the treatment of chronic infectious
diseases; 
 WHEREAS, Vir and Brii Bio wish to collaborate in connection with certain development
activities under each other’s programs (or programs of Parent or of a Party’s Affiliates), and following proof of concept in such programs (or such other earlier time as Vir and Brii Bio may agree), to grant to the applicable Party a
specified number of options, exercisable at times and as further set forth in this Agreement, to obtain exclusive rights to develop and commercialize products arising from such programs; 

WHEREAS, upon each exercise of an option for a Vir Program, Brii Bio wishes to obtain from Vir an
exclusive license to develop and commercialize products arising from such Licensed Vir Program in the China Territory, and Vir is willing to grant such a license to Brii Bio, all in accordance with the terms and conditions set forth herein; and 

WHEREAS, following each exercise of an option by Brii Bio for a Vir Program, Brii Bio will grant to Vir a
corresponding option for a Brii Bio Program; 

 EXECUTION VERSION 

 
 WHEREAS, upon each exercise of an option for a Brii Bio Program,
Vir wishes to obtain from Brii Bio an exclusive license to develop and commercialize products arising from such Licensed Brii Bio Program in the United States, and Brii Bio is willing to grant such a license to Vir, all in accordance with the terms
and conditions set forth herein. 
 NOW, THEREFORE, in consideration of the foregoing
premises and the covenants contained herein, the receipt and sufficiency of which are acknowledged, the Parties hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS

 Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the
respective meanings set forth below: 
 1.1 “Acquisition Affiliate” means an Third Party that becomes an
Affiliate of a Party after the Effective Date as a result of a Change of Control of such Party. 
 1.2 “Active
Ingredient” means the clinically active materials that provide pharmacological activity in a pharmaceutical product (excluding formulation components such as coatings, stabilizers, excipients or solvents, adjuvants or controlled release
technologies). 
 1.3 “Affiliate” means, with respect to an Entity, any Entity that controls, is controlled
by, or is under common control with such Entity. For the purpose of this definition only, “control” (including, with correlative meaning, the terms “controlled by” and “under the common control”) means the actual power,
either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of an Entity, whether by the ownership of more than fifty percent (50%) of the voting stocking of such Entity, by
contract or otherwise. 
 1.4 “Applicable Laws” means collectively all laws, regulations, ordinances, decrees,
judicial and administrative orders (and any license, franchise, permit or similar right granted under any of the foregoing) and any policies and other requirements of any applicable Governmental Authority that govern or otherwise apply to a
Party’s activities in connection with this Agreement. 
 1.5 “Brii Bio
Know-How” means (a) any and all Know-How that is Controlled by Brii Bio or its Affiliates (including Parent) as of the Effective Date or during the Pre-Option Development Period that is [***] in connection with Products arising from Collaboration Programs, and (b) any and all Know-How that is Controlled by Brii Bio
or its Affiliates as of the Option Exercise Date or thereafter during the Term that is [***] the Development, Manufacture, or Commercialization of Licensed Products. Notwithstanding the foregoing, Brii Bio
Know-How will exclude any Know-How Controlled by any Acquisition Affiliate of Brii Bio before such Third Party became an Acquisition Affiliate of Brii Bio. 

1.6 “Brii Bio Option Period” means, for each Vir Program, the period beginning on the earlier of (a) the
date that [***] for such Vir Program (or the date that [***]), or (b) the date that such Vir Program is [***], and expiring on the date that is [***] after the date on which Vir [***] (subject to any applicable extensions to such [***] time
period provided under Section 4.2(a)). 

  
 2 

 EXECUTION VERSION 

 
 1.7 “Brii Bio Option Term” means the
period commencing on the Effective Date, and ending on the earlier of (a) the date that Brii Bio delivers an Option Exercise Notice for the fourth Vir Program under this Agreement, and (b) (i) if Parent has not undergone an IPO, the fifth
anniversary of the Effective Date, or (ii) if Parent has undergone an IPO, the seventh anniversary of the Effective Date. 
 1.8
“Brii Bio Patents” means (a) any and all Patents that are Controlled by Brii Bio or its Affiliates (including Parent) as of the Effective Date or during the Pre-Option Development
Period that are [***] in connection with Products arising from Collaboration Programs, and (b) any and all Patents that are Controlled by Brii Bio or its Affiliates as of the Option Exercise Date or thereafter during the Term that are [***] the
Development, Manufacture, or Commercialization of Licensed Products. Notwithstanding the foregoing, Brii Bio Patents will exclude any Patents Controlled by any Acquisition Affiliate of Brii Bio before such Third Party became an Acquisition Affiliate
of Brii Bio. 
 1.9 “Brii Bio Program” means any Program in the Field that is being conducted by or on behalf
of Brii Bio or Parent, or that is Controlled by Brii Bio or Parent as a result of the grant of development and commercialization rights from a Third Party. 

1.10 “Brii Bio Technology” means the Brii Bio Know-How and the Brii Bio
Patents. 
 1.11 “Business Day” means a day other than a Saturday, Sunday or a day on which banking
institutions in San Francisco, California or Shanghai, China, are required by Applicable Laws to remain closed. 
 1.12
“Calendar Quarter” means the respective periods of three consecutive calendar months ending on March 31, June 30, September 30 and December 31. 

1.13 “Calendar Year” means each twelve (12)-month period commencing on January 1. 

1.14 “CFDA” means the China Food and Drug Administration, and local counterparts thereto, and any successor
agency(ies) or authority thereto having substantially the same function. 
 1.15 “Change of Control” means,
with respect to a Party: (a) the sale of all or substantially all of such Party’s assets or business to which the subject matter of this Agreement relates; (b) a merger, reorganization or consolidation involving such Party in which
the holders of the voting securities of such Party outstanding immediately prior thereto cease to beneficially own at least fifty percent (50%) of the combined voting power of the surviving entity, directly or indirectly, immediately after such
merger, reorganization or consolidation; or (c) a transaction or series of related transactions in which an entity (together with its Affiliates) or individual, or group of entities (and their affiliates) and/or individuals acting in concert,
acquires more than fifty percent (50%) of the voting equity securities of such Party, or (d) the stockholders or equity holders of such Party will approve a plan of complete liquidation of such Party or an agreement

  
 3 

 EXECUTION VERSION 

 
 for the sale or disposition by such Party of all or a substantial portion of its assets,
other than pursuant to the transaction as described above or to an Affiliate. Notwithstanding the foregoing, the sale or issuance of shares in exchange for cash for purposes of a bona fide financing will not constitute a Change of Control.

 1.16 “China Territory” means the People’s Republic of China, Hong Kong, Taiwan, and Macau. 

1.17 “Clinical Trial” means a Phase 1 Trial, Phase 2 Trial, Phase 3 Trial, Pivotal Clinical Trial or
Phase 4 Trial, or such other study in humans that is conducted in accordance with good clinical practices and is designed to generate data in support or maintenance of Regulatory Approval or other similar marketing application. 

1.18 “Collaboration Program” means (a) any Vir Program or Brii Bio Program, as applicable, where
(i) the Parties have agreed to collaborate under and pursuant to this Agreement, by the conduct of Pre-Option Development Activities, or (ii) one Party has elected to conduct Pre-Option Development Activities without the assistance of the other Party in the China Territory (in the case of a Vir Program), or the United States (in the case of a Brii Bio Program) (i.e. where
Section 3.10 or Section 3.12 apply), (b) any Licensed Vir Program, and (c) any Licensed Brii Bio Program. 

1.19 “Commercialization Plan” means, with respect to a Licensed Product, the written strategic and tactical
plans and commercial budget for the Commercialization of such Licensed Product in the applicable Territory. 
 1.20
“Commercialization” or “Commercialize” means those activities conducted by a Party after exercise of an Option with respect to a Collaboration Program directed to marketing, promoting, advertising,
exhibiting, distributing, detailing, selling (and offering for sale or contracting to sell) or otherwise commercially exploiting (including pricing and reimbursement activities) a Licensed Product of such Collaboration Program (including importing
and exporting activities in connection therewith) in the Field in the applicable Territory. 
 1.21 “Commercially
Reasonable Efforts” means, with respect to a Party’s obligations or activities under this Agreement, [***]. 
 1.22
“Competing Product” means, with respect to a particular Licensed Product, a biological or pharmaceutical product that (a) is directed to the same Target as such Licensed Product, (b) is being clinically developed or
commercialized for use in the same indication as such Licensed Product, and (c) has the same mechanism of action as such Licensed Product. 

1.23 “Complete,” “Completed,” or “Completion” means, with
respect to a Clinical Trial, the point in time at which the primary database lock for such study has occurred and, if such study has a statistical analysis plan, the data generated based on that primary database lock under the statistical analysis
plan for such study are available. 

  
 4 

 EXECUTION VERSION 

 
 1.24 “Confidential Information” means any
and all proprietary Know-How and Information, including scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information or
data, whether communicated in writing or orally or by any other method, that is provided by or on behalf of one Party or its Affiliate to the other Party or its Affiliate in connection with this Agreement. Notwithstanding the foregoing, all Know-How and Information [***], and all Know-How and Information [***]. The terms of this Agreement are the Confidential Information of both Parties. 

1.25 “Control” or “Controlled” means, with respect to (a) any Know-How, Patents or other intellectual property rights, that a Party has the legal authority or right (whether by ownership, license or otherwise) to grant to the other Party a license, sublicense, access or right
to use (as applicable) under such Know-How, Patents, or other intellectual property rights, on the terms and conditions set forth herein, and (b) any Program, that a Party has the legal authority or right
(whether by ownership, license, contract or otherwise) to grant to the other Party a license, sublicense, access or other right to Develop and Commercialize Compounds and Products arising from such Program, on the terms and conditions set forth
herein, including in the China Territory (in the case of a Vir Program), or the United States (in the case of a Brii Bio Program), in each case of (a) and/or (b), without breaching the terms of any agreement with a Third Party. 

1.26 “Cover” means, with respect to a claim of a Patent and a Licensed Product, that such claim would be
infringed, absent a license, by the use, offer for sale, sale or importation of such Licensed Product (considering claims of patent applications to be issued as then pending). 

1.27 “Develop” or “Development” or “Developing” means those
activities conducted by a Party after exercise of an Option with respect to a Collaboration Program related to preclinical and clinical drug or biological development activities for Licensed Products in the Field, including test method development,
stability testing, toxicology, formulation, statistical analysis, preclinical and clinical studies and regulatory affairs, making Regulatory Submissions, and seeking and obtaining Regulatory Approval. 

1.28 “Dollar” means the U.S. dollar, and “$” shall be interpreted accordingly. 

1.29 “Effective Date” means the later of (a) the date upon which the conditions set forth in
Section 17.1 are satisfied, and (b) the date upon which the shares are issued to Vir by Brii Bio pursuant to the Share Purchase Agreement. 

1.30 “Entity” means a partnership, limited partnership, limited liability partnership, corporation, limited
liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization. 

1.31 “FDA” means the United States Food and Drug Administration or any successor entity thereto. 

1.32 “Field” means the treatment, palliation, diagnosis, prevention or cure of acute and chronic diseases of
infectious pathogen origin or hosted by pathogen infection. 
 1.33 “First Commercial Sale” means, with
respect to any Licensed Product in any country or jurisdiction, the first sale of such Licensed Product to a Third Party for distribution, use or consumption in such country or jurisdiction after Regulatory Approvals, as applicable, have been
obtained for such Licensed Product in such country or jurisdiction. 

  
 5 

 EXECUTION VERSION 

 
 1.34 “FTE Rate” means a rate of [***].

 1.35 “FTE” means the equivalent of the work of a full-time employee of a Party for a twelve (12)-month
period. 
 1.36 “Fully Burdened Manufacturing Cost” means, with respect to any Licensed Product supplied by or
on behalf of a Party to the other Party hereunder: 
 (a) if such Licensed Product (or any precursor or intermediate thereof) is
Manufactured by a Third Party manufacturer, (i) [***]; or 
 (b) if such Licensed Product (or any precursor or intermediate thereof)
is Manufactured by the supplying Party or its Affiliate, the [***]. Such [***] costs shall be calculated in accordance with GAAP. 

1.37 “GAAP” means United States generally accepted accounting principles, consistently applied. 

1.38 “GCP” means all applicable Good Clinical Practice standards for the design, conduct, performance,
monitoring, auditing, recording, analyses and reporting of clinical trials, including, as applicable (a) as set forth in the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
Harmonized Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) (the “ICH Guidelines”) and any other guidelines for good clinical practice for trials on medicinal products in the applicable Territory,
(b) the Declaration of Helsinki (2004) as last amended at the 52nd World Medical Association in October 2000 and any further amendments or clarifications thereto, (c) U.S. Code of Federal Regulations Title 21, Parts 50 (Protection of
Human Subjects), 56 (Institutional Review Boards) and 312 (Investigational New Drug Application), as may be amended from time to time, and (d) the equivalent Applicable Laws in the applicable Territory, each as may be amended and applicable
from time to time and in each case, that provide for, among other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects. 

1.39 “Generic Product” means, with respect to a Licensed Product in a particular regulatory
jurisdiction, any pharmaceutical product that (a) (i) contains the same active pharmaceutical ingredients as such Licensed Product and is approved by the Regulatory Authority in such country based on reference to data contained in an earlier
regulatory filing of the Licensed Product; or (ii) is A or AB Rated (defined below) with respect to such Licensed Product or otherwise approved by the Regulatory Authority in such country as a substitutable generic for such Licensed Product;
and (b) is sold in such jurisdiction by a Third Party that is not a sublicensee and did not purchase such product or its active pharmaceutical ingredients in a chain of title that included Vir or Brii Bio or their Affiliates or sublicensees.
For purposes of this definition, “A or AB Rated” means “therapeutically equivalent” as determined by the FDA, CFDA, or the applicable Regulatory Authority. 

1.40 “Global Development Plan” means the Vir Global Plan or the Brii Bio Global Plan, as applicable. 

  
 6 

 EXECUTION VERSION 

 
 1.41 “GLP” means all applicable Good
Laboratory Practice standards, including, as applicable, as set forth in the then-current good laboratory practice standards promulgated or endorsed by the U.S. Food and Drug Administration, as defined in 21 C.F.R. Part 58, and the equivalent
Applicable Laws in the applicable Territory, each as may be amended and applicable from time to time. 
 1.42
“GMP” means all applicable current Good Manufacturing Practices, including, as applicable, (a) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts 4, 210, 211, 601, 610 and 820, (b)
European Directive 2003/94/EC and Eudralex 4, (c) the principles detailed in the International Conference on Harmonization’s Q7 guidelines, and (d) the equivalent Applicable Laws in any relevant country or region, each as may be amended
and applicable from time to time. 
 1.43 “Governmental Authority” means any federal, state, national,
state, provincial or local government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or
taxing authority or power, or any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body). 

1.44 “HBV” means human hepatitis B virus. 

1.45 “High-Commercial Potential Program” means (a) any Licensed Vir Program that is [***] or (b) any
Licensed Brii Bio Program that is [***]. 
 1.46 “IND” means an investigational new drug application or
equivalent application filed with a Regulatory Authority in a given country, which application is required to commence human clinical trials in such country. 

1.47 “Information” means any and all tangible and intangible (a) techniques, technology, practices, trade
secrets, inventions (whether patentable or not), methods, knowledge, know-how, skill, experience, test data and results (including pharmacological, toxicological and clinical test data and results), analytical
and quality control data, results or descriptions, software and algorithms, and (b) compositions of matter, cells, cell lines, assays, animal models and physical, biological or chemical material; that, in each case, are not in the public
domain. 
 1.48 “Included Vir Programs” means the Vir Programs listed on Exhibit 1.48. 

1.49 “Invention” means any information, discovery, improvement, modification, process, method, design, protocol,
formula, data, invention, algorithm, forecast, profile, strategy, plan, result, know-how and trade secret, patentable or otherwise, that is discovered, generated, conceived or reduced to practice by or on
behalf of either Party (including by its Affiliates, employees, agents, or contractors), whether solely or jointly, in the course of the performance of this Agreement, including all rights, title and interest in and to the intellectual property
rights therein and thereto. 
 1.50 “IPO” means an initial public offering of the equity securities of Brii
Bio. 

  
 7 

 EXECUTION VERSION 

 
 1.51
“Know-How” means any proprietary scientific or technical information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including databases, safety
information, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, medicinal chemistry, biological, chemical,
biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and Manufacturing Process and development information, results and data. 

1.52 “Licensed Product” means any Product that is part of a Licensed Program. 

1.53 “Licensed Brii Bio Program” means a Brii Bio Program for which Vir has exercised a Vir Option pursuant to
Section 4.3(b). 
 1.54 “Licensed Program” means a Licensed Vir Program or a
Licensed Brii Bio Program, as applicable. 
 1.55 “Licensed Vir Program” means a Vir Program for which Brii
Bio has exercised a Brii Bio Option pursuant to Section 4.3(a). 
 1.56 “Low-Commercial Potential Program” (a) any Licensed Vir Program that is [***] or (b) any Licensed Brii Bio Program that is [***]. 

1.57 “Manufacture”, “Manufactured” or “Manufacturing” means all
activities conducted in connection with the manufacture or production of a Product or Licensed Product, including activities relating to the receipt of materials, labeling, quality control testing, release, and storage of Product or Licensed
Product, as applicable, and all related controls. 
 1.58 “Manufacturing Process” means with respect to
Product or Licensed Product, as applicable, the Manufacturing production steps and control system (e.g., analytical methods), including any improvements or modifications thereto. 

1.59 “Manufacturing Technology Transfer” means the transfer of the Manufacturing Process (and modifications and
improvements thereof from time to time) from the Transferring Party to the Assuming Party, as further provided for in this Agreement and in the Manufacturing Technology Transfer Agreement, in each case to include the provision of (a) copies of
the technical documentation, specifications, procedures and other know-how related to the Manufacturing Process (including all data, documentation, and records describing or otherwise related to the
Manufacturing Process or any part thereof), and (b) technical transfer services by a reasonable number of people knowledgeable and skilled in the Manufacture of Licensed Product, including reasonable access to and consultation with such people.

 1.60 “Mid-Commercial Potential Program” (a) any Licensed Vir
Program that is [***] or (b) any Licensed Brii Bio Program that is [***]. 

  
 8 

 EXECUTION VERSION 

 
 1.61 “Net Sales” means with respect to a
Licensed Product, the aggregate amount billed during the applicable period in a country by the selling Party or its Affiliates, licensees and sublicensees (each of the foregoing, a “Seller”) in such country for all sales of
such Licensed Product to independent, unrelated persons (“Buyers”) in bona fide arm’s length transactions after deducting, if not previously deducted, from the amount invoiced or received, the following deductions
to the extent actually applied or taken with respect to such sales of Licensed Products: 
 (a) [***]; 

(b) [***]; 
 (c)
[***]; 
 (d) [***]; 

(e) [***]; 
 (f)
[***]; 
 (g) [***]; and 

(h) [***]. 
 All such
amounts shall be determined from the books and records of the Seller, maintained in accordance with applicable accounting standards, consistently applied. 

If a Licensed Product is sold in the form of a combination product containing both a Licensed Product and one or more other Active Ingredients
(whether co-formulated or co-packaged) that is not a Licensed Product (a “Combination Product”), the Net Sales of such Licensed Product for the
purpose of calculating royalties owed under this Agreement for sales of such Licensed Product, is determined as follows: first, Seller shall determine the actual Net Sales of such Combination Product (using the above provisions) and then such amount
is multiplied by the fraction A/(A+B), where A is the invoice price of such Licensed Product, if sold separately, and B is the total aggregate invoice price of all other Active Ingredients in such Combination Product if sold separately, in each
case, in the country in which the Combination Product was sold. In each case, A and B will be adjusted on a pro rata basis to account for dosing differences between the amounts of Active Ingredients included in the Combination Product relative to
the amounts of Active Ingredients included in the separately sold product. If any other Active Ingredient in such Combination Product is not sold separately, Net Sales will be calculated by multiplying actual Net Sales of such Combination Product by
a fraction A/C where A is the invoice price of such Licensed Product if sold separately, and C is the invoice price of such Combination Product in such country. If neither such Licensed Product nor any other Active Ingredient in such Combination
Product is sold separately, the adjustment to Net Sales shall be determined by the Parties in good faith to reasonably reflect the fair market value of the contribution of such Licensed Product in such Combination Product to the total fair market
value of such Combination Product. [***]. With respect to any sale of any Licensed Product in a given country for any substantive consideration other than monetary consideration on arm’s-length terms
(which has the effect of reducing the invoiced amount below what it would have been in the absence of such non-monetary consideration), for purposes of calculating the Net Sales, such Licensed Product shall be
deemed to be [***]. Notwithstanding the foregoing, Net Sales excludes amounts (whether actually existing or deemed to exist for purposes of 

  
 9 

 EXECUTION VERSION 

 
 calculation) for Licensed Products distributed for use in Clinical Trials, inter-company
transfers to Affiliates, registration samples, compassionate uses, named patient, and promotional samples (in commercially reasonable quantities), provided that in each case the amounts paid on transfer is no greater than the fully burdened cost to
Manufacture and supply such Licensed Product. 
 If two (2) or more Licensed Products are (i) sold together in the form of a
combination product (whether co-packaged, bundled, or co-formulated), or (ii) sold for use in a combination therapy, including where each Licensed Product is
packaged and sold separately (a “Combination Licensed Product”), then no later than [***] of such Licensed Products in such combination (or for such combination therapy) the Parties will discuss through the JSC to agree upon the
appropriate accounting treatment for Net Sales of such Combination Licensed Product for royalty and sales milestone purposes, which may include, without limitation [***]. 

1.62 “Option” means the Brii Bio Option or the Vir Option, as applicable. 

1.63 “Option Data Package” means, with respect to data and other information from all Pre-Option Development Activities for a given Collaboration Program through the achievement of Proof of Concept, a package of materials comprising copies of: [***]. 

1.64 “Option Exercise Date” means (a) with respect to a Vir Program, the date on which Brii Bio provides
Vir with an Option Exercise Notice for such Vir Program pursuant to Section 4.3(a), and (b) with respect to a Brii Bio Program, the date on which Vir provides Brii Bio with an Option Exercise Notice for such Brii Bio
Program pursuant to Section 4.3(b), as applicable. 
 1.65 “Option Exercise Fee”
means, on a Collaboration Program-by-Collaboration Program basis for which a Brii Bio Option or Vir Option as applicable, is exercised, (a) the amount paid by Brii
Bio to Vir under Section 10.2(a) or (b) the amount paid by Vir to Brii Bio under Section 10.2(b), as applicable. 

1.66 “Option Exercise Notice” means the written notice provided by (a) Vir to Brii Bio, or (b) by Brii
Bio to Vir, in each case to exercise the delivering Party’s Option for a Collaboration Program pursuant to Section 4.3. 

1.67 “Option Period” means the Brii Bio Option Period or the Vir Option Period, as applicable. 

1.68 “Option Term” means the Brii Bio Option Term or the Vir Option Term, as applicable. 

1.69 “Patents” means any U.S., foreign, international or regional patent application or patent in any
jurisdiction (including any provisional, non-provisional, divisional, continuation or continuation-in-part application, and any
patents that issue thereon); and any reissue, renewal, substitution, extension or addition of any of the foregoing patents or applications; and any foreign equivalents of any of the foregoing (as more fully set forth in this Agreement). 

1.70 “Person” means any individual, Entity, unincorporated organization or association, or governmental
authority or agency. 

  
 10 

 EXECUTION VERSION 

 
 1.71 “Phase 1 Trial” means, with respect
to a Product, a first Clinical Trial in human beings of such Product, as further defined in 21 C.F.R. 312.21(a) or the corresponding regulation in jurisdictions other than the United States. 

1.72 “Phase 2 Trial” means, with respect to a Product, a Clinical Trial that is intended to explore the
feasibility, safety, dose ranging or efficacy of such Product, that is prospectively designed to generate sufficient data (if successful) to commence a Pivotal Clinical Trial (or foreign equivalent) of such Product, as further defined in 21 C.F.R.
312.21(b) or the corresponding regulation in jurisdictions other than the United States. 
 1.73 “Phase 3
Trial” means, with respect to a Licensed Product, a Pivotal Clinical Trial in humans performed to gain evidence with statistical significance of the efficacy of such product in a target population, and to obtain expanded evidence of
safety for such Product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA by a Regulatory Authority and to provide an adequate basis for physician labeling, as described in 21
C.F.R. 312.21(c), as amended from time to time, or the corresponding regulation in jurisdictions other than the United States. 
 1.74
“Phase 4 Trial” means, with respect to a Licensed Product, (a) any Clinical Trial conducted to satisfy a requirement of a Regulatory Authority in order to maintain a Regulatory Approval for such Licensed Product or
(b) any Clinical Trial conducted after the first Regulatory Approval in the same disease state for which such Licensed Product received Regulatory Approval other than for purposes of obtaining Regulatory Approval. 

1.75 “Pivotal Clinical Trial” means (a) a Phase 3 Trial, or (b) a human clinical trial of a Licensed
Product that satisfies the requirements of 21 C.F.R. § 312.21(c) and is a registration trial designed to establish statistically significant efficacy and safety of such Licensed Product for the purpose of enabling the preparation and submission
of application for Regulatory Approval to the competent Regulatory Authorities in a given country, as evidenced by (i) an agreement with or statement from the FDA on a Special Protocol Assessment or equivalent in another country or
(ii) other guidance or minutes issued by the FDA, for such registration trial or equivalent in another country, or (iii) a Party’s public statements, with respect to each, where the results of such clinical trial are intended (if
supportive) to be used to establish both safety and efficacy of such Licensed Product in patients that are the subject of such trial and serve as the basis for obtaining initial or supplemental Regulatory Approval in the United States of such
Licensed Product. For clarity, any compassionate use dosing with respect to a Licensed Product shall not be considered the initiation of a Pivotal Clinical Trial with respect to such Licensed Product. 

1.76 “Pre-Option Development Activities” means with respect to a
Collaboration Program prior to exercise of an Option for such Collaboration Program, all activities related to the clinical development of Products and Compounds arising from such Collaboration Program, including, as applicable, [***]. 

1.77 “Pre-Option Development Budget” means the budget for the conduct of
the Pre-Option Development Activities for a given Collaboration Program, as set forth in the Pre-Option Development Plan, as the same may be amended from time to time in
accordance with this Agreement. 

  
 11 

 EXECUTION VERSION 

 
 1.78
“Pre-Option Development Period” means, for each Collaboration Program, the period of time beginning on the date [***] and ending upon the earliest of (a) [***], (b) [***], and (c)
[***]. 
 1.79 “Pre-Option Development Plan” means the written plan,
as it may be amended from time to time by mutual agreement of the Parties, for the conduct by a Party of Pre-Option Development Activities for the other Party’s Collaboration Program in such first
Party’s Territory (i.e., Brii Bio’s conduct of Pre-Option Development Activities for a Vir Program in the China Territory or Vir’s conduct of Pre-Option
Development Activities for a Brii Bio Program in the United States), setting forth, among other things (a) a description of such Pre-Option Development Activities, including an estimated timeline for
performance of such Pre-Option Development Activities, (b) the quantities and timing of supply of Product and Compound for such Pre-Option Development Activities,
(c) the protocol for any Clinical Trials, and (d) the Pre-Option Development Budget for such Pre-Option Development Activities. 

1.80 “Product” means any pharmaceutical or biological compound or product included in a Collaboration Program,
in any form, presentation, formulation or dosage form. 
 1.81 “Program” means, with respect to a Party, a
program of activities (a) conducted internally by or on behalf of such Party, or (b) to which such Party acquires development and commercialization rights from a Third Party, in each case directed to the research, development, manufacture
or commercialization of one or more biological or pharmaceutical products directed to a specified Target. A Program includes all compounds and products directed to such Target, [***]. Notwithstanding the foregoing, if any Third Party becomes an
Acquisition Affiliate of a Party after the Effective Date, the programs of such Acquisition Affiliate existing prior to the date such Third Party became such Party’s Acquisition Affiliate will not be included as a Program under this Agreement.

 1.82 “Proof of Concept” means, with respect to each Collaboration Program, the date upon which Vir provides
written notice to Brii Bio (in the case of a Vir Program), or Brii Bio provides written notice to Vir (in the case of a Brii Bio Program), that [***], provided that if a Controlling Party fails to provide written notice to the other Party of
such achievement, Proof of Concept will be [***]. 
 1.83 “Regulatory Approval” means, with respect to a
Licensed Product in a Territory, all approvals that are necessary for the commercial sale of such Licensed Product in such Territory, excluding any pricing and reimbursement approvals. 

1.84 “Regulatory Authority” means any applicable Governmental Authority responsible for granting
Regulatory Approvals and any pricing or reimbursement approvals, as applicable, for Licensed Products, including the FDA and the CFDA, and any corresponding national or regional regulatory authorities. 

  
 12 

 EXECUTION VERSION 

 
 1.85 “Regulatory Exclusivity” means any
exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a Licensed Product other than Patents, including rights conferred in the United States under the Hatch-Waxman Act or the FDA Modernization
Act of 1997 (but excluding any patent term extension mechanism), in the China Territory by the Regulations for the Implementation of Drug Administration Law of the People’s Republic of China, or rights similar thereto in any other jurisdiction.

 1.86 “Regulatory Submissions” means any filing, application or submission with any Regulatory Authority,
including authorizations, approvals or clearances arising from the foregoing, including Regulatory Approvals and any pricing or reimbursement approvals, as applicable, and all correspondence or communication with or from the relevant Regulatory
Authority, as well as minutes of any material meetings, telephone conferences, or discussions with the relevant Regulatory Authority, in each case, with respect to a Licensed Product. 

1.87 “Share Purchase Agreement” means that certain Share Purchase Agreement between the Parties dated as of the
Effective Date and attached hereto as Exhibit 1.87. 
 1.88 “Target” means (a) a
specific biological molecule that is identified by a GenBank accession number or similar information, or by its amino acid or nucleic acid sequence, (b) any naturally occurring mutant or allelic variant of a molecule disclosed in the foregoing
clause (a), including transcriptional and posttranscriptional isoforms (e.g., alternative splice variants), and post-translational modification variants (e.g., protein processing, maturation and glycosylation variants), and (c) truncated forms
(including fragments thereof); in each case of (b) and (c) that have a biological function substantially identical to that of a molecule disclosed in the foregoing clause (a). 

1.89 “Tax” or “Taxes” means any present or future taxes, levies, imposts, duties,
charges, assessments or fees of any nature (including any interest thereon). For the avoidance of doubt, Taxes includes value add taxes (“VAT”). 

1.90 “Territory” means, with respect to a Licensed Vir Program, the China Territory, or with respect to a
Licensed Brii Bio Program, the United States. 
 1.91 “Territory Development Plan” means the China Development
Plan or the U.S. Development Plan, as applicable. 
 1.92 “Third Party” means any Person other than
(a) Vir and its Affiliates or (b) Brii Bio and its Affiliates. 
 1.93 “United States” means the
United States of America. 
 1.94 “Valid Claim” means, with respect to any claim included in the Vir Patents
(with respect to a Vir Program) or the Brii Bio Patents (with respect to a Brii Bio Program), (a) a claim of an issued, unexpired Patent that has not been revoked, disclaimed, abandoned or held invalid or unenforceable by a court or other body of
competent jurisdiction in an unappealed or unappealable decision and (b) a claim of any patent application included in such Patents that has been pending [***] or less from the date of its earliest priority date, and that has not been abandoned
or finally disallowed without the possibility of appeal or re-filing of the application. 

  
 13 

 EXECUTION VERSION 

 
 1.95
“Vir-Alnylam Agreement” means the Collaboration and License Agreement between Vir and Alnylam Pharmaceuticals, Inc. (“Alnylam”) dated October 2, 2017. 

1.96 “Vir-Alnylam Program” means the Program to which Vir obtained
rights from Alnylam pursuant to the Vir-Alnylam Agreement for the development and commercialization of products that contain or are comprised of one or more siRNAs as an active ingredient that are directed to
HBV as the Target, including [***] (as such terms are defined in the Vir-Alnylam Agreement). 

1.97 “Vir Know-How” means (a) any and all Know-How that is Controlled by Vir or its Affiliates as of the Effective Date or during the Pre-Option Development Period that is [***], and (b) any and all Know-How that is Controlled by Vir or its Affiliates as of the Option Exercise Date or thereafter during the Term that is [***]. Notwithstanding the foregoing, Vir Know-How
will exclude any Know-How Controlled by any Acquisition Affiliate of Vir before such Third Party became an Acquisition Affiliate of Vir. 

1.98 “Vir Option Period” means each period beginning on the date on which Brii Bio exercises a Brii Bio Option
for a Vir Program, and expiring on the date that is [***] after the date on which Brii Bio [***] for a Brii Bio Program that is the subject of Pre-Option Development Activities following the commencement of
and during the Vir Option Period (subject to any applicable extensions to such [***] time period provided under Section 4.2(b)). 

1.99 “Vir Option Term” means the period commencing on the Effective Date, and ending two (2) years
following the expiration of the Brii Bio Option Term. 
 1.100 “Vir Patents” means (a) any and all
Patents that are Controlled by Vir or its Affiliates as of the Effective Date or during the Pre-Option Development Period that are [***] in connection with Products arising from Collaboration Programs, and
(b) any and all Patents that are Controlled by Vir or its Affiliates as of the Option Exercise Date or thereafter during the Term that are [***] the Development, Manufacture, or Commercialization of Licensed Products. Notwithstanding the
foregoing, Vir Patents will exclude any Patents Controlled by any Acquisition Affiliate of Vir before such Third Party became an Acquisition Affiliate of Vir. 

1.101 “Vir Program” means any Program in the Field that is being conducted by or on behalf of Vir, or that is
Controlled by Vir as a result of the grant of development and commercialization rights from a Third Party. 
 1.102 “Vir
Technology” means the Vir Know-How and the Vir Patents. 
 1.103 Additional
Definitions. The following table identifies the location of definitions set forth in various Sections of this Agreement: 

  
 14 

 EXECUTION VERSION 

 
  

			
	 Definition
	  	 Section

	 Agreement
	  	Preamble
	 Alliance Manager
	  	2.2
	 Alnylam
	  	1.94
	 Anti-Corruption Laws
	  	12.7(a)
	 Assuming Party
	  	8.3(b)
	 Arbitration Notice
	  	16.3(a)
	 Arbitrators
	  	16.3(b)
	 Brii Bio Commercial Quality Agreement
	  	8.2(b)
	 Brii Bio Commercial Supply Agreement
	  	8.2(b)
	 Brii Bio Global Plan
	  	6.3(b)
	 Brii Bio Indemnitees
	  	13.2
	 Brii Bio Option
	  	4.1(a)
	 Brii Bio Program Termination Costs
	  	15.5(a)(ii)
	 Brii Bio Program Termination Notice
	  	4.5(b)
	 Brii Bio Publication
	  	11.4(a)
	 Brii Bio Technology Transfer
	  	5.10(b)
	 Brii Bio Pre-Option Inventions
	  	3.11(b)
	 Buyer
	  	1.58
	 China Development Plan
	  	6.2(a)
	 Combination Product
	  	1.58
	 Commercial Potential
	  	10.7(b)
	 Competing Program
	  	5.9(a)
	 Confidentiality Agreement
	  	17.6
	 Controlling Party
	  	3.1(a)(i)
	 Development Records
	  	6.6
	 Different Mechanism
	  	1.78
	 Disclosing Party
	  	11.1(a)
	 Dispute
	  	16.1
	 Early Option Trigger Notice
	  	4.3(d)
	 Effective Date
	  	Preamble
	 Examined Party
	  	10.10
	 Executive Officers
	  	2.3(d)
	 Examined Party
	  	10.10
	 Executive Officers
	  	2.3(d)
	 Global Brand Elements
	  	9.3(c)
	 Global Development Plan
	  	6.3
	 Granting Party
	  	2.1(b)
	 ICH Guidelines
	  	1.37
	 Indemnified Party
	  	13.3
	 Indemnifying Party
	  	13.3
	 Joint Inventions
	  	14.1(a)
	 Joint Patent
	  	14.1(a)
	 JDC
	  	2.4(a)

  
 15 

 EXECUTION VERSION 

 
  

			
	 JSC
	  	2.3(a)
	 Losses
	  	13.1
	 Materials
	  	3.6
	 QA
	  	1.35(a)
	 QC
	  	1.35(a)
	 Option Party
	  	2.1(b)
	 Party/Parties
	  	Preamble
	 Paying Party
	  	10.11(b)
	 Potential Program List
	  	3.1(a)(i)
	 Public Official
	  	12.7(d)
	 Publication
	  	11.4
	 Receiving Party
	  	11.1(a)
	 Recipient
	  	10.11(b)
	 Review Period
	  	11.4(a)
	 Royalty Term
	  	10.5(b)
	 Rules
	  	16.3(a)
	 Safety Agreement
	  	7.3(a)
	 Sales Model
	  	10.7(b)
	 SEC
	  	11.6(c)
	 Seller
	  	1.58
	 Sole Inventions
	  	14.1(a)
	 Sponsor
	  	3.5
	 Term
	  	15.1
	 Terminated Brii Bio Program Products
	  	15.5(a)(ii)
	 Terminated Vir Program Products
	  	15.5(a)(i)
	 Third Party Brii Bio Program IP
	  	5.6
	 Third Party Vir Program IP
	  	5.5(a)
	 Transferring Party
	  	8.3(b)
	 U.S. Development Plan
	  	6.2(b)
	 VAT
	  	1.86
	 Vir Commercial Quality Agreement
	  	8.2(a)
	 Vir Commercial Supply Agreement
	  	8.2(a)
	 Vir Global Plan
	  	6.3(a)
	 Vir Indemnitees
	  	13.1
	 Vir Option
	  	4.1(b)
	 Vir Program Development Costs
	  	15.5(a)(i)
	 Vir Program Termination Notice
	  	4.5
	 Vir Publication
	  	11.4(b)
	 Vir Technology Transfer
	  	5.10(a)
	 Vir Pre-Option Inventions
	  	3.11(a)

  
 16 

 EXECUTION VERSION 

 
 ARTICLE 2 

COLLABORATION OVERVIEW; GOVERNANCE 

2.1 Collaboration Overview. In accordance with the terms and conditions of this Agreement, the Parties shall undertake a
collaboration under this Agreement consisting, in general, of the following major components: 
 (a)
Pre-Option Research and Development Activities. During the Pre-Option Development Period, the Parties will mutually agree upon certain Programs for which they
desire to collaborate to conduct certain discovery, research, preclinical development, and clinical development activities in the China Territory (in the case of Vir Programs) or the United States (in the case of Brii Bio Programs), as further set
forth in Article 3. 
 (b) Option and License. On a Collaboration Program-by-Collaboration Program basis, each Controlling Party will grant the other Party (the “Option Party”) an exclusive option, exercisable by Brii Bio with respect to up to four
(4) Collaboration Programs of Vir during the Brii Bio Option Term and exercisable by Vir only after each exercise by Brii Bio of a Brii Bio Option for up to four (4) Collaboration Programs of Brii Bio during the Vir Option Term, as
applicable, at times specified in and in accordance with Article 4, to be granted the exclusive right to develop and commercialize compounds and products arising from such Collaboration Program. The rights and obligations of the Parties with
respect to the foregoing, and the licenses granted to the Option Party thereafter, are set forth in Article 4 and Article 5. 

(c) Post-Option Development and Commercialization Activities. After an Option Party has exercised an option with respect to a
Collaboration Program, the Parties shall collaborate under mutually agreed development plans with respect to additional clinical development activities directed to obtaining regulatory approval for licensed products within such Collaboration
Program, The rights and obligations of the Parties with respect to the foregoing are set forth in Article 6 and Article 7. Each Party’s rights and obligations with respect to commercialization of Licensed Products are set forth in
Article 9. 
 (d) Manufacturing and Supply. Each Controlling Party shall be responsible for the supply to the Option
Party of all compounds and Products necessary for the conduct of Pre-Option Development, if any, and Licensed Products for Development. Upon the request of the Option Party, the Parties shall negotiate a
commercial supply agreement following exercise of the option. The rights and obligations of the Parties with respect to the foregoing are set forth in Article 8. 

2.2 Alliance Managers. Within fifteen (15) days following the Effective Date, each Party shall appoint a senior
representative having a general understanding of drug manufacturing, Development, and Commercialization issues to act as such Party’s alliance manager under this Agreement (“Alliance Manager”). The Alliance Managers will
be primarily responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration within and among the JSC and the JDC, and between the Parties. Each Party may replace its Alliance Manager on
written notice to the other Party. 

  
 17 

 EXECUTION VERSION 

 
 2.3 Joint Steering Committee. 

(a) Formation. The Parties shall establish a joint steering committee (the “JSC”) to monitor and
coordinate the Development, Manufacture, and Commercialization of Licensed Products. The JSC will be composed of [***] senior executives of each Party, and will be co-chaired by one senior executive from each
Party. 
 (b) Role. The JSC will perform the following functions: 

(i) [***]; 
 (ii)
[***]; 
 (iii) [***]; 

(iv) [***]; 
 (v)
[***]; 
 (vi) [***]; 

(vii) [***]; 

(viii) [***]; 

(ix) [***]; 
 (x)
[***]; 
 (xi) establish and oversee the JDC and additional subcommittees as deemed necessary or advisable to further the purpose of
this Agreement (which may include joint committees for Manufacturing or Commercialization activities), and delegate responsibilities to such subcommittees; 

(xii) resolve any disputes arising at the JDC or additional subcommittees; and 

(xiii) perform such other functions as expressly agreed to by the Parties in writing. 

The JSC shall only have the powers expressly assigned to it in this Section 2.3 and shall not have the authority to (A) modify
or amend the terms and conditions of this Agreement, (B) waive either Party’s compliance with the terms and conditions of this Agreement, or (C) determine any issue in a manner that would conflict with the express terms and conditions
of this Agreement. 
 (c) Meetings. The JSC shall hold meetings at such times as it elects to do so, but shall meet no less
frequently than four (4) times per Calendar Year. The JSC may meet in person or by means of teleconference, Internet conference, videoconference, or other similar communication method wherein all members can hear the other members and be heard
by the 

  
 18 

 EXECUTION VERSION 

 
 other members; provided that at least once each Calendar Year, such meetings will
be conducted in person at a location selected alternately by Vir and then Brii Bio. Each Party shall bear its own expenses related to participation in and attendance at such meetings by its respective JSC representatives. The Alliance Managers will
agree on an agenda for each JSC meeting no later than [***] before each JSC meeting. The Alliance Managers will jointly prepare and circulate minutes for each JSC meeting within [***] of each such meeting and will ensure that such minutes are
reviewed and approved by their respective companies within [***] days thereafter. Each Party may invite a reasonable number of participants, in addition to its representatives, to attend a meeting of the JSC (in a
non-voting capacity) if the planned agenda for such meeting would require such participants’ expertise; provided that if either Party intends to have any Third Party (including any consultant)
attend such a meeting, such Party shall provide prior written notice to the other Party and shall ensure that such Third Party is bound by confidentiality and non-use obligations consistent with this
Agreement. 
 (d) Decision-Making. All decisions of the JSC shall be made by unanimous vote, with each Party’s
representatives having one vote. If after reasonable discussion and good faith consideration of each Party’s view on a particular matter before the JSC, the JSC cannot reach a decision as to such matter within [***] after such matter was
brought to the JSC for resolution, such matter shall be referred to the [***] for resolution. If the [***] cannot resolve such matter within [***] after such matter has been referred to them, then: 

(i) Brii Bio shall have final decision-making authority with respect to [***]; provided that (A) Brii Bio’s decision
is [***]. If Vir reasonably believes that any decision made by Brii Bio pursuant to this Section 2.3(d)(i) is inconsistent with clause (A), (B) or (C) of this Section 2.3(d)(i), then Vir shall
so notify Brii Bio, and [***], and (y) [***] The Parties shall [***], with the [***] by the Parties. Except in cases of [***] on the Parties; 

(ii) Except as provided in subsection (iii) below, Brii Bio shall have the final decision-making authority with respect to [***];
provided that Brii Bio shall not make any decision that would [***] without Vir’s prior written consent. 
 (iii) Vir
shall have final decision-making authority with respect to any [***]; provided that [***]. If Brii Bio reasonably believes that any decision made by Vir pursuant to this Section 2.3(d)(iii) is inconsistent with
clause (1), (2) or (3) of this Section 2.3(d)(iii), then Brii Bio shall so notify Vir, and [***], and [(***]. The Parties shall [***] by the Parties. Except in [***] on the Parties; and 

(iv) Vir shall have the final decision-making authority with respect to [***]; provided that Vir shall not make any decision
that would [***] without Brii Bio’s prior written consent. 
 2.4 Joint Development Committee. 

(a) Formation. Promptly following the Option Exercise Date for each Collaboration Program, the Parties shall establish a joint
development committee (the “JDC”) to monitor and coordinate the Development of Licensed Products arising from such Collaboration Program in the applicable Territory. The JDC will be composed of an equal number of

  
 19 

 EXECUTION VERSION 

 
 representatives of both Parties, as mutually agreed by the Parties. The JDC shall have
an annually rotating chairperson selected alternately by the Party granting the license for such Collaboration Program and then the party receiving the license for such Collaboration Program. The first chair of each JDC shall be the licensor with
respect to such Collaboration Program. The role of the chairperson is to convene and preside at the meetings of the JDC and to prepare meeting minutes, but the chairperson has no additional powers or rights beyond those held by other JDC
representatives. 
 (b) Role. The JDC will [***]; and (vi) perform such other functions as expressly agreed to by the
Parties in writing. The JDC shall only have the powers expressly assigned to it in this Section 2.4 and shall not have the authority to (A) modify or amend the terms and conditions of this Agreement, (B) waive
either Party’s compliance with the terms and conditions of this Agreement, or (C) determine any issue in a manner that would conflict with the express terms and conditions of this Agreement. 

(c) Meetings. The JDC shall hold meetings at such times as it elects to do so, but shall meet no less frequently than four
(4) times per Calendar Year. The JDC may meet in person or by means of teleconference, Internet conference, videoconference, or other similar communication method wherein all members can hear the other members and be heard by the other members;
provided that at least once each Calendar Year, such meetings will be conducted in person at a location selected alternately by Vir and then Brii Bio. Each Party shall bear its own expenses related to participation in and attendance at such
meetings by its respective JDC representatives. The chairperson of the JDC will prepare and circulate minutes for each JDC meeting within [***] days after each meeting and shall ensure that such minutes are reviewed and approved by their respective
companies within [***] days thereafter. Each Party may invite a reasonable number of participants, in addition to its representatives, to attend a meeting of the JDC (in a non-voting capacity) if the planned
agenda for such meeting would require such participants’ expertise; provided that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide prior written notice to the
other Party and shall ensure that such Third Party is bound by confidentiality and non-use obligations consistent with the terms of this Agreement. 

(d) Decision-Making. All decisions of the JDC shall be made by unanimous vote, with each Party’s representatives having one
vote. If after reasonable discussion and good faith consideration of each Party’s view on a particular matter before the JDC, the JDC cannot reach a decision as to such matter within [***] after such matter was brought to the JDC for
resolution, such matter shall be referred to the JSC and resolved pursuant to Section 2.3(d). 

  
 20 

 EXECUTION VERSION 

 
 ARTICLE 3 

PRE-OPTION RESEARCH AND DEVELOPMENT ACTIVITIES 

3.1 Conduct of Research and Development Activities. 

(a) Inclusion of Programs within the Collaboration. 

(i) Within [***] following the Effective Date, each Party shall provide the other Party with a list of Programs Controlled by such
Party, if any, that such Party desires to include within the collaboration and/or believes are suitable for the conduct of Pre-Option Development Activities in the China Territory (in the case of Programs
proposed by Vir), or the United States (in the case of Programs proposed by Brii Bio), and consideration by such other Party for exercise of a Brii Bio Option or Vir Option, as applicable (such list of Programs, the “Potential Program
List”). A Party placing a Program on the Potential Program List and with the right to grant the Option for such Program (and that subsequently grants rights to the other Party under such Program) is the “Controlling
Party” for such Program. The Parties acknowledge and agree that as of the Effective Date, (A) the Included Vir Programs will be included on the Potential Program List, and (B) Brii Bio does not Control any Programs that are
suitable for inclusion on the Potential Program List. At each meeting of the JSC, each Party shall update the Potential Program List with any additional Programs that are Controlled by such Party and that such Party considers are suitable candidates
for inclusion on the Potential Program List. 
 (ii) At each meeting of the JSC, the Parties shall discuss in good faith the Programs
then included on the Potential Program List, and decide whether and when to commence Pre-Option Development Activities in the China Territory or the United States for such Programs, as applicable. If the
Parties elect to proceed with Pre-Option Development Activities for a Program on the Potential Program List, such Program will be deemed a Collaboration Program, and will be removed from the Potential Program
List. For clarity, [***]. Furthermore, except as set forth in Section 3.12, (A) with respect to any Vir Program, Vir shall not grant rights to any Third Party during the Brii Bio Option Period to Develop or Commercialize
compounds or products arising from such Program in the China Territory, and (B) with respect to any Brii Bio Program, Brii Bio shall not grant rights to any Third Party to Develop or Commercialize compounds or products arising from such Program
in the United States during the period commencing on the [***]. The Parties agree that as of the Effective Date, only the Vir-Alnylam Program has reached a stage of Development suitable for negotiation of a Pre-Option Development Plan and commencement of Pre-Option Development Activities. Vir shall be solely responsible for the conduct of all
pre-clinical development activities globally for any Vir Program, and Brii Bio shall be solely responsible for the conduct of all pre-clinical development activities
globally for any Brii Bio Program. 
 (iii) With the exception of the Included Vir Programs, prior to the inclusion of a Vir Program
or a Brii Bio Program, as applicable, on the Potential Program List, or the commencement by a Controlling Party of Pre-Option Development Activities for a Program, whichever is earlier, the Controlling Party
shall have no obligation to include such Program as a Collaboration Program under this Agreement, and the Controlling Party shall be free to grant rights to any Third Party to Develop and Commercialize compounds and products arising from such
Program in the United States (in the case of a Brii Bio Program) or the China Territory (in the case of a Vir Program). Once a Program is placed on the Potential Program List, or a Controlling Party elects to commence
Pre-Option Development Activities, Section 3.1(a)(ii) will apply. 

(b) Vir Programs. During the Pre-Option Development Period, Vir shall be solely
responsible for the conduct of Pre-Option Development Activities in connection with each Vir Program. Upon election by Vir and written agreement by Brii Bio pursuant to this
Section 3.1(b), Vir may designate Brii Bio to conduct certain Pre-Option Development Activities 

  
 21 

 EXECUTION VERSION 

 
 on Vir’s behalf in the China Territory pursuant to an agreed Pre-Option Development Plan (as further described in Section 3.2). If Vir desires to conduct any Pre-Option Development Activities for a Vir Program
in the China Territory, Vir shall prepare a Pre-Option Development Plan for such Vir Program, which shall include any activities that are to be performed by Brii Bio, and shall provide such Pre-Option Development Plan to the JSC for review and comment. Vir shall consider in good faith comments made by Brii Bio in preparing such Pre-Option Development Plan. The
Parties shall [***], which shall include agreeing upon the [***] for such Vir Program. Upon agreement by the Parties of a Pre-Option Development Plan for such Vir Program, Brii Bio shall conduct the Pre-Option Development Activities set forth in such Pre-Option Development Plan in accordance therewith, including the budget for the
Pre-Option Development Plan. If the Parties are unable to agree on a Pre-Option Development Plan for such Vir Program in the China Territory after such good faith
negotiations or Brii Bio declines or ceases to conduct Pre-Option Development Activities for a Vir Program, then, notwithstanding Section 3.12, Vir may, directly or indirectly,
conduct activities in connection with such Vir Program in the China Territory. If Vir elects to conduct activities with respect to such Vir Program in the China Territory without participation from Brii Bio (including if Vir engages Third Parties as
subcontractors), then (i) Vir may conduct such activities at its sole cost and expense, (ii) Vir shall provide Brii Bio with an Option Data Package upon achievement of Proof of Concept with respect to such Vir Program pursuant to
Section 4.2(a), (iii) Brii Bio may exercise a Brii Bio Option with respect to such Vir Program pursuant to Section 4.3(a), and (iv) [***]. 

(c) Brii Bio Programs. During the Pre-Option Development Period, Brii Bio shall be
solely responsible for the conduct of Pre-Option Development Activities in connection with each Brii Bio Program. Upon election by Brii Bio and written agreement by Vir pursuant to this
Section 3.1(c), Brii Bio may designate Vir to conduct certain Pre-Option Development Activities on Brii Bio’s behalf in the United States pursuant to an agreed Pre-Option Development Plan (as further described in Section 3.2). If Brii Bio desires to conduct any Pre-Option Development Activities for a Brii
Bio Program in the United States, Brii Bio shall prepare a Pre-Option Development Plan for such Brii Bio Program, which shall include any activities that are to be performed by Vir, and shall provide such Pre-Option Development Plan to the JSC for review and comment. Brii Bio shall consider in good faith comments made by Vir in preparing such Pre-Option Development Plan. The
Parties shall [***], which shall include agreeing upon the [***] for such Brii Bio Program. Upon agreement by the Parties of a Pre-Option Development Plan for such Brii Bio Program, Vir shall conduct the Pre-Option Development Activities set forth in such Pre-Option Development Plan in accordance therewith, including the budget for the
Pre-Option Development Plan. If the Parties are unable to agree on a Pre-Option Development Plan for such Brii Bio Program in the United States after such good faith
negotiations or Vir declines or ceases to conduct Pre-Option Development Activities for a Brii Bio Program, then, notwithstanding Section 3.12, Brii Bio may, directly or indirectly,
conduct activities in connection with such Brii Bio Program in the United States. If Brii Bio elects to conduct activities with respect to such Brii Bio Program in the United States (including if Brii Bio engages Third Parties as subcontractors),
then (i) Brii Bio may conduct such activities at its sole cost and expense, (ii) Brii Bio shall provide Vir with an Option Data Package upon achievement of Proof of Concept with respect to such Brii Bio Program pursuant to
Section 4.2(b), (iii) Vir may exercise a Vir Option with respect to such Brii Bio Program pursuant to Section 4.3(b), and (iv) [***]. 

  
 22 

 EXECUTION VERSION 

 
 (d) Timing of Vir Option Exercise. For clarity, Vir may
commence conducting Pre-Option Development Activities allocated to it under an agreed Pre-Option Development Plan for Brii Bio Programs at any point after the Effective
Date, but Vir may nevertheless not exercise each Vir Option unless and until Brii Bio has exercised its corresponding Brii Bio Option (e.g., Vir may not exercise its first Vir Option until after Brii Bio exercises its first Brii Bio Option, and Vir
may not exercise its second Vir Option until after Brii Bio has exercised its second Brii Bio Option). 
 3.2 Pre-Option Development Plans. Each Pre-Option Development Plan negotiated by the Parties under Section 3.1(b) or
Section 3.1(c), as applicable, will identify, for each Pre-Option Development Activity, which Party is responsible for conducting such
Pre-Option Development Activity. Each Party may update a Pre-Option Development Plan, including the applicable Pre-Option
Development Budget, by providing an updated Pre-Option Development Plan to the other Party; [***]. The number of FTEs of a Party to be allocated to the conduct of
Pre-Option Development Activities shall be mutually agreed by the Parties prior to commencement of such Pre-Option Development Activities and set forth in the applicable
Pre-Option Development Plan. 
 3.3 Pre-Option
Development Program License. 
 (a) License Grant to Brii Bio. Subject to the terms and conditions of this Agreement, Vir
hereby grants to Brii Bio during the Pre-Option Development Period a non-exclusive, worldwide, royalty-free license, without the
right to sublicense (but with the right to engage subcontractors in accordance with Section 3.7), under the Vir Technology solely to the extent necessary to perform or have performed (in accordance with
Section 3.7) the Pre-Option Development Activities allocated to Brii Bio under a Pre-Option Development Plan in accordance with such Pre-Option Development Plan. Vir hereby grants to Brii Bio a right of reference to all Regulatory Submissions pertaining to compounds and Products of a Vir Program that is the subject of a Pre-Option Development Plan. Brii Bio may use such right of reference to Vir’s Regulatory Submissions solely to perform or have performed (in accordance with Section 3.7) the Pre-Option Development Activities allocated to Brii Bio under a Pre-Option Development Plan in accordance with such Pre-Option
Development Plan. 
 (b) License Grant to Vir. Subject to the terms and conditions of this Agreement, Brii Bio hereby grants to
Vir during the Pre-Option Development Period a non-exclusive, worldwide, royalty-free license, without the right to sublicense
(but with the right to engage subcontractors in accordance with Section 3.7), under the Brii Bio Technology solely to the extent necessary to perform or have performed (in accordance with
Section 3.7) the Pre-Option Development Activities allocated to Vir under a Pre-Option Development Plan in accordance with such Pre-Option Development Plan. Brii Bio hereby grants to Vir a right of reference to all Regulatory Submissions pertaining to compounds and Products of a Brii Bio Program that is the subject of a Pre-Option Development Plan. Vir may use such right of reference to Brii Bio’s Regulatory Submissions solely to perform or have performed (in accordance with Section 3.7) the Pre-Option Development Activities allocated to Vir under a Pre-Option Development Plan in accordance with such Pre-Option Development
Plan. 

  
 23 

 EXECUTION VERSION 

 
 3.4 Performance Standard. Each Party shall perform the Pre-Option Development Activities for which it is responsible in accordance with [***] the terms and conditions of this Agreement. In addition, each Party shall (a) perform all such Pre-Option Development Activities in good scientific manner and in compliance with all Applicable Laws; (b) [***]; (c) prepare and maintain, or shall cause to be prepared and maintained, complete and accurate
written records, accounts, notes and reports in good scientific manner and in sufficient detail for patent and regulatory purposes, which shall fully and properly reflect all work done, results achieved, Information generated, and Inventions made in
whole or in part, by such Party; and (d) upon the reasonable request of the other Party, make such records available to the other Party for inspection or copying. 

3.5 Clinical Trials. Vir shall be the sponsor for any Clinical Trials conducted by Brii Bio under a Pre-Option Development Plan for a Vir Program, and Brii Bio shall be the Sponsor for any Clinical Trials conducted by Vir under a Pre-Option Development Plan for a Brii Bio
Program (such sponsoring Party, the “Sponsor”). The Sponsor shall select Clinical Trial sites and clinical trial investigators, and enter into clinical trial agreements in connection therewith. The Sponsor for a Clinical
Trial shall lead with all interactions with Regulatory Authorities in the applicable Territory and for other regulatory matters related to such Clinical Trial in such Territory as permitted by Applicable Law. The Sponsor shall prepare all Regulatory
Submissions for each Clinical Trial. The Sponsor shall provide the other Party all material Regulatory Submissions reasonably prior to submission thereof and such other Party may review and comment upon such Regulatory Submissions. The Sponsor shall
[***]. The Sponsor shall obtain and maintain (including all routine maintenance) all investigational study applications (including INDs) for the applicable Clinical Trial, and all such INDs, shall be in the name of the Sponsor (or its Affiliate).
The other Party will [***]. 
 3.6 Materials Transfer. In furtherance of any Pre-Option
Development Activities to be conducted by a Party pursuant to a Pre-Option Development Plan, each Party may provide to the other Party chemical compounds or biological materials Controlled by the supplying
Party (collectively, the “Materials”) for use by the other Party in conducting such Pre-Option Development Activities. Except as otherwise expressly provided under this Agreement, all
such Materials delivered to the other Party remain the sole property of the supplying Party. The receiving Party shall use the Materials only in accordance with the Pre-Option Development Plan and the terms
and conditions of this Agreement, shall not use the Materials for the benefit of or deliver the Materials to any Third Party without the prior written consent of the supplying Party, and shall use the Materials in compliance with all Applicable
Laws. The Materials supplied under this Agreement must be used with prudence and appropriate caution in any experimental work because not all of their characteristics may be known. Except as expressly set forth in this Agreement, THE MATERIALS ARE
PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR
VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. 

  
 24 

 EXECUTION VERSION 

 
 3.7 Use of Affiliates and Contractors. 

(a) Affiliates. Each Party may perform any Pre-Option Development Activity allocated to
it under a Pre-Option Development Plan with respect to the other Party’s Program through an Affiliate of such Party; provided, in each case, that (i) such Affiliate is bound by written
agreement to comply with all applicable terms and conditions of this Agreement to the same extent as such Party; (ii) such Party remains fully responsible for the performance of such obligations by such Affiliate and for the compliance of such
Affiliate with the terms and conditions of this Agreement; and (iii) any failure of such Affiliate to comply with the terms and conditions of this Agreement shall be deemed a breach of this Agreement by such Party. For clarity, each Party may
freely perform any Pre-Option Development Activities with respect to its own Program by an Affiliate of such Party. 

(b) Subcontractors. A Party may contract any Pre-Option Development Activity allocated to
it under a Pre-Option Development Plan with respect to the other Party’s Program [***]; provided, in each case, that [***]; and (iv) such Party is responsible for the performance of such
obligations by such subcontractor, for the compliance of such subcontractor with the terms and conditions of this Agreement, and for payment of such subcontractor. For clarity, a subcontractor is not a sublicensee, but may be granted rights by a
Party as are necessary for such subcontract to conduct work on behalf of such Party. 
 3.8 Reports. Throughout the Pre-Option Development Period and in accordance with the requirements of a Pre-Option Development Plan, each Party shall regularly inform the other Party (no less than on a
quarterly basis) through the JSC of (a) the progress and results of Pre-Option Development Activities conducted by or on behalf of such Party pursuant to such
Pre-Option Development Plan and [***]. Each Party shall maintain such reports and the information contained therein in confidence in accordance with Article 11 hereof and shall not use such records or
information except to the extent permitted by this Agreement. 
 3.9 Pre-Option Development
Costs and Expenses. 
 (a) Brii Bio Costs and Expenses. Brii Bio shall be solely responsible for all costs and expenses
related to the conduct of each Brii Bio Program, excluding the internal FTE costs incurred by Vir in the performance of Pre-Option Development Activities, in each case in the United States for a Brii Bio
Program pursuant to a Pre-Option Development Plan. Vir shall [***] for or on behalf of Brii Bio in accordance with the applicable Pre-Option Development Plan and shall
[***]. Brii Bio shall reimburse Vir for [***]. 
 (b) Vir Costs and Expenses. Vir shall be solely responsible for all costs and
expenses related to the conduct of each Vir Program, excluding the internal FTE costs incurred by Brii Bio in the performance of Pre-Option Development Activities, in each case in the China Territory for a Vir
Program pursuant to a Pre-Option Development Plan. Brii Bio shall [***] for or on behalf of Vir in accordance with the applicable Pre-Option Development Plan and shall
[***]. Vir shall reimburse Brii Bio for [***]. 
 3.10 Cessation of Pre-Option
Development. Notwithstanding the remainder of this Article 3, (a) [***], and (b) [***]. Either Party may, when it is the Controlling Party, [***] prior to the exercise of the Option for such Program upon written notice to the other Party.
If such [***], then such Controlling Party shall notify the other Party in writing, indicating [***] 

  
 25 

 EXECUTION VERSION 

 
 Pre-Option Development Activities. Without limiting the foregoing, if a
Controlling Party provides such [***] in accordance with this Section 3.10, and such notice includes the China Territory in the case of a Vir Program, or the United States in the case of a Brii Bio Program, then the other
Party may notify the Controlling Party in writing that it desires to assume responsibility for such Pre-Option Development Activities in the China Territory (where such Party is Brii Bio), or the United States
(where such Party is Vir). Such Party may assume responsibility for Pre-Option Development Activities in the China Territory (in the case of Brii Bio), or the United States (in the case of Vir) by delivering
an Early Option Trigger Notice for such Program, and the provisions of Section 4.3(d) shall apply with respect to the delivery of the Interim Option Data Set and exercise of the Option, provided that if such Party elects to
exercise the Option for such Program on the basis of the Interim Option Data Set in the circumstances set forth in this Section 3.10, and pays the applicable Option exercise fee under Section 10.2,
(i) such Program will become a Licensed Program, (ii) such Party will assume all responsibility for the remainder of the Pre-Option Development Activities and any subsequent Development and
Commercialization activities for such Licensed Program, and (iii) [***] after the early exercise of such Option in conducting Pre-Option Development Activities relating to the China Territory with respect to a
Vir Program and relating to the United States Territory with respect to a Brii Bio Program up to the point of Proof of Concept for such Licensed Program. Notwithstanding the foregoing, if such Party elects not to exercise its [***] from the
Controlling Party, then (A) such Option will terminate, and (B) the Controlling Party shall have no further obligation to progress Pre-Option Development Activities for such Program, provided that if
such Controlling Party subsequently elects to recommence development activities for such Program in the China Territory (in the case of a Vir Program) or the United States (in the case of a Brii Bio Program) (i.e. that would have been Pre-Option Development Activities if conducted under this Agreement), then at the other Party’s election, such Program will again be a Collaboration Program, and if such Party has remaining Option rights under
this Agreement, such Party shall have the right to exercise an Option for such Collaboration Program. 
 3.11 Ownership of Data and
Intellectual Property. 
 (a) Vir Ownership of Vir Program Data and IP. Notwithstanding anything to the contrary, Vir shall
solely own all right, title, and interest in and to all Inventions generated by or on behalf of either Party in the conduct of any Pre-Option Development Activities for a Vir Program (“Vir Pre-Option Inventions”). Brii Bio shall and hereby does assign to Vir all of Brii Bio’s right, title, and interest in and to all Vir Pre-Option Inventions.
Brii Bio shall take (and cause its employees, agents, contractors and sublicensees to take) such further actions reasonably requested by Vir to evidence such assignment and to obtain patent and other intellectual property rights protection for such
Vir Pre-Option Inventions. Brii Bio shall obligate its Affiliates, sublicensees, and contractors to assign all Vir Pre-Option Inventions to Brii Bio so that Brii Bio can
comply with its obligations under this Section 3.11(a). 
 (b) Brii Bio Ownership of Brii Bio Program
Data and IP. Notwithstanding anything to the contrary, Brii Bio shall solely own all right, title, and interest in and to all Inventions generated by or on behalf of either Party in the conduct of any
Pre-Option Development Activities for a Brii Bio Program (“Brii Bio Pre-Option Inventions”). Vir shall and hereby does assign to Brii Bio all of
Vir’s right, title, and interest in and to all Brii Bio Pre-Option Inventions. Vir shall take (and cause its employees, agents, contractors and sublicensees

  
 26 

 EXECUTION VERSION 

 
 to take) such further actions reasonably requested by Brii Bio to evidence such
assignment and to obtain patent and other intellectual property rights protection for such Brii Bio Pre-Option Inventions. Vir shall obligate its Affiliates, sublicensees, and contractors to assign all Brii
Bio Pre-Option Inventions to Vir so that Vir can comply with its obligations under this Section 3.11(b). 

3.12 Pre-Option Exclusivity. 

(a) Vir Programs. On a Vir Program-by-Vir Program
basis, during the Pre-Option Development Period for each Vir Program, and until Brii Bio delivers an Option Exercise Notice for the fourth Vir Program hereunder, Vir shall not, and shall ensure that its
Affiliates do not, engage any Third Party to conduct any research or development with respect to such Vir Program in the China Territory without Brii Bio’s prior written consent. Notwithstanding the foregoing, if Brii Bio declines or ceases to
conduct Pre-Option Development Activities for such Vir Program in the China Territory pursuant to a Pre-Option Development Plan, then (i) Vir may conduct such Vir
Program in the China Territory by itself or through its Affiliates (including the right to subcontract to Third Parties to conduct activities on behalf of Vir or its Affiliates), (ii) Vir shall not have any obligation to report to the JSC in
connection with such Vir Program during the Pre-Option Development Period, and (iii) upon achievement of Proof of Concept for such Vir Program, the provisions of Article 4 shall apply to such Vir
Program as if Brii Bio had conducted such Pre-Option Development Activities, [***] the Option Data Package for such Vir Program. 

(b) Brii Bio Programs. On a Brii Bio
Program-by-Brii Bio Program basis, during the Pre-Option Development Period for each Brii Bio Program, and until Vir delivers an
Option Exercise Notice for the fourth Brii Bio Program hereunder, Brii Bio and Parent shall not, and shall ensure that its and their Affiliates do not, engage any Third Party to conduct any research or development with respect to such Brii Bio
Program in the United States without Vir’s prior written consent. Notwithstanding the foregoing, if Vir declines or ceases to conduct Pre-Option Development Activities for such Brii Bio Program in the
United States pursuant to a Pre-Option Development Plan, then (i) Brii Bio or Parent may conduct such Brii Bio Program in the United States by itself or through its Affiliates (including the right to
subcontract to Third Parties to conduct activities on behalf of Brii Bio or its Affiliates), (ii) Brii Bio and Parent shall not have any obligation to report to the JSC in connection with such Brii Bio Program during the Pre-Option Development Period, (iii) upon achievement of Proof of Concept for such Brii Bio Program, the provisions of Article 4 shall apply to such Brii Bio Program as if Vir had conducted such Pre-Option Development Activities, [***] the Option Data Package for such Brii Bio Program. 
 (c)
Change of Control. Notwithstanding Section 3.12(a) and Section 3.12(b), if a Third Party becomes an Acquisition Affiliate of a Party, and, as of the closing date of such Change of Control
transaction such Acquisition Affiliate is engaged in a program that, but for this Section 3.12(c), would cause a Party to be breach of its exclusivity obligations under Section 3.12(a) or
Section 3.12(b), as applicable, then [***] shall not constitute a breach of such Party’s exclusivity obligations set forth in Section 3.12(a) or Section 3.12(b), as
applicable; provided that [***]. For the avoidance of doubt, this Section 3.12(c) does not apply if [***] a Change of Control of such Party. 

  
 27 

 EXECUTION VERSION 

 
 ARTICLE 4 

OPTION GRANT AND EXERCISE 

4.1 Option Grants. 

(a) Option Grants to Brii Bio. Promptly upon Brii Bio’s formation, Vir shall grant, and hereby grants to Brii Bio, an
exclusive option, exercisable at Brii Bio’s sole discretion during each applicable Brii Bio Option Period, to obtain an exclusive license from Vir for a Vir Program as set forth in Section 5.1 (the “Brii
Bio Option”). Brii Bio may exercise the Brii Bio Option for up to four (4) Vir Programs. For clarity, if a Vir Program achieves Proof of Concept, but Brii Bio elects not to exercise a Brii Bio Option for such
Vir Program during the Brii Bio Option Period for such Vir Program, then upon the expiration of the applicable Brii Bio Option Period, such Vir Program shall no longer be included within this Agreement, and Vir may proceed to grant rights to develop
and commercialize products arising from such Vir Program to Third Parties without further obligations to Brii Bio. For clarity, Vir shall not, and has no obligation to, grant to Parent any Brii Bio Option or other intellectual property rights. 

(b) Option Grant to Vir. Brii Bio hereby grants to Vir an exclusive option, exercisable at Vir’s sole discretion during each
applicable Vir Option Period, to obtain an exclusive license from Brii Bio for a Brii Bio Program as set forth in Section 5.2 (the “Vir Option”). Vir may exercise one
(1) Vir Option for each Brii Bio Option exercised by Brii Bio, such that Vir may exercise a Vir Option for up to a total of four (4) Brii Bio Programs. For clarity, if a Brii Bio Program achieves Proof of Concept, but Vir elects not to
exercise a Vir Option for such Brii Bio Program during the Vir Option Period for such Brii Bio Program, then upon the expiration of the applicable Vir Option Period, such Brii Bio Program shall no longer be included within this Agreement, and Brii
Bio may proceed to grant rights to develop and commercialize products arising from such Brii Bio Program to Third Parties without further obligations to Vir. 

4.2 Option Data Package. 

(a) Vir Program Option Data Package. Within [***] days after achievement of Proof of Concept for a Vir Program, Vir shall provide
an Option Data Package to Brii Bio. Following receipt of the Option Data Package, until the end of the Brii Bio Option Period, Brii Bio [***] thereof; provided that if [***]; provided, further that if Vir, [***]. In addition, if
Vir (or any of its Affiliates) [***] when the Option Data Package was initially delivered to Brii Bio, then Vir shall promptly, but in all cases [***], provide such data, information, reports or correspondence to Brii Bio; provided that,
[***] after the date such information is provided. Concurrent with the delivery of an Option Data Package with respect to a Vir Program, Vir shall provide Brii Bio with [***]. 

(b) Brii Bio Program Option Data Package. Within thirty (30) days after achievement of Proof of Concept for a Brii Bio
Program, Brii Bio shall provide an Option Data Package to Vir. Following receipt of the Option Data Package until the end of the Vir Option Period, Vir [***] thereof; provided that if [***]; provided, further that if Brii Bio,
[***]. In addition, if Brii Bio (or any of its Affiliates) [***] when the Option Data Package was initially delivered to Vir, then Brii Bio shall promptly, but in all cases [***], provide such data, information, reports or correspondence to Vir;
provided that, [***] after the date such information is provided. Concurrent with the delivery of an Option Data Package with respect to a Brii Bio Program, Brii Bio shall provide Vir with [***]. 

  
 28 

 EXECUTION VERSION 

 
 4.3 Option Exercise. 

(a) Brii Bio Option Exercise. During the Brii Bio Option Term, and on a Vir Program-by-Vir Program basis, at any time prior to the expiration of the applicable Brii Bio Option Period, and on up to four (4) occasions, Brii Bio may exercise its Option in its sole discretion by
delivering written notice of such exercise to Vir. Brii Bio shall pay Vir the Option Exercise Fee for such Vir Program set forth in Section 10.2(a) within [***] after delivery of an Option Exercise Notice. [***] and Brii
Bio shall assume all responsibility, at Brii Bio’s sole expense, for the further Development, Manufacture, and Commercialization of all Licensed Products arising from such Vir Program in the China Territory in accordance with this Agreement. If
Brii Bio fails to provide an Option Exercise Notice before the expiration of the applicable Brii Bio Option Period, then such Option will expire and Vir may freely develop and commercialize, or grant to any Third Party rights to develop and
commercialize, products within such Vir Program without further obligation to Brii Bio. Notwithstanding the foregoing, pursuant to the terms of the [***]. 

(b) Vir Option Exercise. During the Vir Option Term, and on a Brii Bio Program-by-Brii Bio Program basis, at any time prior to the expiration of the applicable Vir Option Period, and on up to four (4) occasions, Vir may exercise its Option in its sole discretion by
delivering written notice of such exercise to Brii Bio. Vir shall pay Brii Bio the Option Exercise Fee for such Brii Bio Program set forth in Section 10.2(b) within [***] after delivery of an Option Exercise Notice. [***]
and Vir shall assume all responsibility, at Vir’s sole expense, for the further Development, Manufacture, and Commercialization of all Licensed Products arising from such Brii Bio Program in the United States in accordance with this Agreement.
If Vir fails to provide an Option Exercise Notice before the expiration of the applicable Vir Option Period, then such Option will expire and Brii Bio may freely develop and commercialize, or grant to any Third Party rights to develop and
commercialize, products within such Brii Bio Program without further obligation to Vir. 
 (c) Ongoing Pre-Option Development Activities. If a Party exercises an Option for a Collaboration Program and there are Pre-Option Development Activities then ongoing under the Pre-Option Development Plan for such Collaboration Program, then the Party conducting such Pre-Option Development Activities shall continue to conduct such activities, at its
expense, until completion of all activities that were the responsibility of such Party under the Pre-Option Development Plan. Notwithstanding the foregoing, the Party exercising the Option for such
Collaboration Program may elect, by written notice to the other Party, to assume responsibility for the conduct of such Pre-Option Development Activities. In such case, the Parties shall discuss through the
JSC (or the applicable JDC, once established) and agree upon a transition of such Pre-Option Development Activities to the Party exercising the Option, provided that the Party originally responsible for
such Pre-Option Development Activities shall be responsible for the costs of such Pre-Option Development Activities solely to the extent included in the Pre-Option Development Plan, and not including any costs associated with personnel of the Party exercising the Option that were performing such activities prior to the Option Exercise Date. 

  
 29 

 EXECUTION VERSION 

 
 (d) Early Option Exercise. Either Party may elect to
exercise an Option for a Vir Program or Brii Bio Program, as applicable, during the applicable Option Period prior to delivery of a complete Option Data Package pursuant to Section 4.2, including where the Controlling Party
elects to [***] Pre-Option Development Activities in accordance with Section 3.10 (an “Early Option Exercise”). If a Party believes in good faith that it may
wish to trigger an Early Option Exercise, such Party shall notify the Controlling Party for such Collaboration Program that it wishes to evaluate the exercise of its Option prior to delivery of the Option Data Package (an “Early Option
Trigger Notice”). Within [***] following the date of such Early Option Trigger Notice, the Controlling Party will deliver to the requesting Party [***] (the “Interim Option Data Set”). The requesting Party may
(i) exercise its Option for such Collaboration Program upon delivery of such Interim Option Data Set, by delivering an Option Exercise Notice within [***] following the receipt of the Interim Option Data Set, provided that such Party
[***] prior to exercising such Option, or (ii) elect not to exercise its Option on the basis of the Interim Option Data Set, and to wait to review the full Option Data Package prior to determining whether to exercise its Option for such
Collaboration Program. In the case of an election under the foregoing subclause (ii), such Party shall notify the Controlling Party in writing of its decision within such same [***] period, and following such notice, the Controlling Party shall
continue to conduct the applicable Pre-Option Development Activities towards generating the complete Option Data Package. If a Party elects to exercise its Option in accordance with
Section 4.2 for a Collaboration Program on the basis of the Interim Option Data Set, then [***], (B) the Parties shall complete any ongoing Pre-Option Development Activities in
accordance with Section 4.3(c), and (C) if such Collaboration Program [***], such Option exercise [***], provided that, for clarity, there will be [***]. 

4.4 Option Period Covenants. 

(a) Vir Covenants. During the Brii Bio Option Period for each Vir Program, Vir shall not [***] (i) assign, transfer, convey,
dispose of, or otherwise encumber (including through lien, charge, security interest, mortgage, encumbrance or otherwise) [***] if such assignment, transfer, conveyance, disposal, or other encumbrance would [***] any of the rights, options, or
licenses (including following the exercise of a Brii Bio Option) granted to Brii Bio hereunder, or (ii) license or grant to any Third Party, or [***] if such license or grant would [***] any of the rights, options, or licenses (including
following the exercise of a Brii Bio Option) granted to Brii Bio hereunder. 
 (b) Brii Bio Covenants. During the Vir Option
Period for each Brii Bio Program, Brii Bio shall not [***] (i) assign, transfer, convey, dispose of, or otherwise encumber (including through lien, charge, security interest, mortgage, encumbrance or otherwise) [***] if such assignment, transfer,
conveyance, disposal, or other encumbrance would [***] any of the rights, options, or licenses (including following the exercise of a Vir Option) granted to Vir hereunder, or (ii) license or grant to any Third Party, or [***] if such license or
grant would [***] any of the rights, options, or licenses (including following the exercise of a Vir Option) granted to Vir hereunder. 

  
 30 

 EXECUTION VERSION 

 
 4.5 [***]. On a Licensed Program-by-Licensed Program basis following the exercise of a Vir Option or Brii Bio Option, as applicable, for such Licensed Program, and subject to the term of any agreements between the Controlling Party
and any Third Party that existed as of the date of Option exercise for such Licensed Program: 
 (a) If Vir decides to [***], Vir
shall promptly notify Brii Bio of such decision in writing [***] mutually agreed by the Parties. Brii Bio shall notify Vir [***]. If Brii Bio [***], the Parties shall [***]. If the Parties are unable to [***], then Vir may [***] without further
obligation to Brii Bio. For clarity, nothing herein [***]. 
 (b) If Brii Bio decides to [***], Brii Bio shall promptly notify Vir of
such decision in writing [***] mutually agreed by the Parties. Vir shall notify Brii Bio [***]. If Vir elects to negotiate the terms of such a license or acquisition of rights, the Parties shall [***]. If the Parties are [***], then Brii Bio may
[***] without further obligation to Vir. For clarity, nothing herein [***]. 
 For clarity, the [***] this Section 4.5 shall [***].

 ARTICLE 5 
 LICENSE
GRANTS POST-OPTION EXERCISE 
 5.1 License Grants. 

(a) License Grants to Brii Bio. Subject to the terms and conditions of this Agreement and effective upon Brii Bio’s
payment of the payment of the Option Exercise Fee pursuant to Section 10.2(a), Vir hereby grants to Brii Bio (i) an exclusive (subject to Vir’s retained rights as set forth in
Section 5.3(a)), royalty-bearing license, with the right to grant sublicenses solely in accordance with Section 5.2, under the Vir Technology to Develop, make, have made, distribute, use, sell,
offer for sale, import and otherwise Commercialize Licensed Products for each Licensed Vir Program in the Field in the China Territory, and (ii) a non-exclusive, worldwide license, with the right to grant
sublicenses solely in accordance with Section 5.2, under the Vir Technology to Develop, make, and have made Licensed Products for each Licensed Vir Program for Commercialization in the Field in the China Territory. 

(b) License Grants to Vir. Subject to the terms and conditions of this Agreement and effective upon Vir’s payment of the
payment of the Option Exercise Fee pursuant to Section 10.2(b), each of Parent and Brii Bio hereby grants to Vir (i) an exclusive (subject to Parent and Brii Bio’s retained rights as set forth in
Section 5.3(b)), royalty-bearing license, with the right to grant sublicenses solely in accordance with Section 5.2, under the Brii Bio Technology to Develop, make, have made, distribute, use,
sell, offer for sale, import and otherwise Commercialize Licensed Products for each Licensed Brii Bio Program in the Field in the United States, and (ii) a non-exclusive, worldwide license, with the right
to grant sublicenses solely in accordance with Section 5.2, under the Brii Bio Technology to Develop, make, and have made Licensed Products for each Licensed Brii Bio Program for Commercialization in the Field in the United
States. 

  
 31 

 EXECUTION VERSION 

 
 (c) Limitations on License Grants. 

(i) Brii Bio acknowledges and agrees that any licenses granted to Brii Bio or its Affiliates or Sublicensees with respect to the Vir-Alnylam Program are subject to the terms of the Vir-Alnylam Agreement, including with respect to (A) Vir’s obligation to provide Alnylam with a copy of this
Agreement, redacted except to the extent applicable to the grant of the sublicense to Brii Bio, (B) reporting obligations to Alnylam in connection with Commercialization of applicable Licensed Products, and (C) compliance with the terms of
any upstream license agreements between Alnylam and any Third Party relating to the Vir-Alnylam Program where rights under such agreements are granted to Brii Bio following exercise of the applicable
Option.  
 (ii) Notwithstanding Sections 5.1(a) and 5.1(b), and without limiting the specific terms applicable
to the Vir-Alnylam Program under Section 5.1(c)(i), the Parties acknowledge and agree that on a Vir
Program-by-Vir Program or Brii Bio Program-by-Brii Bio Program basis, as applicable,
(A) any licenses granted by Vir to Brii Bio pursuant to Section 5.1(a) are subject to the terms of any upstream agreements (as such terms are in effect as of the date of the exercise of the Brii Bio Option) between Vir
and any Third Party in connection with the Vir Technology applicable to such Vir Program, and (B) any licenses granted by Brii Bio to Vir pursuant to Section 5.1(b) are subject to the terms of any upstream agreements
(as such terms are in effect as of the date of the exercise of the Vir Option) between Brii Bio and any Third Party in connection with the Brii Bio Technology applicable to such Brii Bio Program. 

5.2 Right to Sublicense. Subject to the terms and conditions of this Agreement, each Party may grant sublicenses of the licenses
granted to it in Section 5.1: (a) to its Affiliates, and (b) to Third Parties with the other Party’s prior written consent, such consent not to be unreasonably withheld, conditioned, or delayed. Each
sublicense shall be subject to a written agreement that is consistent with the terms and conditions of this Agreement, and Brii Bio and Vir shall each ensure that their sublicensees comply with the terms and conditions of this Agreement. Subject to
Section 3.7, each of Vir and Brii Bio may fulfill any of its obligations under this Agreement itself or through its Affiliates and sublicensees, provided however that such Party will remain directly
responsible for all its obligations under this Agreement, regardless of whether any such obligation is delegated, subcontracted, or sublicensed to any of its Affiliates or sublicensees. Each of Vir and Brii Bio shall provide the other Party with
written notice of any sublicense within [***] days after it becomes effective (including the identity of the sublicensee) and shall provide the other Party with a true and complete copy of each sublicense agreement, subject to such first
Party’s right to redact any confidential or proprietary information contained therein that is not necessary for the other Party to determine compliance with this Agreement. 

5.3 Retained Rights. 

(a) Vir Retained Rights. Notwithstanding the exclusive nature of the license granted to Brii Bio in
Section 5.1(a), Vir expressly retains the rights to use the Vir Technology in the Field in the China Territory to (i) perform its obligations under this Agreement, (ii) to conduct research and Development
activities under the Vir Global Plan, and (iii) to Manufacture or have Manufactured Licensed Product, in each case whether directly or through its Affiliates, licensees or contractors. For clarity, Vir retains the exclusive right to practice,
license and otherwise exploit the Vir Technology outside the scope of the license granted to Brii Bio in Section 5.1(a). 

  
 32 

 EXECUTION VERSION 

 
 (b) Brii Bio Retained Rights. Notwithstanding the
exclusive nature of the license granted to Vir in Section 5.1(b), Brii Bio and Parent expressly retain the rights to use the Brii Bio Technology in the Field in the United States to (i) perform its obligations under
this Agreement, (ii) to conduct research and Development activities under the Brii Bio Global Plan, and (iii) to Manufacture or have Manufactured Licensed Product, in each case whether directly or through its Affiliates, licensees or
contractors. For clarity, Brii Bio and Parent each retain the exclusive right to practice, license and otherwise exploit the Brii Bio Technology outside the scope of the license granted to Vir in Section 5.1(b). 

5.4 No Implied Licenses; Negative Covenant. Except as set forth herein, neither Party acquires any license or other intellectual
property interest, by implication or otherwise, under any trademarks, Patents, or patent applications of the other Party. Brii Bio and Parent shall not, and shall not permit any of its or their Affiliates or sublicensees to, practice any Vir
Technology outside the scope of the license granted to Brii Bio in Section 5.1(a). Vir shall not, and shall not permit any of its Affiliates or sublicensees to, practice any Brii Bio Technology outside the scope of the
license granted to Vir in Section 5.1(b). 
 5.5 Third Party IP for Vir Programs. 

(a) Notice. On a Licensed Product-by-Licensed
Product basis, if, during the Term following Brii Bio’s exercise of a Brii Bio Option for the applicable Vir Program, either Party identifies intellectual property rights of a Third Party that such Party considers are [***] the Development,
Manufacture or Commercialization of such Licensed Products in the Field in the China Territory (“Third Party Vir Program IP”), then such Party shall promptly notify the other Party. 

(b) China Territory Rights. [***] shall have the first right [***], but not the obligation, to negotiate with a Third Party to
obtain, and to enter into an agreement with such Third Party granting, a license under such Third Party Vir Program IP solely in the China Territory, [***], and whether [***] desires that [***]. If [***] does not wish to [***], then [***]
shall so notify [***] in writing, and [***] shall have the right, at its discretion, to negotiate and enter into an agreement with the applicable Third Party for the grant of rights in such Third Party Vir Program IP in the China Territory [***].

 (c) Rights Outside the China Territory. If [***] shall have the first right, but not the obligation to negotiate with a
Third Party to obtain, and to enter into an agreement with such Third Party granting a license under such Third Party Vir Program IP, on a worldwide basis, [***] licenses granted to it hereunder. If [***] desires to obtain rights under such
Third Party Vir Program IP, then the Parties shall reasonably cooperate with respect to the negotiation of such license by [***]. [***]. [***]. [***] shall ensure that such license agreement includes the right for [***] with respect to the China
Territory. Notwithstanding the foregoing, [***] may [***]. If [***] of any Third Party Vir Program IP for any given Licensed Program, or for all Licensed Programs, as applicable, then [***] in writing within [***] notice of such Third Party Vir
Program IP and if [***] in such Third Party Vir Program IP in the China Territory, such Third Party Vir Program IP will be [***]. 

  
 33 

 EXECUTION VERSION 

 
 (d) Payment Responsibility. Vir shall be responsible for
any payments to such Third Party that arise from the use of such Third Party Vir Program IP in connection with the Development, Manufacture, and Commercialization of Licensed Products outside the China Territory, and Brii Bio shall be responsible
for any payments to such Third Party that arise from the use of such Third Party Vir Program IP in connection with the Development, Manufacture and Commercialization of Licensed Products within the China Territory, provided that with respect
to [***]. Notwithstanding the foregoing, if [***] elects not to obtain a license under such Third Party Vir Program IP, or if the Parties agree to [***], and [***] negotiates an agreement with the applicable Third Party with respect to the China
Territory pursuant to Section 5.5(b), then Brii Bio shall be responsible for [***] to such Third Party thereunder. 

5.6 Third Party IP for Brii Bio Programs. 

(a) Notice. On a Licensed Product-by-Licensed
Product basis, if, during the Term following Vir’s exercise of a Vir Option for the applicable Brii Bio Program, either Party identifies intellectual property rights of a Third Party that such Party considers are [***] the Development,
Manufacture or Commercialization of such Licensed Products in the Field in the United States (“Third Party Brii Bio Program IP”), then such Party shall promptly notify the other Party. 

(b) United States Rights. [***] shall have the first right, but not the obligation, to negotiate with a Third Party to obtain,
and to enter into an agreement with such Third Party granting, a license under such Third Party Brii Bio Program IP in the United States, [***], and whether [***] desires that [***]. If [***] does not wish to [***], then [***] shall so notify
[***] in writing, and [***] shall have the right, at its discretion, to negotiate and enter into an agreement with the applicable Third Party for the grant of rights in such Third Party Brii Bio Program IP in the United States [***]. 

(c) Rights Outside the United States. If [***] shall have the first right (which may be delegated to Parent), but not the
obligation, to negotiate with such Third Party to obtain, and to enter into an agreement with such Third Party granting, a license under such Third Party Brii Bio Program IP on a worldwide basis, [***] licenses granted to it hereunder. If
[***] desires to obtain rights under such Third Party Brii Bio Program IP, then the Parties shall reasonably cooperate with respect to the negotiation of such license by [***]. ***]. [***]. [***] shall ensure that such license agreement includes the
right for [***] with respect to the United States Territory. Notwithstanding the foregoing, [***] may [***]. If [***] of any Third Party Brii Bio Program IP for any given Licensed Program, or for all Licensed Programs, as applicable, then [***] in
writing within [***] notice of such Third Party Brii Bio Program IP and such Third Party Brii Bio Program IP will be [***]. 
 (d)
Payment Responsibility. Vir shall be responsible for any payments to a Third Party that arise from the use of Third Party Brii Bio Program IP in connection with the Development, Manufacture and Commercialization of Licensed Products in the
United States, and Brii Bio shall be responsible for any payments to a Third Party that arise from the use of 

  
 34 

 EXECUTION VERSION 

 
 Third Party Brii Bio Program IP in connection with the Development, Manufacture and
Commercialization of Licensed Products outside the United States in accordance with Section 5.7, provided that with respect to [***]. Notwithstanding the foregoing, if [***] elects not to obtain a license under such
Third Party Brii Bio Program IP, or if the Parties agree to [***], and [***] negotiates an agreement with the applicable Third Party with respect to the United States pursuant to Section 5.6(b), then Vir shall be
responsible for [***] to such Third Party thereunder. 
 5.7 Reimbursement of Third Party IP. If a Party is required to make
payments to the other Party arising from the use of Third Party Vir Program IP or Third Party Brii Bio Program IP under Section 5.5 or Section 5.6 above (such Party, the “Paying
Party”), the Paying Party shall make such payments as follows: [***], the Paying Party shall pay such amounts [***], and (ii) with respect to any royalty payments accruing from a Party’s Development, Manufacture or
Commercialization of Licensed Products, the Paying Party shall account [***] in accordance with Section 10.5. 

5.8 Non-Compete. 

(a) Vir Obligations. 

(i) Subject to Section 5.9, on a Licensed Brii Bio Program-by-Licensed Brii Bio Program basis, following the Option Exercise Date for a Licensed Brii Bio Program and thereafter during the Term, Vir shall not, and shall ensure that its Affiliates do not,
engage in, independently or for or with any Third Party, any clinical development or commercialization of any product in the United States that is a Competing Product with respect to any Licensed Product being Developed and Commercialized by Vir in
the United States under such Licensed Brii Bio Program. 
 (ii) Subject to Section 5.9, on a Licensed Vir Program-by-Licensed Vir Program basis, at any time during the Term following the exercise of a Brii Bio Option for such Licensed Vir Program, Vir shall not, and shall ensure
that its Affiliates do not, engage in, independently or for or with any Third Party, any clinical development or commercialization of any product in the China Territory that is a Competing Product with respect to any Licensed Product being Developed
and Commercialized by Brii Bio in the China Territory under such Licensed Vir Program. 
 (b) Brii Bio Obligations. 

(i) Subject to Section 5.9, on a Licensed Vir
Program-by-Licensed Vir Program basis, following the Option Exercise Date for a Licensed Vir Program and thereafter during the Term, Brii Bio and Parent shall not, and
shall ensure that its and their Affiliates do not, engage in, independently or for or with any Third Party, any clinical development or commercialization of any product in the China Territory that is a Competing Product with respect to any Licensed
Product being Developed and Commercialized by Brii Bio or Parent in the China Territory under such Licensed Vir Program. 

  
 35 

 EXECUTION VERSION 

 
 (ii) Subject to Section 5.9, on a
Licensed Brii Bio Program-by-Licensed Brii Bio Program basis, at any time during the Term following the exercise of a Vir Option for such Licensed Brii Bio Program, Brii
Bio and Parent shall not, and shall ensure that its and their Affiliates do not, engage in, independently or for or with any Third Party, any clinical development or commercialization of any product in the United States that is a Competing Product
with respect to any Licensed Product being Developed and Commercialized by Vir in the United States under such Licensed Brii Bio Program. 

5.9 Acquisition Products and Programs. 

(a) Change of Control. Notwithstanding the restrictions in Section 5.8(a) and
Section 5.8(b), if a Third Party becomes an Acquisition Affiliate of a Party, and, as of the closing date of such Change of Control transaction such Acquisition Affiliate is engaged in a program directed to the research,
development, manufacture or commercialization of a Competing Product that, if conducted by a Party, would cause such Party to be in breach of its exclusivity obligations set forth in Section 5.8(a) or
Section 5.8(b) (such Third Party program, a “Competing Program”), then Section 5.8(a) or Section 5.8(b), as applicable, shall not apply with
respect to such Competing Program, and such Acquisition Affiliate may continue such Competing Program after such Change of Control and such continuation shall not constitute a breach of such Party’s exclusivity obligations set forth in
Section 5.8(a) or Section 5.8(b), as applicable; provided that such Acquisition Affiliate conducts such Competing Program independently of the activities of this Agreement and does not use
or access any intellectual property or Confidential Information of such Party or the other Party for the conduct of such Competing Program. 

(b) Acquired Program Prior to Proof of Concept. Notwithstanding the restrictions in Section 5.8(a) and
Section 5.8(b), if a Third Party becomes an Affiliate of a Party after the Effective Date but such transaction did not result in a Change of Control of such Party and, as of the closing date of such transaction such Third
Party is engaged in a Competing Program that has not yet achieved Proof of Concept, then (i) to the extent permitted pursuant to the terms of the transaction, and if agreed at the JSC, such Competing Program will on the Potential Program List
under this Agreement, and may become a Collaboration Program in accordance with Section 3.1, or (ii) to the extent the Competing Program is not permitted, pursuant to the terms of the transaction, to be included as a
Collaboration Program under this Agreement, then unless the Parties otherwise agree through the JSC that such Party may continue activities under such Competing Program, such Party and its new Affiliate will be required to complete the Divestiture
of such Competing Program. Such Party and its new Affiliate will have [***] from such decision to wind down or complete the Divestiture of such Competing Program, and such Party’s new Affiliate’s conduct of such Competing Program during
such [***] period will not be deemed a breach of such Party’s exclusivity obligations set forth in Section 5.8(a) or Section 5.8(b), as applicable; provided that such new Affiliate
conducts such Competing Program during such [***] period independently of the activities of this Agreement and does not use or access any intellectual property or Confidential Information of such Party or the other Party for the conduct of such
Competing Program. “Divestiture” means the sale or transfer or exclusive license of rights to the Competing Program to a Third Party without receiving a continuing share of profit, royalty payment, or other economic interest
in the success of such Competing Program. 

  
 36 

 EXECUTION VERSION 

 
 (c) No Change of Control, Competing Program has Achieved Proof
of Concept. Notwithstanding the restrictions in Section 5.8(a) and Section 5.8(b), if a Third Party becomes an Affiliate of a Party after the Effective Date but such transaction did not result
in a Change of Control of such Party and, as of the closing date of such transaction such Third Party is engaged in a Competing Program that has achieved Proof of Concept, then [***]. Notwithstanding the foregoing, (A)the Parties shall [***]. 

5.10 Technology Transfer. 

(a) Transfer to Brii Bio. Except for the Manufacturing Technology Transfer, which is addressed in
Section 8.3, within [***] after the Option Exercise Date for a Licensed Vir Program, Vir shall provide and transfer to Brii Bio the Vir Know-How and the Vir Patents specifically
related to such Licensed Vir Program that exists on the applicable Option Exercise Date and was not previously provided to Brii Bio, and in connection with such transfer, provide Brii Bio with reasonable access to Vir personnel involved in the
Development of Licensed Products for such Licensed Vir Program, either in-person at Vir’s facility or by teleconference. Such assistance shall be provided at Vir’s expense, up to [***]. For the
avoidance of doubt, unless otherwise agreed by the Parties, Vir personnel are not obligated to travel to Brii Bio’s facilities. Thereafter, during the Term, Vir shall, [***], or Brii Bio’s reasonable request. With respect to any payments
for technology transfer hereunder, after [***]. Vir shall invoice Brii Bio on a [***] for the foregoing costs and expenses incurred by Vir, and Brii Bio shall pay the amount invoiced within [***] after the date of any such invoice. 

(b) Transfer to Vir. Except for the Manufacturing Technology Transfer, which is addressed in
Section 8.3, within [***] after the Option Exercise Date for a Licensed Brii Bio Program, Brii Bio shall provide and transfer to Vir the Brii Bio Know-How and Brii Bio Patents
specifically related to such Licensed Brii Bio Program that exists on the applicable Option Exercise Date and was not previously provided to Vir, and in connection with such transfer, provide Vir with reasonable access to Brii Bio personnel involved
in the Development of Licensed Products for such Licensed Brii Bio Program, either in-person at Brii Bio’s facility or by teleconference. Such assistance shall be provided at Brii Bio’s expense, up
to [***]. For the avoidance of doubt, unless otherwise agreed by the Parties, Brii Bio personnel are not obligated to travel to Vir’s facilities. Thereafter, during the Term, Brii Bio shall, [***], or Vir’s reasonable request. With respect
to any payments for technology transfer hereunder, after [***]. Brii Bio shall invoice Vir on a [***] for the foregoing costs and expenses incurred by Brii Bio], and Vir shall pay the amount invoiced within [***] after the date of any such invoice.

 ARTICLE 6 

POST-OPTION DEVELOPMENT & DATA SHARING 

6.1 Responsibilities and Diligence. 

(a) For Licensed Vir Programs. Brii Bio shall be responsible for the Development and Commercialization of Licensed Products of
each Licensed Vir Program in the Field in the China Territory in accordance with the China Development Plan, and for performing the Development activities assigned to Brii Bio under the Vir Global Plan to support the global Development and
registration of Licensed Products for such Licensed Vir Program. Brii Bio 

  
 37 

 EXECUTION VERSION 

 
 shall use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval for
at least one (1) Licensed Product for each Licensed Vir Program. Brii Bio shall use Commercially Reasonable Efforts to conduct the tasks assigned to it in the China Development Plan and each Party shall use Commercially Reasonable Efforts to
conduct the tasks assigned to it in the Vir Global Plan and achieve the objectives set forth therein. Each Party shall conduct such tasks in a timely, professional manner and in compliance with the China Development Plan and Vir Global Plan, as
applicable, and all Applicable Laws, including GLP, GCP, and cGMP. 
 (b) For Licensed Brii Bio Programs. Vir shall be
responsible for the Development and Commercialization of Licensed Products of each Licensed Brii Bio Program in the Field in the United States in accordance with the U.S. Development Plan, and for performing the Development activities assigned to
Vir under the Brii Bio Global Plan to support the global Development and registration of Licensed Products for such Licensed Brii Bio Program. Vir shall use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval for at least one
(1) Licensed Product for each Licensed Brii Bio Program. Vir shall use Commercially Reasonable Efforts to conduct the tasks assigned to it in the U.S. Development Plan and each Party shall use Commercially Reasonable Efforts to conduct the
tasks assigned to it in the Brii Bio Global Plan and achieve the objectives set forth therein. Each Party shall conduct such tasks in a timely, professional manner and in compliance with the U.S. Development Plan and Brii Bio Global Plan, as
applicable, and all Applicable Laws, including GLP, GCP, and cGMP. 
 6.2 Territory Development Plans. 

(a) China Development Plan. Except for the activities allocated to Brii Bio under the Vir Global Plan pursuant to
Section 6.3(a), all Development by Brii Bio of Licensed Products in a Vir Program in the China Territory under this Agreement shall be conducted on a Licensed
Program-by-Licensed Program basis pursuant to a written development plan for such Licensed Program (as amended from time to time in accordance with this
Section 6.2(a) and Section 2.3(b), each, a “China Development Plan”). Following the Option Exercise Date for a Vir Program, and [***], Brii Bio shall provide to Vir an
initial draft of the China Development Plan for such Vir Program for Vir’s review and comment, which China Development Plan shall contain [***]. Brii Bio shall consider such comments in good faith and incorporate such comments where
appropriate. The initial China Development Plan will become effective once submitted to and approved by the JSC. From time to time thereafter, but [***], Brii Bio shall [***]. Once approved by the JSC, the amended China Development Plan shall become
effective. In the event of a dispute about the content of the China Development Plan for a given Licensed Program that is unable to be resolved by the JSC, Section 2.3(d) shall apply. For clarity, the China Development Plan
and amendments thereto must be consistent with the Vir Global Plan and the Vir Global Plan shall take precedent in case of any conflict or inconsistency between the China Development Plan and the Vir Global Plan. 

(b) U.S. Development Plan. Except for the activities allocated to Vir under the Brii Bio Global Plan pursuant to
Section 6.3, all Development by Vir of Licensed Products in a Brii Bio Program in the United States under this Agreement shall be conducted on a Licensed
Program-by-Licensed Program basis pursuant to a written development plan for such Licensed Program (as amended from time to time in accordance with this
Section 6.2(a) and Section 2.3(b), each, a “U.S. Development Plan”). Following the Option Exercise Date for a 

  
 38 

 EXECUTION VERSION 

 
 Licensed Brii Bio Program, and [***], Vir shall provide to Brii Bio an initial draft of
the U.S. Development Plan for such Licensed Brii Bio Program for Brii Bio’s review and comment, which U.S. Development Plan shall contain [***]. Vir shall consider such comments in good faith and incorporate such comments where appropriate. The
initial U.S. Development Plan will become effective once submitted to and approved by the JSC. From time to time thereafter, but [***], Vir shall [***]. Once approved by the JSC, the amended U.S. Development Plan shall become effective. In the event
of a dispute about [***]. For clarity, the U.S. Development Plan and amendments thereto must be consistent with the Brii Bio Global Plan and the Brii Bio Global Plan shall take precedent in case of any conflict or inconsistency between the U.S.
Development Plan and the Brii Bio Global Plan. 
 6.3 Global Development Plans. 

(a) Vir Global Plan. Vir shall have the right to conduct the development and commercialization of Licensed Products that are the
subject of a Licensed Program outside the China Territory at its sole discretion, provided that concurrent with the delivery of an Option Data Package for a Vir Program, Vir shall provide the JSC with a copy of Vir’s global development
plan for the applicable Licensed Products (each, a “Vir Global Plan”), in order to (i) enable Brii Bio to make a decision with respect to whether to exercise a Brii Bio Option, (ii) inform the preparation of the
China Development Plan (and its consistency with such Vir Global Plan) for such Licensed Product, and (iii) enable the Parties to agree upon any activities to be conducted by Brii Bio under the China Development Plan that will support
Vir’s global development of the applicable Licensed Products under the Vir Global Plan. Vir shall provide the JSC with annual updates to the Vir Global Plan [***]. Without limiting the foregoing, if Vir wishes to make any amendment to the Vir
Global Plan with respect to any given Licensed Product, [***]. 
 (b) Brii Bio Global Plan. Brii Bio shall have the right to
conduct the development and commercialization of Licensed Products that are the subject of a Licensed Program outside the United States at its sole discretion, provided that concurrent with the delivery of an Option Data Package for a Vir
Program, Brii Bio shall provide the JSC with a copy of Brii Bio’s global development plan for the applicable Licensed Products (each, a “Brii Bio Global Plan”), in order to (i) enable Vir to make a decision with
respect to whether to exercise a Vir Option, (ii) inform the preparation of the U.S. Development Plan (and its consistency with such Brii Bio Global Plan) for such Licensed Product, and (iii) enable the Parties to agree upon any activities
to be conducted by Vir under the U.S. Development Plan that will support Brii Bio’s global development of the applicable Licensed Products under the Brii Bio Global Plan. Brii Bio shall provide the JSC with annual updates to the Brii Bio Global
Plan [***]. Without limiting the foregoing, if Brii Bio wishes to make any amendment to the Brii Bio Global Plan with respect to any given Licensed Product, [***]. 

6.4 Development Costs. On a Licensed
Program-by-Licensed Program basis: 
 (a) Brii Bio
shall be solely responsible for the costs and expenses incurred by Brii Bio in the Development of Licensed Products in the China Territory, including the performance of Development activities under the China Development Plan and the Development
activities assigned to Brii Bio under the Vir Global Plan; 

  
 39 

 EXECUTION VERSION 

 
 (b) Vir shall be solely responsible for the costs and expenses
incurred by Vir in the Development of Licensed Products in the United States, including the performance of Development activities under the U.S. Development Plan and the Development activities assigned to Vir under the Brii Bio Global Plan; and 

(c) Except as set forth in (a) or (b), each Party shall be solely responsible for all costs associated with its Development and
Commercialization of Licensed Products under the Brii Bio Global Plan (in the case of Brii Bio), or the Vir Global Plan (in the case of Vir). 

6.5 Use of Affiliates and Contractors. 

(a) Affiliates. Each Party may perform any Development activity related to the other Party’s Program for which it is
responsible through an Affiliate of such Party; provided, in each case, that (i) such Affiliate is bound by written agreement to comply with all applicable terms and conditions of this Agreement to the same extent as such Party;
(ii) such Party remains fully responsible for the performance of such obligations by such Affiliate and for the compliance of such Affiliate with the terms and conditions of this Agreement; and (iii) any failure of such Affiliate to comply
with the terms and conditions of this Agreement shall be deemed a breach of this Agreement by such Party. 
 (b)
Subcontractors. A Party may contract any Development activity related to the other Party’s Program for which it is responsible to a Third Party contract service provider; provided, in each case, that (i) none of the other
Party’s rights hereunder are diminished or otherwise adversely affected as a result of such subcontracting; (ii) each such subcontractor undertakes in writing obligations of confidentiality and
non-use regarding Confidential Information at least as stringent as those undertaken by the parties pursuant to Article 11; [***]; and (iv) such Party is responsible for the performance of such
obligations by such subcontractor, for the compliance of such subcontractor with the terms and conditions of this Agreement, and for payment of such subcontractor. 

6.6 Development Records. Each Party shall maintain reasonably complete, current and accurate records of all Development
activities conducted by or on behalf of such Party, its Affiliates or its sublicensees under Licensed Programs for which such Party has exercised its option pursuant to this Agreement and all data and other information resulting from such activities
consistent with its usual practices, in validated computer systems that are compliant with 21 C.F.R. §11, and in accordance with Applicable Laws of both the United States and the China Territory (such records for each Licensed Program, the
“Development Records”). Each Party shall obtain the other Party’s written consent prior to destroying any Development Records for any Vir Program (in the case of Brii Bio’s records) or any Brii Bio Program (in the
case of Vir’s records). Such Development Records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes. Each
Party shall document all non-clinical studies and Clinical Trials in formal written study reports in accordance with Applicable Laws and national and international guidelines (e.g., GCP, GLP, and GMP).
Upon each Party’s request, the other Party shall, and shall cause its Affiliates and sublicensees to, (i) provide the requesting Party with copies of such Development Records, and (ii) allow the requesting Party to access, review, and
copy such Development Records. [***]. Each Party shall ensure that all Development Records or other documents that it transmits to the other Party electronically under this Agreement are transmitted over secure systems that include adequate
encryption safeguards that prevent unauthorized access and maintain data security. 

  
 40 

 EXECUTION VERSION 

 
 6.7 Clinical Trial Audit Rights. 

(a) For Licensed Vir Programs. Up to once per Calendar Year (except in the case of any “for cause” audit, which may be
conducted more frequently upon Vir’s reasonable request) and upon reasonable prior notice by Vir and at Vir’s cost and expense, Brii Bio shall permit Vir or its representatives to conduct an audit of any Clinical Trial sites engaged by
Brii Bio or its Affiliates or sublicensees to conduct Brii Bio’s obligations under [***]. No later than [***] following the completion of any such audit, Vir shall provide Brii Bio with a written summary of Vir’s findings, including any
deficiencies or other areas of remediation that Vir identifies during such audit. Brii Bio shall use Commercially Reasonable Efforts to remediate any such deficiencies within [***] following Brii Bio’s receipt of such report, at Brii Bio’s
cost and expense. In addition, Brii Bio shall provide Vir with copies of all quality oversight or audit reports, including English translations thereof, prepared in connection with any audit that Brii Bio, its Affiliates, or sublicensees conduct of
a Clinical Trial site that Brii Bio, its Affiliates, or sublicensees have engaged or are evaluating to potentially engage to fulfill Brii Bio’s obligations under a Vir Global Plan or a China Development Plan no later than [***] after receiving
or preparing, as applicable, any such report. 
 (b) For Licensed Brii Bio Programs. Up to once per Calendar Year (except in
the case of any “for cause” audit, which may be conducted more frequently upon Brii Bio’s reasonable request) and upon reasonable prior notice by Brii Bio and at Brii Bio’s cost and expense, Vir shall permit Brii Bio or its
representatives to conduct an audit of any Clinical Trial sites engaged by Vir or its Affiliates or sublicensees to conduct Vir’s obligations under [***]. No later than [***] following the completion of any such audit, Brii Bio shall provide
Vir with a written summary of Brii Bio’s findings, including any deficiencies or other areas of remediation that Brii Bio identifies during such audit. Vir shall use Commercially Reasonable Efforts to remediate any such deficiencies within
[***] following Vir’s receipt of such report, at Vir’s cost and expense. In addition, Vir shall provide Brii Bio with copies of all quality oversight or audit reports, including English translations thereof, prepared in connection with any
audit that Vir, its Affiliates, or sublicensees conduct of a Clinical Trial site that Vir, its Affiliates, or sublicensees have engaged or are evaluating to potentially engage to fulfill Vir’s obligations under a Brii Bio Global Plan or a U.S.
Development Plan no later than [***] after receiving or preparing, as applicable, any such report. 
 6.8 Development Reports.
Each Party shall provide the JSC with quarterly written reports summarizing its, its Affiliates’, and its sublicensees’ Development of Licensed Products for all Licensed Programs being conducted by such Party, including a summary of the
data, timelines, and results of such Development. Without limiting the foregoing, such reports shall contain sufficient detail to enable each Party to assess the compliance of the reporting Party with its Development obligations hereunder. Such
reports shall be Confidential Information of the reporting Party pursuant to Article 11. The reporting Party shall promptly respond to reasonable requests of the JSC or the other Party from time to time for additional information regarding
significant Development activities. The Parties shall discuss the status, progress and results of such Development activities at JSC meetings. 

  
 41 

 EXECUTION VERSION 

 
 6.9 Data Exchange and Use. In addition to its adverse
event and safety data reporting obligations pursuant to Section 7.3, each Party shall promptly provide the other Party with electronic copies, in a mutually agreed format, of all data and results and all supporting
documentation (e.g., protocols, CRFs, analysis plans) Controlled by such Party that are generated by or on behalf of such Party or its Affiliates or sublicensees, if applicable, in the Development of Licensed Products for such other Party’s
Program. Brii Bio may use and reference such data and results provided by Vir with respect to any Licensed Brii Bio Programs, without additional consideration, for the purpose of obtaining and maintaining Regulatory Approval and any pricing or
reimbursement approvals, as applicable, of Licensed Products for any Licensed Brii Bio Program outside the United States. Vir may use and reference such data and results provided by Brii Bio with respect to any Licensed Vir Program, without
additional consideration, for the purpose of obtaining and maintaining Regulatory Approval and any pricing or reimbursement approvals, as applicable, of Licensed Products for any Licensed Vir Program outside the China Territory. 

ARTICLE 7 
 POST-OPTION
REGULATORY 
 7.1 Generally. 

(a) Conduct of Activities. After the Option Exercise Date for a Collaboration Program, the Party that exercised the Option shall
be responsible, at its sole cost and expense, for all regulatory activities leading up to and including obtaining Regulatory Approvals and any pricing or reimbursement approvals, as applicable, for Licensed Products in such Licensed Program from
Regulatory Authorities in the applicable Territory (i.e., the China Territory with respect to Vir Programs for which Brii Bio exercised a Brii Bio Option and the United States with respect to Brii Bio Programs for which Vir exercised a Vir Option).
Promptly following the Option Exercise Date for such Collaboration Program and to the extent permitted under Applicable Law, the other Party shall transfer all Regulatory Submissions and Regulatory Approvals for such Collaboration Program to the
Party that exercised the Option. The Party that exercised the Option shall reimburse the other Party for all costs (including internal costs at the FTE Rate and
out-of-pocket costs) incurred by the other Party in relation to any such transfer. Each Party shall keep the other Party informed of regulatory developments related to
Licensed Products for such Licensed Program in the applicable Territory and shall promptly notify the other Party in writing of any decision by any Regulatory Authority in the applicable Territory regarding any Licensed Product for such Licensed
Program. 
 (b) Regulatory Submissions. The Party that exercised the Option shall provide to the other Party for review and
comment drafts of all Regulatory Submissions for a Licensed Program in the applicable Territory a reasonable amount of time prior to submission (as appropriate for the applicable Regulatory Submission), but at least [***] prior to submission if the
applicable Regulatory Authority does not require a response in a shorter time period. The Party that exercised the Option providing the Regulatory Submissions shall consider in good faith any comments received from the other Party. In addition, the
Party that exercised the 

  
 42 

 EXECUTION VERSION 

 
 Option shall notify the other Party of any comments or other correspondences related to
such Regulatory Submissions submitted to or received from any Regulatory Authority in the applicable Territory with respect to such Licensed Program and shall provide the other Party with copies thereof as soon as reasonably practicable, but in all
events within [***] after submission or receipt if the applicable Regulatory Authority does not require a response in a shorter time period. If any such Regulatory Submission, comment or correspondence is not in English, Brii Bio shall also provide
Vir with a certified English translation within [***] after submission or receipt if requested by Vir; provided that Vir shall be responsible for the costs incurred by Brii Bio in obtaining such certified translation. The other Party may
review and comment on such Regulatory Submissions and [***]. Notwithstanding the anything to the contrary in this Section 7.1(b), with respect to applications for a New Drug Application (as defined by the FDA or CFDA, as
applicable) or a Biologics License Application (as defined by the FDA, and the equivalent in the China Territory) or supplemental applications of either of the foregoing, the Party making such Regulatory Submission shall keep the JDC of the
applicable Collaboration Program reasonably informed of the process of preparing such Regulatory Submissions so that the other Party may expeditiously review and provide comments to such Regulatory Submissions, and such other Party shall use
reasonable efforts to provide such comments within [***] after receipt of such Regulatory Submissions. 
 (c) Meetings. The
Party that exercised the Option shall provide the other Party with notice no later than [***] hours after receiving notice of any meeting or discussion with any Regulatory Authority in the applicable Territory related to any Licensed Product for
such Licensed Program. The Party that exercised the Option shall lead any such meeting or discussion, provided, however, that the other Party or its designee may attend and participate in the portion of such meeting or discussion
applicable to the Licensed Product in the applicable Territory. If the other Party elects not to attend such meeting or discussion, the Party that exercised the Option shall provide the other Party with a written summary of the applicable portion of
such meeting or discussion promptly following such meeting or discussion. 
 (d) Further Assurances. The Parties shall work
together and take all actions, including amending this Agreement, as necessary, to give effect to a Party’s rights and obligations as the Party responsible, as permitted and to the extent described herein, for the Development, Manufacture, and
Commercialization of the Licensed Products for each Licensed Program in the applicable Territory. The other Party shall provide support and assistance to the Party that exercised the Option, as may be reasonably requested by such Party, in
preparing, obtaining and maintaining Regulatory Submissions and Regulatory Approvals for Licensed Products in a Licensed Program in the applicable Territory, and in the activities in support thereof, including providing documents or other materials
required by Applicable Law or requested by a Regulatory Authority and otherwise assisting the Party that exercised the Option with answering questions from Regulatory Authorities. 

(e) Licensed Vir Programs. Notwithstanding anything to the contrary in this Section 7.1, if, and solely
for so long as, Brii Bio is not permitted under Applicable Law in the China Territory to make Regulatory Submissions and to obtain and maintain Regulatory Approvals for Licensed Products for a Vir Program in the China Territory, then this
Section 7.1(e) shall apply in addition to the foregoing provisions of Section 7.1 and, in the event of conflict between this Section 7.1(e) and the rest of this
Section 7.1, this Section 7.1(e) shall 

  
 43 

 EXECUTION VERSION 

 
 control. Brii Bio shall conduct regulatory activities (and any and all regulatory
activities delegated to Brii Bio in this Agreement in connection with the Development and Commercialization of Licensed Products for a Licensed Vir Program in the China Territory) as the express and authorized regulatory agent of record for Vir in
the China Territory. Brii Bio shall incorporate all reasonable comments received from Vir to any Regulatory Submissions to which Vir provides comment pursuant to Section 7.1(b). Vir shall own and hold all Regulatory
Submissions, Regulatory Approvals, and any pricing or reimbursement approvals, as applicable, for Licensed Products for all Vir Programs in the China Territory for the benefit of Brii Bio, and shall, promptly upon Brii Bio’s request, provide
access to and copies of such Regulatory Submissions, Regulatory Approvals, and any pricing or reimbursement approvals to Brii Bio, as applicable. Vir shall cooperate with Brii Bio in obtaining any Regulatory Approvals and any pricing or
reimbursement approvals, as applicable, for a Licensed Product in a Licensed Vir Program in the China Territory by providing, to the extent Controlled by Vir, prompt access to Regulatory Approvals, Regulatory Submissions, clinical data, and other
data, information, and documentation for Licensed Products, both inside and outside of the China Territory. [***]. In addition, if following a change in Applicable Law during the Term, Brii Bio is permitted to own and hold the Regulatory
Submissions, Regulatory Approvals and any pricing or reimbursement approvals, as applicable, held by Vir for Licensed Products for a Vir Program in the China Territory, then, promptly following Brii Bio’s request, Vir shall transfer such
Regulatory Submissions and Regulatory Approvals for such Vir Program to Brii Bio. Brii Bio shall reimburse Vir for all costs (including internal costs at the FTE Rate and
out-of-pocket costs) incurred by Vir in relation to any such transfer. 

7.2 Right of Reference. Each Party hereby grants to the other Party the right of reference to all Regulatory Submissions
pertaining to Licensed Products for such first Party’s Programs submitted by or on behalf of such Party or its Affiliates. Each Party shall bear its own costs and expenses associated with providing the other Party with the right of reference
pursuant to this Section 7.2. 
 (a) Licensed Vir Programs. Brii Bio may use such right of reference
to Vir’s Regulatory Submissions for Vir Programs solely for the purpose of seeking, obtaining and maintaining Regulatory Approval and any pricing or reimbursement approvals, as applicable, of Licensed Products for Vir Programs in the Field in
the China Territory. Vir may use the right of reference to Brii Bio’s Regulatory Submissions for Vir Programs, if any, solely for the purpose of seeking, obtaining and maintaining regulatory approval of Licensed Products for a Vir Program
outside the China Territory. 
 (b) Licensed Brii Bio Programs. Vir may use such right of reference to Brii Bio’s
Regulatory Submissions for Licensed Brii Bio Programs solely for the purpose of seeking, obtaining and maintaining Regulatory Approval and any pricing or reimbursement approvals, as applicable, of Licensed Products for Licensed Brii Bio Programs in
the Field in the United States. Brii Bio may use the right of reference to Vir’s Regulatory Submissions for Licensed Brii Bio Programs, if any, solely for the purpose of seeking, obtaining and maintaining regulatory approval of Licensed
Products for a Licensed Brii Bio Program outside the United States. 

  
 44 

 EXECUTION VERSION 

 
 7.3 Adverse Events Reporting. 

(a) Safety Agreement. Promptly following the Option Exercise Date for the first Program, but in no event later than [***]
thereafter, Brii Bio and Vir shall develop and agree in a written agreement to worldwide safety and pharmacovigilance procedures for the Parties with respect to Licensed Products, such as safety data sharing and exchange, adverse events reporting
and prescription events monitoring (the “Safety Agreement”). Such Safety Agreement shall describe the obligations of both Parties with respect to the coordination of collection, investigation, reporting, and exchange of
information between the Parties concerning adverse events or any other safety issue of any significance and product quality and product complaints involving adverse events, in each case with respect to all Licensed Products for all Programs for
which a Party exercises an Option and sufficient to permit each Party and its Affiliates, licensees, or sublicensees to comply with its legal and regulatory obligations with respect thereto. The Parties shall promptly update the Safety Agreement if
required by changes in legal or regulatory requirements. Each Party shall comply with its respective obligations under the Safety Agreement and shall cause its Affiliates, licensees, and sublicensees to comply with such obligations. 

(b) Licensed Vir Programs. 

(i) Brii Bio shall report to the applicable Regulatory Authorities in the China Territory all quality complaints, applicable adverse
events, and safety data related to Licensed Products in a Vir Program for all Clinical Trials conducted in the China Territory under the China Development Plan or the Vir Global Plan, as well as responding to safety issues and to all requests of
Regulatory Authorities related to Licensed Products in a Vir Program in the China Territory. Brii Bio shall provide to Vir access to Brii Bio’s adverse event database for the China Territory for such Licensed Vir Programs. Vir shall maintain a
global pharmacovigilance database (including serious adverse events (SAEs) and suspected unexpected serious adverse reactions (SUSARs) for Clinical Trials conducted under the Global Development Plan at Vir’s cost and expense, and Brii Bio shall
use such database and related processes for the handling and reporting of SAEs and SUSARs for Clinical Trials for a Licensed Vir Program conducted in the China Territory. If there is no development of Licensed Products for such Licensed Vir Program
outside of the China Territory, then Brii Bio shall maintain an adverse event database for Clinical Trials conducted in the China Territory under the China Development Plan for such Licensed Vir Program, at its sole cost and expense, and Brii Bio
shall provide to Vir access to Brii Bio’s pharmacovigilance database for the China Territory for such Licensed Vir Program. 

(ii) Brii Bio shall comply with all Applicable Laws governing adverse events in the China Territory. Brii Bio shall notify Vir in a
timely manner and in any event within [***] hours of receiving notice from a Regulatory Authority, independent review committee, data safety monitoring board or another similar clinical trial or post-marketing monitoring body alleging significant
concern regarding a patient safety issue or other material information relevant to the safety or efficacy of Licensed Products in a Vir Program. 

  
 45 

 EXECUTION VERSION 

 
 (c) Licensed Brii Bio Programs. 

(i) Vir shall report to the applicable Regulatory Authorities in the United States all quality complaints, applicable adverse events,
and safety data related to Licensed Products in a Licensed Brii Bio Program for all Clinical Trials conducted in the United States under the U.S. Development Plan or the Brii Bio Global Plan, as well as responding to safety issues and to all
requests of Regulatory Authorities related to Licensed Products in a Licensed Brii Bio Program in the United States. Vir shall provide to Brii Bio access to Vir’s adverse event database for the United States for such Licensed Brii Bio Programs.
Brii Bio shall maintain a global pharmacovigilance database (including serious adverse events (SAEs) and suspected unexpected serious adverse reactions (SUSARs) for Clinical Trials conducted under the Global Development Plan at Brii Bio’s cost
and expense, and Vir shall use such database and related processes for the handling and reporting of SAEs and SUSARs for Clinical Trials for a Licensed Brii Bio Program conducted in the United States. If there is no development of Licensed Products
for such Licensed Brii Bio Program outside of the United States, then Vir shall maintain an adverse event database for Clinical Trials conducted in the United States under the U.S. Development Plan for such Licensed Brii Bio Program, at its sole
cost and expense, and Vir shall provide to Brii Bio access to Vir’s pharmacovigilance database for the United States for such Licensed Brii Bio Program. 

(ii) Vir shall comply with all Applicable Laws governing adverse events in the United States. Vir shall notify Brii Bio in a timely
manner and in any event within [***] hours of receiving notice from a Regulatory Authority, independent review committee, data safety monitoring board or another similar clinical trial or post-marketing monitoring body alleging significant concern
regarding a patient safety issue or other material information relevant to the safety or efficacy of Licensed Products in a Licensed Brii Bio Program. 

7.4 Safety and Regulatory Audits. 

(a) Licensed Vir Programs. Upon reasonable prior notice to Brii Bio, Vir or its representatives may conduct an audit of safety
and regulatory systems, procedures or practices of Brii Bio, its Affiliates, sublicenses, or subcontractors (including Clinical Trial sites) relating to Licensed Products of a Vir Program. Brii Bio shall promptly notify Vir of any inspection of Brii
Bio, its Affiliates, sublicenses, or subcontractors (including Clinical Trial sites) by any Regulatory Authority relating to Licensed Products of a Vir Program and shall provide Vir with all information pertinent thereto. Vir may be present at any
such inspection. Brii Bio shall also permit Regulatory Authorities outside the China Territory to conduct inspections of Brii Bio, its Affiliates, sublicenses, or subcontractors (including Clinical Trial sites) relating to Licensed Products of a Vir
Program, and shall ensure that such Affiliates, and shall use Commercially Reasonable Efforts to ensure that such sublicensees and subcontractors, permit such inspections. Brii Bio shall provide Vir with a written summary in English of any findings
of a Regulatory Authority following a regulatory audit within [***] following any such audit, and shall provide Vir with an unredacted copy of any report issued by such Regulatory Authority, including a English translation thereof, as soon as
reasonably practicable, but in all events within [***] following such audit. 
 (b) Licensed Brii Bio Programs. Upon reasonable
prior notice to Vir, Brii Bio or its representatives may conduct an audit of safety and regulatory systems, procedures or practices of Vir, its Affiliates, sublicenses, or subcontractors (including Clinical Trial sites) relating to Licensed Products
of a Licensed Brii Bio Program. Vir shall promptly notify Brii Bio of any inspection of Vir, its Affiliates, sublicenses, or subcontractors (including Clinical Trial sites) by any Regulatory Authority relating to Licensed Products of a Licensed Brii
Bio Program 

  
 46 

 EXECUTION VERSION 

 
 and shall provide Brii Bio with all information pertinent thereto. Brii Bio may be
present at any such inspection. Vir shall also permit Regulatory Authorities outside the United States to conduct inspections of Vir, and its Affiliates, sublicensees, or subcontractors (including Clinical Trial sites) relating to Licensed Products
of a Licensed Brii Bio Program, and shall ensure that such Affiliates, and shall use Commercially Reasonable Efforts to ensure that such sublicensees and subcontractors, permit such inspections. Vir shall provide Brii Bio with a written summary in
English of any findings of a Regulatory Authority following a regulatory audit within [***] following any such audit, and shall provide Brii Bio with an unredacted copy of any report issued by such Regulatory Authority, including a English
translation thereof, as soon as reasonably practicable, but in all events within [***] following such audit. 
 7.5 No Harmful
Actions. If either Party believes that the other Party is taking or intends to take any action with respect to a Licensed Product for the other Party’s Program in such other Party’s Territory that could have a material adverse impact
upon the regulatory status of any Licensed Product in its respective territory, then such Party may bring the matter to the attention of the JSC and the Parties shall discuss in good faith a resolution to such concern. Without limiting the
foregoing, unless the Parties otherwise agree (or unless otherwise set forth in a Global Development Plan): (a) neither Party shall communicate with any Regulatory Authority having jurisdiction outside of its respective Territory with respect to any
Licensed Product, unless so ordered by such Regulatory Authority, in which case such Party shall immediately notify the other Party of such order; and (b) neither Party shall submit any Regulatory Submissions or seek regulatory approvals for
any Licensed Product in the other Party’s respective Territory. 
 7.6 Notice of Regulatory Action. 

(a) Licensed Vir Programs. If any Regulatory Authority takes or gives notice of its intent to take any regulatory action with
respect to any activity of Brii Bio relating to any Licensed Product of a Licensed Vir Program, then Brii Bio shall notify Vir of such contact, inspection, or notice or action within [***] hours thereof. Vir may review and comment on any responses
to Regulatory Authorities that pertain to a Licensed Product of a Licensed Vir Program. The costs and expenses of any regulatory action in the China Territory shall be borne solely by Brii Bio. Brii Bio shall, and shall ensure that its
Affiliates and sublicensees will, maintain adequate records to permit the Parties to trace the distribution, sale and use of Licensed Products of a Licensed Vir Program in the China Territory. In addition, each Party shall promptly notify the other
of any information it receives regarding any threatened or pending action, inspection or communication by or from a Third Party that would reasonably be expected to materially affect the Development of Licensed Products of a Licensed Vir Program.

 (b) Licensed Brii Bio Programs. If any Regulatory Authority takes or gives notice of its intent to take any regulatory
action with respect to any activity of Vir relating to any Licensed Product of a Licensed Brii Bio Program, then Vir shall notify Brii Bio of such contact, inspection, or notice or action within [***] hours thereof. Brii Bio may review and comment
on any responses to Regulatory Authorities that pertain to a Licensed Product of a Licensed Brii Bio Program. The costs and expenses of any regulatory action in the United States shall be borne solely by Vir. Vir shall, and shall ensure that
its Affiliates and sublicensees will, maintain adequate records to permit the Parties to trace the distribution, sale and use of Licensed Products of a Licensed Brii Bio Program in the United States. In addition, each Party shall promptly notify the
other of any information it receives regarding any threatened or pending action, inspection or communication by or from a Third Party that would reasonably be expected to materially affect the Development of Licensed Products of a Licensed Brii Bio
Program. 

  
 47 

 EXECUTION VERSION 

 
 ARTICLE 8 

MANUFACTURING 
 8.1
Supply for Pre-Option Development Activities and Post-Option Development. 
 (a) For
Vir Programs. Subject to Section 8.3, Vir shall have the sole right, either by itself or through a Third Party contract manufacturer, to Manufacture and supply to Brii Bio (i) all Products required by Brii Bio for
use in connection with Pre-Option Development Activities in the China Territory under the Pre-Option Development Plan and (ii) all Licensed Products required by
Brii Bio for Development use following the exercise of the Brii Bio Option in the China Territory under the China Development Plan and for Brii Bio’s Development-related responsibilities under the Vir Global Plan. Vir shall supply the Product
or Licensed Product pursuant to this Section 8.1(a) at [***]. Vir shall invoice Brii Bio for the applicable Product or Licensed Product upon delivery in accordance this Section 8.1(a) and Brii Bio
shall pay the amount invoiced within [***] after the date of the invoice. Delivery shall take place [***]. Brii Bio shall obtain all licenses or other authorizations for the exportation and importation of such Product or Licensed Product, and Brii
Bio shall contract for shipment and insurance of such Product or Licensed Product from Vir’s or its contract manufacturer’s facility, at Brii Bio’s cost and expense. Brii Bio shall also be responsible for the clinical packaging,
labeling, QC/QA/QP final release, storage, customs clearance and distribution of such Product or Licensed Product, at Brii Bio’s cost and expense. 

(b) For Brii Bio Programs. Subject to Section 8.3, Brii Bio shall have the sole right, either by itself
or through a Third Party contract manufacturer, to Manufacture and supply to Vir (i) all Products required by Vir for use in connection with Pre-Option Development Activities in the United States under
the Pre-Option Development Plan and (ii) all Licensed Products required by Vir for Development use following the exercise of the Vir Option in the United States under the U.S. Development Plan and for
Vir’s Development-related responsibilities under the Brii Bio Global Plan. Brii Bio shall supply the Product or Licensed Product pursuant to this Section 8.1(a) at [***]. Brii Bio shall invoice Vir for the applicable
Product or Licensed Product upon delivery in accordance this Section 8.1(a) and Vir shall pay the amount invoiced within [***] after the date of the invoice. Delivery shall take place [***]. Vir shall obtain all licenses or
other authorizations for the exportation and importation of such Product or Licensed Product, and Vir shall contract for shipment and insurance of such Product or Licensed Product from Brii Bio’s or its contract manufacturer’s facility, at
Vir’s cost and expense. Vir shall also be responsible for the clinical packaging, labeling, QC/QA/QP final release, storage, customs clearance and distribution of such Product or Licensed Product, at Vir’s cost and expense. 

  
 48 

 EXECUTION VERSION 

 
 (c) Development Supply and Quality Agreements. Within [***], the
Parties shall enter into (i) a master supply agreement (“Development Master Supply Agreement”) and (ii) a master quality agreement (“Development Master Quality Agreement”)
describing the general terms and conditions of Manufacture and supply of Products or Licensed Products pursuant to Section 8.1(a) and Section 8.1(b). The terms and conditions of the Development
Master Supply Agreement and Development Master Quality Agreement will be commercially reasonable and consistent with industry standards and the terms of this Agreement, as well as, if applicable, each Party’s agreements with its Third Party
contract manufacturers. At least [***] prior to commencing any Pre-Option Development Activities or Development activities for a Collaboration Program, the Parties shall enter into a separate work order under
the applicable Development Master Supply Agreement and the Development Master Quality Agreement for the Manufacture and supply of Product or Licensed Product for such Pre-Option Development Activities or
Development activities, as applicable. 
 (d) Audits of Facilities where Licensed Product is Manufactured. Notwithstanding the
supply rights and obligations of Licensed Products following exercise of an Option in Section 8.1(a) and Section 8.1(b), the Party being supplied with Licensed Product may conduct due diligence,
including by conducting on-site audits, of the facilities where Licensed Product is Manufactured for the purpose of ascertaining conformance with Applicable Law and assessing operational capabilities and
performance to supply Licensed Product. If a Party reasonably determines after conducting such due diligence that such Manufacturing facility is unable to meet (i) the applicable specifications for the Licensed Product, (ii) Applicable Law
(including cGMP), or (iii) such Party’s supply needs for Development of such Licensed Product, then such Party may [***]. 

8.2 Commercial Supply. 

(a) For Licensed Vir Programs. Unless Brii Bio elects to initiate a Manufacturing Technology Transfer pursuant to
Section 8.3, the Parties shall [***] for a Vir Program on the principal terms of a commercial supply agreement (the “Vir Commercial Supply Agreement”) and a quality agreement
(“Vir Commercial Quality Agreement”) pursuant to which Brii Bio may purchase commercial supply of a Licensed Product for such Licensed Vir Program from Vir at [***] to fulfill Brii Bio’s obligations under this Agreement,
which terms shall be [***]. At Brii Bio’s request, the Parties shall negotiate such Vir Commercial Supply Agreement and Vir Commercial Quality Agreement in accordance with such agreed-upon terms and conditions. 

(b) For Licensed Brii Bio Programs. Unless Vir elects to initiate a Manufacturing Technology Transfer pursuant to
Section 8.3, the Parties shall [***] for a Licensed Brii Bio Program on the principal terms of a commercial supply agreement (the “Brii Bio Commercial Supply Agreement”) and
quality agreement (“Brii Bio Commercial Quality Agreement”) pursuant to which Vir may purchase commercial supply of a Licensed Product for such Licensed Brii Bio Program from Brii Bio at [***] to fulfill Vir’s
obligations under this Agreement, which terms shall be [***]. At Vir’s request, the Parties shall negotiate such Brii Bio Commercial Supply Agreement and Brii Bio Commercial Quality Agreement in accordance with such agreed-upon terms and
conditions. 

  
 49 

 EXECUTION VERSION 

 
 8.3 Transfer of Manufacturing Responsibility. 

(a) Transfer. Following the Option Exercise Date for a Licensed Program, [***], at such Party’s cost and expense, subject to
and only after such Party’s completion of any studies or testing required by and receipt of any qualifications and Regulatory Approvals from any Regulatory Authorities or other Governmental Authorities necessary to Manufacture such Licensed
Product. Such Party shall be required to ensure that its Manufacturing Process with respect to a Licensed Product is in accordance with the specifications with respect to such Licensed Product, Applicable Laws, including cGMP and ICH Guidelines, and
any published regulatory guidance or procedures applicable to the Manufacture, testing, release and distribution of such Licensed Product. 

(b) Manufacturing Technology Transfer Agreement. If the Parties mutually agree that such Manufacturing responsibility should be
transferred to the Party exercising the Option, then within [***] following such determination, the Parties shall negotiate in good faith and enter into a Manufacturing Technology Transfer agreement (the “Manufacturing Technology Transfer
Agreement”), which will set forth the terms and conditions of the Manufacturing Technology Transfer on commercially reasonable terms, consistent with industry standards and the terms of this Agreement. As part of the technology
transfer, the Party transferring Manufacturing responsibilities (the “Transferring Party”) shall transfer to the Party assuming responsibility for such Manufacture, or its designated Affiliates or mutually agreed Third Party
contractors, (each, an “Assuming Party”) such Transferring Party’s [***]. In addition, upon the request the Assuming Party [***] the applicable Licensed Product. 

(c) Activities. The Parties shall initiate and use Commercially Reasonable Efforts to promptly transfer to the Assuming Party, in
accordance with the Manufacturing Technology Transfer Agreement, the Transferring Party’s Manufacturing Process and technology that is [***]. The Transferring Party shall make its personnel available on a reasonable basis to consult with the
Assuming Party, at [***]. 
 (d) Limitations. Notwithstanding the provisions of this Section 8.3, the
Transferring Party shall not be required to perform a Manufacturing Technology Transfer to (i) any Third Party manufacturer that is then in material breach of any agreement with the Transferring Party or its Affiliate, or that, [***], (ii)
[***], or (iii) [***]. The Transferring Party shall notify the Assuming Party promptly following identification of a potential Third Party manufacturer by the Assuming Party of any basis that the Transferring Party would not conduct such
Manufacturing Technology Transfer and the Parties shall work in good faith to address any such concerns. 
 (e) Existing Contract
Manufacturers. If an Assuming Party requests a Manufacturing Technology Transfer to a Third Party manufacturer that is already a Third Party manufacturer of the Licensed Product for such stage of the supply chain, promptly after the Assuming
Party’s written request, the Transferring Party shall use Commercially Reasonable Efforts to facilitate the Assuming Party’s efforts to enter into an agreement with such Third Party for the Manufacture and supply of such Licensed Product.
The Assuming Party shall be solely responsible for contracting with such Third Party manufacturer (and any other Third Party manufacturer to whom the Transferring Party has initiated a Manufacturing Technology Transfer) for the supply of such
Licensed Product and the Transferring Party shall have no obligations under such agreement between the Assuming Party and such Third Party manufacturer. 

  
 50 

 EXECUTION VERSION 

 
 ARTICLE 9 

POST-OPTION COMMERCIALIZATION 

9.1 Commercialization Diligence. 

(a) Brii Bio Responsibilities. Brii Bio shall be responsible for, and shall use Commercially Reasonable Efforts to, Commercialize
each Licensed Product in a Licensed Vir Program that obtains Regulatory Approval in the Field in the China Territory. Brii Bio shall conduct all Commercialization of Licensed Products in a Licensed Vir Program in the Field in the China Territory in
accordance with the Commercialization Plan for such Licensed Product, at its sole cost and expense. 
 (b) Vir
Responsibilities. Vir shall be responsible for, and shall use Commercially Reasonable Efforts to, Commercialize each Licensed Product in a Licensed Brii Bio Program that obtains Regulatory Approval in the Field in the United States. Brii Bio
shall conduct all Commercialization of Licensed Products in a Licensed Brii Bio Program in the Field in the United States in accordance with the Commercialization Plan for such Licensed Product, at its sole cost and expense. 

9.2 Commercialization Plans. The Commercialization Plan with respect to Licensed Products in each Licensed Program shall contain
in reasonable detail the major Commercialization activities, including revenue targets, planned for such Licensed Product in the China Territory (in the case of Brii Bio) and the United States (in the case of Vir), and the estimated timelines for
achieving such activities. Each Party shall deliver an initial draft of each Commercialization Plan to the JSC for review no later than [***] for a Licensed Product in such Licensed Program. Thereafter, and until the First Commercial Sale of such
Licensed Product, such Party shall provide an updated Commercialization Plan to the JSC for review on an annual basis. 
 9.3
Coordination of Commercialization Activities. 
 (a) The Parties recognize that they may benefit from the coordination of
certain activities in support of the Commercialization of Licensed Products in and outside the China Territory and the United States. As such, the Parties shall coordinate such activities where appropriate, which may include scientific and medical
communication and product positioning. 
 (b) Each Party shall keep the other Party timely informed on the status of any application
for pricing or reimbursement approval for Licensed Products in the other Party’s Program in such first Party’s Territory, including any discussion with Regulatory Authority with respect thereto. Each Party may determine the price of
Licensed Products in the other Party’s Program sold in such first Party’s Territory and neither Party may direct, control or approve the pricing of Licensed Products in the other Party’s Territory. 

  
 51 

 EXECUTION VERSION 

 
 (c) Each Party acknowledges that the other Party may decide to
develop and adopt certain distinctive colors, logos, images, symbols, and trademarks to be used in connection with the Commercialization of Licensed Products in such Party’s Program on a global basis (such branding elements, collectively, the
“Global Brand Elements”). Vir shall own all rights in such Global Brand Elements for all Licensed Vir Programs, and shall grant Brii Bio the exclusive right to use such Global Brand Elements in connection with the
Commercialization of Licensed Products in Licensed Vir Programs in the China Territory. Brii Bio shall Commercialize Licensed Products in the Licensed Vir Program in the China Territory in a manner consistent with the Global Brand Elements. Brii Bio
shall own all rights in such Global Brand Elements for all Licensed Brii Bio Programs, and shall grant Vir the exclusive right to use such Global Brand Elements in connection with the Commercialization of Licensed Products in Licensed Brii Bio
Programs in the United States. Vir shall Commercialize Licensed Products in the Licensed Brii Bio Program in the United States in a manner consistent with the Global Brand Elements. 

9.4 Diversion. Each Party covenants and agrees that it shall not, and shall ensure that its Affiliates and sublicensees shall
not, [***]; provided that each Party is not responsible for [***]. If a Party or its Affiliates or sublicensees receive an order for Licensed Products from a prospective purchaser located in the other Party’s Territory, such Party shall
[***]. 
 ARTICLE 10 

PAYMENTS 
 10.1
Equity. In partial payment for the options, licenses, and other rights granted by Vir to Brii Bio under this Agreement, on or near the Effective Date, Parent, Brii Bio and Vir shall enter into the Share Purchase Agreement, under which Vir
shall receive, and Brii Bio shall pay to Vir, fully paid, non-assessable shares of Parent (the “Shares”) in accordance with the terms set forth therein. Parent agrees to timely
contribute, sell, or transfer to Brii Bio the Shares for Brii Bio’s payment to Vir. This Agreement shall terminate automatically if an investment of [***] at the initial Series A Closing (as defined in the Share Purchase Agreement) does not
occur on or before July 31, 2018, and the Share Purchase Agreement is terminated in accordance with its terms. 
 10.2 Option
Exercise Fee. 
 (a) Brii Bio Option Payments. Within [***] days after the Option Exercise Date for each Licensed Vir
Program, Brii Bio shall pay to Vir for each such Licensed Vir Program a one-time option exercise payment of [***] if such Licensed Vir Program is a High-Commercial Potential Program, (ii) [***] if such
Licensed Vir Program is a Mid-Commercial Potential Program, or (iii) [***] if such Licensed Vir Program is a Low-Commercial Potential Program. 

(b) Vir Option Payments. Within [***] days after the Option Exercise Date for each Licensed Brii Bio Program, Vir shall pay to
Brii Bio for each such Licensed Brii Bio Program a one-time option exercise payment of [***] if such Licensed Brii Bio Program is a High-Commercial Potential Program, (ii) [***] if such Licensed Brii Bio
Program is a Mid-Commercial Potential Program, or (iii) [***] if such Licensed Brii Bio Program is a Low-Commercial Potential Program. 

  
 52 

 EXECUTION VERSION 

 
 10.3 Development Milestone Payments. 

(a) Brii Bio Milestone Payments. On a Licensed
Product-by-Licensed Product basis, Brii Bio shall notify Vir in writing of the achievement by or on behalf of Brii Bio, its Affiliates, or sublicensees of the milestone
event set forth in this Section 10.3(a) promptly after the occurrence thereof. In partial consideration of the rights granted herein, Brii Bio shall pay Vir the non-refundable, non-creditable milestone payment set forth in the table below within [***] after the first achievement of such milestone event by or on behalf of Brii Bio, its Affiliates or sublicensees. 

[***] 
 (b) Vir Milestone Payments.
On a Licensed Product-by-Licensed Product basis, Vir shall notify Brii Bio in writing of the achievement by or on behalf of Vir, its Affiliates, or sublicensees of the
milestone event set forth in this Section 10.3(b) promptly after the occurrence thereof. In partial consideration of the rights granted herein, Vir shall pay Brii Bio the
non-refundable, non-creditable milestone payment set forth in the table below within thirty (30) days after the first achievement of such milestone event by or on
behalf of Brii Bio, its Affiliates or sublicensees. 
 [***] 

(c) Milestone Conditions. Each milestone payment set forth in this Section 10.3 is payable only once
for each Licensed Product, regardless of the number of times it is achieved by such Licensed Product. 
 10.4 Sales Milestone
Payments. 
 (a) Brii Bio Payments to Vir. In partial consideration of the rights granted herein, and subject to the
remainder of this Section 10.4, and on a Licensed Vir Program-by-Licensed Vir Program basis, Brii Bio shall pay to Vir the following milestone
payments within [***] days after the first achievement by or on behalf of Brii Bio, its Affiliates, or sublicensees of the milestone events set forth in this Section 10.4(a). 

[***] 
 (b) Vir Payments to Brii
Bio. In partial consideration of the rights granted herein, and subject to the remainder of this Section 10.4, and on a Licensed Brii Bio
Program-by-Licensed Brii Bio Program basis, Vir shall pay to Brii Bio the following milestone payments within [***] days after the first achievement by or on behalf of
Vir, its Affiliates, or sublicensees of the milestone events set forth in this Section 10.4(b). 
 [***] 

  
 53 

 EXECUTION VERSION 

 
 (c) Milestone Conditions. If annual Net Sales for all
Licensed Products within a Program in a given Calendar Year exceed more than one applicable threshold set forth in Section 10.4(a) or Section 10.4(b), then all corresponding milestone payments are
payable for such Calendar Year. 
 10.5 Royalty Payments. 

(a) Royalty Rates for Licensed Products Generally. On a Collaboration Program-by-Collaboration Program basis, for Licensed Products arising from such Collaboration Program (excluding Licensed Products arising from the Vir-Alnylam Program,
which are subject to Section 10.5(b)), during the Royalty Term for Licensed Products arising from such Collaboration Program and subject to Sections 10.5(c) and 10.5(d), (i) Brii Bio shall make quarterly, non-refundable, non-creditable royalty payments to Vir on Net Sales of the applicable Licensed Products sold in the China Territory calculated by multiplying the applicable
royalty rate set forth below by the aggregate amount of Net Sales of all Licensed Products arising from such Collaboration Program sold in the China Territory in the applicable Calendar Quarter, and (ii) Vir shall make quarterly, non-refundable, non-creditable royalty payments to Brii Bio on Net Sales of all the applicable Licensed Products sold in the United States calculated by multiplying the
applicable royalty rate set forth in TABLE 10.5(A) by the aggregate amount of Net Sales of all Licensed Products arising from such Collaboration Program sold in the United States in the applicable Calendar
Quarter. 
 TABLE 10.5(A) 

 

			
	 For that portion of annual Net Sales of the applicable Licensed
Products arising from a single
Collaboration Program in the applicable Territory
	  	Royalty
Rate
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 (b) Royalty Rates for Licensed Products from Vir-Alnylam
Program. For Licensed Products arising from the Vir-Alnylam Program, during the Royalty Term for an applicable Licensed Product and subject to Sections 10.5(c) and 10.5(d), Brii Bio shall
make quarterly, non-refundable, non-creditable royalty payments to Vir on Net Sales of the applicable Licensed Products sold in the China Territory calculated by
multiplying the applicable royalty rate set forth in TABLE 10.5(B) by the aggregate amount of Net Sales of all Licensed Products arising from the Vir-Alnylam Program
sold in the China Territory in the applicable Calendar Quarter. 
 TABLE 10.5(B) 

 

					
	 For that portion of annual Net Sales of all Licensed
Products arising from the Vir-Alnylam
Program in the China Territory
	  	Royalty
Rate
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  		  	[***]

  
 54 

 EXECUTION VERSION 

 
 (c) Royalty Term. The royalty payments payable under this
Section 10.5 shall be payable on a Licensed Product-by-Licensed Product basis and Territory-by-Territory basis from the First Commercial Sale of such Licensed Product in such region until the latest of: (i) ten (10) years after the First Commercial Sale of such Licensed Product in
such country, (ii) the expiration or abandonment of the last-to-expire Valid Claim in such country that Covers such Licensed Product, and (iii) the expiration
of Regulatory Exclusivity for the Licensed Product in such Territory (the “Royalty Term”). 
 (d) Royalty
Reductions. 
 (i) No Valid Claim. In each Calendar Quarter during the Royalty Term for a particular
Licensed Product of a Program and country in which there is no Valid Claim, the paying Party shall pay royalties to the other Party for such Licensed Product and country at a rate that is reduced by [***] of the royalty rates set forth in
Section 10.5(a). 
 (ii) Generic Reduction. If, in a Territory during the Royalty Term for a
Licensed Product, sales of all Generic Products to such Licensed Product in such Territory in a Calendar Quarter exceed [***]. All such determinations of the unit volume of sales shall be based upon [***]. 

(iii) Anti-Stacking. If the paying Party is required to obtain a license to any Third Party Patent with respect to a Licensed
Product that is reasonably necessary to avoid infringement of such Third Party Patent by such Licensed Product in such Party’s Territory, then, during the Royalty Term, such Party may deduct from any royalty payments to the other Party under
Section 10.5(a), [***] of any payments made by such first Party or its Affiliates or sublicensees to Third Parties in connection with the grant of any such license. 

(iv) Cumulative Deductions. In no circumstances will the royalties payable to the Controlling Party under this
Section 10.5 in any Calendar Year be reduced, as a result of Section 10.5(d)(i)–(iii), below the [***]. The paying Party may carry forward to subsequent Calendar Quarters any deductions that
it was not able to deduct as a result of the foregoing proviso. 
 (e) Royalty Reports and Payments. After the First Commercial
Sale of any Licensed Product in the paying Party’s Territory, within [***] days after each Calendar Quarter, the paying Party shall provide the other Party with a report that contains the following information for the applicable Calendar
Quarter, on a product-by-product basis (i) the amount of gross sales of Licensed Products, (ii) an itemized calculation of Net Sales showing separately each
type of reductions provided for in the definition of “Net Sales,” and (iii) a calculation of the royalty payment due on such sales in Dollars, including the exchange rate. Promptly following the delivery of the applicable quarterly
report, the license-granting Party shall invoice the paying Party for the royalties due to the license-granting Party with respect to Net Sales by the paying Party, its Affiliates, and their respective sublicensees for such Calendar Quarter, and the
paying Party shall pay such amounts to the license-granting Party in Dollars within [***] days following the paying Party’s receipt of such invoice. 

  
 55 

 EXECUTION VERSION 

 
 10.6 Payments to Third Parties. Subject to
Section 5.5 and Section 5.6, each Party shall be solely responsible for any payments due to Third Parties under any agreement entered into by such Party. 

10.7 Determination of Commercial Potential. 

(a) Pre-Option Exercise JSC Discussions. No later than [***] months prior to the
anticipated date of achievement of Proof of Concept by a Collaboration Program, or at such other time as determined by the JSC, the Parties shall discuss in good faith at the JSC the market potential for the anticipated first Product arising from
such Collaboration Program. 
 (b) Initial Assessment of Commercial Potential. For each Licensed Program, the Party exercising
an Option shall include with the Option Exercise Notice a [***] such Licensed Program. Such commercial assessment will be [***]. Based on such assessment, the applicable Program will be classified as (i) a
Low-Commercial Potential Program, (ii) a Mid-Commercial Potential Program, or (iii) a High-Commercial Potential Program (such determination, the
“Commercial Potential”). Subject to Section 10.7(c) and Section 10.7(d), any Commercial Potential designation made by a Party under this
Section 10.7(b) shall apply to the Option Exercise Fee due to the other Party under Section 10.2 and the milestone payments due to the other Party under Section 10.4. For
clarity, a Commercial Potential designation for a given Licensed Program shall apply to [***] Licensed Program. 
 (c) [***]
Assessment of Commercial Potential. If, at any time [***] a Licensed Product, a Party’s good faith commercial assessment of the Commercial Potential for the applicable Licensed Product changes, so that such Licensed Product would fall
within a different classification of Commercial Potential, then such Party shall give prompt [***] written notice to the other Party of such updated assessment of Commercial Potential for such Licensed Product, including [***]. If such updated
assessment resulted in the Commercial Potential designation changing upwards from (i) Low-Commercial Potential Program to either a Mid-Commercial Potential Program
or a High-Commercial Potential Program, or (ii) a Mid-Commercial Potential Program to a High-Commercial Potential Program, then [***]. If such updated assessment resulted in the Commercial Potential
designation changing downwards from (A) a High-Commercial Potential Program to either a Mid-Commercial Potential Program or Low-Commercial Potential Program, or
(B) a Mid-Commercial Potential Program to a Low-Commercial Potential Program, then [***]. For clarity, any revised Commercial Potential designation made by a Party
under this Section 10.7(c) shall apply to the milestone payments due to the other Party under Section 10.4. 

(d) [***]. 

(i) [***]. Notwithstanding a Party’s assessment of [***] any Licensed Product under a Licensed Program [***] then
applicable to such Licensed Program, such Party shall promptly notify the other Party of such occurrence and, within [***] had been made by such Party at the time of Option Exercise Notice and the [***] pursuant to
Section 10.2 and this Section 10.7(d) and (B) [***]. 

  
 56 

 EXECUTION VERSION 

 
 (ii) [***]. Notwithstanding a Party’s assessment of
[***] Licensed Product in such Licensed Program, the [***], and the [***], subject to Section 10.5(d)(iv), the Party who made such [***]. For clarity, if the JSC [***], and there shall be [***] this
Section 10.7(d). 
 10.8 Currency; Exchange Rate. All payments to be made by Brii Bio to Vir or Vir
to Brii Bio under this Agreement shall be made in Dollars by electronic funds transfer in immediately available funds to a bank account designated in writing by Vir or Brii Bio, as applicable. Conversion of Net Sales recorded in local currencies
shall be converted to Dollars at the exchange rate set forth in The Wall Street Journal or any successor thereto for the last day of the Calendar Quarter in which the applicable payment obligation became due and payable. 

10.9 Late Payments. Any payments or portions thereof due hereunder that are not paid on the date such payments are due under this
Agreement shall bear interest at a rate equal to the lesser of (a) [***] as published by The Wall Street Journal or any successor thereto on the first day of each Calendar Quarter in which such payments are overdue and (b) [***], in each case
calculated on the number of days such payment is delinquent, compounded monthly. 
 10.10 Financial Records and Audits. Each
Party shall maintain complete and accurate records in sufficient detail to permit the other Party to confirm the accuracy of the amount of royalty payments and other amounts payable under this Agreement, and such records shall be maintained for at
least [***] following the Calendar Quarter to which such records apply. Upon reasonable prior notice, such records shall be open during regular business hours for a period of [***] from the creation of individual records for examination by an
independent certified public accountant selected by the examining Party and reasonably acceptable to the other Party for the sole purpose of verifying for the examining Party the accuracy of the financial reports furnished by the other Party (the
“Examined Party”) pursuant to this Agreement or of any payments made, or required to be made by such Examined Party, pursuant to this Agreement. Such audits shall not occur more often than once each Calendar Year. Such
auditor shall not disclose the Examined Party’s Confidential Information to the examining Party or to any Third Party, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by the Examined
Party or the amount of payments by the Examined Party under this Agreement. The Examined Party shall pay any amounts shown to be owed to the examining Party within [***] after the accountant’s report, plus interest (as set forth in
Section 10.9) from the original due date. The examining Party shall bear the full cost of such audit unless such audit reveals an underpayment by the Examined Party of more than [***]of the amount actually due for the time
period being audited, in which case the Examined Party shall reimburse the examining Party for the costs for such audit. 
 10.11 Taxes

 (a) Taxes on Income. Except as set forth in this Section 10.11 or
Section 10.12, each Party shall be solely responsible for the payment of any and all Taxes levied on account of all payments it receives under this Agreement. 

  
 57 

 EXECUTION VERSION 

 
 (b) Tax Cooperation. The Parties shall cooperate with
one another in accordance with Applicable Laws and use reasonable efforts to minimize Tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made by each Party to the other Party under this
Agreement. To the extent either Party (the “Paying Party”) is required to deduct and withhold Taxes on any payment to the other Party (the “Recipient”), the Paying Party shall (i) pay the
amount of such Taxes to the proper Governmental Authority in a timely manner, and (ii) promptly transmit to the Recipient an official tax certificate or other evidence of such payment sufficient to enable the Recipient to claim such payment of
Taxes on the Recipient’s applicable tax returns. The Paying Party shall provide the Recipient with advance notice prior to withholding any Taxes from payments payable to the Recipient and shall provide the Recipient with a commercially
reasonable period of time to claim an exemption or reduction in otherwise applicable Taxes. The Recipient shall provide the Paying Party any tax forms that may be reasonably necessary for the Paying Party to not withhold Tax or to withhold Tax
at a reduced rate under an applicable bilateral income tax treaty, to the extent the Paying Party is legally able to do so. The Recipient shall use reasonable efforts to provide any such tax forms to the Paying Party in advance of the due
date. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding Taxes or similar obligations resulting from payments made under this Agreement, such recovery to be for
the benefit of the Paying Party if the Paying Party is the Party bearing such withholding Tax under this Section 10.11.

(c) Transfers and Assignments. Notwithstanding anything to the contrary in this Agreement, if the Paying Party
assigns, transfers, or otherwise disposes of some or all of its rights and obligations to any Person and if, as a result of such action, the withholding or deduction of Tax required by Applicable Laws with respect to payments under this Agreement is
increased, then any amount payable to the Recipient under this Agreement shall be increased to take into account such withheld Taxes as may be necessary so that, after making all required withholdings (including withholdings on the withheld
amounts), the Recipient receives an amount equal to the sum it would have received had no such withholding been made.
 (d)
Transfer Taxes. All transfer, documentary, sales, use, stamp, registration, value added and other such Taxes, and any conveyance fees, recording charges and other fees and charges (including any penalties and interest) incurred in
connection with consummation of the transactions contemplated hereby, if any, shall be borne and paid by the Paying Party. The Paying Party shall prepare and timely file all tax returns required to be filed in respect of any such
Taxes. The Parties shall reasonably cooperate in accordance with Applicable Laws to minimize transfer Taxes in connection with this Agreement.

10.12 Blocked Currency. If by Applicable Law in a country or region in the applicable Territory, conversion into Dollars or
transfer of funds of a convertible currency to the United States becomes restricted, forbidden or substantially delayed, then Brii Bio shall promptly notify Vir and, thereafter, amounts accrued in such country or region under this Article 10
shall be paid to Vir (or its designee) in such country or region in local currency by deposit in a local bank designated by Vir and to the credit of Vir. 

  
 58 

 EXECUTION VERSION 

 
 ARTICLE 11 

CONFIDENTIALITY; PUBLICATION 

11.1 Duty of Confidence. Subject to the other provisions of this Article 11: 

(a) Except to the extent expressly authorized by this Agreement, all Confidential Information of a Party (the “Disclosing
Party”) shall be maintained in confidence and otherwise safeguarded, and not published or otherwise disclosed, by the other Party (the “Receiving Party”) and its Affiliates for the Term and [***] thereafter; 

(b) the Receiving Party may only use any Confidential Information of the Disclosing Party for the purposes of performing its obligations
or exercising its rights under this Agreement; and 
 (c) a Receiving Party may disclose Confidential Information of the Disclosing
Party to: (i) such Receiving Party’s Affiliates, licensees and sublicensees; and (ii) employees, directors, agents, contractors, consultants and advisors of the Receiving Party and its Affiliates and sublicensees, in each case to the
extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this Agreement; provided that such Persons are bound by legally enforceable obligations to maintain the confidentiality of the Disclosing
Party’s Confidential Information in a manner consistent with the confidentiality provisions of this Agreement; provided that each Party shall remain responsible for any failure by its Affiliates, licensees and sublicensees, and
its and its Affiliates’ and licensees’ and sublicensees’ respective employees, directors, agents, consultants, advisors, and contractors, to treat such Confidential Information as required under this
Section 11.1 (as if such Affiliates, licensees, sublicensees employees, directors, agents, consultants, advisors and contractors were Parties directly bound to the requirements of this
Section 11.1). 
 11.2 Exemptions. Information of a Disclosing Party will not be deemed to be
Confidential Information of such Disclosing Party to the extent that the Receiving Party can demonstrate through competent evidence that such information: 

(a) is known by the Receiving Party or any of its Affiliates without an obligation of confidentiality at the time of its receipt from
the Disclosing Party, and not through a prior disclosure by or on behalf of the Disclosing Party, as documented by the Receiving Party’s business records; 

(b) is generally available to the public before its receipt from the Disclosing Party; 

(c) became generally available to the public or otherwise part of the public domain after its disclosure by the Disclosing Party and
other than through any act or omission of the Receiving Party or any of its Affiliates or disclosees in breach of this Agreement; 

(d) is subsequently disclosed to the Receiving Party or any of its Affiliates without obligation of confidentiality by a Third Party who
may rightfully do so and is not under a conflicting obligation of confidentiality to the Disclosing Party; or 
 (e) is developed by
the Receiving Party or any of its Affiliates independently and without use of or reference to any Confidential Information received from the Disclosing Party, as documented by the Receiving Party’s business records. 

  
 59 

 EXECUTION VERSION 

 
 No combination of features or disclosures shall be deemed to fall within the foregoing
exclusions merely because individual features are published or available to the general public or in the rightful possession of the Receiving Party, unless the combination itself and principle of operation are published or available to the general
public or in the rightful possession of the Receiving Party. 
 11.3 Authorized Disclosures. Notwithstanding the obligations
set forth in Section 11.1 and Section 11.5, a Party may disclose the other Party’s Confidential Information (including this Agreement and the terms herein) to the extent such disclosure is
reasonably necessary in the following situations: 
 (a) (i) the prosecution and maintenance of Patents as contemplated by this
Agreement; (ii) regulatory filings and other filings with Governmental Authorities (including Regulatory Authorities), as necessary for the Development or Commercialization of a Licensed Product; or (iii) subject to
Section 11.6, complying with Applicable Laws, including regulations promulgated by securities exchanges; 

(b) disclosure of this Agreement, its terms and the status and results of Pre-Option
Development, Development, or Commercialization activities to actual or bona fide potential investors, acquirors, (sub)licensees, lenders and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual
or potential investment, acquisition, (sub)license, debt transaction or collaboration; provided that in each such case on the condition that such Persons are bound by confidentiality and non-use
obligations consistent with this Agreement or customary for such type and scope of disclosure; 
 (c) such disclosure is required by
judicial or administrative process, provided that in such event such Party shall promptly notify the other Party in writing of such required disclosure and provide the other Party an opportunity to challenge or limit the disclosure
obligations. Confidential Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Article 11, and the
Party disclosing Confidential Information pursuant to Applicable Laws or court order shall take all steps reasonably necessary, including seeking of confidential treatment or a protective order, to ensure the continued confidential treatment of such
Confidential Information; or 
 (d) disclosure pursuant to Section 11.5 and
Section 11.6. 
 Notwithstanding the foregoing, in the event a Party is required or permitted to make a disclosure
of the other Party’s Confidential Information pursuant to Section 11.3(a)(ii) or Section 11.3(a)(iii), it will, except where impracticable, give reasonable advance notice to the other Party of
such disclosure and use reasonable efforts to secure confidential treatment of such information. In any event, each Party agrees to take all reasonable action to avoid disclosure of Confidential Information of the other Party hereunder. 

Nothing in Section 11.1 or this Section 11.3 shall limit either Party in any way from
disclosing to any Third Party such Party’s U.S. or foreign income Tax treatment and the U.S. or foreign income Tax structure of the transactions relating to such Party that are based on or derived from this Agreement, as well as all materials
of any kind (including opinions or other Tax analyses) relating to such Tax treatment or Tax structure, except to the extent that nondisclosure of such matters is reasonably necessary in order to comply with applicable securities laws. 

  
 60 

 EXECUTION VERSION 

 
 11.4 Publications. 

(a) For Vir Programs. Brii Bio shall not publicly present or publish any Clinical Trial data,
non-clinical data or any associated results or conclusions generated by or on behalf of Brii Bio for any Vir Program pursuant to this Agreement (each such proposed presentation or publication, a
“Brii Bio Publication”), except in accordance with Vir’s global publication strategy with respect to Products and Licensed Products, and subject to the additional limitations set forth in this
Section 11.4(a). If Brii Bio desires to publicly present or publish a Publication, Brii Bio shall provide Vir with a copy of such proposed Publication at least [***] prior to the earlier of its presentation or intended
submission for publication; provided that in the case of abstracts, this period shall be at least [***] (such applicable period, the “Review Period”). Brii Bio shall not submit or present any Publication until
(i) Vir has provided written comments during such Review Period on the material in such Publication or (ii) the applicable Review Period has elapsed without written comments from Vir, in which case Brii Bio may proceed and the Publication
will be considered approved in its entirety. If Brii Bio receives written comments from Vir during the applicable Review Period, it shall consider the comments of Vir in good faith, but will retain the sole authority to submit the manuscript for
Publication; provided that Brii Bio shall (A) delete any Confidential Information of Vir that Vir identifies for deletion in Vir’s written comments, (B) [***], and (C) delay such Publication for a period of up to an
additional [***] after the end of the applicable Review Period to enable Vir to draft and file a Patent with respect to any subject matter to be made public in such Publication and to which Vir has the applicable intellectual property rights to file
such Patent. Brii Bio shall provide Vir a copy of the Publication at the time of the submission or presentation. Brii Bio shall acknowledge the contributions of Vir and the employees of Vir in all Publications as scientifically appropriate. Brii Bio
shall require its Affiliates, sublicensees and contractors to comply with the obligations of this Section 11.4(a) as if they were Brii Bio, and shall be liable for their
non-compliance. 
 (b) For Brii Bio Programs. Vir shall not publicly present or publish
any Clinical Trial data, non-clinical data or any associated results or conclusions generated by or on behalf of Vir for any Brii Bio Program pursuant to this Agreement (each such proposed presentation or
publication, a “Vir Publication”), except in accordance with Brii Bio’s global publication strategy with respect to Products and Licensed Products, and subject to the additional limitations set forth
in this Section 11.4(b). If Vir desires to publicly present or publish a Publication, Vir shall provide Brii Bio with a copy of such proposed Publication at least [***] prior to the earlier of its presentation or intended
submission for publication; provided that in the case of abstracts, this period shall be at least [***]. Vir shall not submit or present any Publication until (i) Brii Bio has provided written comments during such Review Period on the
material in such Publication or (ii) the applicable Review Period has elapsed without written comments from Brii Bio, in which case Vir may proceed and the Publication will be considered approved in its entirety. If Vir receives written
comments from Brii Bio during the applicable Review Period, it shall consider the comments of Brii Bio in good faith, but will retain the sole authority to submit the manuscript for Publication; provided that Vir shall (A) delete
any Confidential Information of Brii Bio that Brii Bio identifies for deletion in Brii Bio’s written 

  
 61 

 EXECUTION VERSION 

 
 comments, (B) [***], and (C) delay such Publication for a period of up to an
additional [***] after the end of the applicable Review Period to enable Brii Bio to draft and file a Patent with respect to any subject matter to be made public in such Publication and to which Brii Bio has the applicable intellectual property
rights to file such Patent. Vir shall provide Brii Bio a copy of the Publication at the time of the submission or presentation. Vir shall acknowledge the contributions of Brii Bio and the employees of Brii Bio in all Publications as scientifically
appropriate. Vir shall require its Affiliates, sublicensees and contractors to comply with the obligations of this Section 11.4(b) as if they were Vir, and shall be liable for their
non-compliance. 
 11.5 Publication and Listing of Clinical Trials. Each Party
shall comply, with respect to the listing of Clinical Trials or the publication of Clinical Trial results with respect to Products or Licensed Products and to the extent applicable to its activities conducted under this Agreement, with
(a) the Pharmaceutical Research and Manufacturers of America (PhRMA) Guidelines on the listing of Clinical Trials and the Publication of Clinical Trial results, and (b) any Applicable Law or applicable court order, stipulations, consent
agreements and settlements entered into by such Party; provided that any listings or publications made pursuant to this Section 11.5 shall be considered a Publication hereunder and shall be subject to
Section 11.4. 
 11.6 Publicity; Use of Names. 

(a) The material terms of this Agreement are the Confidential Information of both Parties, subject to the special authorized disclosure
provisions set forth in Section 11.3 and this Section 11.6. The Parties have agreed on a joint press release announcing this Agreement, which is attached hereto as Exhibit 11.6, to be issued
by the Parties on such date and time as may be agreed by the Parties. No other disclosure of the existence or the terms of this Agreement may be made by either Party or its Affiliates except as provided in Section 11.3 and
this Section 11.6. 
 (b) Notwithstanding Section 11.6(a), each Party may publicly
disclose the achievement of milestones under this Agreement by the other Party. After a Publication has been made available to the public, each Party may post such Publication or a link to it on its corporate web site without the prior written
consent of the other Party. 
 (c) A Party may disclose this Agreement in securities filings with the Securities and Exchange
Commission (the “SEC”) or equivalent foreign agency to the extent required by Applicable Laws. In such event, the Party seeking such disclosure shall prepare a draft confidential treatment request and proposed redacted
version of this Agreement to request confidential treatment for this Agreement, and the other Party agrees to promptly (and in any event, no more than [***] after receipt of such confidential treatment request and proposed redactions) give its input
in a reasonable manner in order to allow the Party seeking disclosure to file its request within the time lines prescribed by Applicable Laws. The Party seeking such disclosure shall reasonably consider any comments thereto provided by the other
Party within such [***] period. 

  
 62 

 EXECUTION VERSION 

 
 (d) Each Party acknowledges that the other Party may be legally
required to make public disclosures (including in filings with Governmental Authorities) of certain terms of or material developments or material information generated under this Agreement and agrees that each Party may make such disclosures as
required by Applicable Laws, provided that the Party seeking such disclosure (i) receives advice from counsel that it is legally required to make such public disclosure and (ii) if practicable and permitted by Applicable Laws, first
provides the other Party a copy of the proposed disclosure, and reasonably considers any comments thereto provided by the other Party within [***] after the receipt of such proposed disclosure. 

(e) Other than the press release set forth in Exhibit 11.6 and the public disclosures permitted by
Section 11.6(b), the portions of any news release or other public announcement relating to this Agreement or the performance hereunder that would disclose information other than that already in the public domain, shall
first be reviewed and approved by both Parties (with such approval not to be unreasonably withheld, conditioned, or delayed), except as required by Applicable Laws. 

(f) After a disclosure pursuant to Section 11.6(d) or issuance of a press release (including the initial
press release) or other public announcement pursuant to Section 11.6(a) that has been reviewed and approved by the other Party, the disclosing Party may make subsequent public disclosures reiterating such information
without having to obtain the other Party’s prior consent and approval. 
 (g) Each Party may use the other Party’s name and
logo in presentations, its website, collateral materials and corporate overviews to describe the collaboration relationship, as well as in taglines of press releases issued pursuant to this Section 11.6; provided
that each Party shall use the other Party’s corporate name only in such manner that the distinctiveness, reputation, and validity of any trademarks and corporate or trade names of such other Party shall not be impaired, and consistent with best
practices used by such first Party for its other collaborators. 
 11.7 Attorney-Client Privilege. Neither Party is waiving,
nor shall be deemed to have waived or diminished, any of its attorney work product protections, attorney-client privileges or similar protections and privileges or the like as a result of disclosing information pursuant to this Agreement, or any of
its Confidential Information (including Confidential Information related to pending or threatened litigation) to the Receiving Party, regardless of whether the Disclosing Party has asserted, such privileges and protections. The Parties:
(a) share a common legal and commercial interest in such disclosure that is subject to such privileges and protections; (b) are or may become joint defendants in proceedings to which the information covered by such protections and
privileges relates; (c) intend that such privileges and protections remain intact should either Party become subject to any actual or threatened proceeding to which the Disclosing Party’s Confidential Information covered by such
protections and privileges relates; and (d) intend that after the Effective Date both the Receiving Party and the Disclosing Party may assert such protections and privileges. Notwithstanding the foregoing, nothing in this
Section 11.7 shall apply with respect to a dispute between the Parties (including their respective Affiliates). 

  
 63 

 EXECUTION VERSION 

 
 ARTICLE 12 

REPRESENTATIONS, WARRANTIES, AND COVENANTS 

12.1 Representations, Warranties of Each Party. Each Party represents and warrants to the other as of the Effective Date that:
(a) it is duly organized, validly existing, and in good standing under the laws of its jurisdiction of formation; (b) it has full corporate power and authority to execute and deliver this Agreement, and has taken all corporate action
required by law and its organizational documents to authorize the execution and delivery of this Agreement; (c) this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms (except as the
enforceability thereof may be limited by bankruptcy, bank moratorium, or similar laws affecting creditors’ rights generally and laws restricting the availability of equitable remedies and may be subject to general principles of equity whether
or not such enforceability is considered in a proceeding at law or in equity); (d) all consents, approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by such Party in connection with this
Agreement have been obtained; (e) the execution and delivery of this Agreement and all other instruments and documents required to be executed pursuant to this Agreement, and the consummation of the transactions contemplated hereby do not
conflict with or result in a breach of any provision of its organizational documents, result in a breach of any agreement to which it is a party; or violate any law; and (f) neither such Party nor to the actual knowledge of such Party any
employee, agent or subcontractor of such Party involved or to be involved in any activities performed hereunder has been (i) convicted of an offense related to any federal or state health care program; (ii) excluded from participation as a
provider under any Federal or State health care program or (iii) debarred under subsection (a) or (b) of Section 306 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. §335a). Each Party further represents and warrants that
(A) there are no legal claims, judgments or settlements against or owed by such Party or any of its Affiliates, or pending or, to such Party’s actual knowledge, threatened, legal claims or litigation, in each case, relating to antitrust,
anti-competition, anti-bribery or corruption violations, and (B) such Party has, or can readily obtain, sufficient technical, clinical, and regulatory expertise to perform all of its obligations pursuant to this Agreement, including its
obligations relating to Pre-Option Development, Development, Manufacturing, Commercialization, and obtaining Regulatory Approvals. 

12.2 Representations and Warranties of Brii Bio as of the Option Exercise Date of each Vir Option. On a Licensed
Brii Bio Program-by-Licensed Brii Bio Program basis, Brii Bio represents and warrants to Vir that as of the Option Exercise Date for a Brii Bio Program: 

(a) it has the right under the Brii Bio Technology applicable to such Licensed Brii Bio Program to grant the Vir Option under
Section 4.1(a) and the license under Section 3.3(a), and it has not granted to any Third Party any license or right with respect to the Brii Bio Technology that conflicts with such Vir Option or
the license under Section 3.3(a) for such Licensed Brii Bio Program; 
 (b) to the knowledge of Brii Bio,
the issued patents in the Brii Bio Patents applicable to such Licensed Brii Bio Program are valid and enforceable without any claims, challenges, oppositions, interference or other proceedings pending or threatened in writing; 

(c) to Brii Bio’s knowledge, Brii Bio has not committed any act, or omitted to commit any act, that may cause the Brii Bio Patents
to expire prematurely or be declared invalid or unenforceable; 

  
 64 

 EXECUTION VERSION 

 
 (d) except to the extent not yet due, all necessary and material
application, registration, maintenance and renewal fees in respect of the Brii Bio Patents applicable to such Licensed Brii Bio Program have been paid and, except to the extent not yet due, all necessary documents and certificates have been filed
with the relevant agencies for the purpose of maintaining such Brii Bio Patents; 
 (e) (i) Brii Bio has obtained, or caused its
Affiliates to obtain, assignments from the inventors of all rights and embodiments in and to the Brii Bio Technology that is applicable to such Licensed Brii Bio Program and solely owned by Brii Bio or its Affiliates, (ii) all such assignments
are valid and enforceable, and (iii) the inventorship of the Brii Bio Patents that are solely owned by Brii Bio or its Affiliates is properly identified on each issued patent or patent application in such Brii Bio Patents; 

(f) Brii Bio has taken reasonable precautions consistent with industry practices to preserve the confidentiality of the Brii Bio Know-How applicable to such Licensed Brii Bio Program; and 
 (g) Brii Bio has complied with all
Applicable Laws applicable to the prosecution and maintenance of the Brii Bio Patents applicable to such Licensed Brii Bio Program; and 

(h) there are no agreements or arrangements to which Brii Bio or any of its Affiliates is a party relating to the Brii Bio Technology
applicable to such Licensed Brii Bio Program that would limit the rights granted to Vir under this Agreement. 
 12.3
Representations and Warranties of Vir as of the Date of Exercise of each Brii Bio Option. On a Licensed Vir Program-by-Licensed Vir Program
basis, Vir represents and warrants to Brii Bio that as of the Option Exercise Date for a Brii Bio Program: 
 (a) it has the right
under the Vir Technology applicable to such Licensed Vir Program to grant the Brii Bio Option under Section 4.1(a) and the license under Section 3.3(a), and it has not granted to any Third Party
any license or right with respect to the Vir Technology that conflicts with such Brii Bio Option or the license under Section 3.3(a) for such Licensed Vir Program; 

(b) to the knowledge of Vir, the issued patents in the Vir Patents applicable to such Licensed Vir Program are valid and enforceable
without any claims, challenges, oppositions, interference or other proceedings pending or threatened in writing; 
 (c) to Vir’s
knowledge, Vir has not committed any act, or omitted to commit any act, that may cause the Vir Patents to expire prematurely or be declared invalid or unenforceable; 

(d) except to the extent not yet due, all necessary and material application, registration, maintenance and renewal fees in respect of
the Vir Patents applicable to such Licensed Vir Program have been paid and, except to the extent not yet due, all necessary documents and certificates have been filed with the relevant agencies for the purpose of maintaining such Vir Patents; 

  
 65 

 EXECUTION VERSION 

 
 (e) (i) Vir has obtained, or caused its Affiliates to obtain,
assignments from the inventors of all rights and embodiments in and to the Vir Technology that is applicable to such Licensed Vir Program and solely owned by Vir or its Affiliates, (ii) all such assignments are valid and enforceable, and
(iii) the inventorship of the Vir Patents that are solely owned by Vir or its Affiliates is properly identified on each issued patent or patent application in such Vir Patents; 

(f) Vir has taken reasonable precautions consistent with industry practices to preserve the confidentiality of the Vir Know-How applicable to such Licensed Vir Program; and 
 (g) Vir has complied with all Applicable
Laws applicable to the prosecution and maintenance of the Vir Patents applicable to such Licensed Vir Program; and 
 (h) there are no
agreements or arrangements to which Vir or any of its Affiliates is a party relating to the Vir Technology applicable to such Licensed Vir Program that would limit the rights granted to Brii Bio under this Agreement. 

12.4 Covenants of Brii Bio. Brii Bio covenants to Vir during the Term that: 

(a) in the course of performing its obligations or exercising its rights under this Agreement, Brii Bio shall comply with all Applicable
Laws, including, as applicable, cGMP, GCP, and GLP standards, and shall not employ or engage any Person who has been debarred by any Regulatory Authority, or, to Brii Bio’s knowledge, is the subject of debarment proceedings by a Regulatory
Authority; and 
 (b) Brii Bio shall only engage Clinical Trial sites to perform Clinical Trials under this Agreement that conduct
Clinical Trials in compliance with Applicable Laws, including GCP and the ICH Guidelines, and are approved by the CFDA. 
 12.5
Covenants of Vir. Vir covenants to Brii Bio during the Term that: 
 (a) in the course of performing its obligations or
exercising its rights under this Agreement, Vir shall comply with all Applicable Laws, including, as applicable, cGMP, GCP, and GLP standards, and shall not employ or engage any Person who has been debarred by any Regulatory Authority, or, to
Vir’s knowledge, is the subject of debarment proceedings by a Regulatory Authority; and 
 (b) Vir shall only engage Clinical
Trial sites to perform Clinical Trials under this Agreement that conduct Clinical Trials in compliance with Applicable Laws, including GCP and the ICH Guidelines, and are approved by the FDA. 

12.6 NO OTHER WARRANTIES. EXCEPT AS EXPRESSLY STATED IN THIS Article 12, (A) NO REPRESENTATION, CONDITION OR WARRANTY
WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF VIR OR BRII BIO; AND (B) ALL OTHER CONDITIONS AND WARRANTIES WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE ARE EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. 

  
 66 

 EXECUTION VERSION 

 
 12.7 Compliance with Anti-Corruption Laws. 

(a) Notwithstanding anything to the contrary in this Agreement, each Party agrees that: (i) it shall not, in the performance of
this Agreement, perform any actions that are prohibited by local and other anti-corruption laws (including the provisions of the United States Foreign Corrupt Practices Act, collectively “Anti-Corruption Laws”) that may be
applicable to one or both Parties; (ii) it shall not, in the performance of this Agreement, directly or indirectly, make any payment, or offer or transfer anything of value, or agree or promise to make any payment or offer or transfer anything
of value, to a government official or government employee, to any political party or any candidate for political office or to any other Third Party with the purpose of influencing decisions related to either Party or its business in a manner that
would violate Anti-Corruption Laws; (iii) it will, no later than sixty (60) days following the end of each Calendar Year, verify in writing that to the best of such Party’s knowledge, there have been no violations of Anti-Corruption
Laws by such Party, its Affiliates or sublicensees, or persons employed by or subcontractors used by such Party or its Affiliates or sublicensees in the performance of this Agreement, or shall provide details of any exception to the foregoing; and
(iv) it shall maintain records (financial and otherwise) and supporting documentation related to the subject matter of this Agreement in order to document or verify compliance with the provisions of this Section 12.7,
and upon request of the other Party, up to once per year and upon reasonable advance notice, shall provide the other Party or its representative with access to such records for purposes of verifying compliance with the provisions of this
Section 12.7. 
 (b) Each Party represents and warrants that, to its knowledge, neither such Party nor any
of its Affiliates, or its or their directors, officers, employees, distributors, agents, representatives, sales intermediaries or other Third Parties acting on behalf of such Party or any of its Affiliates: (i) has taken any action in violation
of any applicable Anti-Corruption Laws; or (ii) has corruptly offered, paid, given, promised to pay or give, or authorized the payment or gift of anything of value, directly or indirectly, to any Public Official (as defined in
Section 12.7(d)), for the purposes of: (1) influencing any act or decision of any Public Official in his or her official capacity; (2) inducing such Public Official to do or omit to do any act in violation of his
or her lawful duty; (3) securing any improper advantage; or (4) inducing such Public Official to use his or her influence with a government, governmental entity, or commercial enterprise owned or controlled by any government (including
state-owned or controlled veterinary, laboratory or medical facilities) in obtaining or retaining any business whatsoever. 
 (c) Each
Party further represents and warrants that, as of the Effective Date, none of the officers, directors or employees of such Party or of any of its Affiliates or agents acting on behalf of such Party or any of its Affiliates, in each case that are
employed or reside outside the United States, is a Public Official. 
 (d) For purposes of this
Section 12.7, “Public Official” means (i) any officer, employee or representative of any regional, federal, state, provincial, county or municipal government or government department, agency or
other division; (ii) any officer, employee or representative of any commercial enterprise that is owned or controlled by a government, including any state-owned or controlled veterinary, laboratory or medical facility; (iii) any officer,
employee or representative of any public international organization, such as the African Union, the International Monetary Fund, the United Nations or the World Bank; and (iv) any person acting in an official capacity for any government or
government entity, enterprise or organization identified above. 

  
 67 

 EXECUTION VERSION 

 
 ARTICLE 13 

INDEMNIFICATION 

13.1 By Brii Bio. Brii Bio shall indemnify and hold harmless Vir, its Affiliates, and its and their respective directors,
officers, employees and agents (individually and collectively, the “Vir Indemnitees”) from and against all costs, fees, expenses, losses, liabilities and damages (including reasonable attorneys’ fees and costs) incurred
in connection with any claims, demands, actions or other proceedings by any Third Party (individually and collectively, “Losses”) to the extent arising from (a) of the negligence or material breach by Brii Bio of its
obligations under a Pre-Option Development Plan for any Product in a Vir Program in the China Territory, (b) the Development, Manufacture, or Commercialization of any Product or Licensed Product
(including Licensed Products of a Brii Bio Program outside the United States and actions related to Brii Bio’s role as the authorized regulatory agent of record for Vir pursuant to this Agreement) by or on behalf of Brii Bio or any of its
Affiliates or sublicensees (excluding Vir, its Affiliates, and sublicensees), (c) Brii Bio’s actions (or omissions) in the performance of its obligations with respect to Regulatory Submissions and interactions with Regulatory Authorities, in
each case, as an agent of Vir in the China Territory, (d) the negligence or willful misconduct of Brii Bio or its Affiliates or sublicensees, (e) Brii Bio’s breach of any of its representations or warranties made in or pursuant to
this Agreement or any covenants or obligations set forth in or entered into pursuant to this Agreement, or (f) failure of Brii Bio or its Affiliates or sublicensees to abide by any Applicable Laws, in each case of clauses (a) through (f)
above, except to the extent such Losses arise out of a Vir Indemnitee’s negligence or willful misconduct, breach of this Agreement, or material failure to abide by any Applicable Laws. 

13.2 By Vir. Vir shall indemnify and hold harmless Brii Bio, its Affiliates, and their directors, officers, employees and
agents (individually and collectively, the “Brii Bio Indemnitees”) from and against all Losses to the extent arising from (a) of the negligence or material breach by Vir of its obligations under a Pre-Option Development Plan for any Product in a Brii Bio Program in the United States, (b) the Development, Manufacture, or Commercialization of any Product or Licensed Product (including Licensed Products of
a Vir Program outside the China Territory) by or on behalf of Vir or any of its Affiliates or sublicensees (excluding Brii Bio, its Affiliates, and sublicensees), (c) the negligence or willful misconduct of Vir or its Affiliates or sublicensees,
(d) Vir’s breach of any of its representations or warranties made in or pursuant to this Agreement or any covenants or obligations set forth in or entered into pursuant to this Agreement, or (e) failure of Vir or its Affiliates or
sublicensees to abide by any Applicable Laws, in each case of clauses (a) through (e) above, except to the extent such Losses arise out of a Brii Bio Indemnitee’s negligence or willful misconduct, breach of this Agreement, or material
failure to abide by any Applicable Laws. 
 13.3 Indemnification Procedure. If either Party is seeking indemnification under
Section 13.1 or Section 13.2 (the “Indemnified Party”), it shall inform the other Party (the “Indemnifying Party”) of the claim giving rise to the
obligation to indemnify within ten (10) Business Days after receiving written notice of the claim (it being understood and agreed, however, that the failure or delay by an Indemnified Party to give such notice of a claim shall not

  
 68 

 EXECUTION VERSION 

 
 affect the indemnification provided hereunder except to the extent the Indemnifying
Party is actually and materially prejudiced as a result of such failure or delay to give notice). The Indemnifying Party may assume the defense of any such claim for which it is obligated to indemnify the Indemnified Party. The Indemnified Party
shall cooperate with the Indemnifying Party and the Indemnifying Party’s insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and expense. The Indemnified Party may participate, at its own expense
and with counsel of its choice, in the defense of any claim that has been assumed by the Indemnifying Party. Neither Party shall have the obligation to indemnify the other Party in connection with any settlement made without the Indemnifying
Party’s written consent, which consent shall not be unreasonably withheld, conditioned or delayed. If the Parties cannot agree as to the application of Section 13.1 or Section 13.2 as to any
claim, pending resolution of the dispute pursuant to Article 16, the Parties may conduct separate defenses of such claims, with each Party retaining the right to claim indemnification from the other Party in accordance with
Section 13.1 or Section 13.2 upon resolution of the underlying claim. 
 13.4
[***]. Each Indemnified Party shall take and shall procure that its Affiliates take all such reasonable steps and action as are reasonably necessary or as the Indemnifying Party may reasonably require in order to [***]. 

13.5 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR
INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 13.5 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE
INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 13.1 OR SECTION 13.2, OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF ITS OBLIGATIONS HEREUNDER RELATING TO [***]. 

13.6 Insurance. Each shall procure and maintain insurance, including product liability insurance, with respect to its activities
hereunder that is consistent with normal business practices of prudent companies similarly situated at all times during which any Product or Licensed Product is being clinically tested in human subjects or commercially distributed or sold in the
applicable Territory. Each Party shall provide the other Party with evidence of such insurance upon request and shall provide the other Party with written notice at least sixty (60) days prior to the cancellation,
non-renewal or material changes in such insurance. Such insurance shall not be construed to create a limit of the insured Party’s liability with respect to its indemnification obligations under this
Article 13. 
 ARTICLE 14 

INTELLECTUAL PROPERTY 

14.1 Inventions. 

(a) Ownership. Subject to Section 3.11 (which governs ownership of Inventions arising prior to the
Option Exercise Date for any Program), ownership of all Inventions will be assigned based on inventorship, as determined in accordance with the rules of 

  
 69 

 EXECUTION VERSION 

 
 inventorship under United States patent laws. Each Party owns all Inventions that are
made solely by its and its Affiliates’ employees, agents, and independent contractors (including any employees, agents and independent contractors of any third party service provider working on behalf of such Party and its Affiliates) during
the performance of activities under this Agreement (“Sole Inventions”). The Parties jointly own all Inventions that are made jointly by the employees, agents, and independent contractors of one Party and
its Affiliates together with the employees, agents, and independent contractors of the other Party and its Affiliates (“Joint Inventions”). Patents claiming the Joint Inventions are
“Joint Patents”. Each Party owns an undivided one-half interest in the Joint Inventions (including all intellectual property contained therein such as the Joint
Patents), without a duty of accounting or an obligation to seek consent from the other Party, for the exploitation or license of the Joint Inventions (subject to the licenses granted to the other Party under this Agreement). For clarity, each Party
shall retain any and all income that it obtains from its exploitation or license of the Joint Inventions without any obligation to share the income with the other Party. 

(b) Disclosure. Each Party shall promptly disclose to the other Party all Inventions, including all invention disclosures or
other similar documents submitted to such first Party by its or its Affiliates’ employees, agents, or independent contractors relating thereto, and shall also promptly respond to reasonable requests from the receiving Party for additional
information relating thereto. 
 (c) Non-Exclusive License. 

(i) Licensed Vir Programs. Brii Bio shall and hereby does grant to Vir a worldwide
non-exclusive, perpetual, irrevocable, sublicensable through multiple tiers, royalty-free license under all of Brii Bio’s Sole Inventions, and all intellectual property contained therein, that relate
specifically to the Licensed Product in a Vir Program, solely for Vir’s use in the development, Manufacture or commercialization of any Product or Licensed Product of the Vir Program. 

(ii) Licensed Brii Bio Programs. Vir shall and hereby does grant to Brii Bio a worldwide
non-exclusive, perpetual, irrevocable, sublicensable through multiple tiers, royalty-free license under all of Vir’s Sole Inventions, and all intellectual property contained therein, that relate
specifically to the Licensed Product in a Brii Bio Program, solely for Brii Bio’s use in the development, Manufacture or commercialization of any Product or Licensed Product of the Brii Bio Program. 

14.2 Patent Prosecution. 

(a) Vir Patents. 

(i) As between the Parties, following the exercise of an Option for a given Licensed Vir Program, Vir has the first right to file,
prosecute and maintain all Vir Patents throughout the world at Vir’s cost and expense. Vir shall consult with Brii Bio and keep Brii Bio reasonably informed of the status of the Vir Patents applicable to Licensed Vir Programs in the China
Territory and shall promptly provide Brii Bio with all material correspondence received from any patent authority in the China Territory in connection therewith. In addition, Vir shall 

  
 70 

 EXECUTION VERSION 

 
 promptly provide Brii Bio with drafts of all proposed material filings and
correspondence to any patent authority in the China Territory with respect to Vir Patents applicable to Licensed Vir Programs for Brii Bio’s review and comment prior to the submission of such proposed filings and correspondences, and Vir shall
incorporate all of Brii Bio’s reasonable comments in such proposed filings and correspondences; provided that Vir shall not submit such proposed filings and correspondences without Brii Bio’s consent provided that Brii Bio shall
provide its comments on such proposed filings and correspondences no later than [***] before any final deadline set by the applicable patent authority in the China Territory for making such submission. Notwithstanding the foregoing, [***]. 

(ii) Vir shall notify Brii Bio of any decision to cease prosecution or maintenance of any Vir Patents that Cover a Licensed Product in
the China Territory. Vir shall provide such notice at least [***] prior to any filing or payment due date, or any other due date that requires action, in connection with such Vir Patents applicable to Licensed Vir Programs in the China Territory. In
such event, unless Vir [***], and subject to the terms relating to prosecution and maintenance of such Vir Patents in any license granted to Vir by any Third Party with respect to such Vir Patents, Brii Bio may, at its discretion and at its sole
expense, continue prosecution or maintenance of such Vir Patents applicable to Licensed Vir Programs in the China Territory. Brii Bio’s assumption of responsibility for prosecution or maintenance of such Vir Patents applicable to Licensed Vir
Programs shall not change the Parties’ respective rights and obligations under this Agreement with respect to such Vir Patent other than those expressly set forth in this Section 14.2(a)(ii). 

(b) Brii Bio Patents.  

(i) As between the Parties, following the exercise of an Option for a given Licensed Brii Bio Program, Brii Bio has the first right to
file, prosecute and maintain all Brii Bio Patents that are specific to such Licensed Brii Bio Program in all countries of the world. Brii Bio shall keep Vir reasonably informed of the status of the Brii Bio Patents that Cover a Licensed Product in
the United States and shall promptly provide Vir with all material correspondence received from any patent authority in the United States in connection therewith. In addition, Brii Bio shall promptly provide Vir with drafts of all proposed material
filings and correspondence to any patent authority in the United States with respect to Brii Bio Patents applicable to Licensed Brii Bio Programs for Vir’s review and comment prior to the submission of such proposed filings and correspondences,
and Brii Bio shall incorporate all of Vir’s reasonable comments in such proposed filings and correspondences; provided that Brii Bio shall not submit such proposed filings and correspondences without Vir’s consent provided that Vir
shall provide its comments on such proposed filings and correspondences no later than [***] before any final deadline set by the applicable patent authority in the United States for making such submission. Notwithstanding the foregoing, [***]. 

(ii) Brii Bio shall notify Vir of any decision to cease prosecution or maintenance of any Brii Bio Patents that Cover a Licensed
Product in the United States. Brii Bio shall provide such notice at least [***] prior to any filing or payment due date, or any other due date that requires action, in connection with such Brii Bio Patents that Cover a Licensed Product in the United
States. In such event, unless Brii Bio [***], and subject to the terms relating to prosecution and maintenance of such Brii Bio Patents in any license granted to Brii Bio by any 

  
 71 

 EXECUTION VERSION 

 
 Third Party with respect to such Brii Bio Patents, Vir may, at its discretion and at its
sole expense, continue prosecution or maintenance of such Brii Bio Patents applicable to Licensed Brii Bio Programs in the United States. Vir’s assumption of responsibility for prosecution or maintenance of such Brii Bio Patents applicable to
Licensed Brii Bio Programs shall not change the Parties’ respective rights and obligations under this Agreement with respect to such Brii Bio Patent other than those expressly set forth in this Section 14.2(b)(ii).

 (c) Joint Patents. If any Joint Patents are created hereunder, at either Party’s request, the Parties shall discuss a
mutually acceptable filing and prosecution strategy for any Joint Patents within [***] for the corresponding Joint Invention, provided that absent such agreement, Brii Bio shall control the prosecution and maintenance of any Joint Patents in
the China Territory and Vir shall control the prosecution and maintenance of any Joint Patents in the United States, as set forth in this Agreement. Unless the Parties’ agree in writing on an alternative arrangement, Brii Bio shall be
responsible for all costs of filing, prosecution, and maintenance of Joint Patents in the China Territory and Vir shall be responsible for all costs of filing, prosecution, and maintenance of Joint Patents in the United States. 

(d) Cooperation. Each Party shall provide the other Party all reasonable assistance and cooperation in the filing, prosecution,
and maintenance efforts under this Section 14.2, including providing any necessary powers of attorney and executing (including causing its inventors to execute) any other required documents or instruments for such
prosecution. 
 14.3 Patent Enforcement. 

(a) Notice. Each Party shall notify the other within [***] of becoming aware of any alleged or threatened infringement by a Third
Party of (i) any of the Vir Patents in the China Territory, (ii) any of the Brii Bio Patents and Vir Patents in the China Territory, which infringement of such Brii Bio Patents and Vir Patents adversely affects or is expected to adversely
affect any Licensed Product in the China Territory, (iii) any of the Brii Bio Patents in the United States and any of the Vir Patents in the United States, which infringement of such Vir Patents adversely affects or is expected to adversely
affect and Licensed Product in the United States and, in each case, any related declaratory judgment or patent invalidation process or equivalent action alleging the invalidity, unenforceability or
non-infringement of any Vir Patents or Brii Bio Patents (collectively “Product Infringement”). For clarity, Product Infringement excludes any adversarial prosecution and maintenance
proceedings. 
 (b) Enforcement Rights. 

(i) Vir Programs Prior to Option Exercise. Prior to the Option Exercise Date for a Vir Program, Vir shall have the sole right,
at its discretion, to bring and control any legal action to enforce Vir Patents and Joint Patents which filing, prosecution and maintenance are controlled by Vir pursuant to Section 14.2(c). 

  
 72 

 EXECUTION VERSION 

 
 (ii) Vir Programs After Option Exercise. After the Option
Exercise Date for a Vir Program, Brii Bio shall have the first right to bring and control any legal action to enforce Vir Patents and Joint Patents arising from such Licensed Vir Program against any Product Infringement in the China Territory at its
own expense as it reasonably determines appropriate, and Brii Bio shall consider in good faith the interests of Vir in such enforcement of the Vir Patents and Joint Patents arising from such Licensed Vir Program. If Brii Bio or its designee fails to
abate such Product Infringement in the China Territory or to file an action to abate such Product Infringement in the China Territory within [***] after a written request from Vir to do so, or after becoming aware of such Product Infringement, or if
Brii Bio discontinues the prosecution of any such action after filing without abating such infringement, then Vir may enforce the Vir Patents or Joint Patents arising from such Licensed Vir Program, as applicable, against such Product Infringement
in the China Territory at its own expense as it reasonably determines appropriate provided that [***]. 
 (iii) Brii Bio
Programs Prior to Option Exercise. Prior to the Option Exercise Date for a Brii Bio Program, Brii Bio shall have the sole right, at its discretion, to bring and control any legal action to enforce Brii Bio Patents and Joint Patents which filing,
prosecution and maintenance are controlled by Brii Bio pursuant to Section 14.2(c). 
 (iv) Brii Bio
Programs After Option Exercise. After the Option Exercise Date for a Brii Bio Program, Vir shall have the first right to bring and control any legal action to enforce Brii Bio Patents and Joint Patents arising from such Licensed Brii Bio Program
against any Product Infringement in the United States at its own expense as it reasonably determines appropriate, and Vir shall consider in good faith the interests of Brii Bio in such enforcement of the Brii Bio Patents and Joint Patents arising
from such Licensed Brii Bio Program. If Vir or its designee fails to abate such Product Infringement in the United States or to file an action to abate such Product Infringement in the United States within [***] after a written request from Vir to
do so, or after becoming aware of such Product Infringement, or if Vir discontinues the prosecution of any such action after filing without abating such infringement, then Brii Bio may enforce the Brii Bio Patents or Joint Patents arising from such
Licensed Brii Bio Program, as applicable, against such Product Infringement in the United States at its own expense as it reasonably determines appropriate provided that [***]. 

(c) Cooperation. At the request of the Party bringing an action related to Product Infringement, the other Party shall provide
reasonable assistance in connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required by Applicable Law to pursue such action, at each such Party’s sole
cost and expense. 
 (d) Recoveries. Any recoveries resulting from an enforcement action relating to a claim of Product
Infringement shall be first applied against payment of each Party’s costs and expenses in connection therewith in proportion. Any such recoveries in excess of such costs and expenses shall be, [***]. 

  
 73 

 EXECUTION VERSION 

 
 14.4 Infringement of Third Party Rights. 

(a) Notice. 

(i) If any Licensed Product used or sold by Brii Bio, its Affiliates or sublicensees becomes the subject of a Third Party’s claim
or assertion of infringement of a Patent or other rights in the China Territory that are owned or controlled by such Third Party, Brii Bio shall promptly notify Vir within [***] after receipt of such claim or assertion and such notice shall include
a copy of any summons or complaint (or the equivalent thereof) received regarding the foregoing. Thereafter, the Parties shall promptly meet to consider the claim or assertion and the appropriate course of action and may, if appropriate, agree on
and enter into a “common interest agreement” wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute. The Parties shall assert and not waive the joint defense privilege with respect to any
communications between the Parties in connection with the defense of such claim or assertion. 
 (ii) If any Licensed Product used or
sold by Vir, its Affiliates or sublicensees becomes the subject of a Third Party’s claim or assertion of infringement of a Patent or other rights in the United States that are owned or controlled by such Third Party, Vir shall promptly notify
Brii Bio within [***] after receipt of such claim or assertion and such notice shall include a copy of any summons or complaint (or the equivalent thereof) received regarding the foregoing. Thereafter, the Parties shall promptly meet to consider the
claim or assertion and the appropriate course of action and may, if appropriate, agree on and enter into a “common interest agreement” wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute. The
Parties shall assert and not waive the joint defense privilege with respect to any communications between the Parties in connection with the defense of such claim or assertion. 

(b) Defense. 

(i) Brii Bio shall be solely responsible for the defense of any such infringement claims brought against Brii Bio, at Brii Bio’s
cost and expense; provided that Brii Bio shall not agree to any settlement, consent to judgment or other voluntary final disposition in connection with such defense action without Vir’s consent if such settlement, consent to judgment or
other voluntary final disposition would (A) result in the admission of any liability or fault on behalf of Vir, (B) result in or impose any payment obligations upon Vir, or (C) subject Vir to an injunction or otherwise limit
Vir’s ability to take any actions or refrain from taking any actions under this Agreement or with respect to any Licensed Product. Brii Bio shall keep Vir informed on the status of such defense action, and Vir may participate and be separately
represented in such defense action at its sole option and at its own expense. 
 (ii) Vir shall be solely responsible for the defense
of any such infringement claims brought against Vir, at Vir’s cost and expense; provided that Vir shall not agree to any settlement, consent to judgment or other voluntary final disposition in connection with such defense action without
Brii Bio’s consent if such settlement, consent to judgment or other voluntary final disposition would (A) result in the admission of any liability or fault on behalf of Brii Bio, (B) result in or impose any payment obligations upon
Brii Bio, or (C) subject Brii Bio to an injunction or otherwise limit Brii Bio’s ability to take any actions or refrain from taking any actions under this Agreement or with respect to any Licensed Product. Vir shall keep Brii Bio informed
on the status of such defense action, and Brii Bio may participate and be separately represented in such defense action at its sole option and at its own expense. 

  
 74 

 EXECUTION VERSION 

 
 14.5 Patents Licensed From Third Parties. Each
Party’s rights under this Article 14 with respect to the prosecution and enforcement of any Vir Patent that is licensed by Vir from a Third Party shall be subject to the rights of such Third Party to prosecute and enforce such Patent. Each
Party’s rights under this Article 14 with respect to the prosecution and enforcement of any Brii Bio Patent that is licensed by Brii Bio from a Third Party shall be subject to the rights of such Third Party to prosecute and enforce such
Patent. 
 14.6 Product Trademarks. 

(a) Vir Programs. Brii Bio may brand Licensed Products in the China Territory using trademarks, logos, and trade names it
determines appropriate for such Licensed Products, which may vary by region or within a region (the “Brii Bio Product Marks”); provided, however, that Brii Bio shall provide Vir with a
reasonable opportunity to review and provide comments on each proposed Brii Bio Product Mark, shall give due consideration to Vir’s comments before selecting any Brii Bio Product Mark, and shall not use any trademarks or house marks of Vir
(including Vir’s corporate name) or any trademark confusingly similar thereto without Vir’s prior written consent. Brii Bio shall own all rights in the Brii Bio Product Marks in the China Territory and shall register and maintain the Brii
Bio Product Marks in the China Territory that it determines reasonably necessary, at Brii Bio’s cost and expense. 
 (b) Brii
Bio Programs. Vir may brand Licensed Products in the United States using trademarks, logos, and trade names it determines appropriate for such Licensed Products, which may vary by region or within a region (the “Vir
Product Marks”); provided, however, that Vir shall provide Brii Bio with a reasonable opportunity to review and provide comments on each proposed Vir Product Mark, shall give due consideration to Brii Bio’s
comments before selecting any Vir Product Mark, and shall not use any trademarks or house marks of Brii Bio (including Brii Bio’s corporate name) or any trademark confusingly similar thereto without Brii Bio’s prior written consent. Vir
shall own all rights in the Vir Product Marks in the United States and shall register and maintain the Vir Product Marks in the United States that it determines reasonably necessary, at Vir’s cost and expense. 

14.7 Patent Marking. Each Party shall mark all Licensed Products in accordance with the applicable patent marking laws, and shall
require all of its Affiliates and sublicensees to do the same. To the extent permitted by Applicable Laws, each Party shall indicate on the product packaging, advertisement, and promotional materials that such Licensed Product is in-licensed from the other Party. 
 ARTICLE 15 

TERM AND TERMINATION 

15.1 Term. The term of this Agreement shall commence on the Effective Date and, unless earlier terminated in accordance with
this Article 15, shall continue until this Agreement has expired or been terminated with respect to all Collaboration Programs hereunder (the “Term”). With respect to each Collaboration Program, this Agreement shall
begin on the date that such Program becomes a Collaboration Program and, unless earlier terminated in accordance with this Article 15, shall continue with respect to such Collaboration Program (a) if the Party with the right to exercise
the Option with respect to such Collaboration Program has not exercised such Option prior to such expiration, until the expiration of the Option Period for such Collaboration Program, or (b) if the Option is exercised for such Collaboration
Program, until the expiration of the last-to-expire Royalty Term for any and all Licensed Products within such Collaboration Program. 

  
 75 

 EXECUTION VERSION 

 
 15.2 Termination. 

(a) Termination by Brii Bio for Convenience. At any time, Brii Bio may terminate its rights and obligations with respect to any
Vir Program or Licensed Vir Program by providing written notice of termination to Vir, which notice includes an effective date of termination at least (i) thirty (30) days after the date of the notice if Brii Bio has not exercised the Brii Bio
Option with respect to such Vir Program or (ii) one hundred eighty (180) days after the date of the notice if Brii Bio has exercised the Brii Bio Option with respect to such Licensed Vir Program, provided that such exercise of the Brii Bio
Option shall still count towards the up to the four (4) Brii Options available to Brii Bio under this Agreement. For clarity, this Section 15.2(a) does not give Brii Bio the right to terminate Vir’s rights and
obligations with respect to any Brii Bio Program or Licensed Brii Bio Program, and an election by Brii Bio to terminate its rights and obligations with respect to any Vir Program or Licensed Vir Program has no effect on Vir’s rights and
obligations with respect to any Brii Bio Program or Licensed Brii Bio Program. 
 (b) Termination by Vir for Convenience. At
any time, Vir may terminate its rights and obligations with respect to any Brii Bio Program or Licensed Brii Bio Program by providing written notice of termination to Brii Bio, which notice includes an effective date of termination at least
(i) thirty (30) days after the date of the notice if Vir has not exercised the Vir Option with respect to such Brii Bio Program or (ii) one hundred eighty (180) days after the date of the notice if Vir has exercised the Vir Option
with respect to such Licensed Brii Bio Program, provided that such exercise of the Vir Option shall still count towards the up to four (4) Vir Options available to Vir under this Agreement. For clarity, this
Section 15.2(b) does not give Vir the right to terminate Brii Bio’s rights and obligations with respect to any Vir Program or Licensed Vir Program, and an election by Vir to terminate its rights and obligations with
respect to any Brii Bio Program or Licensed Brii Bio Program has no effect on Brii Bio’s rights and obligations with respect to any Vir Program or Licensed Vir Program. 

(c) Termination for Material Breach. This Agreement may be terminated in its entirety, or on Program-by- Program basis as set forth below, at any time during the Term upon written notice by either Party if the other Party materially breaches this Agreement and such
breach has not been cured within sixty (60) days (or thirty (30) days for failure to make payment) after notice requesting cure of such breach; provided that, if the material breach in question relates to a particular
Program, but not to the entire Agreement, then the Agreement may only be terminated with respect to such Program and not in its entirety. If the allegedly breaching Party in good faith disputes such material breach and provides written notice of
that dispute to the other Party within the applicable period set forth above, the matter shall be addressed under the dispute resolution provisions in Article 16, and the termination shall not become effective unless and until it has been
determined under Article 16 that the allegedly breaching Party is in material breach of this Agreement. 

  
 76 

 EXECUTION VERSION 

 
 (d) Termination for Insolvency. Each Party may terminate
this Agreement upon delivery of written notice to the other Party in the event that (i) such other Party files in any court or agency pursuant to any statute or regulation of any jurisdiction a petition in bankruptcy or insolvency or for
reorganization or similar arrangement for the benefit of creditors or for the appointment of a receiver or trustee of such other Party or its assets, (ii) such other Party is served with an involuntary petition against it in any insolvency
proceeding and such involuntary petition has not been stayed or dismissed [***] of its filing, or (iii) such other Party makes an assignment of substantially all of its assets for the benefit of its creditors. 

(e) Termination for Failure to Meet Certain Conditions. This Agreement will terminate automatically (a) if the Share
Purchase Agreement is terminated in the circumstances set forth in Section 10.1, or (b) if the conditions set forth in Section 17.1 are not met [***] following the Execution Date. 

(f) Full Force and Effect During Notice Period. This Agreement shall remain in full force and effect until the expiration of the
applicable termination notice period, provided that if any milestone event is achieved during the termination notice period, then such milestone payment shall not be payable by the terminating Party. 

15.3 Effect of Expiration. Upon expiration of this Agreement with respect to a Collaboration Program pursuant to clause (a)
of Section 15.1 (but not pursuant to clause (b) thereof), the applicable license granted pursuant to Section 3.3 and the Option with respect to such Program shall automatically terminate. Upon
expiration of this Agreement pursuant to clause (b) of Section 15.1, the applicable license granted under Section 5.1 shall become non-exclusive, royalty-free, fully-paid, irrevocable and perpetual. 
 15.4
Effect of Termination Prior to Exercise of Option. Upon any termination of this Agreement with respect to a Collaboration Program prior to a Party’s exercise of the Option with respect to such Collaboration Program, such Option and all
licenses and rights granted by either party to the other party pursuant to this Agreement with respect to such Program shall automatically terminate and revert to the granting party, and all other rights and obligations of the parties under this
Agreement shall terminate with respect to such Collaboration Program. 
 15.5 Effect of Termination After Exercise of
Option. Upon any termination of this Agreement with respect to a Collaboration Program after a Party’s exercise of the Option with respect to such Program, the following will apply: 

(a) Licenses. 

(i) If such Collaboration Program is a Vir Program, the licenses and all other rights granted by Vir to Brii Bio under the Vir
Technology with respect to the Licensed Products that are the subject of such Vir Program (the “Terminated Vir Program Products”) shall terminate and all sublicenses granted by Brii Bio shall also terminate. In addition, upon
the termination of this Agreement with respect to such Vir Program, except in the case of termination for Vir material breach (where the grant of the following license shall be at Brii Bio’s option), [***]. As [***]. 

  
 77 

 EXECUTION VERSION 

 
 (ii) If such Collaboration Program is a Brii Bio Program, the
licenses and all other rights granted by Brii Bio to Vir under the Brii Bio Technology with respect to the Licensed Products that are the subject of such Brii Bio Program (the “Terminated Brii Bio Program Products”) shall
terminate and all sublicenses granted by Vir shall also terminate. In addition, upon the termination of this Agreement with respect to such Brii Bio Program, except in the case of termination for Brii Bio material breach (where the grant of the
following license shall be at Vir’s option), [***]. As [***]. 
 (b) Regulatory Submissions. 

(i) If such Program is a Vir Program, upon Vir’s written request, Brii Bio shall provide Vir with copies of all Regulatory
Submissions for Licensed Products included in such Vir Program. [***]. In addition, upon Vir’s written request, [***]. The Parties shall discuss and establish appropriate arrangements with respect to safety data exchange, provided that
Vir will assume all safety and safety database activities no later than six months after termination. 
 (ii) If such Program is a
Brii Bio Program, upon Brii Bio’s written request, Vir shall provide Brii Bio with copies of all Regulatory Submissions for Licensed Products included in such Brii Bio Program. [***]. In addition, upon Brii Bio’s written request, [***].
The Parties shall discuss and establish appropriate arrangements with respect to safety data exchange, provided that Brii Bio will assume all safety and safety database activities no later than six months after termination. 

(c) Trademarks. 

(i) If such Program is a Vir Program, Brii Bio shall transfer and assign, and shall ensure that its Affiliates transfer and assign, to
Vir, [***], all Brii Bio Product Marks relating to any Licensed Product in such Vir Program and any applications therefor (excluding any such marks that include, in whole or part, any corporate name or logos of Brii Bio or its Affiliates or
sublicensees). Brii Bio shall also transfer to Vir [***] for any Licensed Product in such Vir Program. 
 (ii) If such Program is a
Brii Bio Program, Vir shall transfer and assign, and shall ensure that its Affiliates transfer and assign, to Brii Bio, [***], all Vir Product Marks relating to any Licensed Product in such Brii Bio Program and any applications therefor (excluding
any such marks that include, in whole or part, any corporate name or logos of Vir or its Affiliates or sublicensees). Vir shall also transfer to Brii Bio [***] for any Licensed Product in such Brii Bio Program. 

(d) Inventory. 

(i) If such Program is a Vir Program, at Vir’s election and request, Brii Bio shall transfer to Vir or its designee some or all
inventory of Licensed Products in such Vir Program (including all final product, bulk drug substance, intermediates, works-in-process, formulation materials, reference
standards, drug product clinical reserve samples, packaged retention samples, and the like) then in the possession or control of Brii Bio, its Affiliates or sublicensees; provided that [***]. 

  
 78 

 EXECUTION VERSION 

 
 (ii) If such Program is a Brii Bio Program, at Brii Bio’s
election and request, Vir shall transfer to Brii Bio or its designee some or all inventory of Licensed Products in such Brii Bio Program (including all final product, bulk drug substance, intermediates, works-in-process, formulation materials, reference standards, drug product clinical reserve samples, packaged retention samples, and the like) then in the possession or control of Vir, its Affiliates or
sublicensees; provided that [***]. 
 (e) Wind Down and Transition. 

(i) If the terminated Program is a Licensed Vir Program, Brii Bio shall be responsible, at its own cost and expense, for the wind-down
of Brii Bio’s, its Affiliates’ and its sublicensees’ Development, Manufacture and Commercialization activities for Licensed Products in such Vir Program. Brii Bio shall, and shall cause its Affiliates and sublicensees to, reasonably
cooperate with Vir to facilitate orderly transition of the Development, Manufacture and Commercialization of Licensed Products in such Vir Program to Vir or its designee, including with respect to the conduct of any Clinical Trial that is ongoing as
of the effective date of termination. 
 (ii) If the terminated Program is a Licensed Brii Bio Program, Vir shall be responsible, at
its own cost and expense, for the wind-down of Vir’s, its Affiliates’ and its sublicensees’ Development, Manufacture and Commercialization activities for Licensed Products in such Brii Bio Program. Vir shall, and shall cause its
Affiliates and sublicensees to, reasonably cooperate with Brii Bio to facilitate orderly transition of the Development, Manufacture and Commercialization of Licensed Products in such Brii Bio Program to Brii Bio or its designee, including with
respect to the conduct of any Clinical Trial that is ongoing as of the effective date of termination. 
 15.6 Return of
Confidential Information. Upon expiration or termination of this Agreement with respect to a Program, the Receiving Party shall return or destroy, at the Disclosing Party’s election, all tangible materials comprising, bearing, or containing
any Confidential Information of the Disclosing Party that are in the Receiving Party’s or its Affiliates’ or sublicensees’ possession or control and provide written certification of such destruction; provided that the Receiving
Party may retain one copy of such Confidential Information for its legal archives, and provided further, that the Receiving Party shall not be required to destroy electronic files containing such Confidential Information that are made in the
ordinary course of its business information back-up procedures pursuant to its electronic record retention and destruction practices that apply to its own general electronic files and information. 

15.7 Survival. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior
to such expiration or termination. Without limiting the foregoing, the provisions of Sections 3.9 (solely with respect to amounts owed as of the effective date of termination), 3.11, 5.4, 6.9, 7.3(b),
7.3(c), 7.6, 10.5(e) (with respect to amounts owed as of the effective date of termination), 10.8 (with respect to amounts owed as of the effective date of termination), 10.9 (with respect to amounts owed as of the
effective date of termination), 10.10, 10.11, 10.12 (with respect to amounts owed as of the effective date of termination), 12.6, 14.1(a), 14.1(c), 15.3, 15.4, 15.5, 15.6,
15.7, and 15.9, and Article 1, Article 11 (excluding Section 11.4) and Article 13, Article 16 and Article 17 (excluding Sections 17.1 and 17.2)
shall survive the expiration or termination of this Agreement. 
  

  
 79 

 EXECUTION VERSION 

 
 15.8 Section 365(n) of the Bankruptcy Code. All rights and
licenses granted under or pursuant to this Agreement by a Party to the other, are and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined
under Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties and their respective Related Parties, as sublicensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections
under the U.S. Bankruptcy Code and any foreign counterpart thereto. The Parties further agree that that upon commencement of a bankruptcy proceeding by or against a Party (the “Bankrupt Party”) under the U.S. Bankruptcy Code, the
other Party (the “Non-Bankrupt Party”) will be entitled to a complete duplicate of, or complete access to (as the Non- Bankrupt Party deems
appropriate), all such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments of such intellectual property will be promptly delivered to the
Non-Bankrupt Party (a) upon any such commencement of a bankruptcy proceeding and upon written request by the Non-Bankrupt Party, unless the Bankrupt Party elects to
continue to perform all of its obligations under this Agreement, or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the Bankrupt Party and upon written request by the Non-Bankrupt Party. The Bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including any
trustee) agrees not to interfere with the exercise by the Non-Bankrupt Party or its Related Parties of its rights and licenses to such intellectual property and such embodiments of intellectual property in
accordance with this Agreement, and agrees to assist the Non-Bankrupt Party and its Related Parties in obtaining such intellectual property and such embodiments of intellectual property in the possession or
control of Third Parties as reasonably necessary or desirable for the Non-Bankrupt Party to exercise such rights and licenses in accordance with this Agreement. The foregoing provisions are without prejudice
to any rights the Non-Bankrupt Party may have arising under the U.S. Bankruptcy Code or other Laws. 

15.9 Termination Not Sole Remedy. Termination is not the sole remedy under this Agreement and, whether or not termination is
effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies shall remain available except as agreed to otherwise herein. 

ARTICLE 16 
 DISPUTE
RESOLUTION 
 16.1 General. The Parties recognize that a dispute may arise relating to this Agreement (a
“Dispute”). Any Dispute, including Disputes that may involve the Affiliates of any Party, shall be resolved in accordance with this Article 16. 

16.2 Negotiation; Escalation. The Parties shall negotiate in good faith and use reasonable efforts to settle any Dispute under
this Agreement. Any Dispute as to the breach, enforcement, interpretation or validity of this Agreement shall be referred to the Executive Officers for attempted resolution. If the Executive Officers are unable to resolve such Dispute within [***]
of such Dispute being referred to them, then, upon the written request of either Party to the other Party, the Dispute shall be subject to arbitration in accordance with Section 16.3. 

 

  
 80 

 EXECUTION VERSION 

 
 16.3 Arbitration. 

(a) Submission. If a Dispute that cannot be resolved between the Parties or the Executive Officers as set forth in
Section 16.2, either Party may institute binding arbitration with respect to such dispute in accordance with this Section 16.3 upon written notice to the other Party (an “Arbitration
Notice”) and seek remedies as may be available. Any dispute unresolved under this Section 16.3 shall be settled by binding arbitration administered by JAMS (or any successor entity thereto) and in accordance
with the Comprehensive Arbitration Rules and Procedures then in effect and the Expedited Procedures contained therein, as modified in this Section 16.3 (the “Rules”), except to the extent such rules
are inconsistent with this Section 16.3, in which case this Section 16.3 shall control. The proceedings and decisions of the arbitrator shall be confidential, final and binding on the Parties, and
judgment upon the award of such arbitrator may be entered in any court having jurisdiction thereof. 
 (b) Selection and
Process. Upon receipt of an Arbitration Notice by a Party, the applicable dispute shall be resolved by final and binding arbitration before [***]. Any Arbitrator chosen hereunder shall have educational training and industry experience sufficient
to demonstrate a reasonable level of scientific, financial, medical and industry knowledge relevant to the particular dispute. Each Party shall promptly select one Arbitrator each, which selections shall in no event be made later than [***] after
receipt of the Arbitration Notice. The third Arbitrator shall be chosen promptly by mutual agreement of the Arbitrators chosen by the Parties, but in no event later than [***] after the date that the last of such Arbitrators was appointed. The
arbitration proceedings shall take place in San Francisco, California, in the English language. 
 (c) Decision. The
Arbitrators’ decision and award will be made within [***] of the filing of the arbitration demand, and the Arbitrators will agree to comply with this schedule before accepting appointment; provided that this time limit may be extended by
agreement of the Parties or by the Arbitrators. The Arbitrators shall be [***], but shall not be authorized to reform, modify, or materially change this Agreement. The Arbitrators will, within [***] after the conclusion of the hearing, issue a
written award and statement of decision describing the material facts and the grounds for the conclusions on which the award is based, including the calculation of any damages awarded. The decision of the Arbitrators will be final, conclusive and
binding on the Parties and enforceable by any court of competent jurisdiction. The Arbitrators shall be required to render the decision in writing and to comply with, and the award shall be limited by, any express provisions of this Agreement
relating to damages or the limitation thereof. All arbitration proceedings and decisions of the Arbitrators under this Section 16.3 are the Confidential Information of both Parties under Article 11. 

(d) Costs and Expenses. Each Party shall bear its own costs and expenses (including legal fees and expenses) relating to the
arbitration proceeding, except that the fees of the Arbitrators and other related costs of the arbitration shall be shared equally by the Parties, unless the Arbitrators determine that a Party has incurred unreasonable expenses due to vexatious or
bad faith positions taken by the other Party, in which event the Arbitrators may make an award of all or any portion of such expenses (including legal fees and expenses) so incurred. 

 

  
 81 

 EXECUTION VERSION 

 
 (e) Conduct during Arbitration. During the period of time
that any arbitration proceeding is pending under this Agreement, (i) the Parties shall continue to comply with all those terms and provisions of this Agreement that are not the subject of the pending arbitration proceeding, and (ii) in the
event that the subject of the dispute relates to the exercise by a Party of a termination right hereunder, including in the case of a material breach of this Agreement, the effectiveness of such termination shall be stayed until the conclusion of
the proceedings under this Section 16.3. 
 16.4 Equitable Relief; Intellectual Property Disputes.
Notwithstanding anything to the contrary in this Article 16, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any patent rights or trademark rights shall be submitted to a court of competent
jurisdiction in the country in which such patent rights or trademark rights were granted or arose. Nothing in this Article 16 will preclude either Party from seeking equitable relief or interim or provisional relief from a court of competent
jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the
status quo pending the arbitration proceeding. 
 ARTICLE 17 

MISCELLANEOUS 
 17.1
Certain Conditions to Effectiveness. The rights and obligations of each of the Parties shall become effective upon the fulfilment of each of the following obligations: 

(a) Promptly, and no later than [***] following the Effective Date, Parent shall establish, or cause to be established, as a wholly
owned subsidiary of Parent organized under the law of the Cayman Islands; 
 (b) Parent shall deliver to Vir a unanimous written
consent or minutes of a meeting of the Board of Directors of Brii Bio, approving Brii Bio’s entry into this Agreement and performance of all Brii Bio’s obligations under this Agreement, (ii) written confirmation by Brii Bio that all
of the representations and warranties set forth in Section 12.1 made by Brii Bio are true and correct on and as of the Effective Date, and (iii) a copy of this Agreement, duly authorized and executed by Brii Bio; 

(c) Parent shall have contributed, sold or transferred to Bri Bio the Shares and Brii Bio shall deliver to Vir reasonable written
documentation reflecting Bri Bio’s acquisition of the Shares; and 
 (d) Parent and Brii Bio shall each have fulfilled their
obligations under the Share Purchase Agreement and Section 10.1 of this Agreement. 

  
 82 

 EXECUTION VERSION 

 
 17.2 Force Majeure. Neither Party shall be held liable to
the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable
control of the affected Party, including embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances (except for a strike, lockout or labor
disturbance with respect to the non-performing Party’s respective employees or agents), fire, floods, earthquakes or other acts of God, or any generally applicable action or inaction by any governmental
authority (but excluding any government action or inaction that is specific to such Party, its Affiliates or sublicensees, such as revocation or non-renewal of such Party’s license to conduct business),
or omissions or delays in acting by the other Party. The affected Party shall notify the other Party in writing of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake and continue diligently all reasonable
efforts necessary to cure such force majeure circumstances or to perform its obligations despite the ongoing circumstances. 
 17.3
Assignment. This Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the prior written consent of the other Party; provided that
each Party may assign its rights to receive payments under this Agreement to one or more Entities without consent of the other Party, and either Party may, without consent of the other Party, assign this Agreement and its rights and obligations
hereunder (a) in whole or in part to an Affiliate of such Party, or (b) in whole to its successor-in-interest in connection with the sale of all or
substantially all of its assets, whether in a merger, acquisition, or similar transaction. Any attempted assignment not in accordance with this Section 17.2 shall be null and void and of no legal effect. Any permitted
assignee shall assume all assigned obligations of its assignor under this Agreement. The terms and conditions of this Agreement shall be binding upon, and shall inure to the benefit of, the Parties and their respected successors and permitted
assigns. 
 17.4 Severability. If any one or more of the provisions contained in this Agreement is held invalid, illegal
or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provisions adversely affects the
substantive rights of the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provisions with valid, legal and enforceable provisions that, insofar as practical, implement the
purposes of this Agreement. 
 17.5 Notices. All notices that are required or permitted hereunder shall be in writing
and sufficient if delivered personally, sent by electronic mail (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified
mail, postage prepaid, return receipt requested, addressed as follows: 
 If to Vir: 

[***] 
 and a copy to (which
shall not constitute notice): 
 [***] 

  
 83 

 EXECUTION VERSION 

 
 If to Brii Bio: 

[***] 
 and a copy to (which
shall not constitute notice): 
 [***] 
 or to
such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given (a) when delivered if personally delivered or sent by
electronic mail on a Business Day (or if delivered or sent on a non-Business Day, then on the next Business Day), (b) on the Business Day after dispatch if sent by nationally-recognized overnight courier, or
(c) on the fifth Business Day following the date of mailing if sent by mail. 
 17.6 Governing Law. This Agreement, and
all claims or causes of action (whether in contract, tort or statute) that may be based upon, arise out of or relate to this Agreement, or the negotiation, execution or performance of this Agreement or the breach thereof (including any claim or
cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Agreement or as an inducement to enter into this Agreement), shall be governed by, and enforced in accordance with, the
internal laws of the State of New York, including its statutes of limitations. 
 17.7 Entire Agreement; Amendments. This
Agreement, together with the Exhibits hereto (including the Share Purchase Agreement), contains the entire understanding of the Parties with respect to the collaboration and the licenses granted hereunder. Any other express or implied agreements and
understandings, negotiations, writings and commitments, either oral or written, in respect to the collaboration and the licenses granted hereunder are superseded by the terms of this Agreement. The Exhibits to this Agreement are incorporated herein
by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both Parties. The Parties agree that, effective as of
the Effective Date, that certain Mutual Non-Disclosure Agreement between Vir and Brii Bio dated as of [***] (the “Confidentiality Agreement”) is superseded by this Agreement, and that
disclosures made prior to the Effective Date pursuant to the Confidentiality Agreement are subject to the confidentiality and non-use provisions of this Agreement. The foregoing shall not be interpreted as a
waiver of any remedies available to either Party or its Affiliates as a result of any breach, prior to the Effective Date, by the other Party or its Affiliates of such Party’s or its Affiliate’s obligations pursuant to the Confidentiality
Agreement. 
 17.8 Headings. The captions to the several Articles, Sections, and subsections hereof are not a part of this
Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections of this Agreement. 

17.9 Independent Contractors. It is expressly agreed that Vir and Brii Bio are independent contractors and that the relationship
between the two Parties does not constitute a partnership, joint venture, or agency. Neither Vir nor Brii Bio has the authority to make any statements, representations or commitments of any kind, or to take any action that is binding on the other
Party without the prior written consent of the other Party. 

  
 84 

 EXECUTION VERSION 

 
 17.10 Waiver. Any waiver of any provision of this
Agreement shall be effective only if in writing and signed by Vir and Brii Bio. No express or implied waiver by a Party of any default under this Agreement will be a waiver of a future or subsequent default. The failure or delay of any Party in
exercising any rights under this Agreement will not constitute a waiver of any such right, and any single or partial exercise of any particular right by any Party will not exhaust the same or constitute a waiver of any other right provided in this
Agreement. 
 17.11 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection
with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

17.12 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and
in addition to any other remedy referred to in this Agreement or otherwise available under Applicable Laws. 
 17.13 Business Day
Requirements. If any notice or other action or omission is required to be taken by a Party under this Agreement on a day that is not a Business Day, then such notice or other action or omission shall be deemed to be required to be taken on the
next occurring Business Day. 
 17.14 Further Actions. Each Party shall execute, acknowledge and deliver such further
instruments, and to do all such other acts, as necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

17.15 Construction. Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed
to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b) the words “include”, “includes” and “including” shall be deemed to be
followed by the phrase “without limitation”, (c) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time
amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (d) any reference herein to any person shall be construed to include the person’s successors and
assigns, (e) the words “herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (f) all
references herein to Sections or Exhibits shall be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement include all Exhibits hereto, (g) the word “notice” means notice in writing (whether or
not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (h) provisions that require that a Party, the Parties or any committee hereunder “agree”,
“consent” or “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (i) references to any specific law, rule or regulation, or Section, section or other division thereof, shall be deemed to include the then-current amendments thereto or any
replacement or successor law, rule or regulation thereof, and (j) the word “or” is disjunctive but not necessarily exclusive. 

  
 85 

 EXECUTION VERSION 

 
 17.16 Counterparts. This Agreement may be executed in two
or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Each Party may rely on the delivery of executed electronic copies of counterpart execution pages of this
Agreement and such electronic copies shall be legally effective to create a valid and binding agreement among the Parties. 
 17.17
Language. This Agreement is in the English language only, which language shall be controlling in all respects, and all versions hereof in any other language shall be for accommodation only and shall not be binding upon the Parties. All
communications and notices to be made or given pursuant to this Agreement, and any dispute proceeding related to or arising hereunder, shall be in the English language. If there is a discrepancy between any translation of this Agreement and this
Agreement, this Agreement shall prevail. 
 {Signature Page Follows} 

  
 86 

 EXECUTION VERSION 

 
 IN WITNESS
WHEREOF, the Parties intending to be bound have caused this Collaboration, Option, and License Agreement to be executed by their duly authorized representatives as of the Effective Date. 

 

									
	VIR BIOTECHNOLOGY, INC.	 		 	 BIIG THERAPEUTICS LIMITED

(DBA BRII BIOSCIENCES LIMITED) 

					
	By:	 	 /s/ Jay Parrish
	 		 	By:	 	 /s/ Zhi Hong

	Name:	 	Jay Parrish	 		 	Name:	 	Zhi Hong
	Title:	 	CBO	 		 	Title:	 	CEO
				
	BRII BIOSCIENCES OFFSHORE LIMITED	 		 		 	
					
	By:	 	 /s/ Zhi Hong
	 		 		 	
	Name:	 	Zhi Hong	 		 		 	
	Title:	 	CEO	 		 		 	

  
 87 

 EXECUTION VERSION 

 
 EXHIBIT 1.48 

Included Vir Programs 
  

	1.	 All Programs Controlled by Vir as of the Effective Date where the Target is HBV, including the Vir-Alnylam Program. 

  

	2.	 [***] 

  

	3.	 [***] 

  
 88 

 EXECUTION VERSION 

 
 EXHIBIT 1.87 

Share Purchase Agreement 

  
 89 

 EXECUTION VERSION 

 
 EXHIBIT 11.6 

Joint Press Release 

  
 90 

 EXECUTION VERSION 

 
 Brii Biosciences Launches to Bring Innovative Medicines to Chinese
Patients 
  

	 	•	 	 Committed funding of $260M includes ARCH Venture Partners, 6 Dimensions Capital, Boyu Capital, Yunfeng Capital,
Sequoia Capital, and Blue Pool Capital 

  

	 	•	 	 Exclusive agreement with Vir Biotechnology grants greater China rights for up to four infectious disease assets

  

	 	•	 	 Partnership with Alibaba Group’s AliHealth to better identify and educate patients, and better connect them
to clinics, healthcare resources and medicines 

 Shanghai, China and Durham, NC, United States, May 24, 2018 – Brii Bio, a
company committed to serving patients’ needs and improving public health in China, today announced its launch with significant partnerships and financing. 

Brii Bio aims to accelerate the development and delivery of breakthrough medicines in China through partnerships, best-in-class research and development, and the disruptive application of digital and data insight. 
 “The
pace of innovation has accelerated over the past decade, resulting in dramatically better treatments and cures for life-threatening diseases, but the reach of those innovations in China has been limited,” said
Co-Founder, President and CEO Dr. Zhi Hong. “Delivering innovative medicines to Chinese patients constitutes not just a market opportunity but an opportunity to significantly improve public health.
China needs faster, affordable access to new therapies, and has the public health infrastructure and advanced digital and data technologies to enable that at scale.” 

Brii, which stands for breakthrough innovation and insight, launches with three foundational and strategic partnerships that will accelerate
infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese health care system and outcomes for patients. These include: 

 

	 	•	 	 A partnership with Vir Biotechnology, a leading U.S.-based biotech working to find cures for infectious diseases,
that grants Brii Bio options on exclusive greater China rights for up to four assets in Vir’s infectious diseases portfolio. This therapeutic pipeline holds the potential to prevent, treat and cure a wide range of infectious diseases.

  

	 	•	 	 A
first-of-its-kind digital and data insight partnership with AliHealth, the health care arm of Alibaba Group to collaborate and
explore disruptive approaches to optimize clinical and commercial development efforts by capturing value evidence and improving patients’ experience with new therapies. This partnership will also explore ways to accelerate the uptake of new
medicines and support appropriate use of new medicines. 

 “China faces significant medical needs in the prevention, treatment, and
cure of serious infectious diseases, yet presents challenges for pharmaceutical innovation,” said Vir CEO George Scangos, Ph.D. “Brii Bio combines a highly successful leadership team, clinical skills and understanding of Chinese medical
and cultural needs. We are happy to be their partner in accelerating the development of medicines for infectious diseases, not only in China, but globally.” 

“Only by providing better health care solutions and broader access to innovative medicines can we deliver real benefits to more patients,” said
AliHealth Chairman Eddie Wu. “The partnership between AliHealth and Brii Bio can bring our cutting edge consumer platforms and digital data capabilities to optimizing the life cycle of medicine discovery, development and delivery. With improved
efficiency, we will deliver more affordable and patient friendlier innovations to China.” 

  
 91 

 EXECUTION VERSION 

 
 In addition to the Vir and AliHealth partnerships, Brii Bio has entered into a
memorandum of understanding with WuXi AppTec and WuXi Biologics for priority access to WuXi’s research and development capabilities. 
 WuXi’s
mission has always been to build a technology and capability platform to enable anyone and any company to discover, develop and manufacture healthcare products to benefit patients,” said Dr. Ge Li, Chairman of WuXi AppTec Group
.. “I share Brii Bio’s mission to improve public health in China, and many of the leadership team members had already delivered some of the biggest medicines in our industry. I look forward to supporting
them.” 
 Brii Bio’s initial funding was led by ARCH Venture Partners, 6 Dimensions Capital, Boyu Capital, Yunfeng Capital, Sequoia Capital, and
Blue Pool Capital. 
 “By bringing together clinically differentiated assets with a world-class team, partners and funders, Brii Bio represents a
long-term investment in building a leading independent biotech company in China and in the country’s public health,” said ARCH Venture Partners co-founder and Managing Director Robert Nelsen. 

The company is headquartered in the People’s Republic of China and the United States, with offices in Shanghai, Beijing, San Francisco and Durham, North
Carolina. Co-Founder, President and CEO Zhi Hong, PhD previously served as Senior Vice President and Head of the Infectious Diseases Therapy Area Unit at GlaxoSmithKline (GSK) for 11 years and is recognized as
the key architect of GSK’s comeback in the Infectious Diseases R&D and HIV business. 
 Company Leadership 

The Brii Bio leadership team includes recognized industry leaders with a strong track record of discovering and developing novel medicines. 

 

	 	•	 	 Li Yan, MD, PhD, Chief Medical Officer—previously served in senior roles at GSK and Merck;

  

	 	•	 	 Lianhong Xu, PhD, SVP and Head of Medicinal Chemistry—co-invented
several blockbuster antiviral therapies at Gilead Sciences; 

  

	 	•	 	 Jean-Luc Girardet, PhD, SVP and Head of Pharmaceutical
Sciences—discovered and launched new gout drugs at Ardea Biosciences (AstraZeneca); 

  

	 	•	 	 Qing Zhu, PhD, VP and Head of Biopharmaceutical Research—brings a decade of biopharma experience at
MedImmune to the new role; 

  

	 	•	 	 Lisa Beck, VP of Business Development—brings over 20 years’ transactional experience and was most
recently at Alexion Pharmaceuticals. 

  

	 	•	 	 James Klein, interim Chief Financial Officer – brings 20 years of experience as CFOs of several biotech and
pharma companies including Triangle Pharmaceuticals. 

 Strategic Advisors 

 

	 	•	 	 John Maraganore, PhD, CEO of Alnylam Pharmaceuticals 

 

	 	•	 	 Moncef Slaoui, PhD, Former Chairman of Global Research and Development and Chairman of Vaccines division at GSK

  

	 	•	 	 David D. Ho, MD, Scientific Director and Chief Executive Officer of the Aaron Diamond AIDS Research Center at the
Rockefeller University 

  
 92 

 EXECUTION VERSION 

 
  

	 	•	 	 Thomas Daniel, MD, former President of Research & Early Development at Celgene 

 

	 	•	 	 Chen Dong, PhD, Dean, School of Medicine at Tsinghua University (Beijing) 

 

	 	•	 	 Clay Thorp, General Partner of Hatteras Venture Partners 

Board of Directors 
  

	 	•	 	 Leon Chen, CEO and founder of 6 Dimensions Capital 

 

	 	•	 	 Zhi Hong, Co-Founder, President and CEO of Brii Bio

  

	 	•	 	 Robert Nelsen, Co-founder and Managing Director of ARCH Venture Partners

  

	 	•	 	 George Scangos, CEO of Vir Biotechnology 

 

	 	•	 	 Neil Shen, Founding and Managing Partner of Sequoia China 

 

	 	•	 	 Sean Tong, Co-founder and Managing Partner of Boyu Capital

  

	 	•	 	 David Yu, Co-founder and Chairman of Yunfeng Capital

 About Brii Biosciences 
 Brii
Biosciences (Brii Bio) is a company committed to serving patients’ needs and improving public health in China. Founded in early 2018 with operations in the People’s Republic of China and the United States, the company focuses on
accelerating innovation and optimizing access to the latest medicines for Chinese patients. Brii Bio helps global partners drive growth and improve return on investment through better understanding of Chinese health care systems and access to the
world’s second largest pharmaceutical market. The company’s focus is treatments for chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses. For more information, visit
www.briibio.com. 
 Media contact 
 Morgan
Warners (US) 
 +1 202-337-0808 

mwarners@gpg.com 
 Michael Wang, PhD. (China) 

michael.wang@briibio.com 

  
 93EX-10.17

 Exhibit 10.17 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION 

COLLABORATION AND LICENSE AGREEMENT 

by and among 
 Vir
Biotechnology, Inc. 
 and 

Alnylam Pharmaceuticals, Inc. 

Dated as of October 16, 2017 
  

 EXECUTION VERSION 
  

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 ARTICLE I DEFINITIONS
	  	 	1	 
	 1.1
	 	Definitions	  	 	1	 
		
	 ARTICLE II GOVERNANCE
	  	 	19	 
	 2.1
	 	Joint Steering Committee	  	 	19	 
	 2.2
	 	Meetings	  	 	20	 
	 2.3
	 	Alliance Managers	  	 	20	 
	 2.4
	 	JSC Responsibilities	  	 	21	 
	 2.5
	 	Appointment of Subcommittees, Project Teams and Collaboration Managers	  	 	21	 
	 2.6
	 	Decision-Making Authority	  	 	21	 
	 2.7
	 	Limitation on JSC Authority	  	 	22	 
	 2.8
	 	Expenses	  	 	22	 
	 2.9
	 	Dissolution of JSC	  	 	22	 
		
	 ARTICLE III COLLABORATION
	  	 	23	 
	 3.1
	 	Overview	  	 	23	 
	 3.2
	 	Development Plans	  	 	24	 
	 3.3
	 	ID Program Development Candidate Selection; Replacement ID Target	  	 	24	 
	 3.4
	 	Collaboration Funding	  	 	25	 
	 3.5
	 	Diligence	  	 	26	 
	 3.6
	 	Reports	  	 	27	 
	 3.7
	 	Records	  	 	28	 
	 3.8
	 	Regulatory Matters	  	 	28	 
	 3.9
	 	Pharmacovigilance	  	 	28	 
	 3.10
	 	Third Parties	  	 	29	 
	 3.11
	 	Collaborations	  	 	29	 
		
	 ARTICLE IV OPTION RIGHTS
	  	 	29	 
	 4.1
	 	Vir ID Program Option	  	 	29	 
	 4.2
	 	Alnylam Profit-Sharing Option	  	 	30	 
		
	 ARTICLE V MANUFACTURE AND SUPPLY OF LICENSED PRODUCTS
	  	 	32	 
	 5.1
	 	Responsibilities for Licensed Product Supply	  	 	32	 
	 5.2
	 	Development Supply Agreements	  	 	33	 
	 5.3
	 	Technology Transfer	  	 	33	 
	 5.4
	 	Additional Licensed Product Supply	  	 	34	 
		
	 ARTICLE VI GRANT OF LICENSE RIGHTS
	  	 	34	 
	 6.1
	 	License Grants to Vir	  	 	34	 
	 6.2
	 	License Grants to Alnylam	  	 	36	 
	 6.3
	 	Joint Collaboration IP	  	 	37	 
	 6.4
	 	Section 365(n) of the Bankruptcy Code	  	 	37	 
	 6.5
	 	No Other Rights	  	 	38	 
	 6.6
	 	Alnylam In-Licenses and Existing Alnylam Third Party Agreements	  	 	38	 
	 6.7
	 	No Reach Through to Acquirer IP	  	 	39	 

  
 i 

 EXECUTION VERSION 
  

							
		
	 ARTICLE VII FINANCIAL PROVISIONS
	  	 	39	 
	 7.1
	 	Upfront Fee	  	 	39	 
	 7.2
	 	License Grant Equity Consideration	  	 	39	 
	 7.3
	 	Development and Regulatory Milestone Fees	  	 	39	 
	 7.4
	 	Sales Milestone Fees	  	 	40	 
	 7.5
	 	Royalties	  	 	41	 
	 7.6
	 	Program Transaction Revenue	  	 	43	 
	 7.7
	 	Payments	  	 	44	 
	 7.8
	 	Reporting	  	 	44	 
	 7.9
	 	Audits	  	 	44	 
	 7.10
	 	Currency Exchange	  	 	45	 
	 7.11
	 	Manner of Payment	  	 	45	 
	 7.12
	 	Tax Withholding	  	 	45	 
	 7.13
	 	Other Tax Liability	  	 	46	 
	 7.14
	 	Late Payments	  	 	46	 
	 7.15
	 	Blocked Payments	  	 	46	 
		
	 ARTICLE VIII INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS
	  	 	46	 
	 8.1
	 	Inventorship	  	 	46	 
	 8.2
	 	Ownership	  	 	46	 
	 8.3
	 	Prosecution and Maintenance of Patent Rights	  	 	46	 
	 8.4
	 	Cooperation	  	 	48	 
	 8.5
	 	Patent Expenses	  	 	48	 
	 8.6
	 	Patent Term Extension	  	 	49	 
	 8.7
	 	Third Party Infringement	  	 	49	 
	 8.8
	 	Trademarks	  	 	51	 
		
	 ARTICLE IX CONFIDENTIAL INFORMATION
	  	 	51	 
	 9.1
	 	Nondisclosure Obligation	  	 	51	 
	 9.2
	 	Publication and Publicity	  	 	52	 
		
	 ARTICLE X REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	54	 
	 10.1
	 	Mutual Representations and Warranties	  	 	54	 
	 10.2
	 	Representations, Warranties and Covenants of Alnylam	  	 	55	 
	 10.3
	 	Representations and Warranties of Vir	  	 	57	 
	 10.4
	 	No Warranties	  	 	57	 
	 10.5
	 	Additional Covenants	  	 	57	 
		
	 ARTICLE XI TERM AND TERMINATION
	  	 	58	 
	 11.1
	 	Term	  	 	58	 
	 11.2
	 	Termination Rights	  	 	58	 
	 11.3
	 	Effect of Termination	  	 	59	 
	 11.4
	 	Effect of Expiration or Termination; Survival	  	 	61	 
		
	 ARTICLE XII INDEMNIFICATION
	  	 	62	 
	 12.1
	 	General Indemnification	  	 	62	 
	 12.2
	 	Indemnification Procedure	  	 	62	 
	 12.3
	 	General Limitation of Liability	  	 	63	 
	 12.4
	 	Insurance	  	 	63	 

  
 ii 

 EXECUTION VERSION 
  

							
		
	 ARTICLE XIII DISPUTE RESOLUTION
	  	 	63	 
	 13.1
	 	Dispute Resolution	  	 	63	 
	 13.2
	 	Arbitration	  	 	63	 
	 13.3
	 	Baseball Arbitration	  	 	64	 
		
	 ARTICLE XIV MISCELLANEOUS
	  	 	65	 
	 14.1
	 	Governing Law	  	 	65	 
	 14.2
	 	Waiver of Jury Trial	  	 	65	 
	 14.3
	 	Assignment	  	 	66	 
	 14.4
	 	Entire Agreement; Amendments	  	 	66	 
	 14.5
	 	Notices	  	 	66	 
	 14.6
	 	Force Majeure	  	 	67	 
	 14.7
	 	No Strict Construction	  	 	67	 
	 14.8
	 	Headings	  	 	67	 
	 14.9
	 	No Implied Waivers; Rights Cumulative	  	 	67	 
	 14.10
	 	Severability	  	 	67	 
	 14.11
	 	Interpretation	  	 	67	 
	 14.12
	 	Actions of Affiliates	  	 	68	 
	 14.13
	 	Relationship of the Parties	  	 	68	 
	 14.14
	 	Binding Effect; No Third Party Beneficiaries	  	 	68	 
	 14.15
	 	Further Assurances	  	 	68	 
	 14.16
	 	Counterparts	  	 	68	 

  

  
 iii 

 EXECUTION VERSION 
  

 COLLABORATION AND LICENSE AGREEMENT 

THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of October 16, 2017 (the “Effective
Date”), by and among Vir Biotechnology, Inc., a Delaware corporation, having a place of business at 499 Illinois Street, San Francisco, CA 94158 (“Vir”), and Alnylam Pharmaceuticals, Inc., a Delaware corporation, having a
place of business at 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142, USA (“Alnylam”). 
 INTRODUCTION

 1. Vir is engaged in the business of developing therapeutic products to treat infectious disease. 

2. Alnylam has developed, acquired and licensed technology useful for the development, manufacture, characterization, and commercialization of
therapeutic products that function through the mechanism of RNAi, including the proprietary compounds known as ALN-HBV and ALN-HBV02, and the Parties desire to research,
develop and commercialize RNAi products for certain infectious disease targets. 
 3. Alnylam desires to grant licenses to such technology to
Vir, and the Parties desire to collaborate on certain development activities, in each case upon the terms and conditions set forth in this Agreement. 

NOW, THEREFORE, in consideration of the respective representations, warranties, covenants and agreements contained herein, and for other
valuable consideration, the receipt and adequacy of which are hereby acknowledged, Alnylam and Vir agree as follows: 
 ARTICLE I 

DEFINITIONS 
 1.1
Definitions. For the purpose of this Agreement, the following terms, whether used in singular or plural form, shall have the respective meanings set forth below: 

1.1.1 “Abandoned ID Target” shall have the meaning set forth in Section 3.3(b). 

1.1.2 “Accounting Period” shall have the meaning set forth in Section 7.7. 

1.1.3 “Achievement of Human POC” shall mean that the Parties reasonably determine that the results from the POC Study support
the continuation of preparation and conduct of a Phase II Study and that [***] based on the results of the POC Study. 
 1.1.4
“Acquired Party” shall have the meaning set forth in Section 6.7. 
 1.1.5 “Acquirer” shall have the
meaning set forth in Section 6.7. 
 1.1.6 “Additional Alnylam Activity” shall mean any Development activity for ALN-HBV02 that (a) is outside of the then-current applicable HBV Development Plan, (b) is reasonably required to support the preparation of an IND for ALN-HBV02 in a
Major Market, and (c) will not, [***] materially adversely impact the HBV Program. 

  
 1 

 EXECUTION VERSION 
  

 1.1.7 “Additional Alnylam
In-Licenses” shall mean the agreements set forth in Section 2 of Schedule A. 

1.1.8 “Additional Funding Activity” shall mean any Development activity for ALN-HBV02
that (a) is outside of the then-current applicable HBV Development Plan, (b) is reasonably required to support the Completion of a POC Study for ALN-HBV02 (for clarity, including any Additional
Alnylam Activity), and (c) will not, [***] materially adversely impact the HBV Program. 
 1.1.9 “Affiliate” shall mean
any Person who directly or indirectly controls or is controlled by or is under common control with another Person. For purposes of this definition, “control” or “controlled” shall mean, with respect to a Person,
(a) any corporation or business entity of which fifty percent (50%) or more of the securities or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or
indirectly, by such Person; (b) any corporation or business entity which, directly or indirectly, owns, controls or holds fifty percent (50%) (or the maximum ownership interest permitted by Law) or more of the securities or other ownership
interests representing the equity, the voting stock or, if applicable, the general partnership interest, of such Person; or (c) any corporation or business entity, of which fifty percent (50%) or more of the securities or other ownership
interests representing the equity of such corporation or business entity is directly or indirectly owned, controlled or held by the same corporation, business entity or security holders, or holders of ownership interests, that own, control or hold
fifty percent (50%) or more of the securities or other ownership interests representing the equity or the voting stock of such Person. 

1.1.10 “Agreement” shall have the meaning set forth in the Preamble, and shall include, for the avoidance of doubt, all
Exhibits and Schedules attached hereto. 
 1.1.11 “Alliance Manager” shall have the meaning set forth in the
Section 2.3(a). 
 1.1.12 “ALN-HBV” shall mean an siRNA Controlled by Alnylam,
comprising the [***], as further described on Schedule B. 
 1.1.13
“ALN-HBV Study” shall mean the Clinical Study of ALN-HBV, protocol #2015-004360-10, A Phase 1/2, Randomized,
Single-Blind, Placebo-Controlled, Single-Ascending and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Antiviral Efficacy Study of Subcutaneously Administered ALN-HBV in Healthy Adult
Subjects and Non-cirrhotic Patients with Chronic Hepatitis B Virus (HBV) Infection. 
 1.1.14
“ALN-HBV02” shall mean an siRNA Controlled by Alnylam, comprising the [***], as further described on Schedule B. 

1.1.15 “Alnylam” shall have the meaning set forth in the Preamble. 

1.1.16 “Alnylam Collaboration IP” shall mean (a) any improvement, discovery or
Know-How, patentable or otherwise, first conceived or reduced to practice or, with respect to inventions and discoveries other than patentable inventions, otherwise identified, discovered, made or developed,
solely by individuals who are employees, agents or consultants of Alnylam or its Affiliates and Controlled by Alnylam at any time during the Term, in each case in the conduct of the Collaboration or otherwise under this Agreement, and (b) any
Patent Rights that claim such improvements, discoveries or Know-How. Alnylam Collaboration IP excludes Alnylam’s interest in Joint Collaboration IP. Patent Rights constituting Alnylam Collaboration IP are
either Alnylam Core Technology Patent Rights or Alnylam Product-Specific Patent Rights, as the case may be. 

  
 2 

 EXECUTION VERSION 
  

 1.1.17 “Alnylam Core Technology Patent Rights” shall mean Patent Rights
Controlled by Alnylam at any time during the Term that are reasonably necessary or useful to Develop, Manufacture or Commercialize Licensed Products, in each case other than Alnylam Product-Specific Patent Rights and Patent Rights comprising Joint
Collaboration IP. Alnylam Core Technology Patent Rights includes the Patent Rights set forth on Schedule C-1 and may include Patent Rights that constitute Alnylam Collaboration IP.

 1.1.18 “Alnylam HBV Program Completion” shall have the meaning set forth in Section 3.1(a). 

1.1.19 “Alnylam In-Licenses” shall mean (a) the Existing Alnylam In-Licenses and (b) any agreement between Alnylam (or its Affiliates) and a Third Party entered into after the Effective Date pursuant to which Alnylam acquires Control of
Know-How or Patent Rights that are reasonably necessary or useful to Develop, Manufacture or Commercialize Licensed Products in the Field in the Territory (excluding any Unlicensed Component of a Combination
Product), but in the case of any such agreement described in clause (b), solely to the extent that such agreement is designated as an Alnylam In-License pursuant to Section 6.6(b). 

1.1.20 “Alnylam Indemnitees” shall have the meaning set forth in Section 12.1(a). 

1.1.21 “Alnylam Intellectual Property” shall mean collectively, Alnylam Know-How,
Alnylam Patent Rights, Alnylam Collaboration IP and Alnylam’s interest in Joint Collaboration IP. 
 1.1.22 “Alnylam Know-How” shall mean Know-How Controlled by Alnylam at any time during the Term that is reasonably necessary or useful to Develop, Manufacture and/or Commercialize
Licensed Products in the Field in the Territory. 
 1.1.23 “Alnylam Patent Rights” shall mean Alnylam Core Technology Patent
Rights and Alnylam Product-Specific Patent Rights. 
 1.1.24 “Alnylam Product-Specific Patent Rights” shall mean, with
respect to a Licensed Product, Patent Rights Controlled by Alnylam at any time during the Term that solely claim (a) an siRNA contained in such Licensed Product, which siRNA is Directed to a Collaboration Target, and pharmaceutical compositions
thereof; (b) such Licensed Product or specific components thereof to the extent such components are unique to such Licensed Product; (c) methods of using the compositions described in clause (a) or (b) above in the Field, or to
be Directed to the Collaboration Target of such Licensed Product, or to inhibit expression of such Collaboration Target, and foreign equivalents of such method claims; (d) methods and compositions directed to the synthesis or analysis of the
compositions described in clause (a) or (b); or (e) Alnylam Collaboration IP that is applicable solely to such Licensed Product; provided, however, that any such patents that include claims that are directed to subject matter
applicable to siRNA or siRNA delivery in general will not be considered Alnylam Product-Specific Patent Rights but will be considered Alnylam Core Technology Patent Rights. Alnylam Product-Specific Patent Rights excludes Joint Collaboration IP,
includes the Patent Rights set forth on Schedule C-2 and may include Patent Rights that constitute Alnylam Collaboration IP. 

1.1.25 “Alnylam Product-Specific Collaboration IP” shall mean Alnylam Collaboration IP that relates to a Licensed Product or a
Collaboration Target and does not (a) have general applicability to RNAi Products, (b) relate to RNAi Products other than a Licensed Product, or (c) relate to targets other than a Collaboration Target; excluding in each case any
Alnylam Collaboration IP to the extent such Alnylam Collaboration IP specifically relates to or discloses any Licensed Product or Collaboration Target. 

  
 3 

 EXECUTION VERSION 
  

 1.1.26 “Applicable Accounting Standards” shall mean then current United
States generally accepted accounting principles, consistently applied. 
 1.1.27 “Approved Product” shall have the meaning
set forth in Section 7.3(b). 
 1.1.28 “Back-Up Product” shall have the meaning
set forth in Section 7.3(b). 
 1.1.29 “Bankrupt Party” shall have the meaning set forth in Section 6.4. 

1.1.30 “Bulk Drug Substance” shall mean an siRNA (including chemical modifications and covalent conjugates) or other active
ingredient in bulk form manufactured for use as an active pharmaceutical ingredient in a Licensed Product. 
 1.1.31 “Business
Day” shall mean a day on which banking institutions in both Boston, Massachusetts and San Francisco, California are open for business. 

1.1.32 “Calendar Quarter” shall mean the respective periods of three (3) consecutive calendar months ending on
March 31, June 30, September 30 and December 31 of each Calendar Year; provided, that (a) the first Calendar Quarter of the Term shall begin on the Effective Date and end on the first to occur of March 31,
June 30, September 30 or December 31 thereafter and the last Calendar Quarter of the Term shall end on the last day of the Term, and (b) the first Calendar Quarter of a Royalty Term for a Licensed Product in a country shall begin
on the First Commercial Sale of such Licensed Product in such country and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of a Royalty Term shall end on the
last day of such Royalty Term. 
 1.1.33 “Calendar Year” shall mean each successive period of twelve (12) months
commencing on January 1 and ending on December 31; provided, that (a) the first Calendar Year of the Term shall begin on the Effective Date and end on the first December 31 thereafter and the last Calendar Year of the Term
shall end on the last day of the Term, and (b) the first Calendar Year of a Royalty Term for a Licensed Product in a country shall begin on the First Commercial Sale of such Licensed Product in such country and end on the first December 31
thereafter and the last Calendar Year of the Term shall end on the last day of such Royalty Term. 
 1.1.34 “Challenge”
shall have the meaning set forth in Section 11.2(d). 
 1.1.35 “Challenging Party” shall have the meaning set forth in
Section 11.2(d). 
 1.1.36 “Change of Control” shall mean with respect to a Person, any of the following: (a) the
sale or disposition of all or substantially all of the assets of such Person or its direct or indirect controlling Affiliate to a Third Party, other than to an entity of which more than fifty percent (50%) of the voting capital stock are owned after
such sale or disposition by shareholders of such Person or its direct or indirect controlling Affiliate (in either case, whether directly or indirectly through any parent entity); or (b) (i) the acquisition by a Third Party, alone or together
with any of its Affiliates, other than an employee benefit plan (or related trust) sponsored or maintained by such Person or any of its Affiliates, of more than fifty percent (50%) of the outstanding shares of voting capital stock of such Person or
its direct or indirect controlling Affiliate, or (ii) the acquisition, merger or consolidation of such Person or its direct or indirect controlling Affiliate with or into another Person, other than, in the case of this clause (b), an
acquisition or a merger or consolidation of such Person or its controlling Affiliate in which the holders of shares of voting capital stock of such Person or its controlling Affiliate, as the case may be, immediately prior to such acquisition,
merger or consolidation will beneficially own, directly or indirectly, at least fifty percent (50%) of the shares of voting capital stock of the acquiring Third Party or the surviving corporation in such acquisition, merger or consolidation, as the
case may be, immediately after such acquisition, merger or consolidation. 

  
 4 

 EXECUTION VERSION 
  

 1.1.37 “Clinical Study” shall mean any clinical study of a Licensed Product
in humans. 
 1.1.38 “Collaboration” shall mean the collaboration between the Parties regarding the Development of potential
RNAi Products Directed to a Collaboration Target in each Program during the applicable Collaboration Term for such Program, which the Parties shall conduct pursuant to the terms of Article III. 

1.1.39 “Collaboration IP” shall mean the collective reference to the Alnylam Collaboration IP, the Vir Collaboration IP and
the Joint Collaboration IP. 
 1.1.40 “Collaboration Target” shall mean each of (a) HBV and (b) the ID
Collaboration Targets. 
 1.1.41 “Collaboration Term” shall mean, with respect to (a) the HBV Program, the period
commencing on the Effective Date and ending on expiration of Alnylam’s Profit-Sharing Option Period with respect to all HBV Licensed Products; and (b) each ID Program, the period commencing on the date that an ID Collaboration Target is
designated for such Program, and ending on the expiration of Alnylam’s Profit-Sharing Option Period with respect to all ID Licensed Products for such ID Program. 

1.1.42 “Combination Product” shall mean a Licensed Product and any other clinically active therapeutic or prophylactic
ingredient, mechanism or device. 
 1.1.43 “Commercialization” or “Commercialize” shall mean, with respect
to a product, activities directed to marketing, promoting, detailing, distributing, importing, having imported, exporting, having exported, selling or offering to sell, or seeking to obtain reimbursement for, such product, whether before or after
Regulatory Approval for such product has been obtained. 
 1.1.44 “Commercially Reasonable Efforts” shall mean (a) with
respect to the obligations of a Party under this Agreement that relate to the Development, Manufacture or Commercialization of a Licensed Product, the carrying out of such obligations [***], taking into account the following factors to the extent
reasonable and relevant: [***] in the marketplace, the patent or other proprietary position of such Licensed Product, the regulatory structure involved and the potential profitability of such Licensed Product marketed or to be marketed, [***]; and
(b) with respect to other obligations under this Agreement, the carrying out of such obligations in a diligent, expeditious and sustained manner using efforts and resources, including reasonably necessary personnel and financial resources, that
biopharmaceutical companies of comparable size and resources typically devote to similar obligations. 
 1.1.45 “Commitment Letter
Date” shall mean July 28, 2017. 
 1.1.46 “Competing Program” shall have the meaning set forth in
Section 10.5(a). 

  
 5 

 EXECUTION VERSION 
  

 1.1.47 “Competitive Infringement” shall have the meaning set forth in
Section 3.3. 
 1.1.48 “Completion” shall mean, with respect to a Clinical Study, database lock for such Clinical
Study. 
 1.1.49 “Compulsory License” shall mean, with respect to a Licensed Product in a country, a compulsory sublicense
under the Alnylam Intellectual Property obtained by a Third Party (the “Compulsory Licensee”) through the order, decree, or grant of a Governmental Authority in such country, authorizing such Compulsory Licensee to Develop,
Manufacture, or Commercialize such Licensed Product in the Field in such country. A Compulsory Licensee shall not be deemed to be a Sublicensee. 

1.1.50 “Compulsory License Compensation” shall mean, for a given Licensed Product and a given country in the Territory, the
[***] received from a Compulsory Licensee by Vir or any of its Related Parties under a Compulsory License. 
 1.1.51 “Compulsory
License Royalty Rate” has the meaning set forth in Section 7.5(f)(ii). 
 1.1.52 “Confidential Disclosure
Agreement” shall mean that certain Confidential Disclosure Agreement by and between the Parties effective as of February 23, 2017. 

1.1.53 “Confidential Information” of a Party shall mean the terms of this Agreement and all
Know-How and other information that is of a confidential and proprietary nature to such Party (including Know-How and information of Third Parties) and that is disclosed
to the other Party under this Agreement. Confidential Information includes Know-How or other information (whether or not patentable) regarding a Party’s technology, products, business information or
objectives and reports and audits under Sections 7.8 and 7.9, and all proprietary biological materials (and data and information associated therewith) of a Party. Alnylam Intellectual Property (other than Joint Collaboration IP) is Confidential
Information of Alnylam, except that Alnylam Product-Specific Collaboration IP is the Confidential Information of both Parties. Vir Intellectual Property (other than Joint Collaboration IP) is Confidential Information of Vir. Joint Collaboration IP
is the Confidential Information of both Parties, with each Party being considered both the Disclosing Party and the Receiving Party. Confidential Information shall include: (a) the terms and conditions of this Agreement, which shall be the
Confidential Information of both Parties; and (b) Confidential Information disclosed by either Party pursuant to the Confidential Disclosure Agreement. 

1.1.54 “Control” or “Controlled” shall mean, with respect to any
Know-How, Patent Right or other intellectual property right and a Party, the ability of such Party or its Affiliates (whether by ownership or license, other than pursuant to a license granted under this
Agreement) to assign, transfer, or grant access to, or a license or sublicense of, such item or right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party; provided, that, with respect
to rights to any Third Party Know-How, Patent Rights or other intellectual property right that are licensed to, or otherwise obtained by, (i) Alnylam or its Affiliates pursuant to an agreement entered
into by Alnylam or any of its Affiliates after the Effective Date, or (ii) Alnylam or its Affiliates pursuant to any Additional Alnylam In-License, such Third Party
Know-How, Patent Rights or other intellectual property right shall be deemed not to be under the Control of such Party or its Affiliates, or Alnylam or its Affiliates, respectively, unless and until the
agreement pursuant to which such rights are obtained becomes an Alnylam In-License pursuant to Section 6.6(b) or (c), as the case may be. 

  
 6 

 EXECUTION VERSION 
  

 1.1.55 “Cover”, “Covered” or “Covering”
shall mean, as to a product and Patent Rights, that, in the absence of a license granted under, or ownership of, such Patent Rights, the research, development, manufacture, use, offer for sale, sale, or importation of such product would infringe
such Patent Rights or, as to a pending claim included in such Patent Rights, the research, development, manufacture, use, offer for sale, sale, or importation of such product would infringe such Patent Rights if such pending claim were to issue in
an issued patent. 
 1.1.56 “CPI” shall mean the Consumer Price Index – Urban Wage Earners and Clerical Workers, U.S.
City Average, All Items, 1982-84 = 100, published by the United States Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the United States. 

1.1.57 “DC Workplan” shall have the meaning set forth in Section 3.2(a). 

1.1.58 “Debar”, “Debarred” or “Debarment” shall mean (a) being debarred, or being
subject to a pending debarment, pursuant to section 306 of the FDCA, 21 U.S.C. § 335a, (b) being listed by any federal and/or state agencies, excluded, debarred, suspended or otherwise made ineligible to participate in federal or
state healthcare programs or federal procurement or non-procurement programs (as that term is defined in 42 U.S.C. § 1320a-7b(f), or being subject to any
pending process by which any such listing, exclusion, debarment, suspension or other ineligibility could occur, (c) being disqualified by any government or regulatory agency from performing specific services, or being subject to a pending
disqualification proceeding, or (d) being convicted of a criminal offense related to the provision of healthcare items or services or being subject to any pending criminal action related to the provision of healthcare items or services. 

1.1.59 “Develop” or “Development” shall mean, with respect to a product, discovery, research, preclinical
development, clinical development, and regulatory activities with respect to such product, including test method development and stability testing, design, compatibility testing, toxicology, animal efficacy studies, formulation, quality
assurance/quality control development, statistical analysis, clinical studies (including Clinical Studies), regulatory affairs, product approval and registration, chemical development and Manufacturing development, packaging development and
Manufacturing and development documentation efforts in support of development activities anywhere in the world, whether before or after Regulatory Approval for such product has been obtained. 

1.1.60 “Development Candidate” shall have the meaning set forth in Section 3.3(a). 

1.1.61 “Development Plan” shall have the meaning set forth in the Section 3.2(a). 

1.1.62 “Development Supply Agreement” shall have the meaning set forth in the Section 5.2. 

1.1.63 “Directed to” shall mean, with respect to an siRNA and a Target, that such siRNA [***] of the messenger RNA of such
Target, and with respect to a product and a Target, that such product contains an siRNA that [***] of the messenger RNA of such Target. 

1.1.64 “Disclosing Party” shall have the meaning set forth in Section 9.1(a). 

1.1.65 “Divest”, “Divesting” and “Divestiture” shall have the meaning set forth in
Section 10.5(a). 
 1.1.66 “Dollars” and “$” shall mean United States dollars. 

  
 7 

 EXECUTION VERSION 
  

 1.1.67 “Drug Product” shall mean the finished product formulation of a
Licensed Product, containing Bulk Drug Substance, filled into unit packages (but excluding, in the case of supply by Alnylam or its Affiliates, any delivery device) for final labeling and packaging. 

1.1.68 “Effective Date” shall have the meaning set forth in the Preamble. 

1.1.69 “EMA” shall mean the European Medicines Agency and any successor Governmental Authority having substantially the same
function. 
 1.1.70 “End-of-Phase 2 Meeting”
shall mean an end-of-phase 2 meeting with the FDA as described in 21 CFR §312.47(b), or the equivalent meeting with the EMA. 

1.1.71 “Equity Consideration” shall have the meaning set forth in the Section 7.2. 

1.1.72 “Executive Officer” shall mean, with respect to Vir, Vir’s Chief Executive Officer (or his or her designee), and,
with respect to Alnylam, Alnylam’s Chief Executive Officer (or his or her designee). 
 1.1.73 “Existing Alnylam In-Licenses” shall mean (a) the Third Party agreements identified as such in Section 1 of Schedule A and (b) any Additional Alnylam
In-License included within the definition of Existing Alnylam In-Licenses pursuant to Section 6.6(c). 

1.1.74 “Existing Alnylam Third Party Agreements” shall mean the Third Party agreements identified as such in Section 3 of
Schedule A. 
 1.1.75 “Failed Product” shall have the meaning set forth in Section 7.3(b).

 1.1.76 “FDA” shall mean the United States Food and Drug Administration or any successor Governmental Authority having
substantially the same function. 
 1.1.77 “Field” shall mean all uses and purposes, including the treatment, palliation,
diagnosis or prevention of any human disease, disorder or condition, but excluding applications in agriculture, horticulture, forestry, aquaculture, and/or residential markets relating to plants, fish, arthropods and/or pests and pathogens thereof
(e.g., home, lawn and/or garden). 
 1.1.78 “First Commercial Sale” shall mean the first commercial sale of a Licensed
Product by Vir or its Related Parties in a country following Regulatory Approval of such Licensed Product in that country or, if no such Regulatory Approval or similar marketing approval is required, the date upon which such Licensed Product is
first commercially sold in such country to end users. Sales for compassionate use, test marketing or clinical trial purposes shall not constitute a First Commercial Sale. 

1.1.79 “Follow-On Product” shall have the meaning set forth in Section 7.3(b).

 1.1.80 “FTE” shall mean the number of full-time-equivalent person-years (each consisting of a total of [***] hours) of
scientific, technical, regulatory, marketing or managerial work by each Party’s personnel on or directly related to the applicable activity conducted hereunder. 

1.1.81 “FTE Cost” shall mean the amount obtained by multiplying (a) the number of FTEs by (b) [***], increased or
decreased annually by the percentage increase or decrease in the CPI as of December 31 of the then most recently ended Calendar Year over the level of the CPI on December 31, 2017 (i.e., the first such increase or decrease would
occur on January 1, 2019). For clarity, the amount specified in subsection (b) [***] an FTE in a Calendar Year. For purposes of this calculation, no individual may account for more than one FTE in a Calendar Year.

  
 8 

 EXECUTION VERSION 
  

 1.1.82 “Generic Product” shall mean, with respect to a Licensed Product in a
country in the Territory, any product sold by a Third Party approved in such country by way of an abbreviated regulatory mechanism by the Regulatory Authority in such country that, in each case, meets the equivalency determination by the applicable
Regulatory Authority (including a determination that the product is “comparable”, “interchangeable”, “bioequivalent”, “biosimilar” or other term of similar meaning, with respect to such Licensed Product). A
product shall not be considered to be a Generic Product if (a) Vir or any of its Related Parties was involved in or authorized the Development or Commercialization of such product, (b) Vir or any of its Related Parties has granted a
license to such Third Party in respect of such product, or (c) such product is Commercialized by any Person who obtained such product in a chain of distribution that included Vir or any of its Related Parties. 

1.1.83 “Global Access Program” shall mean a program intended to make therapeutic, prophylactic, or diagnostic products
available to a developing geographic area or neglected patient population outside of the Major Markets and China, at a reasonable cost for such area or population. 

1.1.84 “Governmental Authority” shall mean any applicable government authority, court, tribunal, arbitrator, agency,
legislative body, commission or other instrumentality of (a) any government of any country or territory, (b) any state, province, county, city or other political subdivision thereof or (c) any supranational body. 

1.1.85 “HBV” shall mean human hepatitis B virus. 

1.1.86 “HBV Development Plan” shall have the meaning set forth in Section 3.1(a). 

1.1.87 “HBV Licensed Product” shall mean each of (i) ALN-HBV and (ii) ALN-HBV02, and (iii) any other RNAi Product Directed to HBV that is Controlled by Alnylam (x) on the Effective Date or, subject to Section 10.5(a)(ii), during the Term, and/or
(y) Developed in the HBV Program. 
 1.1.88 “[***] Completion” shall have the meaning set forth in
Section 5.1(a)(i). 
 1.1.89 “HBV Program” shall mean the collaboration between the Parties regarding the Development
of RNAi Products Directed to HBV, including ALN-HBV and ALN-HBV02. 

1.1.90 “HBV Program Joint Funding Period” [***]. 

1.1.91 “ICC Rules” shall have the meaning set forth in Section 13.2(a). 

1.1.92 “ID Collaboration Target” shall mean an ID Target that is designated for an ID Program pursuant to Section 3.1(b).

 1.1.93 “ID Development Plan” shall have the meaning set forth in Section 3.2(a). 

1.1.94 “ID Licensed Product” shall mean any RNAi Product Directed to an ID Collaboration Target that is either
(a) Developed in an ID Program or (b) otherwise Controlled by Alnylam as of the date of that Vir exercises its Program Option for such ID Collaboration Target in accordance with Section 4.1(a).

  
 9 

 EXECUTION VERSION 
  

 1.1.95 “[***] Completion” shall have the meaning set forth in
Section 5.1(a)(ii). 
 1.1.96 “ID Program” shall have the meaning set forth in the Section 3.2(a). 

1.1.97 “ID Target” shall mean a Target primarily for intervention in the treatment, palliation, diagnosis or prevention of
Infectious Disease in humans or animals. 
 1.1.98 “IND” shall mean an application submitted to a Regulatory Authority to
initiate human clinical trials, including (a) an Investigational New Drug application or any successor application or procedure filed with the FDA, (b) any equivalent of a U.S. Investigational New Drug application in any country outside
the United States, and (c) all supplements and amendments that may be filed with respect to the foregoing. 
 1.1.99 “Infectious
Disease” shall mean diseases of infectious pathogen origin or hosted by pathogen infection. 
 1.1.100 “Initiation”
shall mean the first dosing of a human subject participating in a Clinical Study. 
 1.1.101 “Joint Collaboration IP” shall
mean collectively, (a) any improvement, discovery or Know-How, patentable or otherwise, first conceived or reduced to practice or, with respect to inventions and discoveries other than patentable
inventions, otherwise identified, discovered, made or developed, jointly by individuals who are employee(s), agent(s) or consultant(s) of Alnylam or its Affiliates, on the one hand, and individuals who are employee(s), agent(s) or consultant(s) of
Vir or its Affiliates, on the other hand, in the conduct of the Collaboration or otherwise under this Agreement, and (b) any Patent Rights that claim such improvements, discoveries or Know-How during the
Term. 
 1.1.102 “JSC” shall have the meaning set forth in Section 2.1(a). 

1.1.103 “Know-How” shall mean any biological materials and other tangible materials or
intangible information, including data, inventions, practices, methods, protocols, formulas, knowledge, know-how, trade secrets, processes, assays, skills, experience, techniques, governmental or regulatory
correspondence (including conversation logs), and results of experimentation and testing, including pharmacological, toxicological and pre-clinical and clinical data and analytical and quality control data,
patentable or otherwise. 
 1.1.104 “Knowledge” of a Party shall mean (a) the actual knowledge of any “executive
officer” (as defined in Rule 3b-7 promulgated under the Securities Exchange Act of 1934) of such Party, or (b) with respect to Alnylam, Alnylam’s Vice President, Intellectual Property and
any other Alnylam employee with direct operational responsibility for filing and maintaining the Alnylam Patent Rights who is a Senior Director or above. 

1.1.105 “Law” shall mean any applicable law, statute, rule, regulation, ordinance or other pronouncement having the effect of
law of any Governmental Authority. 
 1.1.106 “Licensed Product” shall mean any (i) HBV Licensed Product or
(ii) ID Licensed Product, in each case, in all dosage forms, formulations and modes/methods of administration, alone or as Combination Products. For avoidance of doubt, Licensed Product includes any Profit-Sharing Product. For 

  
 10 

 EXECUTION VERSION 
  

 clarity, the inclusion of Combination Products in Licensed Products shall not be read to provide a license
under this Agreement for any Unlicensed Component under independent intellectual property of Alnylam or its Affiliates covering such Unlicensed Component on a stand-alone basis apart from its inclusion in a Combination Product. 

1.1.107 “Licensor Party” shall have the meaning set forth in Section 11.2(d). 

1.1.108 “Losses” shall have the meaning set forth in Section 12.1(a). 

1.1.109 “Major Market” shall mean each of the [***]. 

1.1.110 “Manufacture” or “Manufacturing” shall mean, with respect to a product and as applicable, all
activities associated with the production, manufacture, supply, processing, filling, packaging, labeling, shipping, and storage of such product and/or any components thereof, including process and formulation development, process validation,
stability testing, manufacturing scale-up, preclinical, clinical and commercial manufacture and analytical development, product characterization, quality assurance and quality control development, testing and
release. 
 1.1.111 “Manufacturing Costs” shall mean, with respect to the manufacture of Licensed Product by a Party or its
Affiliate, to the extent (a) such Party or its Affiliates Manufactures such Licensed Product, the reasonable internal and external costs incurred by such Party and its Affiliates in Manufacturing such Licensed Product, including the fully
allocated cost of Manufacture of such Licensed Product, consisting of direct material and direct labor costs (including direct material and labor costs incurred for Licensed Product manufacturing process
start-up and validation), plus overhead directly attributable to the Manufacture of such Licensed Product (including all directly incurred Manufacturing variances and a reasonable allocation of Manufacturing
administrative and facilities operations and facilities depreciation costs for such Licensed Product, but in all cases excluding corporate administrative overhead), all calculated strictly in accordance with Applicable Accounting Standards, and
(b) such Licensed Product is Manufactured by a Third Party manufacturer, the actual fees paid by such Party to the Third Party for the Manufacture and supply of such Licensed Product, including any prepayments, reservation, and cancellation
fees, costs of failed batches and any value-added tax or similar tax due for amounts paid to such Third Party directly attributable to such Licensed Product; provided that any such Manufacturing Costs [***]. Any Development or Manufacturing
costs that can be classified under costs of goods pursuant to Applicable Accounting Standards will be classified as such for the purposes of calculating Manufacturing Costs, and such calculation shall be made in accordance with Applicable Accounting
Standards. 
 1.1.112 “MicroRNA” or “miRNA” shall mean a structurally defined functional RNA molecule
usually between [***] nucleotides in length, which is derived from an endogenous, genetically-encoded non-coding RNA which is predicted to be processed into a hairpin RNA structure that is a substrate for the
double-stranded RNA-specific ribonuclease Drosha and subsequently is predicted to serve as a substrate for the enzyme Dicer, a member of the RNase III enzyme family. 

1.1.113 “MicroRNA Mimic” shall mean a single-stranded or double-stranded oligonucleotide with the same or substantially
similar-base composition and sequence (including chemically modified bases) as a particular natural miRNA and which is designed to mimic the activity of such miRNA. For clarity, MicroRNA Mimic excludes a double-stranded oligonucleotide which
functions or is designed to function as an siRNA. 

  
 11 

 EXECUTION VERSION 
  

 1.1.114 “Milestone Payment” shall have the meaning set forth in
Section 7.3(a). 
 1.1.115 “NDA” shall mean a New Drug Application, Biologics License Application, Marketing
Authorization Application or similar application or submission filed with a Regulatory Authority in a country or group of countries to obtain marketing approval for a biological, pharmaceutical or other therapeutic or prophylactic product in that
country or in that group of countries, and all supplements and amendments that may be filed with respect to the foregoing. 
 1.1.116
“Net Sales” shall mean for any period and for any country in the Territory, the total aggregate amount billed during such period in such country by Vir or its Related Parties in such country for all sales of the Licensed Products to
Third Parties (other than to a Sublicensee of Vir or its Affiliates) after deducting, if not previously deducted, from the amount invoiced or received, the following deductions to the extent actually applied or taken with respect to such sales of
Licensed Products: [***] 
 Such amounts shall be determined from the books and records of Vir and its Related Parties, maintained in accordance with
Applicable Accounting Standards, consistently applied. 
 If any Licensed Product is sold as a Combination Product, the Net Sales from the
Combination Product, for the purposes of determining milestones and royalties, shall be determined by multiplying the Net Sales of the Combination Product during the applicable Calendar Quarter, by the fraction, A/(A+B), where A is the average sale
price of a Sole Compound Product (as defined below) when sold separately in 

  
 12 

 EXECUTION VERSION 
  

 finished form and B is the average sale price of the other active compounds or active ingredients included in
the Combination Product when sold separately in finished form, in each case during the applicable Calendar Quarter or, if sales of both the Sole Compound Product and the other active compounds or active ingredients did not occur in such period, then
in the most recent Calendar Quarter in which sales of both occurred. If such average sale price cannot be determined for both the Sole Compound Product and all other active compounds or active ingredients included in the Combination Product, Net
Sales for the purposes of determining milestones and royalties shall be calculated by multiplying the Net Sales of the Combination Product by the fraction of C/(C+D) where C is the fair market value of the Sole Compound Product and D is the fair
market value of all other active compounds or active ingredients included in the Combination Product. In such event, Vir shall in good faith make a determination of the respective fair market values of the Sole Compound Product and all other active
compounds or active ingredients included in the Combination Product, and shall notify Alnylam of such determination and provide Alnylam with Vir’s basis for such determination. If Alnylam in good faith does not agree with such determination,
Alnylam shall give Vir written notice of its disagreement within [***] after receiving the relevant report pursuant to Section 7.9, and the matter shall be submitted for final and binding resolution pursuant to the baseball arbitration
provisions in Section 13.3. “Sole Compound Product” shall mean a product containing no active compounds or active ingredients other than an siRNA. 

In the case of any sale or other disposal for value, such as barter or counter-trade, of Licensed Product, or part thereof, other than in an arm’s length
transaction exclusively for cash, Net Sales shall be calculated as above on the value of the non-cash consideration received or the fair market price (if higher) of the Licensed Product in the country of sale
or disposal, as determined in accordance with Applicable Accounting Standards. 
 Sales between or among Vir and its Related Parties shall be excluded from
the computation of Net Sales, but Net Sales shall include sales to the first Third Party (other than a Sublicensee of Vir or its Affiliate) thereafter by Vir or its Related Parties. 

1.1.117 “Neutral Expert” shall have the meaning set forth in Section 13.3(a). 

1.1.118 “Non-Acquired Party” shall have the meaning set forth in Section 6.7.

 1.1.119 “Non-Bankrupt Party” shall have the meaning set forth in
Section 6.4. 
 1.1.120 “Notice Date” shall have the meaning set forth in Section 13.3(a). 

1.1.121 “Operating Profits/Losses” shall have the meaning set forth in Schedule E. 

1.1.122 “Party” shall mean Alnylam or Vir; 

1.1.123 “Parties” shall mean Alnylam and Vir collectively. 

1.1.124 “Patent Rights” shall mean patents, patent applications and/or provisional patent applications, utility models and
utility model applications, design patents or registered industrial designs and design applications or applications for registration of industrial designs, and all substitutions, divisionals, continuations, continuation-in-part applications, continued prosecution applications, requests for continued examinations, reissues, reexaminations and extensions thereof, in any country of the world. For clarity, any
Patent Rights shall include any future Patent Rights that claim priority to or common priority with such Patent Rights. 

  
 13 

 EXECUTION VERSION 
  

 1.1.125 “Permitted Transaction” shall mean an agreement between Alnylam and
[***]. 
 1.1.126 “Person” shall mean any corporation, limited or general partnership, limited liability company, joint
venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual. 

1.1.127 “Pharmacovigilance Agreement” shall have the meaning set forth in Section 3.10. 

1.1.128 “Phase I Study” shall mean a study of a Licensed Product in human volunteers or patients the purpose of which is
preliminary determination of safety and tolerability of a dosing regime and for which there are no primary endpoints (as recognized by the FDA or other Regulatory Authorities) in the protocol relating to efficacy. 

1.1.129 “Phase II Study” shall mean a study of a Licensed Product to evaluate preliminary efficacy and establish safety,
appropriate dosage and pharmacological activity in the target patient population. 
 1.1.130 “Phase III Study” shall mean a
human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain Regulatory Approval to market such product in patients having the disease or
condition being studied as described in U.S. 21 C.F.R. § 312.21(c), or a similar clinical study in a country other than the United States. 

1.1.131 “Pivotal Study” shall mean a Phase III Study and any other Clinical Study in humans prospectively designed as a
pivotal study to demonstrate whether the product is safe and effective for use in the indication under investigation in a manner sufficient to file a drug approval application for such indication in a Major Market, whether or not such trial is
called a “Phase III” Study. Without limiting the generality of the foregoing, a clinical study will be deemed to be a Pivotal Study if such study has been designated by the sponsor as a Phase III clinical trial on
www.clinicaltrials.gov (or any successor website maintained by the U.S. National Institutes of Health or any successor agency of the U.S. government) or any analogous website in a Major Market. 

1.1.132 “POC Study” shall mean (a) with respect to the HBV Program, a Clinical Study of
ALN-HBV02 to evaluate safety in human volunteers and [***] as further described in the HBV Development Plan; and (b) with respect to an ID Program, a Clinical Study of an ID Licensed Product Directed to
the ID Collaboration Target in such ID Program that is designed to demonstrate human safety and [***], as further described in the applicable ID Development Plan. 

1.1.133 “Pre-Existing Affiliates” shall have the meaning set forth in
Section 6.7. 
 1.1.134 “Product Trademark(s)” shall mean the trademark(s) and service mark(s) for use in connection
with the distribution, marketing, promotion and sale of Licensed Products, and/or accompanying logos, trade dress and/or indicia of origin. Product Trademarks specifically excludes the corporate names and logos of the Parties and their Related
Parties. 

  
 14 

 EXECUTION VERSION 
  

 1.1.135 “Profit-Sharing Agreement” shall have the meaning set forth in
Section 4.2(a). 
 1.1.136 “Profit-Sharing Option” shall have the meaning set forth in Section 4.2(a). 

1.1.137 “Profit-Sharing Option Data Package” shall mean the information set forth on Schedule K. 

1.1.138 “Profit-Sharing Option Period” shall have the meaning set forth in Section 4.2(b). 

1.1.139 “Profit-Sharing Product” shall have the meaning set forth in Section 4.2(c). 

1.1.140 “Profit-Sharing Term” shall mean, with respect to a Licensed Product, the period commencing with the exercise by
Alnylam of its Profit-Sharing Option with respect to such Licensed Product and ending upon the termination or expiration of the Profit-Sharing Agreement with respect to such Licensed Product. 

1.1.141 “Program” shall have the meaning set forth in the Section 3.2(a). 

1.1.142 “Program Costs” shall mean, with respect to a Program, the following costs in each case as set forth and budgeted in
the applicable Development Plan or as otherwise approved by the JSC: 
 (a) with respect to Development of Licensed Products under such
Program, (i) the direct and documented out-of-pocket costs and expenses incurred by a Party or its Affiliates in conducting Development activities (including any
costs of Manufacturing-related activities and regulatory activities designed to support the preparation of the Chemistry, Manufacturing and Controls (CMC) sections of any regulatory submissions or Regulatory Approval for such Program to the extent
such costs are not included in the Supply Price for such Licensed Products), and (ii) FTE Costs of internal personnel that are attributable or reasonably allocable to such activities or the management of Third Parties performing Manufacturing
activities, in each case as determined in accordance with Applicable Accounting Standards, and 
 (a) with respect to the supply of Licensed
Product by Alnylam pursuant to Section 5.1 for such Program, the Supply Price for such Licensed Product. 
 1.1.143 “Program
Cost Reconciliation Payment” shall have the meaning set forth in Section 3.4(d)(i). 
 1.1.144 “Program
License” shall mean, with respect to an ID Program, the licenses granted by Alnylam to Vir with respect to such ID Program set forth in Section 6.1(b)(ii). 

1.1.145 “Program Option” shall have the meaning set forth in Section 4.1(a). 

1.1.146 “Program Option Exercise Fee” shall mean the amount of [***]. 

1.1.147 “Program Option Notice” shall have the meaning set forth in Section 4.1(a). 

1.1.148 “Program Option Period” shall have the meaning set forth in Section 4.1(a). 

  
 15 

 EXECUTION VERSION 
  

 1.1.149 “Program Transaction” shall mean (a) a sublicense by Vir or its
Affiliate of any rights to any Alnylam Intellectual Property (or sale of a covenant not to sue), (b) a license by Vir or its Affiliate of any rights to any Vir Collaboration IP (or sale of a covenant not to sue) to the extent in connection with a
Licensed Product, (c) an assignment by Vir or its Affiliate (other than in connection with a Change of Control of Vir) of any rights to any Alnylam Intellectual Property, (d) the grant by Vir or its Affiliates of an option to acquire any
of the foregoing, in each case with respect to a Licensed Product. Notwithstanding the foregoing, Program Transactions exclude agreements with Third Parties for any Change of Control of Vir, distributors of Licensed Product in the ordinary course of
trade, contract manufacturing organizations (CMOs), contract research organizations (CROs), academic research organizations (AROs) and other contractors, or academic, non-profit or governmental entities, in
each case where (i) the agreement counterparty is performing services for or collaborating with Vir or its Affiliates and the counterparty and its Affiliates are not granted any Commercialization rights of any kind with respect to any Alnylam
Intellectual Property or Licensed Product(s) (including options for commercial rights and whether pursuant to the same or under a different agreement) and (ii) no revenue will be received by Vir or any of its Affiliates. 

1.1.150 “Program Transaction Revenue” shall mean all consideration actually received by Vir or its Affiliate from any Person
from or pursuant to a Program Transaction, excluding only: 
 (a) [***]; 

(b) research and development reimbursement for research and development prior to or to be performed after the date of the Program Transaction,
accounted for at reasonable and customary rates, on a full time equivalent basis (any excess over a reasonable and customary FTE rate is included in Program Transaction Revenue) or in the form of external costs billed through on a pass-through basis
[***]; 
 (c) reimbursement of patent or other intellectual property expenses on a pass-through basis, [***]; 

(d) payments for equity of Vir to the extent at fair market value (the amount of any premium is included in Program Transaction Revenue); 

(e) proceeds of repayable loans that are not forgiven (if later forgiven, the amount of the forgiven debt is included in Program Transaction
Revenue); 
 (f) payments for supply of Licensed Product to the extent of Vir’s (or its Affiliate’s) fully burdened manufacturing
cost [***]; and 
 (g) research and development funding from governmental or non-profit entities to
the extent required to be spent on research and development occurring after the date the Program Transaction is signed. 
 (h) If Vir or its
Affiliate receives consideration from any Person from or pursuant to a Program Transaction in respect of Licensed Product(s) on the one hand, and rights to exploit any other compound(s) or product(s) on the other hand, then (i) such
consideration shall be reasonably allocated by Vir between, as applicable, the Licensed Product(s) and such other compound(s) or product(s), and the portion allocated to Licensed Product(s) will be the Program Transaction Revenue for such Program
Transaction, and (ii) Vir shall promptly notify Alnylam of, and provide Alnylam with a copy of all relevant 

  
 16 

 EXECUTION VERSION 
  

 Program Transaction agreements, along with an explanation of any allocation with respect to the consideration
under such agreements in accordance with the immediately preceding sentence. If Alnylam does not agree with Vir’s allocation of such consideration, Alnylam shall provide written notice of such disagreement (“Allocation Dispute
Notice”) within [***] after receipt of such allocation and Vir and Alnylam will negotiate and endeavor to agree in good faith on an allocation within [***] after the receipt of the Allocation Dispute Notice. If the Parties agree within such
[***] period, the Parties will use such agreed-upon allocation to determine the Program Transaction Revenue. If despite such good faith efforts, the Parties are unable to agree upon such allocation within such [***] period, then the matter shall be
submitted for final and binding resolution pursuant to the baseball arbitration provisions in Section 13.3. 
 1.1.151
“Receiving Party” shall have the meaning set forth in Section 9.1(a). 
 1.1.152 “Regulatory Approval”
shall mean the approval of the applicable Regulatory Authority necessary for the marketing and sale of a Licensed Product for a particular indication in a country, including separate pricing and/or reimbursement approvals that may be required. 

1.1.153 “Regulatory Authority” shall mean the federal, national, multinational, state, provincial or local regulatory agency,
department, bureau or other governmental entity with authority over the testing, manufacture, use, storage, import, promotion, marketing or sale of a Licensed Product in a country or territory. 

1.1.154 “Regulatory Lead” shall have the meaning set forth in Section 3.9(a). 

1.1.155 “Related Party” shall mean, with respect to a Party, such Party’s Affiliates and permitted Sublicensees. 

1.1.156 “Replacement ID Target” shall have the meaning set forth in Section 3.3(b). 

1.1.157 “Representative Expert” shall have the meaning set forth in Section 13.3(b). 

1.1.158 “Reserved Target” shall have the meaning set forth in Section 3.1(b). 

1.1.159 “RNAi Product” shall mean any product that contains or is comprised of one or more siRNAs as an active ingredient.

 1.1.160 “Royalty Patent” shall have the meaning set forth in Section 7.5(d). 

1.1.161 “Royalty Term” shall have the meaning set forth in Section 7.5(d). 

1.1.162 “Sales Milestone” shall have the meaning set forth in Section 7.4(a). 

1.1.163 “siRNA” shall mean an oligonucleotide composition of native or chemically modified RNA that targets a gene through
activation of the RNA interference pathway, and that is not a MicroRNA, MicroRNA antagonist or MicroRNA Mimic. 
 1.1.164 “Stock
Purchase Agreement” shall mean that certain Stock Purchase Agreement between the Parties dated as of the Effective Date and attached hereto as Schedule G. 

1.1.165 “Sublicensee” shall mean, with respect to Vir or Alnylam, as the case may be, a Third Party to whom such Party grants
a sublicense under any Alnylam Intellectual Property or Vir Intellectual Property, respectively (or a license, in the case of Joint Collaboration IP) to Develop, Manufacture or Commercialize a Licensed Product in the Field pursuant to
Section 6.1 or Section 6.2, as applicable. 

  
 17 

 EXECUTION VERSION 
  

 1.1.166 “Supply Notice” shall have the meaning set forth in
Section 5.1(a)(ii). 
 1.1.167 “Supply Price” shall mean, with respect to quantities of Licensed Product supplied by
Alnylam pursuant to Section 5.1(a), Alnylam’s Manufacturing Cost for such Licensed Product [***]. 
 1.1.168
“Target” shall mean (a) a polypeptide that is a site or potential site of therapeutic intervention by a therapeutic agent, or a nucleic acid which is required for expression of such polypeptide; (b) variants of a
polypeptide (including any splice variant thereof), cellular entity or nucleic acid described in the foregoing clause (a); or (c) a defined non-peptide entity, including a microorganism, virus, bacterium,
fungus, or single-cell parasite; provided, that the entire genome of a virus shall be regarded as a single Target. 
 1.1.169
“Term” shall have the meaning set forth in Section 11.1. 
 1.1.170 “Terminated Product” shall have
the meaning set forth in Section 11.3. 
 1.1.171 “Terminated Program” shall have the meaning set forth in
Section 11.3. 
 1.1.172 “Territory” shall mean all countries of the world. 

1.1.173 “Third Party” shall mean any Person other than Alnylam or Vir and their respective Affiliates. 

1.1.174 “Third Party License Payment” shall mean royalties, upfront fees, milestones or other amounts payable under an Alnylam
In-License. 
 1.1.175 “Transaction Agreements” shall mean, collectively, this
Agreement, any Development Supply Agreement, any quality agreement between the Parties with respect to the supply of Licensed Product, the Pharmacovigilance Agreement and any Profit-Sharing Agreement. 

1.1.176 “United States” or “U.S.” shall mean the United States of America and its territories and
possessions. 
 1.1.177 “Unlicensed Component” shall mean any clinically active therapeutic or prophylactic ingredient,
mechanism or device component of a Combination Product that is not an HBV Licensed Product or an ID Licensed Product. 
 1.1.178
“Valid Claim” shall mean a claim of: (a) an issued and unexpired Patent Right, which claim has not been (i) revoked or held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of
competent jurisdiction, which is not appealable or has not been appealed within the time allowed for appeal, or (ii) abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue,
re-examination or disclaimer or otherwise, or (b) a patent application that has been pending less than [***], which claim has not been cancelled, withdrawn or abandoned, or finally rejected by an
administrative agency action from which no appeal can be taken. 

  
 18 

 EXECUTION VERSION 
  

 1.1.179 “VAT” shall have the meaning set forth in Section 7.13. 

1.1.180 “Vir” shall have the meaning set forth in the Preamble. 

1.1.181 “Vir Collaboration IP” shall mean (a) any improvement, discovery or
Know-How, patentable or otherwise, first conceived or reduced to practice or, with respect to inventions and discoveries other than patentable inventions, otherwise identified, discovered, made or developed,
solely by individuals who are employees, agents or consultants of Vir or its Affiliates and Controlled by Vir at any time during the Term, in each case in the conduct of the Collaboration or otherwise under this Agreement, and (b) any Patent
Rights which claim such improvements, discoveries or Know-How. Vir Collaboration IP excludes Vir’s interest in Joint Collaboration IP. 

1.1.182 “Vir Improvements” means any patented improvement, discovery or Know-How that
(a) is first conceived or reduced to practice, or with respect to inventions and discoveries other than patentable inventions, otherwise identified, discovered, made or developed, solely by individuals who are employees, agents or consultants
of Vir or its Affiliates in the course of conducting Development, Manufacturing or Commercialization activities with respect to Licensed Products under this Agreement, (b) is Controlled by Vir or its Affiliates, and (c) constitutes an
improvement that would otherwise be dominated by Alnylam Core Technology Patent Rights, including, as applicable, formulation technology. 

1.1.183 “Vir Indemnitees” shall have the meaning set forth in Section 12.1(b). 

1.1.184 “Vir Intellectual Property” shall mean collectively, Vir Know-How, Vir Patent
Rights, Vir Collaboration IP and Vir’s interest in Joint Collaboration IP. 
 1.1.185 “Vir
Know-How” shall mean Know-How Controlled by Vir at any time during the Term that is reasonably necessary or useful to Develop, Manufacture or Commercialize
Licensed Products, other than Alnylam Know-How and Patent Rights comprising Vir Collaboration IP or Joint Collaboration IP. 

1.1.186 “Vir Patent Rights” shall mean Patent Rights Controlled by Vir at any time during the Term that are reasonably
necessary or useful to Develop, Manufacture or Commercialize Licensed Products, other than Alnylam Patent Rights and Patent Rights comprising Vir Collaboration IP or Joint Collaboration IP. 

1.1.187 “Withholding Amount” has the meaning set forth in Section 7.12. 

ARTICLE II 

GOVERNANCE 
 2.1
Joint Steering Committee. 
 (a) Within [***] after the Effective Date the Parties shall establish a Joint Steering Committee (the
“JSC”) that shall oversee the activities of the Parties under the Collaboration. The JSC shall be comprised of [***] representatives designated by Alnylam and [***] representatives designated by Vir. Each Party’s JSC
representatives shall be of the seniority and experience appropriate for service on the JSC in light of the functions, responsibilities and authority of the JSC, with at least [***]. Each Party may replace any or all its representatives on the JSC
with individual(s) of appropriate experience and seniority at any time upon written notice to the other Party. Additional representatives or consultants may from time to time, by mutual consent of the Parties, be invited to attend JSC meetings,
subject to such representatives and consultants (or the representative’s or consultant’s employer) undertaking confidentiality obligations, whether in a written agreement or by operation of law, no less stringent than the requirements of
Article IX. 

  
 19 

 EXECUTION VERSION 
  

 (b) JSC Chairperson. The JSC shall be
co-chaired, with one chairperson designated by Alnylam and one chairperson designated by Vir, whose responsibilities shall include conducting meetings, including, when feasible, ensuring that objectives for
each meeting are set and achieved. Responsibility for running each meeting of the JSC will alternate between the co-chairpersons from
meeting-to-meeting, with Alnylam’s chairperson running the first meeting. 

2.2 Meetings. The JSC shall each meet at least once per Calendar Quarter, and more frequently as Alnylam and Vir deem appropriate or as
reasonably requested by either Party, on such dates, and at such places and times, as the Parties shall agree; provided, that the Parties shall endeavor to have the first meeting of the JSC within [***] Business Days after establishment. At
least [***] meetings in each Calendar Year should be in person. Meetings of the JSC in person shall alternate between the offices of Alnylam and Vir, or such other place as the Parties may agree, with the first such meeting for the JSC being at
Alnylam’s offices. The members of the JSC also may convene or be polled or consulted from time to time by means of telecommunications, video conferences, electronic mail or correspondence, as deemed necessary or appropriate. At least [***] JSC
representatives from each Party must be present at a meeting of the JSC to have a quorum. 
 2.3 Alliance Managers. 

(a) Each Party shall appoint an alliance manager who is an employee of such Party (each, an “Alliance Manager”). Each Alliance
Manager shall be responsible to ensure a collaborative work environment between the Parties to ensure that the Collaboration is run smoothly, professionally and productively. Each Alliance Manager shall act in his or her discretion to facilitate the
execution of the Collaboration throughout their organization and will oversee and support implementation plans; promote effectiveness of the governance model and implementation of contractual provisions and lead any changes to enhance the alliance;
and facilitate the JSC (and other bodies) for effective decision making in a timely manner. The Alliance Managers will serve as a primary point of contact for the other Party under the Collaboration and will undertake such other tasks as are
detailed in this Agreement, the Profit-Sharing Agreement (if applicable) or as may be assigned by the JSC. Each Alliance Manager shall attend each meeting of the JSC. Each Party may change its Alliance Manager at any time in its sole discretion with
written notice to the other Party. 
 (b) The Alliance Managers shall be responsible for (i) scheduling meetings of the JSC,
(ii) setting agendas for meetings with solicited input from other members and (iii) for acting as secretary at each meeting and preparing the draft minutes of such meeting, which shall provide a description in reasonable detail of the
discussions held at the meeting and a list of any actions, decisions or determinations approved by the JSC. Within [***] days after each meeting, the drafting Alliance Manager shall provide the draft minutes to the other Alliance Manager for review
and comment. The drafting Alliance Manager shall reasonably consider all comments from the other Alliance Manager that are provided within [***] days. The drafting Alliance Manager shall prepare and submit revised minutes for approval within [***]
days after receipt of such comments or upon the expiration of such [***] day comment period. Beginning with Alnylam’s Alliance Manager, such responsibilities shall alternate between the Alliance Managers on a meeting-by-meeting basis after each meeting of the applicable committee 

  
 20 

 EXECUTION VERSION 
  

 2.4 JSC Responsibilities. The JSC shall have the following responsibilities with respect to
the Development, Manufacturing and Commercialization of Licensed Products from the Programs pursuant to the Collaboration: 
 (a)
coordinating the activities of the Parties under the Collaboration, including FTEs and other budget matters; 
 (b) overseeing the JSC’s
subcommittees and ensuring effective participation in each such committee’s operations by any of its members; 
 (c) consulting
regarding ID Targets that Vir proposes to be ID Collaboration Targets or the Replacement ID Target; 
 (d) developing and agreeing upon
Development Plans for the ID Programs, including Development Candidate criteria and deliverables; 
 (e) developing and approving updates and
amendments to Development Plans; 
 (f) for each ID Program, reviewing, discussing and selecting Development Candidates; 

(g) reviewing and discussing Third Party collaborations pursuant to Section 3.12; 

(h) discussing, subject to applicable Third Party confidentiality obligations, regulatory matters, safety concerns, or product quality issues
relating generally to RNAi Products that may have a material effect on the Development, Regulatory Approval or Commercialization of Licensed Products; 

(i) addressing any other matters referred to the JSC by the terms of the Collaboration Agreement; and 

(j) performing such other activities as the Parties agree in writing shall be the responsibility of the JSC. 

2.5 Appointment of Subcommittees, Project Teams and Collaboration Managers. The JSC shall be empowered to create such subcommittees of itself
and project teams as it may deem appropriate or necessary. Each such subcommittee and project team shall report to the JSC, which shall have authority to approve or reject recommendations or actions proposed thereby subject to the terms of this
Agreement. The provisions of Sections 2.1 and 2.2 shall apply to each subcommittee, mutatis mutandis, unless otherwise determined by the JSC. 

2.6 Decision-Making Authority. 

(a) Subject to the remainder of this Section 2.6, all decisions of the JSC shall be made by consensus, with each Party’s JSC
representatives collectively having one vote. Upon [***] Business Days’ prior written notice, either Party may convene a special meeting of the JSC for the purpose of resolving any failure to reach agreement on a matter within the scope of the
authority and responsibility of the JSC. 
 (b) If the JSC is unable to reach a consensus with respect to a dispute within [***] days, then
the dispute shall be submitted to the Executive Officers of Alnylam and Vir for resolution. 

  
 21 

 EXECUTION VERSION 
  

 (c) If such escalated dispute cannot be resolved within [***] of the dispute being submitted
to the Executive Officers, then subject to clause (d) below, the Executive Officer of Vir shall have the deciding vote on any matter involving (i) the Development, Manufacture or Commercialization of HBV Licensed Products in the Field in
the Territory, including updates and modifications to the Development Plan for the HBV Program, and (ii) the Development, Manufacture or Commercialization of ID Licensed Products in the Field in the Territory, including the selection of
Development Candidates in an ID Program, the creation of an applicable Development Plan, and updates and modifications to the Development Plans for such ID Program, for the applicable ID Program. 

(d) Notwithstanding the foregoing, Vir may not exercise its final decision-making authority (i) with respect to the HBV Program, during
the HBV Program Joint Funding Period or thereafter, to cause Alnylam to undertake any activities or financial obligations beyond those for which it is responsible under the then-current applicable HBV Development Plan; provided that Alnylam
shall (x) undertake an Additional Alnylam Activity to the extent it has the resources to do so, and if Alnylam does not have the resources to do so, Vir may, in its sole discretion conduct (or have conducted) such Additional Alnylam Activity,
and (y) fund Alnylam’s share of the Program Costs incurred by each of the Parties for any Additional Funded Activity during the HBV Program Joint Funding Period if such Additional Funded Activity does not result in the applicable shared
Program Cost budget in the then current HBV Development Plan during the HBV Program Joint Funding Period increasing by more than [***] (for clarity, if such Additional Funded Activity increases the shared Program Cost budget by more than [***], then
Vir may elect to fund [***] of such Additional Funded Activity, subject to partial reimbursement by Alnylam pursuant to Section 4.2(c)(v) in the event that Alnylam exercises its Profit-Sharing Option with respect to the ALN-HBV02; and Vir may conduct, at its sole expense, any Development activity for any HBV Licensed Product that will not [***], (ii) with respect to any ID Program, to make material changes to Alnylam’s DC
Workplan under the ID Development Plan for such ID Program or to cause Alnylam to undertake any obligations beyond those for which it is responsible under the then-current applicable ID Development Plan, provided that Alnylam shall not
unreasonably withhold its consent to any material changes to a DC Workplan that Vir reasonably and in good faith determines are necessary in order for the JSC to select a Development Candidate and that are funded by Vir, and [***]. 

2.7 Limitation on JSC Authority. The JSC shall conduct its activities in good faith and shall not have the power to (a) amend or modify
the Parties’ respective rights and obligations under this Agreement or (b) resolve any dispute between the Parties regarding such rights and obligations. 

2.8 Expenses. Each Party shall be responsible for all costs and expenses for its members and other representatives to attend meetings of, and
otherwise participate on, a committee, including all travel and related costs and expenses. 
 2.9 Dissolution of JSC. The JSC’s
responsibilities with respect to a Program shall terminate upon the expiration of the Collaboration Term with respect to such Program. The JSC shall be dissolved upon the expiration of all Collaboration Terms with respect to all Programs;
provided, that after the [***] Alnylam shall have the right, but not the obligation, to participate in the JSC. Should Alnylam elect to cease to participate in the JSC, Vir may dissolve the JSC. Subject to the exercise of Alnylam’s
Profit-Sharing Option with respect to a Licensed Product, upon the dissolution of the JSC, Vir shall have the sole right and authority to take any action that had been within the JSC’s purview. 

  
 22 

 EXECUTION VERSION 
  

 ARTICLE III 

COLLABORATION 
 3.1
Overview. The Collaboration of the Parties under this Agreement shall include the HBV Program and up to four (4) other Programs as set forth below. 

(a) HBV Program. Prior to the Effective Date, Alnylam has been engaged in the Development of
ALN-HBV and ALN-HBV02, each an RNAi Product Directed to HBV. Under this Agreement, the Parties will collaborate in the Development of HBV Licensed Products in the HBV
Program. Initially the HBV Program will be comprised of the Development of ALN-HBV02, with (i) Alnylam retaining responsibility as set forth in the Development Plan for the HBV Program (the “HBV
Development Plan”) for the Development of ALN-HBV02 to support the preparation of an IND for ALN-HBV02 and the preparation of such IND for filing by Vir with
the applicable Regulatory Authority (“Alnylam HBV Program Completion”), and (ii) Vir assuming all other responsibility for the Development of HBV Licensed Products; provided, that Alnylam shall retain responsibility, at
its sole expense, for completion and issuance of the final study report for the ALN-HBV Study. No Clinical Studies of ALN-HBV shall be conducted without mutual agreement
of the Parties. Upon Alnylam HBV Program Completion, subject to the exercise by Alnylam of its Profit-Sharing Option pursuant to Section 4.2 with respect to an HBV Licensed Product and Alnylam’s responsibilities for HBV Licensed Product
Manufacturing at Vir’s expense pursuant to Article V, Vir shall assume all responsibility for the further Development, Manufacture and Commercialization of HBV Licensed Products. 

(b) Other Infectious Disease Programs and ID Collaboration Target Selection. The Parties also intend to
collaborate in a program to Develop RNAi Products Directed to up to four (4) ID Collaboration Targets in addition to HBV, until Development Candidate selection pursuant to Section 3.3 below. Vir shall have the right to select [***] initial
ID Collaboration Targets in consultation with the JSC within [***] after the Effective Date and up to [***] additional ID Collaboration Targets in the subsequent [***] period, in each case in accordance with the procedures in this
Section 3.1(b); provided, however, that if [***]. Vir shall also have the right, within [***] after the Effective Date to select up to [***] ID Targets to be held in reserve as such potential replacements for designated ID Collaboration
Targets until Alnylam has completed all work under the DC Workplans for each of the four (4) ID Collaboration Targets (each, a “Reserved Target”). Once designated, the ID Collaboration Targets shall be listed on
Schedule D, and Schedule D shall be updated to indicate any Reserved Targets. Vir shall have the right to propose ID Targets to the JSC (including those ID Targets set forth on
Schedule D as of the Effective Date) and, to the extent that a proposed ID Target is not [***], Alnylam shall permit Vir to designate such ID Target as an ID Collaboration Target pursuant to this Section 3.1(b). During
the [***] following the Effective Date, [***]. Notwithstanding the foregoing, Alnylam may enter into a Permitted Transaction. 

  
 23 

 EXECUTION VERSION 
  

 3.2 Development Plans. 

(a) Development Plans. The activities to be undertaken in the course of the Collaboration for each Collaboration Target (each, a
“Program”) shall be set forth in a detailed workplan and budget of Program Costs (“Development Plan”). The Parties agree to conduct all of their Development activities relating to RNAi Products Directed to
Collaboration Targets during the applicable Collaboration Term in accordance with the applicable Development Plan. The HBV Development Plan is attached hereto as Schedule F and sets forth each Party’s obligations and
responsibilities during the Collaboration Term for the HBV Program. Within [***] after an ID Collaboration Target is designated, the JSC will develop in good faith and agree upon, with neither Party unreasonably withholding agreement, a Development
Plan for a Program to Develop one or more RNAi Products Directed to such ID Collaboration Target (each such program, an “ID Program”). Each such Development Plan shall set forth each Party’s obligations and responsibilities in
connection with such Program, and the Program Cost budget for the Development and Manufacturing activities in such Program and relevant deliverables and Development Candidate criteria for such ID Collaboration Target. [***]. In the Development Plans
for the ID Programs (each, an “ID Development Plan”), Alnylam shall be responsible for [***] pursuant to Section 3.3 below. The scope, deliverables and budget for such work shall be set forth in a workplan included in such ID
Development Plan that is substantially the same as the workplan template attached hereto as Schedule J, (each such workplan, a “DC Workplan”). Alnylam shall not be responsible for activities or deliverables
under an ID Development Plan that are not set forth in a DC Workplan unless and to the extent explicitly agreed in writing by the Parties. Alnylam shall commence work on the DC Workplan in an ID Development Plan within [***] after the ID Development
Plan is agreed by the JSC. [***]. 
 (b) Updates to Development Plans. The JSC shall review and agree upon updates to the
Development Plan for each Program from time to time, but at least [***] each Calendar Year during the Collaboration Term for such Program. 

3.3 ID Program Development Candidate Selection; Replacement ID Target. 

(a) Development Candidate Selection. Within [***] after the date on which Alnylam has completed its responsibilities under the
applicable DC Workplan for an ID Program, including delivering to Vir all data and information generated under such DC Workplan, the JSC shall select one or more of the RNAi Products identified, generated or developed in such ID Program that meets
the applicable Development Candidate criteria for such ID Program to further Develop (each such product selected by the JSC, the “Development Candidate”); provided, however, that Vir shall have the right to waive the
applicable Development Candidate criteria should it wish to designate such an RNAi Product as a Development Candidate despite such RNAi Product failing to meet such criteria. [***]. 

  
 24 

 EXECUTION VERSION 
  

 (b) Replacement ID Target. The Parties understand and agree that the discovery of RNAi
Products is inherently uncertain and there can be no guarantee of success. If (i) [***], to create suitable RNAi Products Directed to an ID Collaboration Target that meet the mutually agreed upon Development Candidate criteria for such ID Program
within the timeframe designated in the applicable DC Workplan, or (ii) Alnylam has completed the DC Workplan for an ID Program and the JSC reasonably determines that none of the RNAi Products Directed to the ID Collaboration Target for such ID
Program that were identified, generated or developed under the DC Workplan meets the applicable Development Candidate criteria, then in either case Vir may, [***] elect to propose a new ID Target to the JSC to replace such ID Collaboration Target.
If such proposed replacement ID Target is not [***] that would preclude such ID Target from being an ID Collaboration Target under this Agreement, then Alnylam shall permit Vir to designate such proposed replacement ID Target as an ID Collaboration
Target pursuant to this Section 3.3(b) (such replacement, a “Replacement ID Target”). If Vir’s proposed replacement ID Target does not meet the criteria of a Replacement ID Target, then Vir may propose another replacement
ID Target that does meet such criteria. Upon designation of the Replacement ID Target, such Replacement ID Target shall be an ID Collaboration Target under this Agreement and the Parties shall develop an ID Development Plan for the Replacement ID
Target in accordance with Section 3.2(a). The ID Target that is replaced by the Replacement ID Target (“Abandoned ID Target”) shall cease to be an ID Collaboration Target under this Agreement, Vir’s Program Option and
other rights under this Agreement with respect to such Abandoned ID Target and any RNAi Products Directed to such Abandoned ID Target shall terminate and the provisions of Section 4.1(b) shall apply to the Abandoned ID Target and the ID Program
for such Abandoned ID Target. Unless otherwise mutually agreed by the Parties, Vir shall [***], provided that such expiration date shall be extended to account for the period of any delay that arises as the result of occurrences outside of
Vir’s reasonable control. 
 3.4 Collaboration Funding. 

(a) HBV Program. During the HBV Program Joint Funding Period the Parties shall share [***] the Program Costs incurred by each of the
Parties in conducting the HBV Program with respect to the Development activities required to file an IND for ALN-HBV02 and Complete the POC Study for ALN-HBV02,
including supply of ALN-HBV02 for such activities, in each case pursuant to the Development Plan for the HBV Program. For clarity, the POC Study may be a component of a Clinical Study. Subject to the exercise
by Alnylam of its Profit-Sharing Option pursuant to Section 4.2, with respect to each HBV Licensed Product all other Development, Manufacture and Commercialization of such HBV Licensed Product shall be at Vir’s sole expense, including
(i) all Development and Manufacturing activities conducted during the HBV Program Joint Funding Period that are not required to file an IND for ALN-HBV02 nor required to Complete the POC Study for ALN-HBV02 (it being understood that, as between the Parties, Alnylam is solely responsible for the costs of completion and issuance of the final study report for the ALN-HBV
Study), (ii) the cost of HBV Licensed Product supplied by Alnylam pursuant to Section 5.1(a)(i)(x) for Development and Manufacturing activities other than those activities required to file an IND for
ALN-HBV02 or required to Complete the POC Study for ALN-HBV02, and (iii) all Development and Manufacturing activities following the HBV Program Joint Funding
Period. During the HBV Program Joint Funding Period, the annual updates to the Development Plan for the HBV Program prepared by the JSC pursuant to Section 3.2(b) will set forth the number of FTEs each Party will commit to the HBV Program
during the next Calendar Year (if any) and the budget for out-of-pocket Program Costs. 

  
 25 

 EXECUTION VERSION 
  

 (b) ID Programs. Subject to the exercise by Alnylam of its Profit-Sharing Option
pursuant to Section 4.2, with respect to an ID Licensed Product, Vir shall bear [***] of the Program Costs incurred by the Parties during the Collaboration Term for each ID Program in conducting each ID Program pursuant to the Development Plan
for such ID Program, including ID Licensed Product supplied by Alnylam pursuant to Section 5.1(a)(ii). 
 (c) FTE
Commitment. Each Party shall provide such number of FTEs as specified in a Development Plan to perform the activities allocated to such Party under such Development Plan. 

(d) Reconciliation and Payments. 

(i) HBV Program Costs During the HBV Program Joint Funding Period. Within [***] following the end of each Calendar Quarter in the HBV
Program Joint Funding Period in which a Party incurs any Program Costs in connection with the HBV Program, each Party shall prepare and deliver to the other Party a quarterly report detailing its Program Costs incurred during such period, including
supporting documentation for such Program Costs. Each Party shall submit any additional information reasonably requested by the other Party related to the Program Costs included in its report within [***] of its receipt of such request. Vir shall
also submit an estimate of such Program Costs incurred by it to Alnylam within [***] after the end of such Calendar Quarter. Within [***] after the receipt of the report delivered by Vir to Alnylam and delivery to Vir of the Alnylam report pursuant
to this Section 3.4(d), Alnylam shall prepare and deliver to Vir a composite report that: (i) summarizes the Program Costs incurred by each Party for such Calendar Quarter; (ii) identifies the Program Costs to be shared [***] pursuant
to Section 3.4(a); and (iii) computes the total amount due to Vir or Alnylam, as applicable (each, a “Program Cost Reconciliation Payment”). The Party to whom a Program Cost Reconciliation Payment is due shall issue an
invoice to the other Party for the Program Cost Reconciliation Payment, and such other Party shall pay all undisputed amounts within [***] after its receipt of the invoice. Each Party shall have the right to audit the records of the other Party with
respect to any Program Costs included in such reports, in accordance with Section 7.9. 
 (ii) ID Program Costs and HBV Program
Costs After the HBV Program Joint Funding Period. Within [***] following the end of each Calendar Quarter (x) during the Collaboration Term for an ID Program and (y) after the HBV Program Joint Funding Period for the HBV Program, in
either case in which Calendar Quarter Alnylam incurs any Program Costs in connection with such Program, Alnylam shall prepare and deliver to Vir an invoice detailing its Program Costs incurred during such period, including supporting documentation
for such Program Costs, and Vir shall pay all undisputed amounts within [***] after its receipt of the invoice. Without limiting the generality of the foregoing, Alnylam shall prepare and deliver to Vir an invoice detailing all outstanding Program
Costs incurred by Alnylam in connection with an ID Program since the last invoice for such ID Program delivered to Vir pursuant to the foregoing sentence not later than [***] after the date on which the JSC selects one or more Development Candidates
for such ID Program pursuant to Section 3.3. Vir shall have the right to audit the records of Alnylam with respect to any Program Costs included in such invoices, in accordance with Section 7.9. 

3.5 Diligence. 
 (a)
Collaboration Diligence. During the applicable Collaboration Term, each Party shall use Commercially Reasonable Efforts to perform its respective Development and Manufacturing activities under each Development Plan in accordance with
this Agreement and according to the priorities set forth in the Development Plans and as established by the JSC. 

  
 26 

 EXECUTION VERSION 
  

 (b) HBV Program. Vir shall use Commercially Reasonable Efforts to Develop, obtain
Regulatory Approval and following Regulatory Approval, Commercialize [***] HBV Licensed Product in the Field in [***] Major Markets. 
 (c)
ID Programs. After exercise of its Program Option with respect to an ID Program, Vir shall use Commercially Reasonable Efforts to Develop, obtain Regulatory Approval and following Regulatory Approval Commercialize [***] ID Licensed Product
Directed to the ID Collaboration Target in such ID Program in the Field in [***] Major Markets. 
 3.6 Reports. 

(a) Collaboration Term. During the Collaboration Term for each Program, each Party shall provide the JSC (i) on [***] with a
presentation regarding the activities performed by such Party under the Collaboration in the prior [***] and (ii) on an [***] a written report regarding the activities performed by such Party under the Collaboration in the prior [***]. Each
such presentation and report shall summarize in reasonable detail the activities undertaken by such Party during the [***], as well as the results of such activities. Such presentations and reports will be accurate and, where appropriate, will
contain raw data from studies carried out by or on behalf of such Party. Each Party will provide the members of the JSC with copies of all slide decks and reports they intend to present at a JSC meeting. Each Party may also request specific material
data or information related to Collaboration activities in advance of any meeting, and the Party or appropriate committee to whom such request is made shall as promptly as practicable provide to the other Party or JSC such data or information. 

(b) Additional Reports During Profit-Sharing Option Period. Until the expiration of the Profit-Sharing Option Period for a
Licensed Product, in addition to the presentations and reports provided by Vir to the JSC pursuant to Section 3.6(a) above, upon written request by Alnylam, Vir shall provide Alnylam with the applicable Profit-Sharing Option Data Package,
together with any additional information, materials and data relating to such Licensed Product reasonably requested by Alnylam to facilitate Alnylam’s evaluation of whether to exercise its Profit-Sharing Option. Vir shall provide such
information as promptly as practicable after receipt of Alnylam’s written request [***] Program. In addition, consistent with commercially reasonable due diligence practices, Vir shall make available its personnel during normal business hours
and upon reasonable notice for consultation regarding the foregoing, as reasonably necessary for Alnylam to evaluate whether or not to exercise its Profit-Sharing Option with respect to such Licensed Product pursuant to Section 4.2. 

(c) After Profit-Sharing Option Period. After the expiration of the Profit-Sharing Option Period for a Licensed Product without
Alnylam exercising its Profit-Sharing Option with respect to such Licensed Product, Vir shall prepare and deliver to Alnylam, by no later than [***], written reports summarizing Development and Commercialization activities for such Licensed Products
performed to date (or updating such report for activities performed since the last such report submitted hereunder, as applicable). In addition, with respect to each such Licensed Product, Vir shall provide Alnylam with written notice of the
achievement of each applicable Milestone Event in Section 7.3(a) and 7.4(a), the First Commercial Sale in the Territory, and receipt of any Program Transaction Revenue within [***] after such event; provided, however, that to the
extent reasonably practicable and except as required by Law, Vir shall inform Alnylam of such event prior to public disclosure of such event by Vir. To the extent such information is available, Vir shall also provide such other information to
Alnylam as Alnylam may reasonably request from time to time but not more than [***], with respect to Vir’s Development and Commercialization activities for Licensed Products in order for Alnylam to monitor Vir’s compliance with its
obligations under this Agreement. [***]. 

  
 27 

 EXECUTION VERSION 
  

 3.7 Records. Each Party will maintain scientific records, in sufficient detail and in good
scientific manner appropriate for patent and regulatory purposes, which will fully and properly reflect all work done and results achieved in the performance of the Development activities with respect to each Licensed Product by such Party. 

3.8 Regulatory Matters. 
 (a)
Regulatory Lead. Except as set forth in the applicable Development Plan, Alnylam shall be the “Regulatory Lead” with respect to ALN-HBV and
ALN-HBV02 until [***], and Vir shall be the Regulatory Lead thereafter. Except as set forth in the applicable Development Plan, Alnylam shall be the Regulatory Lead with respect to each RNAi Product in an ID
Program until [***], at which point Vir shall be the Regulatory Lead for such ID Program. 
 (b) Regulatory Filings and Interactions.
Except as otherwise provided in the applicable Development Plan, during the Collaboration Term for a Program (A) each Party will own the INDs, the NDAs and related regulatory documents submitted to the applicable Regulatory Authorities by it
with respect to Licensed Products in such Program and (B) the Regulatory Lead will, as to such Licensed Products, (x) oversee, monitor and coordinate all regulatory actions, communications and filings with, and submissions to, each
Regulatory Authority, (y) be responsible for interfacing, corresponding and meeting with each Regulatory Authority, and (z) be responsible for maintaining all regulatory filings. While Alnylam is the Regulatory Lead for a Program, Alnylam
will promptly notify the JSC in writing of all material communications received by it from Regulatory Authorities, and of all filings and submissions made by it to Regulatory Authorities regarding the Licensed Products in such Program;
provided, however, that once Alnylam is no longer the Regulatory Lead, [***]. With respect to each HBV Licensed Product and any ID Licensed Product, Vir shall provide Alnylam with written notice of all Regulatory Approvals [***] and
the filing of any IND for such Licensed Product within [***] after such event; provided, however, that to the extent reasonably practicable and except as required by Law, Vir shall [***]. 

(c) IND Transfer; Right of Reference. Upon Vir’s written request, Alnylam will [***] promptly transfer to Vir, [***]
(i) after [***], Alnylam’s IND(s) for ALN-HBV and ALN-HBV02, and (ii) Alnylam’s IND(s) (if any) for any ID Licensed Product in an ID Program. During
the Collaboration Term, each Party will have the right to reference the other Party’s INDs, and other filings with and submissions to Regulatory Authorities with respect to Licensed Products for the purpose of conducting its Development
activities under the applicable Development Plans for such Licensed Products. Following the Collaboration Term, Vir will have the right to reference Alnylam’s INDs and other filings with and submissions to Regulatory Authorities with respect to
a Licensed Product to obtain Regulatory Approval in the Territory for such Licensed Product. 
 3.9 Pharmacovigilance. Within [***] after the
Effective Date, the Parties will develop and agree in writing upon a pharmacovigilance agreement (“Pharmacovigilance Agreement”) that will include safety data exchange procedures governing the coordination of collection,
investigation, reporting, and exchange of information concerning any adverse experiences, and any product quality and product complaints involving adverse experiences, related to Licensed Products, sufficient to enable each Party to comply with its
legal and regulatory obligations. Alnylam shall notify Vir of any regulatory matters, 

  
 28 

 EXECUTION VERSION 
  

 
safety concerns or product quality issues relating generally to RNAi Products of which Alnylam has Knowledge, and that, [***] have a material effect on the Development, Regulatory Approval or
Commercialization (including patient safety or product quality) of Licensed Products; provided, however, that the foregoing shall not require Alnylam to violate any agreements with or confidentiality obligations owed to any Third
Party. 
 3.10 Third Parties. The Parties shall be entitled to utilize the services of Third Party contract research and contract
manufacturing organizations to perform their respective Development and Manufacturing activities under this Agreement; provided, that (a) each Party shall ensure that any such Third Party it utilizes operates in a manner consistent with
the terms of this Agreement and (b) each Party shall remain at all times fully liable for its responsibilities under this Agreement. Each Party shall ensure that any agreement with any such Third Party shall include confidentiality and non-use provisions that are no less stringent than those set forth in Section 9.1 of this Agreement and shall use Commercially Reasonable Efforts to obtain ownership of, and/or a fully sublicenseable license
under and to, any Know-How and Patent Rights that are developed or used by such Third Party in the performance of such agreement and are reasonably necessary or useful to Develop, Manufacture and/or
Commercialize the applicable Licensed Products in the Field. 
 3.11 Collaborations. The Parties agree that it may be necessary or useful to
enter into Third Party collaborations that provide intellectual property that is necessary or useful for the Development or Commercialization of Licensed Products under this Agreement, including Combination Products. Such Third Party collaborations
shall not conflict with the terms and conditions of this Agreement. With respect to the HBV Program during the HBV Program Joint Funding Period and each ID Program with respect to which Vir has not exercised its Program Option, the JSC shall review
for approval by the Parties any Third Party collaborations that [***] for such Program. Thereafter, during the Collaboration Term for a Program, the JSC shall review and discuss any [***]. The Party entering into any such Third Party collaboration
shall use Commercially Reasonable Efforts to ensure that, to the extent possible, that such Third Party collaboration provides that [***] and shall include confidentiality and non-use provisions that are no
less stringent than those set forth in Article IX of this Agreement. In addition, the Party entering into such Third Party collaboration shall use Commercially Reasonable Efforts to obtain a right to [***]. For clarity, such Third Party
collaboration shall not include agreements with any contract research or contract manufacturing organization entered into in accordance with the provisions set forth in Section 3.11, or with a Sublicensee of the Licensed Product. 

ARTICLE IV 
 OPTION
RIGHTS 
 4.1 Vir ID Program Option. 

(a) With respect to each ID Program, Alnylam hereby grants Vir an exclusive option (“Program Option”) to obtain a Program
License for such ID Program. Vir may exercise its Program Option with respect to an ID Program by written notice to Alnylam (“Program Option Notice”) at any time prior to the date that is [***] after the earlier of (i) [***] and
(ii) the date that is [***] after [***] (“Program Option Period”). Upon Vir’s giving a Program Option Notice to Alnylam, Vir shall pay Alnylam (x) the 

  
 29 

 EXECUTION VERSION 
  

 
Program Option Exercise Fee, which is payable within [***] after Vir’s exercise of such Program Option for such ID Program, and (y) any outstanding undisputed Program Costs due to
Alnylam for such ID Program, within [***] after receipt by Vir of any invoice therefor. Upon payment in full of the Program Option Exercise Fee and any outstanding undisputed Program Costs as set forth above, (i) Alnylam shall and hereby does
grant to Vir the Program License with respect to such ID Program as set forth in Section 6.1(b)(ii), and (ii) subject to the exercise by Alnylam of its Profit-Sharing Option pursuant to Section 4.2 with respect to an ID Licensed
Product and Alnylam’s responsibilities for ID Licensed Product Manufacturing at Vir’s expense pursuant to Section 5.1(a), Vir shall assume all responsibility, [***], for the further Development, Manufacture and Commercialization of
the ID Licensed Products in such ID Program. 
 (b) If Vir does not deliver such Program Option Notice to Alnylam within the Program Option
Period for an ID Program, then Vir shall be deemed to have declined to exercise its Program Option for such ID Program. In the event that Vir does not deliver such Program Option Notice to Alnylam within the Program Option Period or notifies Alnylam
that it declines to exercise its Program Option with respect to an ID Program, then (i) Vir’s Program Option and all other rights of Vir under the Transaction Agreements with respect to such ID Program and any RNAi Products Directed to the
ID Target for such ID Program shall terminate, (ii) such ID Target shall cease to be an ID Collaboration Target and such ID Program shall cease to be a Program for purposes of the Transaction Agreements, and (iii) Vir and its Affiliates
shall (w) immediately return to Alnylam all information, data and materials (including all Alnylam Intellectual Property) to the extent relating to such ID Program, (x) promptly pay [***] to Alnylam for such ID Program following receipt of
an invoice therefor from Alnylam, (y) grant and hereby grants to Alnylam an (A) exclusive (except as provided below), fully-paid, perpetual, irrevocable, fully sublicenseable and transferable license under any Vir Collaboration IP and
Vir’s interest in Joint Collaboration IP that covers or claims any RNAi Product Directed to such ID Target identified in the ID Program, to develop, manufacture, use, sell, have sold, import, and otherwise commercialize RNAi Products Directed
to such ID Target in the Field in the Territory; provided, that to the extent such Collaboration IP covers or claims the ID Target generally [***], then the foregoing license shall be non-exclusive; and
(z) be prohibited, for a period of [***] commencing on the final day of the applicable Program Option Period, from Developing or Commercializing, either alone or with or through any Third Party, any RNAi Product Directed to such ID Target. 

4.2 Alnylam Profit-Sharing Option. 

(a) Profit-Sharing Option. Alnylam shall have the right, on a Licensed
Product-by-Licensed Product basis, to elect to participate with Vir in the Development and Commercialization of a Licensed Product in the Territory as set forth in this
Section 4.2 (the “Profit-Sharing Option”) and in accordance with other commercially reasonable terms and conditions set forth in an agreement (the “Profit-Sharing Agreement”) to be negotiated in good faith
between the Parties for a period of [***] after the Profit-Sharing Option exercise date, which agreement shall be based on the terms and conditions substantially the same as those set forth in Schedule E, and consistent
with this Agreement. In the event the Parties are unable to agree upon a definitive Profit-Sharing Agreement within such time period, either Party may seek a final and binding resolution regarding the commercially reasonable terms of such definitive
agreement pursuant to the baseball arbitration provisions in Section 13.3. Notwithstanding the foregoing, in the event that Alnylam does not exercise its Profit-Sharing Option for any Licensed Product Directed to a Collaboration Target, then
[***], and Vir shall have no further obligations, under this Section 4.2 with respect thereto. For clarity, the foregoing sentence shall not apply to any Licensed Product directed to such Collaboration Target with respect to which Alnylam has
exercised its Profit-Sharing Option. 

  
 30 

 EXECUTION VERSION 
  

 (b) Exercising Profit-Sharing Option. Alnylam may exercise its Profit-Sharing
Option with written notice to Vir (i) in the case of an HBV Licensed Product, at any time from the Effective Date until [***] after (x) [***], and (ii) in the case of an ID Licensed Product, at any time from Vir’s Program Option
exercise date for the applicable ID Program until [***] after (x) [***] (each such period in (i) and (ii) above, a “Profit-Sharing Option Period”). If Vir does not have [***] as of the date described in clauses (i)(x) or
(ii)(x) above, as the case may be, then Vir shall provide Alnylam with an explanation for the absence of such item, but such absence shall not extend the Profit-Sharing Option Period. Notwithstanding the foregoing sentence, Alnylam may elect to
extend the Profit-Sharing Option Period for [***] to permit additional time for Vir to provide any of the remaining items in the Profit-Sharing Option Data Package, provided that (A) [***], (B) if Alnylam does not exercise its Profit-Sharing
Option during such [***], such Profit-Sharing Option shall expire pursuant to Section 4.2(d), and (C) if Alnylam exercises its Profit-Sharing Option at any time during such [***], Section 4.2(c) shall be deemed to apply and be
effective as of the date the initial Profit-Sharing Option Period would have expired had Alnylam not elected to extend it pursuant to this sentence. 

(c) Effects of Exercising Profit-Sharing Option. If Alnylam exercises the Profit-Sharing Option as to a Licensed Product, then
from and after such exercise (i) such Licensed Product shall be deemed a “Profit-Sharing Product” and Vir shall remain responsible for the Development and Commercialization of such Profit-Sharing Product in accordance with the
Profit-Sharing Agreement, (ii) Vir’s obligation to pay the royalty set forth in Section 7.5 and Program Transaction Revenue set forth in Section 7.6 with respect to the applicable Profit-Sharing Product shall terminate [***],
(iii) all future milestone payments that become payable by Vir pursuant to Sections 7.3 and 7.4 with respect to such Licensed Product which becomes a Profit-Sharing Product will terminate, (iv) the Parties shall share equally the
Operating Profits/Losses with respect to such Profit-Sharing Product as set forth in Schedule E and the Profit-Sharing Agreement, and (v) if pursuant to Section 2.6(d)(i)(y) Alnylam has not shared equally any
Program Costs actually incurred by Vir in conducting, or having conducted, as applicable, any Additional Funded Activity, then Vir shall prepare and deliver to Alnylam an invoice detailing such Program Costs, including supporting documentation for
such Program Costs, and Alnylam shall reimburse Vir for [***] of the undisputed amount of such Program Costs within [***] after its receipt of such invoice. 

(d) Expiration of Profit-Sharing Option. Failure by Alnylam to give written notice of exercise within the applicable time-period
set forth in Section 4.2(b) above shall result in the expiration of the Profit-Sharing Option with respect to the applicable Licensed Product. 

  
 31 

 EXECUTION VERSION 
  

 ARTICLE V 

MANUFACTURE AND SUPPLY OF LICENSED PRODUCTS 

5.1 Responsibilities for Licensed Product Supply. 

(a) Alnylam Supply. 
 (i)
HBV Program. Alnylam shall be solely responsible for obtaining supply of ALN-HBV02 Drug Product that is reasonably required for the conduct of the Parties’ obligations under the HBV Development
Plan through [***] (“[***] Completion”). Alnylam will supply such Drug Product at the Supply Price for such Drug Product. For clarity, unless and to the extent mutually agreed by the Parties, Alnylam shall not be responsible for any
Manufacturing activities (including process and method development and scale-up) conducted before or after [***] Completion that are required to supply such Drug Product for [***]. 

(ii) ID Programs. With respect to each ID Program, Alnylam will be responsible for obtaining supply of the non-GMP Drug Product reasonably required for the conduct of the Parties’ obligations under the Development Plan for such ID Program prior to Vir’s exercise of its Program Option with respect to such ID
Program. [***] of such ID Licensed Product in such ID Program [***] (“[***] Completion”), in each case at the Supply Price for such Drug Product. Vir shall notify Alnylam in writing of such election on a Licensed Product-by-Licensed Product basis (“Supply Notice”), reasonably in advance of [***] to enable Alnylam to meet requested timelines. After such election by Vir,
Alnylam shall be solely responsible for such supply through [***] Completion. For clarity, unless and to the extent mutually agreed by the Parties, [***]. 

(b) Vir Supply. 
 (i)
HBV Program. Except as set forth in Section 5.1(a)(i) above and subject to Section 5.4 below, Vir shall have the right and responsibility, at Vir’s expense, to Manufacture and supply HBV Licensed Product for Development and
Commercialization in the Territory under the applicable Development Plan for the HBV Program following the successful completion of the transfer of Alnylam Know-How to Vir or its designated Third Party
contract manufacturers pursuant to Section 5.3 and the applicable Development Supply Agreement. 
 (ii) ID Programs.
Except as set forth in Section 5.1(a)(ii) above and subject to Section 5.4 below, upon Vir’s exercise of its Program Option with respect to an ID Program, Vir will have the right and responsibility, at Vir’s expense, to
Manufacture and supply ID Licensed Product for Development and Commercialization in the Territory under the applicable Development Plan for such ID Program following the successful completion of the transfer of Alnylam
Know-How to Vir or its designated Third Party contract manufacturers pursuant to Section 5.3 and the applicable Development Supply Agreement. 

  
 32 

 EXECUTION VERSION 
  

 (iii) Profit-Sharing Product. Except as set forth in Section 5.1(a) above,
responsibility to Manufacture and supply Profit-Sharing Product shall be addressed in the applicable Profit-Sharing Agreement. 
 5.2
Development Supply Agreements. 
 (a) Alnylam’s supply of each Drug Product pursuant to Section 5.1(a) and the technology transfer
to enable Vir or its Third Party contract manufacturers to Manufacture such Licensed Product pursuant to Section 5.1(b) described in Section 5.3 will be governed by a supply and technical transfer agreement with respect to such Licensed
Product (a “Development Supply Agreement”). The terms and conditions of each Development Supply Agreement shall be commercially reasonable and consistent with industry standards, [***]. 

(b) The Parties will negotiate in good faith and enter into a Development Supply Agreement for Drug Product for
ALN-HBV02 within [***] after the Effective Date. For each ID Licensed Product with respect to which Vir has provided a Drug Product Supply Notice, the Parties will negotiate in good faith and enter into a
Development Supply Agreement for such Drug Product as soon as reasonably practicable but within [***] after receipt of such Supply Notice by Alnylam. In the event the Parties are unable to reach a definitive Development Supply Agreement with respect
to a Licensed Product within the applicable time period, either Party may seek a final and binding resolution regarding the commercially reasonable terms of such definitive agreement pursuant to the baseball arbitration provisions in
Section 13.3. 
 5.3 Technology Transfer. Upon Vir’s written request delivered (a) no earlier than [***] and (b) upon or
anytime following Vir’s exercise of its Program Option with respect to an ID Program, [***], product specifications, batch records, CMC data, and other relevant information, and shall make available its personnel on a reasonable basis to
consult with Vir or such Third Party manufacturer(s) with respect thereto, [***]. Alnylam shall not be required to perform technology transfer to (i) any Third Party manufacturer that is then in material breach of a supply agreement with
Alnylam or its Affiliate, or that, in [***] would not be expected to (x) have the capability, skills or facilities to manufacture the Licensed Product in accordance with applicable Law or the specifications for such Licensed Product, or
(y) comply with the confidentiality and non-use provisions applicable to the Alnylam Intellectual Property as demonstrated by reasonable evidence, (ii) [***], or (iii) any Third Party manufacturer
that is already a Third Party manufacturer of the Licensed Product [***] 

  
 33 

 EXECUTION VERSION 
  

 
of a Licensed Product or Alnylam shall cooperate with Vir, and use Commercially Reasonable Efforts to facilitate, Vir’s efforts to enter into an agreement with such Third Party for the
manufacture and supply of such Licensed Product. Such assignment shall be subject to the terms and conditions of such agreement, including any required consents of such Third Party (which Alnylam shall use Commercially Reasonable Efforts to obtain)
and [***], but Alnylam shall remain solely responsible for its obligations under such agreement arising prior to such assignment. Except as provided in the immediately preceding sentence, Vir shall be solely responsible for contracting with such
Third Party manufacturer (and any other Third Party manufacturer to whom Alnylam has initiated technology transfer as set forth in this Section 5.3) for the supply of such Licensed Product and Alnylam shall have no obligations under such
agreement between Vir and such Third Party manufacturer. Alnylam shall use Commercially Reasonable Efforts to obtain any such consent in a form reasonably acceptable to Vir. 

5.4 Additional Licensed Product Supply. With respect to Licensed Products other than Profit-Sharing Products, Vir agrees to consider, and the
Parties agree to discuss in good faith for a period of [***], the manufacture and supply of custom starting materials, Bulk Drug Substance, and/or Drug Product by Alnylam (or its designee) to Vir after expiration of Alnylam’s supply obligations
in Section 5.1(a) for Vir’s further Development activities and/or for commercial sale in the Territory; provided, however, that nothing in the foregoing sentence shall be construed to require the Parties to agree to such an
arrangement. 
 ARTICLE VI 

GRANT OF LICENSE RIGHTS 

6.1 License Grants to Vir. 
 (a)
HBV Program Licenses. 
 (i) Development and Commercialization License. Subject to the
terms and conditions of this Agreement, including those set forth in Sections 4.2 and 6.1(d), Alnylam hereby grants Vir a non-transferable (except as provided in Section 14.3), sublicenseable
(through multiple tiers and subject to Section 6.1(c)), exclusive license under the Alnylam Intellectual Property to Develop, use, sell, have sold, import, and otherwise Commercialize HBV Licensed Products in the Field in the Territory. Such
license shall be royalty-bearing for the Royalty Term applicable to each such HBV Licensed Product in each country in the Territory, and, after the expiration of the Royalty Term applicable to such HBV Licensed Product in such country, shall convert
to a [***], fully paid-up, irrevocable and perpetual license for such HBV Licensed Product in the Field in such country. 

(ii) Manufacturing License. Subject to the terms and conditions of this Agreement, including those set forth in
Sections 4.2 and 6.1(d) and Article V, Alnylam hereby grants Vir a non-transferable (except as provided in Section 14.3), sublicenseable (through multiple tiers and subject to
Section 6.1(c)), worldwide, royalty-bearing, exclusive license under Alnylam Intellectual Property to Manufacture HBV Licensed Products for Development of HBV Licensed Products after [***] and for Commercialization in the Field in the
Territory. Such license shall be royalty-bearing for the Royalty Term applicable to each HBV Licensed Product in each country in the Territory, and, after the expiration of the Royalty Term applicable to such HBV Licensed Product in such country,
shall convert to a [***], fully paid-up, irrevocable, and perpetual license for such HBV Licensed Product in the Field in such country. 

  
 34 

 EXECUTION VERSION 
  

 (b) ID Program Licenses. 

(i) Program Option Period License. Subject to the terms and conditions of this Agreement, during the Program Option Period for an ID
Program, Alnylam hereby grants Vir a non-transferable (except as provided in Section 14.3), sublicenseable (subject to Section 6.1(c)), exclusive, worldwide, royalty-free license, under Alnylam
Intellectual Property, solely to perform Vir’s Development obligations pursuant to the Development Plan for such ID Program and to conduct research and evaluation of the results of such ID Program as reasonably necessary for Vir to evaluate
whether or not to exercise its Program Option with respect to such ID Program pursuant to Section 4.1(a). 
 (ii) Licenses Upon
Program Option Exercise. 
 (A) Development and Commercialization License. Subject to the terms and
conditions of this Agreement, including those set forth in Sections 4.2 and 6.1(d), upon exercise by Vir of its Program Option for an ID Program [and payment of the Program Option Exercise Fee and all undisputed Program Costs reimbursable to
Alnylam for such ID Program pursuant to Section 4.1(a)], Alnylam shall grant and hereby grants Vir a non-transferable (except as provided in Section 14.3), sublicenseable (through multiple tiers and
subject to Section 6.1(c)), exclusive license under Alnylam Intellectual Property to Develop, use, sell, have sold, import, and otherwise Commercialize ID Licensed Products in the Field in the Territory. Such license shall be royalty-bearing
for the Royalty Term applicable to each such ID Licensed Product in each country in the Territory, and, after the expiration of the Royalty Term applicable to such ID Licensed Product in such country, shall convert to a [***], fully paid-up, irrevocable, and perpetual license for such ID Licensed Product in the Field in such country. 

(B) Manufacturing License. Subject to the terms and conditions of this Agreement, including those set forth in Sections 4.2
and 6.1(d) and Article V, upon exercise by Vir of its Program Option for an ID Program and payment of the Program Option Exercise Fee and all [***] Program Costs reimbursable to Alnylam for such ID Program pursuant to Section 4.1(a),
Alnylam shall grant and hereby grants Vir a non-transferable (except as provided in Section 14.3), sublicenseable (through multiple tiers and subject to Section 6.1(c)), worldwide, royalty-bearing,
exclusive license under Alnylam Intellectual Property to Manufacture ID Licensed Products for Development of ID Licensed Products to the extent that Vir elects to Manufacture or have Manufactured such ID Licensed Products in the Field in the
Territory. Such license shall be royalty-bearing for the Royalty Term applicable to each ID Licensed Product in each country in the Territory, and, after the expiration of the Royalty Term applicable to such ID Licensed Product in such country,
shall convert to a [***], fully paid-up, irrevocable, and perpetual license for such ID Licensed Product in the Field in such country. 

(c) Sublicensing Terms. 

(i) Vir shall have the right to sublicense (through multiple tiers) any of its rights under Sections 6.1(a) and 6.1(b) to any Affiliate
of Vir so long as it remains an Affiliate of Vir, and to any Third Party [***]. Any such sublicense shall comply with the applicable terms of this Agreement, including the requirements of this Section 6.1(c) and payment to Alnylam of its share
of any Program Transaction Revenue pursuant to Section 7.6. 
 (ii) Each sublicense granted by Vir pursuant to this Section 6.1(c)
shall be subject to the terms and conditions of this Agreement, including Alnylam’s Profit-Sharing Option, and shall contain terms and conditions consistent with the relevant terms in this Agreement. Vir shall promptly provide Alnylam with a
copy of the fully executed sublicense agreement covering any Commercialization sublicense granted hereunder, provided that Vir shall have the right to redact commercially sensitive 

  
 35 

 EXECUTION VERSION 
  

 
terms in such sublicense to the extent that such redacted terms are not necessary for Alnylam to confirm its rights under this Agreement, and each such sublicense agreement shall contain the
following provisions: (A) a requirement that the Sublicensee comply with confidentiality and non-use provisions that are no less stringent than Section 9.1 with respect to Alnylam’s Confidential
Information; provided, however, that if such sublicense agreement contains a sublicense of Licensed Product sales rights, such sublicense agreement shall also contain the following provisions:[***]. 

(iii) Vir shall use Commercially Reasonable Efforts to ensure that, to the extent possible, each such sublicense agreement provides that any
and all data and results, discoveries, and inventions, whether patentable or not, arising out of the sublicense and in connection with the Licensed Products may be used by each Party and its Related Parties to perform such Party’s obligations
and to exploit such Party’s rights under the relevant Transaction Agreements. In addition, Vir shall [***]. 
 (iv) Notwithstanding any
sublicense, Vir shall remain primarily liable to Alnylam for the performance of all of Vir’s obligations under, and Vir’s compliance with all terms and conditions of, this Agreement, including all obligations delegated to its Sublicensees.

 (d) Retained Rights. Notwithstanding the license grants in Sections 6.1(a) and 6.1(b), Alnylam retains the rights under
Alnylam Intellectual Property (a) to Develop and Manufacture Licensed Products in the Field in the Territory solely for the purpose and only to the extent necessary for the performance of its obligations under this Agreements, and
(b) subject to Alnylam’s obligations under Section 10.5(a), for [***]. 
 6.2 License Grants to Alnylam. 

(a) Development and Manufacturing License. Subject to the terms and conditions of this Agreement, Vir hereby grants
Alnylam a non-transferable (except as provided in Section 14.3), sublicenseable (subject to Section 6.2(c)), non-exclusive, worldwide, royalty-free license,
under the Vir Intellectual Property, solely to perform Alnylam’s Development and Manufacturing obligations with respect to Licensed Products under this Agreement. 

(b) Vir Improvements License. Subject to the terms and conditions of this Agreement, Vir hereby grants Alnylam a
non-transferable (except as provided in Section 14.3), sublicenseable (subject to Section 6.2(c)), worldwide, non-exclusive, royalty-free license under any Vir Improvements solely for research
use in connection with [***]. Such license is subject to the exclusive license grants to Vir under Section 6.1 and the terms of [***]. [***]. 

  
 36 

 EXECUTION VERSION 
  

 (c) Sublicensing Terms. 

(i) Alnylam shall have the right to sublicense any of its rights under Section 6.2(a) or Section 11.3(b) to any of its Affiliates or
to any Third Party [***], subject to the requirements of this Section 6.2(c). 
 (ii) Each sublicense granted by Alnylam pursuant to
this Section 6.2(c) shall be subject to the terms and conditions of this Agreement and shall contain terms and conditions consistent with those in this Agreement. Alnylam shall promptly provide Vir with a copy of the fully executed sublicense
agreement covering any Commercialization sublicense granted hereunder, provided that Alnylam shall have the right to redact commercially sensitive terms in such sublicense to the extent that such redacted terms are not necessary for Vir to
confirm its rights under this Agreement, and each such sublicense agreement shall contain a requirement that the Sublicensee comply with confidentiality and non-use provisions that are no less stringent than
Section 9.1 with respect to Vir’s Confidential Information. 
 (iii) Alnylam shall use Commercially Reasonable Efforts to ensure
that, to the extent possible, each such sublicense agreement with a sublicense of Alnylam’s rights under Section 6.2(a) provides that any and all data and results, discoveries, and inventions, whether patentable or not, arising out of the
sublicense may be used by each Party and its Related Parties to perform such Party’s obligations and to exploit such Party’s rights under the relevant Transaction Agreements. In addition, Alnylam shall use Commercially Reasonable Efforts
to obtain a right to sublicense to Vir and its Related Parties any intellectual property arising out of the sublicense for use in connection with the performance of Vir’s obligations and exploitation of Vir’s rights under the relevant
Transaction Agreements. 
 (iv) Notwithstanding any sublicense, Alnylam shall remain primarily liable to Vir for the performance of all of
Alnylam’s obligations under, and Alnylam’s compliance with all terms and conditions of, this Agreement, including any obligations delegated to its Sublicensees. 

6.3 Joint Collaboration IP. Subject to the rights and licenses granted to, and the obligations of, each Party under this Agreement, including
each Party’s obligations under Section 10.5(a), each Party shall have the right to exploit its interest in Joint Collaboration IP without the consent of and without accounting to the other Party. 

6.4 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to this Agreement by a Party to the other,
including those set forth in Sections 6.1 and 6.2, are and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined under
Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties and their respective Related Parties, as sublicensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under
the U.S. Bankruptcy Code and any foreign counterpart thereto. The Parties further agree that that upon commencement of a bankruptcy proceeding by or against a Party (the “Bankrupt Party”) under the U.S. Bankruptcy Code, the other
Party (the “Non-Bankrupt Party”) will be entitled to a complete duplicate of, or complete access to (as the Non-Bankrupt Party deems appropriate), all
such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments of such intellectual property will be promptly delivered to the Non-Bankrupt Party
(a) upon any such commencement of a bankruptcy proceeding and upon written request by the Non-Bankrupt Party, unless the Bankrupt Party elects to continue to perform all of its obligations under this
Agreement, or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the Bankrupt Party and upon written request by the Non-Bankrupt Party. The Bankrupt Party
(in any capacity, including debtor-in-possession) and its successors and assigns (including any trustee) agrees not to interfere with the exercise by the Non-Bankrupt Party or its Related Parties of its rights and licenses to such intellectual property and such embodiments of intellectual property in 

  
 37 

 EXECUTION VERSION 
  

 accordance with this Agreement, and agrees to assist the Non-Bankrupt
Party and its Related Parties in obtaining such intellectual property and such embodiments of intellectual property in the possession or control of Third Parties as reasonably necessary or desirable for the
Non-Bankrupt Party to exercise such rights and licenses in accordance with this Agreement. The foregoing provisions are without prejudice to any rights the Non-Bankrupt
Party may have arising under the U.S. Bankruptcy Code or other Laws. 
 6.5 No Other Rights. Except as otherwise expressly provided in this
Agreement, under no circumstances shall a Party, as a result of this Agreement, obtain any ownership interest or other right in any Know-How, Patent Rights or other intellectual property rights of the other
Party, including items owned, controlled or developed by the other Party, or provided by the other Party to the receiving Party at any time pursuant to this Agreement. 

6.6 Alnylam In-Licenses and Existing Alnylam Third Party Agreements. 

(a) Compliance with Alnylam In-Licenses. All licenses and other rights granted to Vir
under this Article 6 (including any sublicense rights) are subject to the applicable rights and obligations of Alnylam and its Affiliates under the Existing Alnylam In-Licenses set forth in
Schedule A-1, any Alnylam In-Licenses designated as such pursuant to Section 6.6(b) and the Existing Alnylam Third Party Agreements. Vir
shall comply with all applicable terms and conditions of the Alnylam In-Licenses and [***]. Without limiting the foregoing, Vir [***]. 

(b) Acceptance of Future Alnylam In-Licenses. In the event that Alnylam or its Affiliate
enters into an agreement with a Third Party after the Effective Date that meets the criteria set forth in clause (b) of the definition of Alnylam In-License, then Alnylam will promptly provide Vir with
notice and a copy of the applicable Third Party agreement. Within [***] following receipt of such notice, Vir will decide, [***]. In the event that Vir declines to accept such agreement as an Alnylam
In-License, any rights granted to Vir thereunder will not be deemed to be “Controlled” by Alnylam or licensed to Vir under this Agreement, and will not be subject to the payment provisions under this
Agreement relating to In-Licenses. In the event that Vir accepts such Third Party agreement as an Alnylam In-License, such agreement will thereafter be included within
the definition of Alnylam In-License and the Parties will update Schedule A-1 accordingly, and any rights granted to Alnylam thereunder will be
deemed to be “Controlled” by Alnylam and sublicensed to Vir pursuant to the terms of this Agreement. 
 (c) [***]

  
 38 

 EXECUTION VERSION 
  

 (d) Payments Under Alnylam In-Licenses.
Vir shall bear and reimburse Alnylam for [***], in each case other than a Profit-Sharing Product. 
 6.7 No Reach Through to Acquirer IP.
Notwithstanding anything in this Agreement to the contrary, following the closing of a Change of Control of a Party (the “Acquired Party”), the Parties agree that the other Party (the
“Non-Acquired Party”) shall not obtain rights or access to the Patent Rights or Know-How controlled by the Acquirer (as defined below) or any of the
Affiliates of such Acquirer (other than the Acquired Party and its Affiliates that exist immediately prior to the closing of such Change of Control (such Affiliates, the “Pre-Existing
Affiliates”)); and the Acquirer and its Affiliates (other than the Acquired Party and its Pre-Existing Affiliates) shall not obtain rights or access to the Patent Rights or Know-How controlled by the Non-Acquired Party or any of its Affiliates pursuant to this Agreement, or be bound by the restrictions set forth in Section 10.5(a)(i),
subject to Section 10.5(a)(ii). For clarity but without limitation, the Non-Acquired Party’s rights in all Patent Rights and Know-How Controlled by the
Acquired Party or any of its Pre-Existing Affiliates, which Patent Rights and Know-How exist as of the date of the closing of such Change of Control and are then
licensed hereunder to the Non-Acquired Party, shall remain licensed to such Non-Acquired Party after the date of the closing of such Change of Control in accordance with
and subject to the terms and conditions of this Agreement and shall not be affected in any manner by virtue of such Change of Control. “Acquirer” shall mean, with respect to the Acquired Party, the Third Party that acquires such
Acquired Party or its direct or indirect controlling Affiliate, or that acquires all or substantially all of the assets of the Acquired Party or its direct or indirect controlling Affiliate. 

ARTICLE VII 

FINANCIAL PROVISIONS 

7.1 Upfront Fee. As partial consideration for the licenses and other rights granted by Alnylam to Vir under this Agreement, within [***] after
the Effective Date, Vir shall pay Alnylam a non-refundable, non-creditable initial payment of Ten Million Dollars ($10,000,000). 

7.2 License Grant Equity Consideration. In partial consideration for the licenses and other rights granted by Alnylam to Vir under this
Agreement, on the Effective Date, Vir shall issue to Alnylam, or cause to be issued to Alnylam, 10,000,000 shares of fully paid, non-assessable common stock, [par value $0.0001 per share, of Vir (the
“Equity Consideration”) in accordance with the Stock Purchase Agreement. 
 7.3 Development and Regulatory Milestone Fees.

 (a) As partial consideration for the licenses and other rights granted by Alnylam to Vir in this Agreement, Vir shall make the non-refundable, non-creditable milestone payments (“Milestone Payment”) to Alnylam set forth below no later than [***] after the earliest date on which Vir
becomes aware that the corresponding milestone event has first been achieved with respect to the applicable Licensed Product. 
 (i) HBV
Licensed Products: [***] 

  
 39 

 EXECUTION VERSION 
  

 [***] 

(ii) ID Licensed Products with respect to which Vir has exercised its Program Option: [***] 

(b) Milestone Payments Payable Only Once; Follow-On Product. Each Milestone
Payment with respect to a Licensed Product under Section 7.3(a) shall be payable only once in relation to each Collaboration Target as set forth below, irrespective of dosage, formulation forms, route of administration or indications for a
particular Licensed Product. For purposes of clarity, [***]. However, once Regulatory Approval of an NDA for a Licensed Product has occurred (“Approved Product”) and Development of a Licensed Product Directed to the same
Collaboration Target as the Approved Product and that is not solely [a variation of dosage, formulation form, or route of administration of such Approved Product, or for a new indication for such Approved Product] (“Follow-On Product”), commences or continues, then (i) Milestone Payments shall be due and payable with respect to the Development and Regulatory Approval of the
Follow-On Product, and [***]. 
 7.4 Sales Milestone Fees. 

(a) As partial consideration for the licenses and other rights granted by Alnylam to Vir in this Agreement, Vir shall make the non-refundable, non-creditable milestone payments to Alnylam set forth below no later than [***] after the end of the Calendar Year in which the corresponding milestone event
(a “Sales Milestone”) has first been achieved with respect to the Licensed Products: 

  
 40 

 EXECUTION VERSION 
  

 (i) HBV Licensed Products: 

[***] 
 (ii) ID Licensed Products with
respect to which Vir has exercised its Program Option: 
 [***] 

(b) With respect to the foregoing Sales Milestones, payment shall be made on a Collaboration Target by Collaboration Target basis, and only
once for each milestone regardless of the number of times aggregate Calendar Year Net Sales for all Licensed Products Directed to the same Collaboration Target in the Territory reach a particular dollar threshold. In no event shall the total
milestone payments under this Section 7.4 exceed [***] for each ID Collaboration Target. If Licensed Products Directed to the same Collaboration Target achieve a higher Sales Milestone in a Calendar Year without having first achieved a lower
Sales Milestone in any previous Calendar Year, then the milestone payment(s) for the lower Sales Milestone(s) shall be due and payable to Alnylam concurrently with the milestone payment for the higher Sales Milestone that has been achieved. 

7.5 Royalties. 
 (a) Royalties
Payable on HBV Licensed Products. Subject to the terms and conditions of this Agreement, as partial consideration for the licenses and other rights granted by Alnylam to Vir in this Agreement, Vir shall pay to Alnylam royalties on Net
Sales by Vir and its Related Parties of HBV Licensed Products calculated using the following royalty rate based on the aggregate Calendar Year Net Sales of all HBV Licensed Products in the Territory: 

[***] 
 (b) Royalties Payable on ID
Licensed Products. Subject to the terms and conditions of this Agreement, as partial consideration for the licenses and other rights granted by Alnylam to Vir in this Agreement, Vir shall pay to Alnylam royalties on Net Sales by Vir and its
Related Parties of each ID Licensed Product Directed to a Collaboration Target, calculated using the following royalty rate based on the aggregate Calendar Year Net Sales of all ID Licensed Products Directed to such Collaboration Target in the
Territory: 

  
 41 

 EXECUTION VERSION 
  

 [***] 

(c) For the avoidance of doubt, Vir’s obligation to pay royalties under this Section 7.5 is imposed only once with respect to the
same unit of Licensed Product, including by reason of such Licensed Product being Covered by more than one Valid Claim of Alnylam Patent Rights. 

(d) Royalty Term. The period during which the royalties set forth in this Section 7.5 shall be payable, on a Licensed Product-by-Licensed Product and country-by-country basis, shall commence with the First
Commercial Sale of such Licensed Product in such country and continue until the later of (i) the expiration of the last Valid Claim of any Alnylam Patent Right or any Patent Right included in the Collaboration IP (“Royalty
Patent”) that Covers [***] the Licensed Product in such country of sale, and (ii) the tenth (10th) anniversary of the First Commercial Sale of the Licensed Product in such country
(each such period, a “Royalty Term”). 
 (e) Royalty Reductions. 

(i) Know-How Royalty. If the Royalty Term for a given Licensed Product in a country
extends beyond the last to expire Valid Claim of a Royalty Patent in such country, then the royalty rate applicable to such Licensed Product in such country shall be reduced [***] of the rate set forth in Section 7.5(a) or (b) above, as
the case may be, (in each case, for clarity without giving effect to any royalty reduction provided in Section 7.5(a)(ii)) for any remaining portion of the Royalty Term that applies to such Licensed Product in such country. 

(ii) Generic Entry. If one or more Generic Products is sold in a country in the Territory during the Royalty Term for a Licensed
Product in such country, the royalty rates provided in Section 7.5(a) or (b), as applicable, (in each case, for clarity, without giving effect to any royalty reduction provided in Section 7.5(a)(i)) for such Licensed Product shall be
reduced in such country by (1) [***] for such Calendar Quarter if the unit volume sales of all Generic Products in such country as a percentage of the total unit volume sales of such Licensed Product (other than Generic Products) and all such
Generic Products in such Calendar Quarter in such country is [***] as a percentage of the total unit volume sales of such Licensed Product (other than Generic Products) and all such Generic Products in such Calendar Quarter in such country [***].
Percentage of unit sales of Licensed Product and Generic Products shall be based on data provided by IMS Health Incorporated, Fairfield, Connecticut (or, with respect to any region, such other independent data provider as the Parties determine, in
good faith, provides more accurate data than IMS Health Incorporated, Fairfield, Connecticut) or if such data is not available, the Parties shall agree upon a methodology for estimating the percentage of unit sales based on market share of such
Generic Product(s) in such region. 
 (iii) Third Party Licenses. If Vir or its Related Parties is required to obtain a license from
a Third Party under any Patent Rights of such Third Party that [***] (excluding any Patent Rights Covering any Unlicensed Component of a Combination Product), then Vir shall have the right to credit [***] of the amount of the payments actually paid

  
 42 

 EXECUTION VERSION 
  

 by it or its Related Parties to such Third Party pursuant to such license only to the extent such payments
are reasonably attributable or allocable to the Development, Manufacture, use or Commercialization of such Licensed Product (excluding any Unlicensed Component of a Combination Product) in the Field and the Territory, against [***] owed to Alnylam
hereunder with respect to such Licensed Product. 
 (iv) Royalty Floor. Notwithstanding the foregoing clauses (i)-(iii), with respect
to any Licensed Product in any Calendar Quarter, the operation of clause (i), (ii), and (iii) above, individually or in combination, shall not reduce by more than [***] the royalties that would otherwise have been due under Section 7.5(a)
or (b), as applicable, (for clarity, in each case without giving effect to any royalty or royalty rate reduction provided in clause (i), (ii) and (iii) above) with respect to Net Sales of such Licensed Product during such Calendar Quarter. Vir
may carry forward to subsequent Calendar Quarters any amounts that it was not able to credit under Section 7.5(e)(iii) on account of such royalty floor, subject to the royalty floor for all subsequent Calendar Quarters. 

(f) Royalty Payments for Compulsory Licenses and Global Access Programs. 

(i) Sales of Licensed Products pursuant to a Compulsory License or Global Access Program shall not be included in any Net Sales calculation
for purposes of Section 7.5(a) or 7.5(b), as applicable, and no royalties or milestones shall be payable on such Net Sales. 
 (ii)
With respect to each Licensed Product, for each Calendar Year commencing with the Calendar Year in which the First Commercial Sale of such Licensed Product occurs, Vir shall pay to Alnylam a royalty on all Compulsory License Compensation received by
Vir or its Related Parties from a Compulsory Licensee during the Royalty Term (the “Compulsory License Royalty Rate”) calculated for the respective Calendar Year as follows: 

[***] 
 At the end of the Calendar Year, Vir shall
pay to Alnylam the Compulsory License Compensation received for a Licensed Product for a given country in the Territory multiplied by the applicable Compulsory License Royalty Rate. 

(iii) With respect to Net Sales of a Licensed Product in a country pursuant to a Global Access Program in a given Calendar Year, if the
aggregate such Net Sales of such Licensed Product in such country during such Calendar Year are [***], then Vir shall pay Alnylam a [***] royalty on such Net Sales. Such royalty shall not be subject to adjustment pursuant to Section 7.5(e).

 7.6 Program Transaction Revenue. Subject to the terms and conditions of this Agreement, as partial consideration for the licenses and
other rights granted by Alnylam to Vir in this Agreement, Vir shall pay to Alnylam a percentage of all Program Transaction Revenue, which percentage shall be determined based on the date of the Program Transaction generating such Program Transaction
Revenue with respect to a Licensed Product as follows: 
 [***] 

  
 43 

 EXECUTION VERSION 
  

 [***] 
 Such
payment is due within [***] after receipt of the applicable Program Transaction Revenue by Vir or its Affiliate; provided, that payment is not due immediately if the Person receiving the sublicense, assignment or grant constituting the
Program Transaction is a wholly-owned subsidiary of Vir, but is due if and when such Person ceases to be a wholly-owned subsidiary of Vir. 

7.7 Payments. Vir shall calculate royalties on Net Sales quarterly as of March 31, June 30, September 30 and December 31
(each being the last day of an “Accounting Period”) and shall pay royalties on Net Sales of Licensed Products (other than Profit-Sharing Product) within [***] after the end of each Accounting Period in which such Net Sales occur.
Royalties on applicable Net Sales shall be paid by Vir in Dollars. All calculations of payments under this Agreement shall be made in accordance with the Applicable Accounting Standards. 

7.8 Reporting. With each payment Vir shall provide in writing for the relevant Accounting Period the following information on a Licensed Product-by-Licensed Product, and country-by-country basis: (a) Net Sales, (b) any
deductions from gross amounts received to determine Net Sales, (c) calculation of any applicable royalty or royalty rate reduction pursuant to Section 7.5(e), [***], (d) calculation of any royalty payment pursuant to
Section 7.5(f), [***], (e) the applicable royalty rates for such Licensed Product, (e) the exchange rates used in calculating any of the foregoing, and (f) the total royalties payable for the applicable period, in each case in
reasonable detail to enable Alnylam to confirm the accuracy of the royalty calculation and as existing and not unduly burdensome to Vir. 

7.9 Audits. Each Party shall keep, and shall require its Affiliates and sublicensees to keep, complete and accurate records of the latest [***]
relating to Net Sales sufficient to allow amounts payable under this Agreement to be determined, and each Party shall keep and require its Affiliates to keep complete and accurate records of the latest [***] relating to Net Sales and all information
relevant to calculating the foregoing. For the sole purpose of verifying amounts payable hereunder or for calculating Net Sales, as applicable, each Party shall have the right, no more than [***] per Calendar Year (absent evidence of breach or
fraud), at such Party’s expense, to retain an independent certified public accountant selected by the auditing Party and reasonably acceptable to the audited Party, to review such records in the location(s) where such records are maintained by
the audited Party, its Affiliates and sublicensees upon [***] prior written notice and during regular business hours. Any such auditor shall execute a confidentiality agreement with the audited Party in customary form and shall not disclose the
audited Party’s Confidential Information to the auditing Party, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished the audited Party or the amount of payments by the audited Party under
this Agreement. The right to audit any royalty report or payment shall extend for [***] from the end of the Accounting Period to which such royalty report or such payment relates, provided that absent evidence of breach or fraud, any
Accounting Period may be audited no more than [***]. All records made available for audit shall be deemed to be Confidential Information of the audited Party. The results of each audit, if any, shall be binding on both Parties. The audited Party
shall promptly pay the auditing Party the amount of any underpayment revealed by such audit together with interest 

  
 44 

 EXECUTION VERSION 
  

 calculated in the manner provided in Section 3. If the underpayment is equal to or greater than five
[***] of the amount that was otherwise due, the auditing Party shall be entitled to have the audited Party reimburse the auditing Party’s reasonable out-of-pocket
costs of such review. The auditing Party shall promptly return to the audited Party any overpayment revealed by such audit. 
 7.10 Currency
Exchange. With respect to sales of Licensed Products invoiced in Dollars, the sales and royalties payable shall be expressed in Dollars. With respect to sales of Licensed Products invoiced in a currency other than Dollars, the sales and any amounts
payable hereunder on such sales shall be expressed in their Dollar equivalent calculated using a Party’s own standard currency translation methodology for the conversion of foreign sales currencies into Dollars, which methodology shall be in
accordance with the Applicable Accounting Standards and shall be the methodology generally used by a Party for currency conversions in such Party’s audited financial statements. 

7.11 Manner of Payment. Any payment to be made by one Party to the other under this Agreement shall be payable in Dollars and shall be paid by
wire transfer in immediately available funds to the bank account designated by the relevant Party. Either Party shall have the right to change such information at any time by providing written notice to the other Party; provided, that such
new bank information shall not be deemed effective until the date that is [***] after the receipt of such new information. 
 7.12 Tax
Withholding. Each Party shall use reasonable efforts to minimize tax withholding, including any interest and penalties that may be imposed thereon (together with the tax paid, the “Withholding Amount”), on payments made to the other
Party and whenever possible to make such payments from a United States Person if Party is a United States Person. If such Party concludes that the Withholding Amount under the Laws of any country are required with respect to payments to the other
Party, such Party shall use reasonable efforts to notify the other Party and provide such Party the opportunity to determine whether there are actions such receiving Party can undertake to avoid such withholding before the paying Party makes such
payment. Any amount so withheld shall be treated as paid to the other Party in accordance with the terms of this Agreement. The paying Party shall make such payment and withhold the required amount and pay it to the appropriate Governmental
Authority in a timely manner in compliance with applicable Law. In such case, the withholding Party shall promptly provide the other Party with copies of receipts or other evidence available to the withholding Party that are reasonably required and
sufficient to allow the other Party to document such Withholding Amounts adequately for purposes of claiming foreign tax credits and similar benefits. At the receiving Party’s expense and reasonable request, the Parties will use reasonable
efforts to cooperate in completing and filing documents required under the provisions of any applicable tax laws or under any other applicable Law, in connection with any claim to a refund of or credit for any such payment. The Parties will
cooperate in completing and filing documents required under the provisions of any applicable tax laws in connection with the making of any required Withholding Amounts. In the event that a Governmental Authority retroactively determines that a
payment made pursuant to this Agreement should have been subject to Withholding Amounts, and the payor remits such Withholding Amounts, if the payor has been compliant with applicable Law in a timely manner, then the payor will have the right:
(a) to offset the Withholding Amount against future payment obligations of the payor under this Agreement; (b) to invoice the payee for the Withholding Amount (which will be payable by the payee within [***] of its receipt of such
invoice); or (c) to pursue reimbursement of the Withholding Amount by any other available remedy. Notwithstanding the foregoing, if, as a result of (i) the assignment of this Agreement by the paying Party to an Affiliate or a Third Party
outside of the United States or (ii) the exercise by the paying Party of its rights under this Agreement through an Affiliate or Third Party outside of the United States, foreign withholding tax in excess of the foreign withholding tax amount
that would have been payable in the absence of such assignment or exercise of rights becomes payable with respect to amounts due to the payee hereunder, such amount due to the payee will be increased so that the amount actually paid to the payee
(after withholding of the excess withholding tax) equals the amount that would have been payable to the payee in the absence of such excess withholding. 

  
 45 

 EXECUTION VERSION 
  

 7.13 Other Tax Liability. In the case of value added or similar taxes incurred by a Party
with respect to payments made to a Party hereunder or the activities underlying such payments (the “VAT”), each Party and its Affiliates will use reasonable efforts to secure available exemption(s) from VAT and/or to cooperate with
the other Party’s efforts to obtain maximum recovery of VAT paid or incurred by such Party or any Affiliate, to the extent permitted by applicable Law. 

7.14 Late Payments. The paying Party shall pay interest to the other Party on the aggregate amount of any payments (except for those payments
which are the subject of a reasonable, good faith dispute) that are not paid on or before the date such payments are due under this Agreement at a rate of one [***] from the due date until paid in full or the highest rate permitted by applicable
Law, calculated on the number of days such payments are paid after the date such payments are due. In the event that the paying Party in reasonable good faith disputes any amounts due under this Agreement, the interest rate in the preceding sentence
shall not apply to the amounts so disputed during the period of time that the Parties are resolving such dispute. 
 7.15 Blocked Payments.
If, by reason of Laws in any jurisdiction in the Territory, it becomes impossible or illegal for a Party to transfer milestone payments, royalties or other payments under this Agreement to the other Party, the payor shall promptly notify the payee.
During any such period described above, the payor shall deposit such payments in local currency in the relevant jurisdiction to the credit of the payee in a recognized banking institution designated by the payee or, if none is designated by the
payee within a period of [***], in a recognized banking institution selected by the payor and identified in a written notice given to the payee. 

ARTICLE VIII 

INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS 

8.1 Inventorship. Inventorship for patentable inventions conceived or reduced to practice during the course of the performance of activities
pursuant to this Agreement shall be determined in accordance with United States patent laws for determining inventorship. 
 8.2 Ownership.
Alnylam shall own the entire right, title and interest in and to all inventions and discoveries (and Patent Rights claiming patentable inventions therein) first conceived or reduced to practice or, with respect to inventions and discoveries other
than patentable inventions, otherwise identified, developed, made or discovered, solely by employees or consultants of Alnylam or acquired solely by Alnylam in the course of conducting the Collaboration. Vir shall own the entire right, title and
interest in and to all inventions and discoveries (and Patent Rights claiming patentable inventions therein) first conceived or reduced to practice or, with respect to inventions and discoveries other than patentable inventions, otherwise
identified, developed, made or discovered, solely by employees or consultants of Vir or acquired solely by Vir in the course of conducting the Collaboration. The Parties shall jointly own any inventions and discoveries (and Patent Rights claiming
patentable inventions therein) first conceived or reduced to practice or, with respect to inventions and discoveries other than patentable inventions, otherwise identified, developed, made or discovered, jointly in the course of conducting the
Collaboration. 
 8.3 Prosecution and Maintenance of Patent Rights. 

(a) Vir Intellectual Property. Vir has the sole right and responsibility to, at Vir’s discretion, file, conduct prosecution, and
maintain (including the defense of any interference, opposition or any other pre- or post-grant proceedings or challenges), all Patent Rights comprising Vir Intellectual Property (other than Joint
Collaboration IP), in Vir’s name. 

  
 46 

 EXECUTION VERSION 
  

 (b) Alnylam Intellectual Property. 

(i) Subject to Sections 8.3(b)(ii) and 8.3(b)(iii), [***] has the sole right and responsibility to, at [***] discretion, file, conduct
prosecution, and maintain (including the defense of any interference, opposition or any other pre- or post-grant proceedings or challenges, but excluding with respect to any Alnylam Product-Specific Patent
Rights and Alnylam Core Technology Patent Rights included in Alnylam Collaboration IP), all Patent Rights comprising Alnylam Intellectual Property (other than Joint Collaboration IP), in [***] name. [***] agrees to [***] prosecute and maintain such
Alnylam Patent Rights in the Major Markets, and to prosecute and maintain Alnylam Product-Specific Patent Rights and Alnylam Core Technology Patent Rights that arise out of any Alnylam Collaboration IP in all other countries [***]. Notwithstanding
the foregoing, Alnylam and Vir shall jointly agree (not to be unreasonably withheld) on the preparation and filing of any Alnylam Product-Specific Patent Rights and Alnylam Core Technology Patent Rights that arise out of any Alnylam Collaboration IP
with the objective of maximizing patent protection and commercial value for the Licensed Products in the Field in the Territory. 
 (ii)
[***] shall provide [***], sufficiently in advance for [***] to comment, with copies of all patent applications and other material submissions and correspondence intended to be filed with any patent counsel or patent authorities pertaining to Patent
Rights comprising Alnylam Product-Specific Patent Rights and, to the extent the Alnylam Core Technology Patent Rights would not be materially adversely affected, Alnylam Core Technology Patent Rights included in Alnylam Collaboration IP, and Alnylam
shall consider in good faith and reasonably incorporate [***] reasonable and promptly provided comments and advice with respect to the prosecution or maintenance strategy with respect to such Patent Rights; provided, however, that if
[***] determines in good faith that [***] comments or advice are not reasonable, [***] shall promptly notify [***] thereof and the Parties shall promptly use good faith efforts to resolve any such determination. [***] shall promptly provide [***]
with copies of all material correspondence received from any patent counsel or patent authorities pertaining to Patent Rights comprising Alnylam Product-Specific Patent Rights. In addition, [***] shall promptly notify [***] in writing of any
interference, opposition or any other pre- or post-grant proceeding or challenge for any Alnylam Core Technology Patent Right included in Alnylam Collaboration IP and any Alnylam Product-Specific Patent Right.

 (iii) In the event that [***] elects not to seek or continue to seek or maintain patent protection on any Alnylam Product-Specific Patent
Rights, [***], [***] shall notify [***] of such decision in [***] so as to permit [***] to decide whether to seek, prosecute and maintain such Patent Right [***], and [***] shall have the right (but not the obligation), at its expense, to seek,
prosecute and maintain in any country patent protection on such Alnylam Product-Specific Patent Rights [***]. [***] shall make available to [***] its documentation, and use Commercially Reasonable Efforts to make available its authorized attorneys,
agents or representatives, and such of its employees, as are reasonably necessary to assist [***] in obtaining and maintaining the patent protection described under this Section 8.3(b)(iii). [***] shall sign, or use Commercially Reasonable
Efforts to have signed, all legal documents necessary to file and prosecute such patent applications or to obtain or maintain such patents. 

  
 47 

 EXECUTION VERSION 
  

 (c) Joint Collaboration IP. 

(i) [***] shall have the first right to, at [***] discretion, file, prosecute and maintain (including the defense of any interference,
opposition or any other pre- or post-grant proceedings or challenges), all Patent Rights comprising Joint Collaboration IP, in the names of both Alnylam and Vir. [***] shall provide [***], sufficiently in
advance for [***] to comment, with copies of all patent applications and other material submissions and correspondence intended to be filed with any patent counsel or patent authorities pertaining to Patent Rights comprising Joint Collaboration IP,
and [***] shall consider in good faith [***] reasonable and promptly provided comments and advice with respect to the prosecution or maintenance strategy with respect to such Patent Rights; provided, however, that if [***] determines
that [***] comments or advice are not reasonable, [***] shall promptly notify [***] thereof and the Parties shall promptly discuss such determination. [***] shall promptly provide [***] with copies of all material correspondence received from any
patent counsel or patent authorities pertaining to Patent Rights comprising Joint Collaboration IP. Each Party shall sign, or use Commercially Reasonable Efforts to have signed, all legal documents necessary to file and prosecute patent applications
or to obtain or maintain patents in respect of such Joint Collaboration IP, at its own cost. 
 (ii) In the event that [***] elects not to
file or continue to prosecute or maintain patent protection on any Joint Collaboration IP in the Territory, [***] shall notify [***] of such decision in [***] so as to permit [***] to decide whether to seek, prosecute and maintain such Patent Right
and to take any necessary actions without losing patent protection, and [***] shall have the right (but not the obligation), to file, prosecute and maintain in any country Patent Rights comprising Joint Collaboration IP in the names of both Alnylam
and Vir. [***] shall make available to [***] its documentation, and its authorized attorneys, agents or representatives, and such of its employees, as are reasonably necessary to assist [***] in obtaining and maintaining the patent protection
described under this Section 8.3(c)(ii). [***] shall sign, or use Commercially Reasonable Efforts to have signed, all legal documents necessary to file and prosecute such patent applications or to obtain or maintain such patents. 

8.4 Cooperation. With respect to the rights granted to a Party under Sections 8.3(b) or 8.3(c), each Party hereby agrees: (a) to make
its employees, agents and consultants reasonably available to the other Party (or to the other Party’s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable such Party to undertake patent prosecution;
(b) to provide the other Party with copies of all material correspondence pertaining to prosecution with the patent offices; (c) to cooperate, if necessary and appropriate, with the other Party in gaining patent term extensions wherever
applicable to Patent Rights licensed under this Agreement; and (d) to endeavor in good faith to coordinate its efforts with the other Party to minimize or avoid interference with the prosecution and maintenance of the other Party’s patent
applications. 
 8.5 Patent Expenses. Except as provided below with respect to Alnylam Product-Specific Patent Rights and Patent Rights
comprising Joint Collaboration IP in the Territory, the patent filing, prosecution and maintenance expenses incurred after the Effective Date with respect to Patent Rights comprised of Alnylam Intellectual Property and Vir Intellectual Property
shall be borne by each Party having the right to file, prosecute and maintain such Patent Rights under Section 8.3. Except as set forth in any Profit-Sharing Agreement, [***] with respect to all of the reasonable and documented out-of-pocket Third Party patent filing, prosecution and maintenance expenses incurred [***] (a) after the Effective Date with respect to [***], and (b) after the Program
Option exercise effective date with respect to [***]. The Parties shall agree 

  
 48 

 EXECUTION VERSION 
  

 on the selection of any outside counsel used to prepare and prosecute any new Alnylam Product-Specific Patent
Rights not in existence as of the Effective Date, along with an anticipated budget [***]. If during the Term a bona fide conflict arises between [***], then the Parties shall use good faith efforts to resolve any such conflict and [***]. The Parties
shall share [***] the out-of-pocket patent filing, prosecution and maintenance expenses incurred with respect to Patent Rights comprising Joint Collaboration IP and
[***] shall reimburse [***] on a Calendar Quarter basis (and within [***] after receipt of an invoice) with respect to [***] of all of the reasonable and documented
out-of-pocket Third Party patent filing, prosecution, and maintenance expenses incurred by [***] with respect thereto. Each Party shall keep complete and accurate
records with respect to such amount required to be paid by the other Party, and such other Party shall have the right to audit such records in accordance with Section 7.9. 

8.6 Patent Term Extension. [***] Vir Patent Rights and Patent Rights comprising Joint Collaboration IP, to the extent applicable, that will be
designed to maximize patent protection and commercial value for the Licensed Products in the Field in the Territory, and the Parties, subject to the provisions of any Alnylam In-License, will seek patent term
extensions, restorations, supplementary protection certificates and other extensions in all relevant countries in the Territory for such Patent Rights as selected by [***] in accordance with that strategy. If [***] determines not to so file for any
extension, restoration or supplementary protection certificates for any of such Patent Rights in any relevant country of the Territory, it will give notice of such determination to Alnylam at least [***] prior to the date on which such a filing must
be made or the right to do so is lost, and [***] will have the right to make such filing. Where required under national law, [***] will make the filings for such extensions, restorations and supplementary protection certificates for Alnylam
Product-Specific Patent Rights and, as applicable, will make, or cooperate with [***] to make, the filing for Patent Rights comprising Joint Collaboration IP in the Territory, in each case as directed by [***]. Each Party will execute such
authorizations and other documents and take such other actions as may be reasonably requested by the other Party to obtain any such extensions, restorations and supplementary protection certificates in the Territory. 

8.7 Third Party Infringement. 

(a) Notices. Each Party shall promptly report in writing to the other Party any (a) known or suspected infringement of any Alnylam
Intellectual Property or Vir Intellectual Property, or (b) unauthorized use or misappropriation of any Confidential Information or Know-How of a Party by a Third Party of which it becomes aware, in each
case to the extent such infringing, unauthorized or misappropriating activities involve, as to a Licensed Product, a competing product in the Field (“Competitive Infringement”), and shall provide the other Party with all available
evidence of such infringement, unauthorized use or misappropriation. 
 (b) Rights to Enforce. 

(i) Vir Intellectual Property. Vir shall have the sole and exclusive right to initiate an infringement or other appropriate suit
anywhere in the world against any Third Party as to any infringement, or suspected infringement of, any Patent Rights, or of any use or suspected use without proper authorization of any Know-How, comprising
Vir Intellectual Property (other than Vir’s interest in Joint Collaboration IP). Vir will consider in good faith any request from Alnylam to initiate an infringement or other appropriate suit against any Third Party with respect to a
Competitive Infringement in the Territory of Vir Intellectual Property (other than Vir’s interest in Joint Collaboration IP); provided, however, that Vir shall not be required to initiate any such suit or permit Alnylam to
initiate any such suit. 

  
 49 

 EXECUTION VERSION 
  

 (ii) Alnylam Intellectual Property and Joint Collaboration IP. Subject
to the provisions of any Existing Alnylam In-License set forth in Schedule A-1, any Alnylam In-Licenses
designated as such pursuant to Section 6.6(b) and any Existing Alnylam Third Party Agreement: [***], or, (y) in each case with Alnylam’s prior written consent, any (A) Alnylam Core Technology Patent Rights (other than Alnylam
Core Technology Patent Rights included in Alnylam Collaboration IP), or (B) Alnylam Know-How (other than Alnylam’s interest in Joint Collaboration IP). With respect to the Alnylam Core Technology
Patent Rights (other than Alnylam Core Technology Patent Rights included in Alnylam Collaboration IP) and Alnylam Know-How (other than Alnylam’s interest in Joint Collaboration IP), [***] with respect to
a Competitive Infringement in the Territory of any Alnylam Core Technology Patent Right (other than Alnylam Core Technology Patent Rights included in Alnylam Collaboration IP) or such Alnylam Know-How (other
than Alnylam’s interest in Joint Collaboration IP); provided, however, that Alnylam shall not be required to initiate any such suit or permit Vir to initiate any such suit unless, [***]. In such case, Alnylam will use reasonable
and good faith efforts, subject to the applicable provisions of any Existing Alnylam In-License set forth in Schedule A-1, any Alnylam In-Licenses designated as such pursuant to Section 6.6(b) or any Existing Alnylam Third Party Agreement, to cooperate with Vir to assert such Alnylam Core Technology Patent Rights or such Alnylam Know-How, as the case may be, in a manner that does not materially and adversely affect the scope of such Alnylam Core Technology Patent Rights or such Alnylam Know-How in
such country. 
 (iii) Step-In Right. If within [***] after Vir’s receipt of a notice of
a Competitive Infringement with respect to any Alnylam Product-Specific Patent Right or Joint Collaboration IP (or at least [***] before the loss of the right to take an action as described in Section 8.7(b)(ii) and permitted hereunder with
respect to such Competitive Infringement, except if Vir has notified Alnylam in writing that it intends to, and actually does within a commercially reasonable time period, take action as described in Section 8.7(b)(ii) and permitted hereunder
against such Competitive Infringement), Vir does not take any action as described in Section 8.7(b)(ii) and permitted hereunder against such Competitive Infringement in the relevant country in the Territory, Alnylam may in its sole discretion,
bring and control any legal action in connection therewith at its sole expense. 
 (c) Procedures; Expenses and Recoveries. The Party
having the right to initiate any infringement suit under Section 8.7(b) above shall have the sole and exclusive right to select counsel for any such suit and shall pay all expenses of the suit, including attorneys’ fees and court costs and
reimbursement of the other Party’s reasonable out-of-pocket expense in rendering assistance requested by the initiating Party. If required under applicable Law in
order for the initiating Party to initiate and/or maintain such suit, or if either Party is unable to initiate or prosecute such suit solely in its own name or it is otherwise advisable to obtain an effective legal remedy, in each case, the other
Party shall join as a party to the suit and will execute and cause its Affiliates to execute all documents, and take all actions, reasonably necessary for the initiating Party to initiate litigation and maintain such action. In addition, at the
initiating Party’s request, the other Party shall provide other reasonable assistance to the initiating Party in connection with an infringement suit at no charge to the initiating Party except for reimbursement by the initiating Party of
reasonable out-of-pocket expenses incurred in rendering such assistance. The non-initiating Party shall have the right to
participate and be represented in any such suit under 

  
 50 

 EXECUTION VERSION 
  

 
Section 8.7(b)(ii) or 8.7(b)(iii) by its own counsel at its own expense. If the Parties obtain from a Third Party, in connection with any such suit under Section 8.7(b)(ii) or
8.7(b)(iii), any damages, license fees, royalties or other compensation (including any amount received in settlement of such litigation), such amounts shall be allocated in all cases as follows: 

(i) first, [***]; and 
 (ii)
second, the balance shall be paid as follows: [***]. 
 8.8 Trademarks. Vir and its Related Parties have the sole right to use any trademark
it owns or controls for Licensed Products in the Territory at its sole discretion, and each Party and its Related Parties shall retain all right, title and interest in and to its and their respective corporate names and logos. Vir will develop one
or more Product Trademark(s) for use by Vir and its Related Parties in the Territory to Commercialize Licensed Products which have received Regulatory Approval in the Field in the Territory. Vir (or its Related Parties, as appropriate) shall own all
rights to such Product Trademarks and all goodwill associated therewith, throughout the Territory, and the rights to any Internet domain names incorporating the applicable Product Trademarks or any variation or part of such Product Trademarks used
as its URL address or any part of such address. For the avoidance of doubt, neither Party shall have any right to use the other Party’s or the other Party’s Related Parties’ corporate names or logos in connection with
Commercialization of Licensed Products without the prior written consent of the other Party. 
 ARTICLE IX 

CONFIDENTIAL INFORMATION 

9.1 Nondisclosure Obligation. 

(a) All Confidential Information disclosed by one Party (“Disclosing Party”) to the other Party (“Receiving
Party”) hereunder shall be maintained in confidence by the Receiving Party and shall not be published or otherwise disclosed to a Third Party or used for any purpose except as expressly set forth herein without the prior written consent of
the Disclosing Party. Each Party may use the other Party’s Confidential Information solely to the extent required to perform its obligations or exercise any rights under this Agreement. The confidentiality and
non-use provisions of this Article IX shall not apply to the extent that such Confidential Information: 

(i) is known by the Receiving Party at the time of its receipt, and not through a prior disclosure by the Disclosing Party, as documented by
the Receiving Party’s business records; 
 (ii) is in the public domain or publicly known by use and/or publication before its receipt
from the Disclosing Party (or, with respect to Joint Collaboration IP, before its development hereunder), or thereafter enters the public domain or becomes publicly known through no fault of the Receiving Party; 

  
 51 

 EXECUTION VERSION 
  

 (iii) is subsequently disclosed to the Receiving Party by a Third Party who may lawfully do
so and is not under an obligation of confidentiality to the Disclosing Party; or 
 (iv) is developed by the Receiving Party independently
of Confidential Information received from the Disclosing Party (including any Joint Collaboration IP), as documented by the Receiving Party’s business records. 

(b) Notwithstanding the obligations of confidentiality and non-use set forth above and in
Section 9.2 below, a Receiving Party may disclose Confidential Information disclosed to it, and disclose the existence and terms of this Agreement, to the extent such disclosure is reasonably required to (i) Related Parties, and its and
their employees, directors, agents, consultants, advisors, and Third Party contractors who have a need to know such Confidential Information for the performance of its obligations in the Transaction Agreements (or for such entities to determine
their interest in performing such activities) in accordance with this Agreement, in each case who are obligated to keep such Confidential Information confidential on terms no less stringent than those in this Section 9.1; (ii) Governmental
Authorities or other Regulatory Authorities in order to obtain and maintain patents and regulatory approvals in accordance with this Agreement, or otherwise perform its obligations or exploit its rights under this Agreement; provided, that
such Confidential Information shall be disclosed only to the extent reasonably necessary to do so; (iii) prosecuting or defending litigation, including responding to a subpoena in a Third Party litigation; (iv) the extent required by a
court or administrative order or Law, including by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States or of any stock exchange or listing entity;
(v) any bona fide actual or prospective underwriters, investors, lenders, other financing sources, acquirers, permitted sublicensees, collaborators or strategic partners and to consultants and advisors of such Party, in each case who are
obligated to keep such Confidential Information confidential on terms no less stringent than those in this Section 9.1; and (vi) Third Parties solely to the extent a Receiving Party is required to do so pursuant to the terms of an Alnylam In-License and subject to the terms of such Alnylam In-License. 

If a Receiving Party is required by Law (including regulations promulgated by securities exchanges or listing entities) to disclose
Confidential Information of the Disclosing Party pursuant to Sections 9.1(b)(ii), 9.1(b)(iii), or 9.1(b)(iv), such Party shall, to the extent permitted by Law, promptly inform the Disclosing Party of the disclosure that is being sought in order
to provide the Disclosing Party an opportunity to challenge or limit the disclosure obligations and the Receiving Party shall endeavor in good faith, at the Disclosing Party’s expense, to secure confidential treatment of such Confidential
Information and/or reasonably assist the Disclosing Party in seeking a protective order or other confidential treatment. Confidential Information that is required to be disclosed by Law shall remain otherwise subject to the confidentiality and non-use provisions of this Section 9.1 and Section 9.2. If either Party concludes that a copy of this Agreement must be filed with the United States Securities and Exchange Commission or similar regulatory
agency in a country other than the United States, at least [***] in advance of any such filing such Party will provide the other Party with a copy of this Agreement showing any provisions hereof as to which the Party proposes to request confidential
treatment, will provide the other Party with a reasonable opportunity to comment on any such proposed redactions and to suggest additional redactions, and will take such Party’s reasonable and timely comments into consideration before so filing
the Agreement. 
 9.2 Publication and Publicity. 

(a) Publication. Vir and Alnylam each acknowledge the other Party’s interest in publishing the results of the Collaboration. Except
to the extent required by Law or Alnylam’s obligations to Third Parties under its clinical trial agreements existing as of the Effective Date, (i) [***], 

  
 52 

 EXECUTION VERSION 
  

 however, [***], (ii) neither Party shall publish Development results relating to ALN-HBV without the prior written consent of the other Party, and (iii) with respect to each ID Program, prior to exercise by Vir of its Program Option with respect to such ID Program, Vir shall not publish
Development results resulting from the ID Program without the prior written consent of Alnylam. Each Party also recognizes the mutual interest in obtaining valid patent protection and in protecting trade secret information. Consequently, except for
disclosures permitted pursuant to Section 9.1, 9.2(b)(i), 9.2(b)(iii) or 9.2(b)(iv), either Party wishing to make a publication or public presentation of Development results that contains the Confidential Information of the Disclosing Party
shall deliver to the Disclosing Party a copy of any proposed written publication or presentation of Development results at least [***] prior to submission for publication or presentation. The Disclosing Party shall have the right (i) to propose
modifications to the publication or presentation for patent reasons, trade secret reasons or business reasons, which proposals the publishing Party shall consider in good faith, and (ii) to request a reasonable delay in publication or
presentation in order to protect patentable information in accordance with Article VIII. Following the expiration of the applicable time period for review, the publishing Party shall be free to submit for publication or otherwise disclose to
the public such results, subject to the procedures set forth in the remainder of this Section 9.2(a). If the Disclosing Party provides written notice to the publishing Party requesting a delay pursuant to clause (ii) in this
Section 9.2(a), the publishing Party shall delay such submission or presentation for a period of an additional [***] to enable Alnylam to file patent applications on the disclosed subject matter. The publishing Party shall thereafter be free to
publish or disclose such information, except that the publishing Party may not disclose any Confidential Information of the Disclosing Party in violation of Section 9.1. With respect to any proposed publications or disclosures by clinical
investigators or academic or non-profit collaborators, such materials shall be subject to review under this Section 9.2 to the extent that Vir or Alnylam, as the case may be, has the right and ability
(after using Commercially Reasonable Efforts to obtain such right and ability) to do so. 
 (b) Publicity. 

(i) Except as set forth in Section 9.1 above and clause (ii) below or expressly permitted by the terms of the Transaction
Agreements, the terms of this Agreement may not be disclosed by either Party, and no Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity, news release or disclosure relating to this Agreement
or its subject matter, without the prior express written permission of the other Party, except as may be required by Law. 
 (ii) Following
the Effective Date , the Parties shall issue a joint press release agreed to in writing by the Parties. After such initial press release, except as provided in Sections 9.1, 9.2(b)(i), 9.2(b)(iii) or 9.2(b)(iv), neither Party shall issue a
press release or public announcement relating to this Agreement without the prior written approval of the other Party, which approval shall not be unreasonably withheld, conditioned or delayed, except that a Party may (A) once a press release
or other public statement is approved in writing by both Parties, make subsequent public disclosure of the information contained in such press release or other written statement without the further approval of the other Party, and (B) issue a
press release or public announcement as required, in the reasonable judgment of such Party, by Law, including by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory agency in a country other than
the United States or of any stock exchange or listing entity. 
 (iii) Vir may issue a press release or make a public disclosure relating to
this Agreement or the Parties’ activities under this Agreement to the extent, in each case, that such disclosure describes the commencement and/or “top-line” results of Clinical Studies of a
Licensed Product, the achievement of any material Development events with respect to a Licensed Product or the filing for or receipt of Regulatory Approval with respect to the Licensed Product in the Territory, or amounts paid

  
 53 

 EXECUTION VERSION 
  

 to Alnylam in respect of the achievement of any milestone events. Notwithstanding the foregoing,
(x) during the Profit-Sharing Option Period for the HBV Program, [***], and [***] to [***] relating to the topics described in the foregoing sentence. Prior to making any such disclosure, to the extent practicable, Vir shall provide Alnylam
with a draft of such proposed disclosure at least [***] (or, to the extent faster timely disclosure of a material event is required by Law or stock exchange or stock market rules, such shorter period of time sufficiently in advance of the disclosure
so that Alnylam will have the opportunity to comment upon the disclosure and Vir will be able to comply with its obligations) prior to making any such disclosure, for Alnylam’s review and comment, [***]. 

(iv) Subject to Sections 9.2(b)(ii) and 9.2(b)(iii), Vir and its Related Parties may make public announcements or disclosures reasonably
necessary or useful to Develop or Commercialize the Licensed Products in the Field in the Territory, including disclosures necessary to recruit subjects to clinical trials and disclosures to advertise, promote and otherwise Commercialize the
Licensed Products. 
 ARTICLE X 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

10.1 Mutual Representations and Warranties. Each Party represents and warrants to the other Party that, as of the Commitment Letter Date: 

(a) Representations of Authority. It is duly organized and validly existing under the laws of its jurisdiction of incorporation or
formation, and has full corporate right, power and authority to enter into this Agreement and to perform its obligations under this Agreement. 

(b) Consents. All necessary consents, approvals and authorizations of all government authorities and other Persons required to be
obtained by it as of the Commitment Letter Date in connection with the execution, delivery and performance of this Agreement have been obtained. 

(c) No Conflict. The execution and delivery of this Agreement and the performance of its obligations hereunder (i) do not violate
or conflict with the provisions of its certificate of incorporation or by-laws, (ii) do not conflict with or violate any requirement of applicable Law effective as of the Commitment Letter Date, and
(iii) do not and will not conflict with, violate, breach or constitute a default under any contractual obligations of it or any of its Affiliates existing as of the Commitment Letter Date. 

(d) Authorization and Binding Nature. The execution, delivery and performance of this Agreement and the performance of all obligations
hereunder have been duly authorized by all requisite corporate action on the part of such Party and this Agreement constitutes valid and legally binding obligations of such Party, limited by applicable bankruptcy, insolvency, reorganization,
moratorium and other Laws of general application affecting the enforcement of creditors’ rights generally and as may be limited by Laws relating to the availability of specific performance, injunctive relief or other equitable remedies. 

(e) Employee Obligations. All of its employees, officers and consultants have executed agreements or have existing obligations under Law
requiring assignment to such Party of all intellectual property and proprietary rights made during the course of and as the result of their association with such Party, and obligating such individuals to maintain as confidential the Confidential
Information of such Party, of a Disclosing Party under this Agreement, and of a Third Party which such Party may receive. 

  
 54 

 EXECUTION VERSION 
  

 (f) No Debarment. Neither it nor any of its Affiliates, nor its or their
respective employees, have been Debarred or are subject to Debarment. 
 10.2 Representations, Warranties and Covenants of Alnylam. Except as
provided in Schedule I, Alnylam represents and warrants to Vir that, as of the Commitment Letter Date, and solely with respect to (i) Alnylam Intellectual Property existing as of the Commitment Letter Date;
(ii) the HBV Licensed Products as such products are formulated and manufactured as of the Commitment Letter Date (for clarity, Alnylam makes no representation or warranty in this Section with respect to any ID Licensed Product); and
(iii) covenants during the Term as to the matters set forth in subsections (i) and (j): 
 (a) Ownership. (i) Alnylam
is the sole and exclusive owner of, or otherwise has the right to license to Vir as set forth in this Agreement, pursuant to an Alnylam In-License (or will Control pursuant to an Additional Alnylam In-License at such time that such Additional Alnylam In-License is included as an Alnylam In-License pursuant to Section 6.6(c)),
the Alnylam Intellectual Property. (ii) Alnylam has the right to grant the licenses hereunder. (iii) The Alnylam Intellectual Property and the Patent Rights licensed by Alnylam pursuant to the Additional Alnylam In-Licenses constitute all the intellectual property that Alnylam or its Affiliates own or have rights under that are or may be reasonably necessary or useful for the Development, Manufacturing and Commercialization
of the Licensed Products. 
 (b) Alnylam Patent Rights. (i) To Alnylam’s Knowledge, Schedule C-1 sets forth a complete and accurate list of the Alnylam Core Technology Patent Rights. (ii) To Alnylam’s knowledge,
Schedule C-2 sets forth a complete and accurate list of the Alnylam Product-Specific Patent Rights.
(iii) Schedules C-1 and C-2 collectively set forth a complete and accurate list of the Alnylam Patent Rights owned or Controlled by
Alnylam or its Affiliates. Upon Vir’s request, [***], Alnylam shall update Schedules C-1 and C-2. (iv) To Alnylam’s Knowledge,
each issued Alnylam Patent Right remains in full force and effect. (v) Alnylam or its Affiliates (or, to Alnylam’s Knowledge, the applicable Third Party in the case of Existing Alnylam In-Licenses,
Additional Alnylam In-License, and Existing Alnylam Third Party Agreements) have timely paid all filing and renewal fees payable with respect to such Alnylam Patent Rights. 

(c) Validity. (i) To Alnylam’s Knowledge, the Alnylam Patent Rights, are, or, upon issuance will be, valid and enforceable
patents. (ii) Alnylam has not been served with or received any other written notice that a Third Party has challenged or threatened in writing to challenge the scope, validity or enforceability of any Alnylam Product-Specific Patent Right.
(iii) Alnylam (or, to Alnylam’s Knowledge, the applicable Third Party in the case of Existing Alnylam In-Licenses, Additional Alnylam In-License, and Existing
Alnylam Third Party Agreements) has complied with all applicable Laws, including any duties of candor to applicable patent offices, in connection with its filing, prosecution and maintenance of the Alnylam Patent Rights. 

(d) (i) Section 1 and Section 2 of Schedule A set forth a complete and accurate list of all agreements
that Alnylam or any of its Affiliates, on the one hand, and a Third Party(ies), on the other hand, have entered into on or prior to the Commitment Letter Date and pursuant to which Alnylam or any of its Affiliates licenses or acquires (or may have
licensed or acquired) any intellectual property rights owned or Controlled by Alnylam or its Affiliates that are reasonably necessary or useful to Develop, Manufacture or Commercialize Licensed Products in the Field. (ii) Alnylam and its
Affiliates have not granted any Third Party, and are not under any obligation to grant any Third Party, any right to Develop, Manufacture or Commercialize Licensed Products in the Field in the Territory, [***]. (iii) In the [***] period immediately
prior to the Commitment Letter Date, Alnylam and its Affiliates have not received any written notice from a [***]. (iv) Alnylam Controls all Know-How and Patent Rights licensed to Alnylam under the Existing Alnylam
In-Licenses that are necessary or useful for Vir to Develop, Manufacture and/or Commercialize Licensed Products in the Field in the Territory. 

  
 55 

 EXECUTION VERSION 
  

 (e) Alnylam has provided Vir with true and complete copies of all Existing Alnylam In-Licenses, Additional Alnylam In-Licenses and Existing Alnylam Third Party Agreements; provided, however, that, (i) to the extent that the terms of any
such agreements require Alnylam to redact any provisions thereof before providing such agreements, or relevant portion thereof, to Vir, Alnylam has provided Vir with copies of such agreements, that are true and complete to the fullest extent
possible under such agreements and that any provisions or portions which have not been provided to Vir are not relevant to any obligations owed by Vir, or rights granted to Vir, under such agreement or any Transaction Agreement; and
(ii) Alnylam is not required by this Section 10.2(e) to provide to Vir copies of any amendment or side letter to any Existing Alnylam In-License, Additional Alnylam
In-License or Existing Alnylam Third Party Agreement that is not relevant to the rights granted to, and the obligations imposed on, Vir under this Agreement. 

(f) To Alnylam’s Knowledge, the research, Development, Manufacture, and Commercialization of HBV Licensed Products, as contemplated under
this Agreement [***] in each case in existence as of the Commitment Letter Date. 
 (g) There is no (i) claim, demand, suit, proceeding,
arbitration, inquiry, investigation or other legal action of any nature, civil, criminal, regulatory or otherwise, pending or, to Alnylam’s Knowledge, threatened against Alnylam or any of its Affiliates or (ii) judgment or settlement
against or owed by Alnylam or any of its Affiliates, in each case in connection with the Alnylam Intellectual Property or any Licensed Product. Alnylam shall not resolve any such claim, demand, suit, proceeding, arbitration, inquiry, investigation,
or other legal action in any manner that would materially adversely impact the rights granted to Vir hereunder, and shall be solely responsible for any amounts owed to a Third Party as a result thereof. 

(h) The Development of Licensed Products in the Territory to date by Alnylam has been conducted by Alnylam and its Affiliates and its
subcontractors, in compliance (in all material respects) with all applicable Laws. 
 (i) [***]. 

(j) Alnylam shall use Commercially Reasonable Efforts to maintain each Existing Alnylam In-License in
full force and effect to the extent such agreement relates to the rights granted to Vir hereunder. If Alnylam receives any notice of material breach under an Existing Alnylam In-License such that it would
materially adversely affect the rights of Vir under this Agreement, and if Alnylam reasonably determines in good faith that it cannot or chooses not to cure or otherwise resolve any such alleged breach or default, then Alnylam shall notify Vir of
such determination; provided that Alnylam shall not make any such determination with respect to any alleged breach or default of a payment obligation for which Vir is obligated to pay [***] pursuant to Section 6.6(d). [***]. 

  
 56 

 EXECUTION VERSION 
  

 10.3 Representations and Warranties of Vir. Vir represents, warrants and covenants to Alnylam
that, as of the Commitment Letter Date: 
 (a) Vir has sufficient available funds and resources to fully satisfy when due its obligations
during the HBV Program Joint Funding Period as set forth in and in accordance with the budget for the HBV Program Joint Funding Period. 

10.4 No Warranties. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF
ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY TECHNOLOGY, LICENSED PRODUCT, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE AND NON-INFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF THE
LICENSED PRODUCTS PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO THE LICENSED PRODUCTS WILL BE ACHIEVED. 

10.5 Additional Covenants. 
 (a)
Exclusivity. 
 (i) During the Term, but subject to this Agreement including Sections 6.1(d) and 6.7 and to the rights granted
to Third Parties under the Existing Alnylam Third Party Agreements specified in 3.a., 3.c. and 3.d. of Schedule A, neither Party nor its Affiliates will, without the prior written agreement of the other Party, alone or with or for an
Affiliate or Third Party, develop or commercialize in any country of the Territory any [***] Directed to a Collaboration Target, other than a Licensed Product pursuant to this Agreement (a “Competing Program”). 

(ii) Notwithstanding the foregoing, Alnylam may enter into a Permitted Transaction, and in the event that after the Effective Date: 

(A) a Change of Control of a Party is consummated and as a result of such Change of Control (x) a Third Party becomes an assignee of this
Agreement or an Affiliate of such Party, and (y) such Third Party, as of the closing date of such Change of Control transaction, is engaged in the development or commercialization of a Competing Program, [***]; or 

(B) a Party becomes an Affiliate of a Third Party as a result of a Change of Control of such Third Party, and as of the closing date of such
Change of Control transaction such Third Party is engaged in the development or commercialization of a Competing Program, [***]. 
 As used in this
Section 10.4(a)(ii), [***]. 
 (b) Compliance. Each Party and its Related Parties shall conduct the Collaboration and the
Development, Manufacture and Commercialization of the Licensed Products in material accordance with all Laws and industry standards, including, to the extent applicable, current governmental regulations concerning good laboratory practices, good
clinical practices and good manufacturing practices. Neither Party shall export any technology licensed to it by the other Party under this Agreement except in compliance with U.S. export laws and regulations. 

  
 57 

 EXECUTION VERSION 
  

 (c) Debarment. Neither Party nor any of its Affiliates will use in any capacity, in
connection with the Collaboration or the performance of its obligations under this Agreement, any Person that has been Debarred. Each Party agrees to inform the other Party in writing promptly if it learns that it or any Person that is performing
activities in the Collaboration or under this Agreement is Debarred or is subject to Debarment, or, to the notifying Party’s Knowledge, if Debarment of the notifying Party or any Person used in any capacity by such Party or any of its
Affiliates in connection with the Collaboration or the performance of its other obligations under this Agreement, is threatened. 

ARTICLE XI 
 TERM AND
TERMINATION 
 11.1 Term. This Agreement shall be effective as of the Effective Date and, unless terminated earlier pursuant to
Section 11.2, this Agreement shall continue in effect on a Licensed Product-by-Licensed Product and
country-by-country basis until expiration of the last Program Option Period, Profit-Sharing Option Period, Royalty Term and Profit-Sharing Term to expire under this
Agreement (“Term”). 
 11.2 Termination Rights. 

(a) Termination for Convenience. Vir shall have the right to terminate this Agreement with respect to a Program (i.e., all
Licensed Products Directed to the same Collaboration Target) or in its entirety, at any time after the one (1) year anniversary of the Effective Date on ninety (90) days’ prior written notice to Alnylam. 

  
 58 

 EXECUTION VERSION 
  

 (b) Termination for Cause. This Agreement may be terminated at any time during the
Term upon written notice by either Party (the “Non-Breaching Party”) if the other Party (the “Breaching Party”) is in material breach of its obligations hereunder and has not
cured such breach within thirty (30) days in the case of a payment breach, or within sixty (60) days in the case of all other breaches, after notice requesting cure of the breach, or, if cure of such breach other than non-payment cannot reasonably be effected within such sixty (60) day period, to deliver to the Non-Breaching Party a plan reasonably calculated to cure such breach within
a timeframe that is reasonably prompt in light of the circumstances then prevailing, but in no event more than [***]. Following delivery of such a plan, the Breaching Party will carry out the plan and cure the breach. If the Breaching Party fails to
cure a material breach of this Agreement as provided above, then the Non-Breaching Party may terminate this Agreement upon written notice to the Breaching Party; provided that if the Breaching Party is
Vir and such material breach relates solely to one or more Programs under the Agreement (but not to all Programs), then Alnylam shall have the right to terminate this Agreement pursuant to this Section 11.2(b) solely with respect to such
Program(s). 
 (c) Disputed Breach. If the alleged Breaching Party disputes in good faith the existence or materiality of a breach
specified in a notice provided by the other Party in accordance with Section 11.2(b), or disputes that it has not timely cured such breach, and such alleged Breaching Party provides the other Party notice of such dispute within such sixty (60)-day period, then the Non-Breaching Party shall not have the right to terminate this Agreement under Section 11.2(b) unless and until such dispute is resolved in
accordance with Article XIII. It is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective
obligations hereunder. 
 (d) Challenges of Patent Rights. In the event that a Party (the “Challenging
Party”) or any of its Related Parties (i) commences or participates in any action or proceeding (including any patent opposition, re-examination or any other
pre- or post-grant challenge or proceeding), or otherwise asserts any claim, challenging or denying the validity or enforceability (such an action or proceeding, a “Challenge”) of any of the
Patent Rights licensed to such Challenging Party by the other Party (the “Licensor Party”) under this Agreement or any claim thereof or (ii) actively assists any other Person in bringing or prosecuting any action or proceeding
(including any patent opposition, re-examination or any other pre- or post-grant challenge or proceeding) challenging or denying the validity or enforceability of any of
such Patent Rights or any claim thereof, then (A) such Challenging Party shall give notice thereof to such Licensor Party within [***] of taking such action or of learning that its Related Party has taken such action, and (B) such Licensor
Party will have the right, in its sole discretion, to give notice to such Challenging Party that this Agreement will terminate thirty (30) days following such notice (or such longer period as such Licensor Party may designate in such notice),
and, unless, with respect to a Challenge brought by such Challenging Party, such Challenging Party withdraws, or, with respect to a Challenge brought by its Affiliates, causes, or, with respect to a Challenge brought by its Sublicensee, [***] within
such thirty (30)-day (or longer) period, this Agreement will so terminate. In the event that such Licensor Party is not permitted under Law to terminate this Agreement as contemplated in this
Section 11.2(d), then the Parties agree to construe this provision to permit such Licensor Party to terminate only the licenses to that portion of such Patent Rights with respect to which such Licensor Party may terminate consistent with Law.

  
 59 

 EXECUTION VERSION 
  

 11.3 Effect of Termination. Without limiting any other legal or equitable remedies that
either Party may have, if this Agreement is terminated by Alnylam, or by Vir in accordance with Section 11.2(a), then, with respect to each terminated Program (“Terminated Program”) and the Licensed Products Directed to the
Collaboration Target in such Terminated Program that were Developed or Commercialized under this Agreement (the “Terminated Products”): 

(a) If this Agreement is terminated by Alnylam, Vir’s obligations under Section 10.5(a) shall survive for a period of [***] after the
effective date of termination. If this Agreement is terminated by Vir, Vir’s obligations under Section 10.5(a) shall survive for a period of [***] after the effective date of termination; 

(b) Subject to the terms and conditions of this Agreement and the agreement on financial terms as provided below in this subsection (a), Vir
shall and hereby does grant to Alnylam a transferable, sublicenseable (subject to Section 6.2(c)), worldwide, exclusive, royalty-bearing license, under any Vir Collaboration IP solely to Develop, Manufacture, use, sell, have sold, import, and
otherwise Commercialize the Terminated Products in the Field in the Territory. The licenses and other rights conveyed under this Section 11.3 shall be granted on commercially reasonable terms negotiated in good faith by the Parties, including
commercially reasonable milestone and royalty payments. In connection with such grant, Alnylam shall be responsible for all payments owed to Third Parties in connection with any of the grant of rights described in this Section 11.3 for
Alnylam’s Development, Manufacture, use, sale, import and other Commercialization of such Terminated Products. In the event that the Parties cannot mutually agree upon such terms within [***] following the effective date of termination, either
Party may seek a final and binding resolution regarding the commercially reasonable terms of such definitive agreement pursuant to the baseball arbitration provisions in Section 13.3; 

(c) Vir shall wind down or complete (whether to wind down or complete being in Vir’s sole discretion subject to patient safety and
well-being), at Vir’s expense, all Clinical Studies ongoing at the effective date of termination and shall use Commercially Reasonable Efforts to [***] transfer to Alnylam or Alnylam’s designee (i) possession and ownership of all
governmental or regulatory correspondence, conversation logs, filings and approvals (including all Regulatory Approvals and pricing and reimbursement approvals) in Vir’s or its Affiliates’ possession and Control relating to the
Development, Manufacture or Commercialization of the Terminated Products and all Product Trademarks, (ii) copies of all data, reports, records and materials, and other sales and marketing related information in Vir’s or its
Affiliates’ possession and Control to the extent that such data, reports, records, materials or other information relate to the Development, Manufacture or Commercialization of Terminated Products, including all
non-clinical and clinical data relating to Terminated Products, and customer lists and customer contact information and all adverse event data in Vir’s possession and Control, and (iii) all records
and materials in Vir’s possession and Control containing Confidential Information of Alnylam. Vir shall further appoint Alnylam as Vir’s and/or Vir’s Affiliates’ agent for all Terminated Product-related matters involving
Regulatory Authorities in the Territory until all such Regulatory Approvals and other regulatory filings have been transferred to Alnylam or its designee. To the extent that any of the foregoing items cover Terminated Products and other products,
then Vir shall exclusively license (not assign) such items to Alnylam for the Terminated Products and grant rights sufficient to give effect to Alnylam’s continued Development, Manufacture or Commercialization of such Terminated Products; 

(d) If the effective date of termination is after First Commercial Sale, then Vir shall appoint Alnylam as its exclusive distributor of the
Terminated Product in the Territory and grant Alnylam the right to appoint sub-distributors, until the earlier of (i) [***] after the effective date of termination, or (ii) such time as all such
Regulatory Approvals in the Territory have been transferred to Alnylam or its designee; provided, that Alnylam shall [***] complete such transfer as promptly as practicable; 

(e) If Vir or its Affiliates are Manufacturing or having Manufactured on its or their behalf the Terminated Product, then at Alnylam’s
option, Vir shall use Commercially Reasonable Efforts to supply the Terminated Product to Alnylam in the Territory at a supply price equal to [***], for a period of up to [***] after the effective date of termination provided, that
Alnylam shall use Commercially Reasonable Efforts to obtain alternative supply of such Terminated Product as promptly as practicable. [***]; 

  
 60 

 EXECUTION VERSION 
  

 (f) If Alnylam so requests, Vir shall use Commercially Reasonable Efforts to assign to
Alnylam any Third Party agreements solely relating to the Development, Manufacture or Commercialization of the Terminated Product to which Vir is a party, subject to any required consents of such Third Party, which Vir shall use Commercially
Reasonable Efforts to obtain promptly. Such assignment shall be subject to the terms of such agreement and Alnylam’s written agreement to assume all the obligations of Vir under such agreement to be undertaken after such assignment, but Vir
shall remain solely responsible for its obligations under such agreement arising prior to such assignment; 
 (g) Vir shall promptly transfer
and assign to Alnylam all of Vir’s and its Affiliates’ rights, title and interests in and to the Product Trademark(s) owned by Vir or its Affiliates and solely used for the Terminated Products in the Field in the Territory; 

(h) Vir shall transfer to Alnylam any inventory of Terminated Products Controlled by Vir or its Affiliates as of the termination date, at a
price equal to [***]; and 
 (i) For the [***] immediately following the effective date of termination, Vir shall use [***], [***];
provided, that that Alnylam shall use Commercially Reasonable Efforts to so proceed as expeditiously as practicable. 
 (j) Vir
shall, [***], execute all documents and use Commercially Reasonable Efforts to take all such further actions as may be reasonably requested by Alnylam in order to give effect to the foregoing clauses. 

11.4 Effect of Expiration or Termination; Survival. Expiration or termination of this Agreement shall not relieve the Parties of any obligation
accruing prior to such expiration or termination. Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued under this Agreement prior to expiration or termination, including
the obligation to pay royalties for any Licensed Product sold prior to such expiration or termination. The following provisions shall survive any expiration or termination of this Agreement: Articles 1 (Definitions), 12 (Indemnification), 13
(Dispute Resolution), and 14 (Miscellaneous) and Sections 3.4(d), 3.7, 4.1(b) (to the extent applicable), 6.2(b), 6.2(c) (to the extent applicable), 6.3, 6.4 (to the extent applicable), 6.5, 6.6(d) (to the extent reimbursement obligations are
incurred prior to the effective date of termination), 6.7, 7.7 (to the extent payment obligations are incurred prior to the effective date of termination), 7.8, 7.9, 7.10, 7.11, 7.12, 7.13, 7.14, 7.15, 8.1, 8.2, 8.7(c), 9.1, 10.4 and 11.3 (solely to
the extent applicable), and this 11.4 shall survive any expiration or termination of this Agreement. Except as set forth in this Article 11, upon termination or expiration of this Agreement all other rights and obligations of the Parties under
this Agreement cease. 

  
 61 

 EXECUTION VERSION 
  

 ARTICLE XII 

INDEMNIFICATION 

12.1 General Indemnification. 

(a) By Vir. Except as expressly otherwise set forth in a Transaction Agreement, Vir shall indemnify, hold harmless,
and defend Alnylam, its Affiliates, and their respective directors, officers, employees and agents (“Alnylam Indemnitees”) from and against any and all Third Party claims, suits, losses, liabilities, damages, costs, fees and
expenses (including reasonable attorneys’ fees) (collectively, “Losses”) to the extent such Losses arise out of or result from, directly or indirectly, (i) any breach of any representation or warranty made by Vir in the
Transaction Agreements or any breach of any covenant or agreement of Vir in the Transaction Agreements, (ii) the negligence or willful misconduct of Vir and its Related Parties, and their respective directors, officers, employees and agents, in
the performance of Vir’s obligations under the Transaction Agreements, or (iii) the Development, Manufacture or Commercialization of Licensed Products by Vir or its Related Parties, contractors, or distributors. Notwithstanding the
foregoing, Vir shall have no obligation to indemnify the Alnylam Indemnitees to the extent that the Losses arise out of or result from, directly or indirectly, (1) any breach of any representation or warranty made by Alnylam in the Transaction
Agreements, (2) any breach of any covenant or agreement of Alnylam in the Transaction Agreements, (3) the negligence or willful misconduct of any of the Alnylam Indemnitees or any other Alnylam Related Parties and their respective
directors, officers, employees and agents, or (4) or the Development, Manufacture, or Commercialization of Licensed Products by Alnylam or its Related Parties, contractors, or distributors. 

(b) By Alnylam. Except as expressly otherwise set forth in a Transaction Agreement, Alnylam shall indemnify, hold harmless, and
defend Vir, its Affiliates and their respective directors, officers, employees and agents (“Vir Indemnitees”) from and against any and all Losses to the extent such Losses arise out of or result from, directly or indirectly,
(i) any breach of any representation or warranty made by Alnylam in the Transaction Agreements or any breach of any covenant or agreement of Alnylam in the Transaction Agreements, (ii) the negligence or willful misconduct of Alnylam and
its Affiliates, and their respective directors, officers, employees and agents, in the performance of Alnylam’s obligations under the Transaction Agreements, (iii) the Development or Manufacture of Licensed Products by Alnylam or its
Related Parties, contractors, or distributors, (iv) the exercise by Alnylam or its Related Parties of its rights in Section 6.2(b), or (v) the Development, Manufacture, or Commercialization of Terminated Products by Alnylam or its
Related Parties, contractors, or distributors. Notwithstanding the foregoing, Alnylam shall have no obligation to indemnify the Vir Indemnitees to the extent that the Losses arise out of or result from, directly or indirectly, (1) any breach of
any representation or warranty made by Vir in the Transaction Agreements, (2) any breach of any covenant or agreement of Vir in the Transaction Agreements, (3) the negligence or willful misconduct of any of the Vir Indemnitees or any other
Vir Related Parties and their respective directors, officers, employees and agents, or (4) the Development, Manufacture or Commercialization of Licensed Products by Vir or its Related Parties, contractors, or distributors. 

12.2 Indemnification Procedure. In the event of any such claim against any Vir Indemnitee or Alnylam Indemnitee, the indemnified Party shall
promptly notify the other Party in writing of the claim once the indemnified Party learns of it, and the indemnifying Party shall manage and control, at its sole expense, the defense of the claim and its settlement. The indemnified Party shall
cooperate with the indemnifying Party, at the indemnifying Party’s reasonable request and expense, in the preparation and defense of the claim, and may, at the indemnified Party’s option and expense, be represented by counsel of its own
choosing in any such action or proceeding. The indemnifying Party shall not be liable for any settlements, litigation costs or expenses incurred by any the indemnified Party without the indemnifying Party’s prior written authorization. The
indemnifying Party shall not settle any such claim without the 

  
 62 

 EXECUTION VERSION 
  

 indemnified Party’s consent, not to be unreasonably withheld, conditioned, or delayed, unless such
settlement requires only payments by the indemnifying Party and no admission of wrong-doing or fault by the indemnified Party. Notwithstanding the foregoing, if the indemnifying Party reasonably believes that any of the exceptions to its obligation
of indemnification of the indemnified Party set forth in Section 12.1 may apply, the indemnifying Party shall promptly notify the indemnified Party, which shall then have the right to be represented in any such action or proceeding by separate
counsel at its own expense; provided, that the indemnifying Party shall be responsible for payment of such expenses if the indemnified Party is ultimately determined to be entitled to indemnification from the indemnifying Party for the
matters to which the indemnifying Party notified the indemnified Party that such exception(s) may apply. 
 12.3 General Limitation of
Liability. NEITHER PARTY HERETO WILL BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS
AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, EXCEPT AS A RESULT OF A PARTY’S WILLFUL MISCONDUCT, A MATERIAL BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS IN ARTICLE IX.
NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 12.3 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER SECTION 12.1. 

12.4 Insurance. Each Party shall maintain insurance during the Term and for a period of at least [***] after the last commercial sale of any
Licensed Product under this Agreement by such Party or its Related Parties, with a reputable, solvent insurer in an amount appropriate for its business and products of the type that are the subject of this Agreement, and for its obligations under
this Agreement. Specifically, Vir shall maintain product liability insurance of at least [***] per occurrence prior to the Initiation of Clinical Studies by Vir, and at least [***] per occurrence thereafter. Upon reasonable request, each Party shall
provide the other Party with evidence of the existence and maintenance of such insurance coverage. 
 ARTICLE XIII 

DISPUTE RESOLUTION 

13.1 Dispute Resolution. Should a dispute arise under this Agreement or any other Transaction Agreement that the Parties are not initially
able to resolve, such dispute shall be referred to the Executive Officers (or their designees), who shall promptly initiate discussions in good faith to resolve such dispute. If such dispute is not resolved by the Executive Officers within [***]
after the date the Executive Officers first met to consider such dispute (or such other period as may apply pursuant to Section 2.6), and neither Party has final decision-making authority as to such dispute pursuant to Section 2.6, and a
Party wishes to pursue the matter, then except as otherwise expressly provided for in this Agreement or a Transaction Agreement, such Party may file suit to have such dispute adjudicated in a court of competent jurisdiction or the Parties may
mutually agree to resolve such dispute in accordance with Section 13.2. 
 13.2 Arbitration. 

(a) If the Parties do not resolve a dispute as provided in Section 13.1 and mutually agree to resolve such dispute through binding
arbitration, then unless such dispute is an Excluded Claim, such dispute shall be resolved by binding arbitration in accordance with the Rules of Arbitration of the International Chamber of Commerce as then in effect (the “ICC
Rules”), which ICC Rules are deemed to be incorporated by reference into this clause and judgment on the arbitration award may be entered in any court having jurisdiction thereof. The decision rendered in any such arbitration will be final
and not appealable. 

  
 63 

 EXECUTION VERSION 
  

 (b) The arbitration shall be conducted by a panel of three (3) arbitrators appointed in
accordance with the ICC Rules, none of whom shall be a current or former employee or director, or a then-current stockholder, of either Party, their respective Affiliates, or any Sublicensee. The place of arbitration shall be [***], and all
proceedings and communications shall be in English. 
 (c) It is the intention of the Parties that discovery, although permitted as described
herein, will be limited except in exceptional circumstances. The arbitrators will permit such limited discovery necessary for an understanding of any legitimate issue raised in the arbitration, including the production of documents. No later than
[***] after selection of the arbitrators, the Parties and their representatives shall hold a preliminary meeting with the arbitrators, to mutually agree upon and thereafter follow procedures seeking to assure that the arbitration will be concluded
within [***] from such meeting. Failing any such mutual agreement, the arbitrators will design and the Parties shall follow procedures to such effect. 

(d) Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is
otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending the
arbitration award. The arbitrators shall [***]. The arbitrators shall have the power to order that all or part of the legal or other costs incurred by a Party in connection with the arbitration be paid by the other Party. Any determination pursuant
to this Section 13.2 that a Party is in material breach of its material obligations hereunder shall [***]. Each Party shall bear an equal share of the arbitrators’ and any administrative fees of arbitration. 

(e) Except to the extent necessary to confirm or enforce an award or as may be required by applicable Laws, neither a Party nor an arbitrator
may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the
dispute, controversy, or claim would be barred by the applicable New York statute of limitations. 
 (f) As used in this Section, the term
“Excluded Claim” shall mean a dispute, controversy, or claim that concerns [***]. Disputes regarding Excluded Claims shall be brought in a court of competent jurisdiction in which such patent or trademark rights or copyright was
granted or arose or in which such law or regulation applies. 
 13.3 Baseball Arbitration. Notwithstanding the provisions of
Section 13.1, any dispute for which arbitration pursuant to this Section 13.3 is specifically provided for in this Agreement shall be finally decided by expedited arbitration in accordance with the following abbreviated dispute resolution
procedures: 
 (a) If the dispute is not resolved within [***] after referral to the Party’s respective Executive Officers, then either
Party may send the other Party a written notice that it wishes to resolve the dispute by using a neutral Third Party who is an expert with at least [***] of experience in area of the dispute (the “Neutral Expert”). The date of the
other Party’s receipt of such written notices shall be the “Notice Date.” 

  
 64 

 EXECUTION VERSION 
  

 (b) Within [***] of the Notice Date, each Party shall notify the other Party in writing of
its appointed Expert (each, a “Representative Expert”). The Representative Experts for each Party shall jointly appoint the Neutral Expert within [***]. 

(c) Within [***] after the appointment of the Neutral Expert, each Party shall submit to the other Party and the Neutral Expert a written
summary regarding its position with respect to the dispute. Contemporaneously with the submission of its written summary regarding its position, each Party shall provide the other Party and the Neutral Expert with copies of all documents it relied
upon in its written summary; provided that each Party may redact any portion of such documents which are covered by an applicable privilege or do not relate to the subject matter of this Agreement. Within [***] of receipt of the other
Party’s written summary regarding its position, each Party may submit an opposition statement of no more than [***] in length (excluding exhibits and declarations). Neither Party will be allowed to conduct any discovery. Neither Party may have
any communications (either written or oral) with the other Party’s Representative Experts or the Neutral Expert other than for the sole purpose of engaging the expert panel or as expressly permitted in this Section 13.3; provided,
that oral presentations and follow-up written submissions may be made to the Neutral Expert at such Neutral Expert’s request. The Neutral Expert may consult in writing with the Representative Experts
regarding the submissions made by either Party; provided that both Representative Experts are aware of such consultation and provided an opportunity to respond. Evaluating each Party’s written submissions, the Neutral Expert shall,
within [***] of receipt of the written opposition statement, select in total, either Vir’s submission or Alnylam’s submission. Such decision shall be final, binding, and not appealable. 

(d) [***]. 
 ARTICLE XIV

 MISCELLANEOUS 

14.1 Governing Law. This Agreement shall be construed and the respective rights of the Parties determined according to the substantive laws of
the State of New York, U.S.A., excluding (a) any of its conflicts of laws principles to the contrary; (b) the United Nations Conventions on Contracts for the International Sale of Goods; (c) the 1974 Convention on the Limitation
Period in the International Sale of Goods; and (d) the Protocol amending the 1974 Convention on the Limitation Period in the International Sale of Goods, done at Vienna, April 11, 1980. 

14.2 Waiver of Jury Trial. The Parties hereby (a) irrevocably submit to the jurisdiction of the state and federal courts in the State of
New York and agree that all claims shall be heard and determined in any such court; (b) waive any defense of inconvenient forum to the maintenance of any such claims and further agree not to bring any such claims in any other court;
(c) irrevocably consent to service of process by certified mailing, postage prepaid, or delivering such service to the Party at its respective notice address set forth in Section 14.5; (d) waive any right to a trial by jury in any action
or proceeding to enforce or defend any rights under this Agreement or under any amendment, instrument, document or agreement delivered in connection herewith or hereafter and agree that any such action or proceeding shall be tried before a court and
not before a jury; and (e) agree that a final judgment shall be conclusive and may be enforced by suit on the judgment or in any other manner provided by law or at equity. Notwithstanding anything to the contrary in this Section 14.2,
either Party may seek injunctive relief in any court in any jurisdiction where appropriate. 

  
 65 

 EXECUTION VERSION 
  

 14.3 Assignment. Except as provided in this Section 14.3, this Agreement may not be
assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the prior written consent of the other Party. However, either Party may, without the other Party’s consent, assign
or otherwise transfer this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate or to a Person that acquires, by merger, sale of assets or otherwise, all or substantially all of the business of the assigning Party
to which the subject matter of this Agreement relates; provided, however, [***]. 
 14.4 Entire Agreement; Amendments. This Agreement,
together with that certain Commitment Letter entered into by and between the Parties on the Commitment Letter Date and the Stock Purchase Agreement, contain the entire understanding of the Parties with respect to the subject matter hereof, and
supersede all previous arrangements with respect to the subject matter hereof, whether written or oral, including the Confidential Disclosure Agreement. This Agreement (including the Schedules hereto) may be amended, or any term hereof
modified, only by a written instrument duly-executed by authorized representatives of both Parties. 
 14.5 Notices. All notices which are
required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:

 Notices to Alnylam shall be addressed to: 

[***] 
 with a copy that shall
not constitute notice to: 
 [***] 

Notices to Vir shall be addressed to: 

[***] 
 with a copy that shall
not constitute notice to: 
 [***] 
 or to such
other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered on a Business Day
(or if delivered or sent on a non-Business Day, then on the next Business Day); (b) on receipt if sent by overnight courier; and/or (c) on receipt if sent by mail. 

  
 66 

 EXECUTION VERSION 
  

 14.6 Force Majeure. Neither Party shall be held liable to the other Party nor be deemed to
have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent that such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party,
potentially including embargoes, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by
any Governmental Authority or the other Party. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such
force majeure circumstances. 
 14.7 No Strict Construction. This Agreement has been prepared jointly and shall not be strictly
construed against any Party. 
 14.8 Headings. The captions or headings of the Sections or other subdivisions hereof are inserted only
as a matter of convenience or for reference and shall have no effect on the meaning of the provisions hereof. 
 14.9 No Implied Waivers;
Rights Cumulative. No failure on the part of Alnylam or Vir to exercise, and no delay in exercising, any right, power, remedy or privilege under this Agreement, or provided by statute or at law or in equity or otherwise, shall impair, prejudice or
constitute a waiver of any such right, power, remedy or privilege or be construed as a waiver of any breach of this Agreement or as an acquiescence therein, nor shall any single or partial exercise of any such right, power, remedy or privilege
preclude any other or further exercise thereof or the exercise of any other right, power, remedy or privilege. 
 14.10 Severability. If any
provision hereof should be held invalid, illegal or unenforceable in any respect in any jurisdiction, the Parties shall substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions, which valid provisions
best reflect the original intent of the Parties and in their economic effect are sufficiently similar to the invalid, illegal or unenforceable provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with
such valid provisions. In case such valid provisions cannot be agreed upon, the invalid, illegal or unenforceable of one or several provisions of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal
or unenforceable provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provisions. 

14.11 Interpretation. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The
words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the word
“shall.” Unless the context requires otherwise, (a) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to
time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (b) any reference to any Laws herein shall be construed as referring to such Laws as they
from time to time may be enacted, repealed or amended, (c) any reference herein to any Person shall be construed to include the Person’s successors and assigns, (d) the words “herein”, “hereof’ and
“hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (e) any reference herein to the words “mutually agree” or “mutual
written agreement” shall not impose any obligation on either Party to agree to any terms relating thereto or to engage in discussions relating to such terms except as such Party may determine in such Party’s sole discretion, (f) all
references herein to Articles, Sections, Exhibits or Schedules shall be construed to refer to Articles, Sections, Exhibits and Schedules of this Agreement, (g) the word “or” shall be construed to have the same meaning and
effect as “and/or” unless the context dictates otherwise because the subjects of the conjunction are mutually exclusive, and (h) a term not defined herein but reflecting a different part of speech than a term which is defined herein
shall be interpreted in a correlative manner. 

  
 67 

 EXECUTION VERSION 
  

 14.12 Actions of Affiliates. Each Party shall be liable for any failure by its Affiliates to
comply with the restrictions, limitations and obligations set forth in this Agreement. Neither Party shall permit any of its Affiliates to commit any act (including any act of omission) that such Party is prohibited hereunder from committing
directly. To the extent that the rights granted to a Party hereunder may be and are exercised by an Affiliate of such Party, such Affiliate shall be bound by the corresponding obligations of such Party. 

14.13 Relationship of the Parties. It is expressly agreed that Alnylam and Vir are independent contractors and that the relationship between
the two Parties will not constitute a partnership, joint venture, or agency. Neither Alnylam nor Vir will have the authority to make any statements, representations, or commitments of any kind, or to take any action, which will be binding on the
other Party, without the prior written consent of the other Party. Nothing contained in this Agreement shall be deemed to make any member of the JSC or any subcommittee (or any other committees or working groups) a partner, agent, or legal
representative of the other Party, or to create any fiduciary relationship for any purpose whatsoever. Except as may be explicitly provided in this Agreement, no member of the JSC, any subcommittee (or any other committee or working group) will have
any authority to act for, or to assume any obligation or responsibility on behalf of, any other member of (or any other committee or working group) of the other Party. 

14.14 Binding Effect; No Third Party Beneficiaries. As of the Effective Date, this Agreement shall be binding upon and inure to the benefit of
the Parties and their respective successors and permitted assigns. Except as expressly set forth in this Agreement, no Person other than the Parties and their respective Affiliates and permitted assignees hereunder shall be deemed an intended third
party beneficiary hereunder or have any right to enforce any obligation of this Agreement. 
 14.15 Further Assurances. Each Party agrees to
duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including, without limitation, the filing of such additional assignments, agreements, documents
and instruments, as the other Party may at any time and from time to time reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes of, or to better assure of and confirm unto such other Party
its rights and remedies under, this Agreement. 
 14.16 Counterparts. The Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures and signatures transmitted via PDF shall be treated as original signatures. 

[Remainder of This Page Intentionally Left Blank] 

  
 68 

 EXECUTION VERSION 
  

 IN WITNESS WHEREOF, Alnylam and Vir have caused this Agreement to be duly executed by their authorized
representatives, as of the Effective Date. 
  

			
	ALNYLAM PHARMACEUTICALS, INC.
		
	By:	 	/s/ John Maranganore
		 	Name: John Maraganore
		 	Title: Chief Executive Officer

  

			
	VIR BIOTECHNOLOGY, INC.
		
	By:	 	/s/ George Scangos
		 	Name: George Scangos, Ph.D.
		 	Title: Chief Executive Officer

  
 69 

 SCHEDULE A 

ALNYLAM IN-LICENSES AND EXISTING ALNYLAM THIRD PARTY AGREEMENTS 

[***] 

  
 70 

  

 SCHEDULE A-1 

CERTAIN EXISTING ALNYLAM IN-LICENSES 

[***] 

  
 71 

 SCHEDULE B 

ALN- HBV AND ALN-HBV02 

[***] 

  
 72 

 SCHEDULE C-1 

ALNYLAM CORE TECHNOLOGY PATENT RIGHTS 

(See attached) 
 [***] 

  
 73 

 SCHEDULE C-2 

ALNYLAM PRODUCT-SPECIFIC PATENT RIGHTS 

(See attached) 
 [***] 

  
 74 

 SCHEDULE D 

ID TARGETS, RESERVED TARGETS AND ID COLLABORATION TARGETS 

[***] 

  
 75 

 SCHEDULE E 

PROFIT-SHARING AGREEMENT TERMS 
 [***]

  
 76 

 SCHEDULE F 

HBV PROGRAM DEVELOPMENT PLAN 
 [***] 

  
 77 

 SCHEDULE G 

STOCK PURCHASE AGREEMENT 

(See attached) 

  
 78 

 SCHEDULE H 

[INTENTIONALLY OMITTED] 

  
 79 

 SCHEDULE I 

ALNYLAM DISCLOSURE SCHEDULE 

[***] 

  
 80 

 SCHEDULE J 

ALNYLAM DC WORKPLAN TEMPLATE 
 [***] 

  
 81 

 SCHEDULE K 

PROFIT-SHARING OPTION DATA PACKAGE 
 [***]

  
 82

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]